# Kelleher_2022_Skin care interventions in infants for preventing eczema and food allergy.

Cochrane
Library

Cochrane Database of Systematic Reviews

Skin care interventions in infants for preventing eczema and food
allergy (Review)

Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Carlsen KCL, Skjerven HO, Rehbinder EM,
Lowe AJ, Dissanayake E, Shimojo N, Yonezawa K, Ohya Y, Yamamoto-Hanada K, Morita K, Axon
E, Cork M, Cooke A, Van Vogt E, Schmitt J, Weidinger S, McClanahan D, Simpson E, Duley L, Askie
LM, Williams HC, Boyle RJ

Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Carlsen KC Lødrup, Skjerven HO, Rehbinder EM, Lowe AJ, Dissanayake E,
Shimojo N, Yonezawa K, Ohya Y, Yamamoto-Hanada K, Morita K, Axon E, Cork M, Cooke A, Van Vogt E, Schmitt J, Weidinger S,
McClanahan D, Simpson E, Duley L, Askie LM, Williams HC, Boyle RJ. 
Skin care interventions in infants for preventing eczema and food allergy. 
Cochrane Database of Systematic Reviews 2022, Issue 11. Art. No.: CD013534. 
DOI: 10.1002/14651858.CD013534.pub3.

www.cochranelibrary.com

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on
behalf of The Cochrane Collaboration.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
RISK OF BIAS................................................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 1: Eczema
by 1 to 3 years.......................................................................................................................................................................................
Analysis 1.2. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 2: Sensitivity
analysis: Eczema by 1 to 3 years including aggregate trial data.......................................................................................................
Analysis 1.3. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 3: Sensitivity
analysis: Eczema by 1 to 3 years (UKWP only)....................................................................................................................................
Analysis 1.4. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 4: Sensitivity
analysis: Eczema by 1 to 3 years (including data from all 4 arms of PreventADALL)........................................................................
Analysis 1.5. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 5: Sensitivity
analysis: Eczema by 1 to 3 years (using PreventADALL 36-month outcome)....................................................................................
Analysis 1.6. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 6: Sensitivity
analysis: Eczema by 1 to 3 years - low risk of bias.............................................................................................................................
Analysis 1.7. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 7: Sensitivity
analysis: Eczema by 1 to 3 years - excluding non-prospectively acquired data................................................................................
Analysis 1.8. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 8: Sensitivity
analysis: Eczema by 6 months to 3 years............................................................................................................................................
Analysis 1.9. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 9: Sensitivity
analysis: Eczema after the intervention period (at 1 year or beyond - up to 3 years) .....................................................................
Analysis  1.10.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  10:
Subgroup analysis (study level): Eczema by 1 to 3 years by intervention type................................................................................
Analysis  1.11.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  11:
Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention duration ......................................................
Analysis  1.12.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  12:
Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention timing...........................................................
Analysis  1.13.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  13:
Participant-level treatment interaction: Eczema by 1 to 3 years for treatment initiation < 4 days versus ≥ 4 days of age..............
Analysis  1.14.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  14:
Participant-level treatment interaction: Eczema by 6 months to 3 years for treatment initiation < 4 days versus ≥ 4 days of age....
Analysis  1.15.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  15:
Participant-level treatment interaction: Eczema by 1 to 3 years by FLG genotype (0 mutations versus 1/2 mutations).................
Analysis  1.16.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  16:
Participant-level treatment interaction: Eczema by 6 months to 3 years by FLG genotype (0 mutations versus 1/2 mutations).....
Analysis  1.17.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  17:
Participant-level treatment interaction: Eczema by 1 to 3 years by chromosome 11 status (C:C versus C:T or T:T).......................

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

1
3
5
8
11
11
18
19
27
28
29
30
33
36
37
39
59
114
125
130

131

131

132

132

133

133

134

134

135

135

136

136

136

137

137

137

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  1.18.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  18:
Participant-level treatment interaction: Eczema by 1 to 3 years by FLG mutation and chromosome 11 status (no FLG and C:C
versus FLG mutation and/or chromosome 11 C:T or T:T)..................................................................................................................
Analysis  1.19.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  19:
Participant-level treatment interaction: Eczema by 1 to 3 years by ≥ 1 first-degree relative with history of allergic disease ........
Analysis  1.20.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  20:
Participant-level treatment interaction: Eczema by 1 to 3 years by ≥ 1 first-degree relative with history of allergic disease and/
or FLG genotype (0 mutations versus 1/2 mutations)........................................................................................................................
Analysis 1.21. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 21: CACE:
Eczema by 1 to 3 years for use over intervention period ≥ 3 days a week........................................................................................
Analysis 1.22. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 22: CACE
sensitivity: Eczema by 1 to 3 years for use over intervention period ≥ 5 days a week.....................................................................
Analysis 1.23. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 23: CACE
sensitivity: Eczema by 1 to 3 years for use over intervention period 7 days  a week ......................................................................
Analysis 1.24. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 24: CACE
sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 3 days a week..............................................................................
Analysis 1.25. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 25: CACE
sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 5 days a week..............................................................................
Analysis 1.26. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 26: CACE
sensitivity: Eczema by 1 to 3 years for use over first 3 months 7 days a week.................................................................................
Analysis  1.27.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  27:
Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period ≥ 3 days a week.........
Analysis  1.28.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  28:
Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period ≥ 5 days a week.........
Analysis  1.29.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  29:
Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over intervention period 7 days a week............
Analysis  1.30.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  30:
Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months ≥ 3 days a week..................
Analysis  1.31.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  31:
Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months ≥ 5 days a week..................
Analysis  1.32.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  32:
Sensitivity analysis: Eczema by 1 to 3 years for studies included in CACE for use over first 3 months 7 days a week.....................
Analysis 1.33. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 33: Food
allergy by 1 to 3 years..........................................................................................................................................................................
Analysis  1.34.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  34:
Sensitivity analysis: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator assessment).........................
Analysis  1.35.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  35:
Sensitivity analysis: Food allergy by 1 to 3 years (parent report of doctor diagnosis).....................................................................
Analysis  1.36.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  36:
Participant-level  treatment  interaction:  Food  allergy  by  1  to  3  years  (diagnosed  by  oral  food  challenge  or  investigator
assessment) by FLG genotype (0 mutations versus 1/2 mutations)..................................................................................................
Analysis  1.37.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  37:
Participant-level  treatment  interaction:  Food  allergy  by  1  to  3  years  (diagnosed  by  oral  food  challenge  or  investigator
assessment) by chromosome 11 status (C:C versus C:T or T:T).........................................................................................................
Analysis  1.38.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  38:
Participant-level  treatment  interaction:  Food  allergy  by  1  to  3  years  (diagnosed  by  oral  food  challenge  or  investigator
assessment) by FLG mutation and chromosome 11 status (no FLG and C:C versus FLG mutation and/or chromosome 11 C:T
or T:T).....................................................................................................................................................................................................
Analysis 1.39. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 39: CACE:
Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period ≥ 3 days a week............
Analysis 1.40. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 40: CACE
sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period ≥ 5 days a
week.......................................................................................................................................................................................................
Analysis 1.41. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 41: CACE
sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over intervention period 7 days a
week.......................................................................................................................................................................................................

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

137

138

138

138

138

139

139

139

139

140

140

140

141

141

141

142

142

142

143

143

143

143

144

144

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.42. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 42: CACE
sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months ≥ 3 days a week......
Analysis 1.43. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 43: CACE
sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months  ≥ 5 days a week.....
Analysis 1.44. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 44: CACE
sensitivity: Food allergy (oral food challenge or panel assessment) by 1 to 3 years for use over first 3 months 7 days a week.......
Analysis 1.45. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 45: Adverse
event: skin infection.............................................................................................................................................................................
Analysis 1.46. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 46: Adverse
event: stinging or allergic reaction to moisturisers............................................................................................................................
Analysis 1.47. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 47: Adverse
event: slippage accidents.....................................................................................................................................................................
Analysis 1.48. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 48: Serious
adverse events......................................................................................................................................................................................
Analysis  1.49.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  49:
Clinician-assessed eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe)...........................................
Analysis  1.50.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  50:
Clinician-assessed eczema severity at 1 to 3 years (standardised mean difference)........................................................................
Analysis 1.51. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 51: Parent-
reported eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe)...........................................................
Analysis 1.52. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 52: Parent-
reported eczema severity at 1 to 3 years (mean difference)..............................................................................................................
Analysis 1.53. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 53: Time
to onset of eczema...............................................................................................................................................................................
Analysis  1.54.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  54:
Subgroup analysis: Time to onset of eczema (< 1-year follow-up versus ≥ 1-year follow-up).........................................................
Analysis 1.55. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 55: Parent
report of immediate (< 2 hours) reaction to a known common food allergen.................................................................................
Analysis 1.56. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 56: Parent
report of immediate (< 2 hours) reaction to milk...............................................................................................................................
Analysis 1.57. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 57: Parent
report of immediate (< 2 hours) reaction to egg................................................................................................................................
Analysis 1.58. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 58: Parent
report of immediate (< 2 hours) reaction to peanut..........................................................................................................................
Analysis 1.59. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 59: Allergic
sensitisation to common foods or inhalants at 1 to 3 years..............................................................................................................
Analysis 1.60. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 60: Allergic
sensitisation to common foods at 1 to 3 years...................................................................................................................................
Analysis 1.61. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 61: Allergic
sensitisation to milk at 1 to 3 years....................................................................................................................................................
Analysis 1.62. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 62: Allergic
sensitisation to egg at 1 to 3 years......................................................................................................................................................
Analysis 1.63. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 63: Allergic
sensitisation to peanut at 1 to 3 years................................................................................................................................................
Analysis 1.64. Comparison 1: Skin care intervention versus standard skin care or no skin care intervention, Outcome 64: Allergic
sensitisation to inhalants at 1 to 3 years............................................................................................................................................
Analysis  1.65.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  65:
Sensitivity analysis: Allergic sensitisation to common foods at 6 months to 3 years.......................................................................
Analysis  1.66.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  66:
Sensitivity analysis: Allergic sensitisation to milk at 6 months to 3 years........................................................................................
Analysis  1.67.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  67:
Sensitivity analysis: Allergic sensitisation to egg at 6 months to 3 years.........................................................................................
Analysis  1.68.  Comparison  1:  Skin  care  intervention  versus  standard  skin  care  or  no  skin  care  intervention,  Outcome  68:
Sensitivity analysis: Allergic sensitisation to peanut at 6 months to 3 years....................................................................................
ADDITIONAL TABLES....................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

144

144

145

145

145

146

146

147

147

147

147

148

148

149

149

149

149

150

150

151

151

151

152

152

153

153

154

154
162

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

168
168
168
169
171
172
172

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

iv

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Skin care interventions in infants for preventing eczema and food
allergy

Maeve M Kelleher1, Rachel Phillips2, Sara J Brown3, Suzie Cro2, Victoria Cornelius2, Karin C Lødrup Carlsen4,5, Håvard O Skjerven4, Eva M
Rehbinder5,6, Adrian J Lowe7, Eishika Dissanayake8, Naoki Shimojo9a, Kaori Yonezawa10, Yukihiro Ohya11, Kiwako Yamamoto-Hanada11,
Kumiko Morita12, Emma Axon13, Michael Cork14, Alison Cooke15, Eleanor Van Vogt2, Jochen Schmitt16, Stephan Weidinger17, Danielle
McClanahan18, Eric Simpson18, Lelia Duley19, Lisa M Askie20, Hywel C Williams13, Robert J Boyle1,21

1National Heart & Lung Institute, Section of Inflammation and Repair, Imperial College London, London, UK. 2Imperial Clinical Trials
Unit, Imperial College London, London, UK. 3Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh,
UK. 4Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway. 5Faculty of Medicine, Institute of Clinical
Medicine, University of Oslo, Oslo, Norway. 6Department of Dermatology, Oslo University Hospital, Oslo, Norway. 7Allergy and Lung
Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia. 8Department of
Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. 9Center for Preventive Medical
Sciences, Chiba University, Chiba, Japan. 10Department of Midwifery and Women's Health, Graduate School of Medicine, The University
of Tokyo, Tokyo, Japan. 11Allergy Center, National Center for Child Health and Development, Tokyo, Japan. 12Department of Pediatrics,
Keio University School of Medicine, Tokyo, Japan. 13Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
14Sheffield Dermatology Research, Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, Sheffield,
UK. 15Division of Nursing, Midwifery and Social Work, School of Health Sciences, The University of Manchester, Manchester, UK. 16Center
for Evidence-Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden, Dresden, Germany.
17Department of Dermatology and Allergy, University Hospital Scheswig-Holstein, Kiel, Germany. 18Department of Dermatology, Oregon
Health & Science University, Portland, Oregon, USA. 19Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.
20NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia. 21Cochrane Skin, Centre of Evidence Based Dermatology,
University of Nottingham, Nottingham, UK

aDuring the course of the review, Prof. Shimojo retired from Department of Pediatrics, Graduate School of Medicine, and now works at
the Center for Preventive Medical Sciences, Chiba University.

Contact: Robert J Boyle, r.boyle@nhs.net.

Editorial group: Cochrane Skin Group.
Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 11, 2022.

Citation: Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Carlsen KC Lødrup, Skjerven HO, Rehbinder EM, Lowe AJ, Dissanayake E,
Shimojo N, Yonezawa K, Ohya Y, Yamamoto-Hanada K, Morita K, Axon E, Cork M, Cooke A, Van Vogt E, Schmitt J, Weidinger S,
McClanahan D, Simpson E, Duley L, Askie LM, Williams HC, Boyle RJ. Skin care interventions in infants for preventing eczema and food
allergy. Cochrane Database of Systematic Reviews 2022, Issue 11. Art. No.: CD013534. DOI: 10.1002/14651858.CD013534.pub3.

Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.

Background

A B S T R A C T

Eczema and food allergy are common health conditions that usually begin in early childhood and often occur in the same people. They
can be associated with an impaired skin barrier in early infancy. It is unclear whether trying to prevent or reverse an impaired skin barrier
soon after birth is effective for preventing eczema or food allergy.

Objectives

Primary objective

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

To assess the effects of skin care interventions such as emollients for primary prevention of eczema and food allergy in infants.

Secondary objective

To identify features of study populations such as age, hereditary risk, and adherence to interventions that are associated with the greatest
treatment benefit or harm for both eczema and food allergy.

Search methods

We performed an updated search of the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, and Embase in September 2021. We
searched two trials registers in July 2021. We checked the reference lists of included studies and relevant systematic reviews, and scanned
conference proceedings to identify further references to relevant randomised controlled trials (RCTs).

Selection criteria

We included RCTs of skin care interventions that could potentially enhance skin barrier function, reduce dryness, or reduce subclinical
inflammation in healthy term (> 37 weeks) infants (≤ 12 months) without pre-existing eczema, food allergy, or other skin condition. Eligible
comparisons were standard care in the locality or no treatment. Types of skin care interventions could include moisturisers/emollients;
bathing products; advice regarding reducing soap exposure and bathing frequency; and use of water softeners. No minimum follow-up
was required.

Data collection and analysis

This is a prospective individual participant data (IPD) meta-analysis. We used standard Cochrane methodological procedures, and primary
analyses used the IPD dataset. Primary outcomes were cumulative incidence of eczema and cumulative incidence of immunoglobulin
(Ig)E-mediated food allergy by one to three years, both measured at the closest available time point to two years. Secondary outcomes
included adverse events during the intervention period; eczema severity (clinician-assessed); parent report of eczema severity; time to
onset of eczema; parent report of immediate food allergy; and allergic sensitisation to food or inhalant allergen.

Main results

We identified 33 RCTs comprising 25,827 participants. Of these, 17 studies randomising 5823 participants reported information on one or
more outcomes specified in this review.  We included 11 studies, randomising 5217 participants, in one or more meta-analyses (range 2
to 9 studies per individual meta-analysis), with 10 of these studies providing IPD; the remaining 6 studies were included in the narrative
results only. 

Most  studies  were  conducted  at  children's  hospitals.  Twenty-five  studies,  including  all  those  contributing  data  to  meta-analyses,
randomised  newborns  up  to  age  three  weeks  to  receive  a  skin  care  intervention  or  standard  infant  skin  care.  Eight  of  the  11  studies
contributing  to  meta-analyses  recruited  infants  at  high  risk  of  developing  eczema  or  food  allergy,  although  the  definition  of  high  risk
varied between studies. Durations of intervention and follow-up ranged from 24 hours to three years. All interventions were compared
against no skin care intervention or local standard care. Of the 17 studies that reported information on our prespecified outcomes, 13
assessed emollients.

We assessed most of the evidence in the review as low certainty and had some concerns about risk of bias. A rating of some concerns was
most often due to lack of blinding of outcome assessors or significant missing data, which could have impacted outcome measurement
but was judged unlikely to have done so. We assessed the evidence for the primary food allergy outcome as high risk of bias due to the
inclusion of only one trial, where findings varied based on different assumptions about missing data.

Skin care interventions during infancy probably do not change the risk of eczema by one to three years of age (risk ratio (RR) 1.03, 95%
confidence interval (CI) 0.81 to 1.31; risk difference 5 more cases per 1000 infants, 95% CI 28 less to 47 more; moderate-certainty evidence;
3075 participants, 7 trials) or time to onset of eczema (hazard ratio 0.86, 95% CI 0.65 to 1.14; moderate-certainty evidence; 3349 participants,
9 trials). Skin care interventions during infancy may increase the risk of IgE-mediated food allergy by one to three years of age (RR 2.53, 95%
CI 0.99 to 6.49; low-certainty evidence; 976 participants, 1 trial) but may not change risk of allergic sensitisation to a food allergen by age
one to three years (RR 1.05, 95% CI 0.64 to 1.71; low-certainty evidence; 1794 participants, 3 trials). Skin care interventions during infancy
may slightly increase risk of parent report of immediate reaction to a common food allergen at two years (RR 1.27, 95% CI 1.00 to 1.61;
low-certainty evidence; 1171 participants, 1 trial); however, this was only seen for cow’s milk, and may be unreliable due to over-reporting
of milk allergy in infants. Skin care interventions during infancy probably increase risk of skin infection over the intervention period (RR
1.33, 95% CI 1.01 to 1.75; risk difference 17 more cases per 1000 infants, 95% CI one more to 38 more; moderate-certainty evidence; 2728
participants, 6 trials) and may increase the risk of infant slippage over the intervention period (RR 1.42, 95% CI 0.67 to 2.99; low-certainty
evidence; 2538 participants, 4 trials) and stinging/allergic reactions to moisturisers (RR 2.24, 95% 0.67 to 7.43; low-certainty evidence;
343 participants, 4 trials), although CIs for slippages and stinging/allergic reactions were wide and include the possibility of no effect or
reduced risk.

Preplanned subgroup analyses showed that the effects of interventions were not influenced by age, duration of intervention, hereditary
risk, filaggrin (FLG) mutation, chromosome 11 intergenic variant rs2212434, or classification of intervention type for risk of developing

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

eczema. We could not evaluate these effects on risk of food allergy. Evidence was insufficient to show whether adherence to interventions
influenced the relationship between skin care interventions and eczema or food allergy development.

Authors' conclusions

Based on low- to moderate-certainty evidence, skin care interventions such as emollients during the first year of life in healthy infants are
probably not effective for preventing eczema; may increase risk of food allergy; and probably increase risk of skin infection. Further study
is needed to understand whether different approaches to infant skin care might prevent eczema or food allergy.

P L A I N   L A N G U A G E   S U M M A R Y

Skin care interventions for preventing eczema and food allergy

Does moisturising baby skin prevent eczema or food allergies?

Key messages

Skin care treatments in babies, such as using moisturisers on the skin during the first year of life, probably do not prevent babies from
developing eczema; may increase the chance of food allergy; and probably increase the chance of skin infection. This review looked at the
prevention of eczema and food allergy only. Skin care treatments are still important to treat eczema.

What are allergies?

An immune response is how the body recognises and defends itself against substances that appear harmful. An allergy is a reaction of the
body's immune system to a particular food or substance (an allergen) that is usually harmless. Different allergies affect different parts of
the body, and their effects can be mild or serious.

Food allergies and eczema

Eczema is a common skin condition  that causes dry, itchy, cracked skin. Eczema is common in children, often developing before their first
birthday, and may be long-lasting.

Allergies to food can cause itching in the mouth, a raised itchy red rash, swelling of the face, stomach symptoms, or difficulty breathing.
They usually happen within two hours after a food is eaten.

People with food allergies often have other allergic conditions, such as asthma, hay fever, and eczema.

Why we did this Cochrane Review

We wanted to learn how skin care affects the risk of a baby developing eczema or food allergies. Skin care treatments included:

• putting moisturisers on a baby's skin;

• bathing babies with water containing moisturisers or moisturising oils;

• advising parents to use less soap, or to bathe their child less often;

• using water softeners.

We also wanted to know if these skin care treatments cause any unwanted effects.

What did we do?

We searched for studies of different types of skin care for healthy babies (aged up to one year) with no previous food allergy, eczema, or
other skin condition.

Search date: we incorporated evidence published up to July 2021.

We were interested in studies that reported:

• how many children developed eczema, or food allergy, by age one to three years;

• how severe the eczema was (according to a researcher and to parents);

• how long it took for eczema to develop;

• parents' reports of immediate (under two hours) reactions to a food allergen;

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

3

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• how many children developed sensitivity to a particular food allergen;

• any unwanted effects.

We assessed the strengths and weaknesses of each study to determine how reliable the results might be, and then combined the results
of the relevant studies and looked at overall effects. 

What we found

We found 33 studies, involving 25,827 babies, that assessed any type of skin intervention. The included studies took place in Europe,
Australia, Japan, and the USA, most often at children's hospitals. Skin care was compared against no skin care or usual skin care for babies
in that country. Treatment and follow-up times ranged from 24 hours to three years. Many studies (13) tested the use of moisturisers; the
other studies mainly tested the use of bathing and cleansing products and how often they were used.

Of the 33 included studies, only 11 studies had comparable outcomes of eczema, food allergy, or adverse effects and were combined for
analysis. All of these studies enrolled babies before they were one month old, and  eight of these studies included babies thought to be
at high risk for developing eczema.

What are the main results of our review?

Compared to no skin care or standard care, moisturisers:

• probably do not change the chance of developing eczema by age one to three years (7 studies; 3075 babies), or the time needed for
eczema to develop (9 studies; 3349 babies);

• may increase the chance of developing a food allergy as judged by a researcher (1 study; 976 babies) by age one to three years;

• may slightly increase the number of immediate reactions to a common food allergen at two years, as reported by parents (1 study; 1171
babies);

• probably cause more skin infections (6 studies; 2728 babies);

• may increase unwanted effects, such as a stinging feeling or an allergic reaction to moisturisers (4 studies; 343 babies);

• may increase the chance of babies slipping (4 studies; 2538 babies);

• may not affect the chance of developing sensitivity to food allergens (3 studies; 1797 babies) by age one to three years.

Confidence in our results

We are moderately confident in our results for developing eczema and the time needed to develop eczema. We are less confident about our
results for food allergy or sensitivity, which are based on small numbers of studies with widely varying results. These results are likely to
change when more evidence becomes available. Our confidence in the review findings for skin infections is moderate, but low for stinging
or allergic reactions and slipping.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

4

 
 
C
o

l
l
a
b
o
r
a
t
i
o
n

.

C
o
p
y
r
i
g
h
t

©
2
0
2
2
T
h
e
A
u
t
h
o
r
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s
p
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

o
n
b
e
h
a
l
f
o
f
T
h
e
C
o
c
h
r
a
n
e

S
k
i
n
c
a
r
e
i

n
t
e
r
v
e
n
t
i
o
n
s
i

n

i

n
f
a
n
t
s
f
o
r
p
r
e
v
e
n
t
i
n
g
e
c
z
e
m
a
a
n
d
f
o
o
d
a
l
l
e
r
g
y
(
R
e
v
i
e
w

)

5

S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   Skin care intervention compared to standard skin care or no skin care intervention for the prevention of eczema and food
allergy

Patient or population: infants age 12 months or younger

Setting: prevention

Intervention: skin care intervention

Comparison: standard skin care or no skin care intervention

Correspond-
ing risk

Assumed risk

Outcome

Standard
care

Skin care in-
tervention

Relative ef-
fect (95% CI)

No. partici-
pants (stud-
ies)

Certainty of
the evidence
(GRADE)

Comments

Eczema diagnosis
by 1 to 3 years

150 per 1000

155 per 1000
(122 to 197)

RR 1.03 (0.81
to 1.31)

 3075 (7)

MODERATEa

IgE-mediated food
allergy (oral food
challenge) by 1 to 3
years

50 per 1000

127 per 1000
(50 to 335)

RR 2.53 (0.99
to 6.49)

976 (1) 

LOWb

In a sensitivity analysis that included studi-
es that measured eczema using Hanifin and
Rajka, or UK Working Party methods only,
total N = 2919 (6), the pooled treatment ef-
fect for eczema by 1 to 2 years was RR 1.02,
95% CI 0.78 to 1.34.  In a separate sensitivity
analysis including studies rated as low risk
of bias only, total N = 1739 (3), the pooled
treatment effect for eczema by 1 to 2 years
was RR 0.97, 95% CI 0.81 to 1.17. In sensi-
tivity analysis using a 3-year eczema out-
come instead of a 1-year eczema outcome
from 1 trial, the pooled treatment effect for
eczema by 1 to 3 years was RR 1.00, 95% CI
0.88 to 1.14.

In a sensitivity analysis that examined IgE-
mediated food allergy as measured by oral
food challenge or based on a panel assess-
ment of clinical history and/or allergic sen-
sitisation by 1 to 3 years, total N = 2081 (2),
the pooled treatment effect was RR 1.45,

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o

l
l
a
b
o
r
a
t
i
o
n

.

C
o
p
y
r
i
g
h
t

©
2
0
2
2
T
h
e
A
u
t
h
o
r
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s
p
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

o
n
b
e
h
a
l
f
o
f
T
h
e
C
o
c
h
r
a
n
e

S
k
i
n
c
a
r
e
i

n
t
e
r
v
e
n
t
i
o
n
s
i

n

i

n
f
a
n
t
s
f
o
r
p
r
e
v
e
n
t
i
n
g
e
c
z
e
m
a
a
n
d
f
o
o
d
a
l
l
e
r
g
y
(
R
e
v
i
e
w

)

6

95% CI 0.98 to 2.15. For parent report of a
doctor diagnosis of food allergy at 1 to 3
years, total N = 1614 (3), the pooled treat-
ment effect was RR 1.02, 95% CI 0.80 to
1.31. No low risk of bias sensitivity analysis
was possible.

20 per 1000

29 per 1000
(14 to 87)

RR 1.42 (0.67
to 2.99)

 2538 (4)

LOWc

50 per 1000

67 per 1000
(51 to 88)

RR 1.33 (1.01
to 1.75)

 2728 (6)

MODERATEd

40 per 1000

90 per 1000
(27 to 298) 

RR 2.24 (0.67
to 7.43)

 343 (4)

LOWc

Slippages (over the
intervention peri-
od)

Skin infection (over
the intervention
period)

Stinging/allergic
reactions to mois-
turisers (over the
intervention peri-
od)

Time to onset of
eczema

24 months

27.9 months
(21.1 to 36.9
months) 

HR 0.86 (0.65
to 1.14)

3349 (9)

MODERATEe

Parent report of
immediate reac-
tion to common
food allergen (at 2
years)

Allergic sensitisa-
tion to a food aller-
gen (at 1 to 3 years)

160 per 1000

204 per 1000
(160 to 258)

RR 1.27 (1.00
to 1.61)

 1171 (1)

LOWf

90 per 1000

95 per 1000
(58 to 154)

RR
1.05 (0.64 to
1.71)

1794 (3) 

LOWg

CI, confidence interval; HR, hazard ratio; IgE, immunoglobulin E; RR risk ratio
aDowngraded one level for heterogeneity driven by one trial (PreventADALL) contributing 21.8% of the weight of the analysis; a clear explanation for this heterogeneity could not
be identified. PreventADALL used a bathing intervention, whereas the other trials used direct emollient application to the skin; PreventADALL also initiated treatment later than
the other trials. There was no significant heterogeneity in a sensitivity analysis using the 3-year outcome instead of the 1-year outcome from the PreventADALL study (Analysis 1.5).
bDowngraded one level for overall risk of bias due to missing outcome data (29%) and one level for imprecision due to small numbers of events from a single study, with wide
confidence intervals including both a harmful effect and no effect. There was increased information for the sensitivity analysis of food allergy diagnosed by oral food challenge
or investigator assessment, where overall risk of bias was assessed as 'some concerns' and confidence intervals were narrower.
cDowngraded by two levels for imprecision due to small numbers of events, with wide confidence intervals including both a harmful effect and a beneficial effect.
dDowngraded by one level for imprecision due to wide confidence intervals including both a harmful effect and no effect.
eDowngraded one level for heterogeneity driven by more than one trial, for which a plausible explanation could not be identified.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
fDowngraded two levels for imprecision due to small numbers of events from a single study, with wide confidence intervals including both a harmful effect and no effect.
gDowngraded one level for heterogeneity, for which a plausible explanation could not be identified, and one level for imprecision due to wide confidence intervals including both
a harmful and a beneficial effect.

C
o

l
l
a
b
o
r
a
t
i
o
n

.

C
o
p
y
r
i
g
h
t

©
2
0
2
2
T
h
e
A
u
t
h
o
r
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s
p
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

o
n
b
e
h
a
l
f
o
f
T
h
e
C
o
c
h
r
a
n
e

S
k
i
n
c
a
r
e
i

n
t
e
r
v
e
n
t
i
o
n
s
i

n

i

n
f
a
n
t
s
f
o
r
p
r
e
v
e
n
t
i
n
g
e
c
z
e
m
a
a
n
d
f
o
o
d
a
l
l
e
r
g
y
(
R
e
v
i
e
w

)

7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

See Table 1 for explanations of specific terms used in this review.

Description of the condition

Allergic diseases such as eczema and food allergy are some of the
most common long-term health conditions in children and young
people  (Bai  2017;  Van  Cleave  2010).  There  is  no  definitive  cure
for allergic disease, although treatments can be used to alleviate
symptoms.  The  burden  of  allergic  disease  on  the  individual,  the
family,  and  society  is  significant  (Gupta  2004;  Pawankar  2014).
The  prevalence  of  allergic  disease  appears  to  have  increased;
traditionally, higher prevalence was seen in high-income countries,
but prevalence of allergic disease is now increasing in urban cities
of low- and middle-income countries (Deckers 2012; Prescott 2013).

Eczema  is  a  chronic  inflammatory  skin  disorder,  diagnosed
clinically  based  on  a  collection  of  symptoms,  primarily  including
itch.  Its  aetiology  is  complex  and  involves  interaction  between
genes,  environment,  the  immune  system,  and  impairment  of
the  skin  barrier  (Leung  2004).  Eczema  with  immunoglobulin
(Ig)E  sensitisation,  either  by  IgE  antibody  or  by  skin  prick
test,  is  classified  as  atopic  eczema  (Johansson  2003).  This
review  is  focused  on  prevention  of  eczema  and  food  allergy  in
infants  and  children  and  does  not  address  adult-onset  eczema,
which  has  different  associations  from  childhood  atopic  eczema
(Abuabara 2019). Likewise, this review did not address adult-onset
food allergy, which accounts for a small proportion of food allergy
amongst adults, where there is a loss of tolerance to a food that was
previously tolerated (Ramesh 2017).

Atopic  eczema  (atopic  dermatitis)  is  most  often  associated  with
other  atopic  diseases  and  typically  presents  in  younger  children,
and may be the first step along the so-called 'allergic march' (Leung
2004).  Eczema  often  occurs  in  families  with  atopic  diseases  such
as  asthma,  allergic  rhinitis/hay  fever,  and  food  allergy.  These
diseases share a common pathogenesis and are frequently present
in  the  same  individual  and  family.  The  word  'atopy'  refers  to  the
tendency to produce IgE antibodies in response to small quantities
of  common  environmental  proteins  such  as  pollen,  house  dust
mites,  and  food  allergens  (Stone  2002;  Thomsen  2015).  Around
30%  of  people  with  eczema  develop  asthma,  and  35%  develop
allergic  rhinitis  (van  der  Hulst  2007  ).  However,  it  is  understood
that  atopy  does  not  concurrently  occur  in  all  people  with  atopic
eczema. In view of this, it has been proposed that the term 'eczema'
should be used to define people both with and without atopy. In
agreement  with  the  'Revised  nomenclature  for  allergy  for  global
use'  (Johansson  2003),  and  similar  to  other  Cochrane  Reviews
evaluating eczema therapies (Van Zuuren 2017), we use the term
'eczema' throughout the review.

The  main  mechanism  of  this  disease  is  the  combination  of  an
epidermal  barrier  function  defect  and  cutaneous  inflammation.
Barrier  dysfunction  can  be  attributed  in  part  to  a  genetic
susceptibility,  such  as  a  mutation  in  the  filaggrin  gene  (FLG).
Cutaneous  inflammation  is  demonstrated  by  inflammatory  cell
infiltration  of  the  dermis,  predominantly  by  Th2  cells  (Weidinger
2016).

Eczema is diagnosed clinically by its appearance and predilection
for  certain  skin  sites,  which  is  age-dependent  (Spergel  2003).  In
a  research  setting,  the  most  commonly  used  diagnostic  criteria

Cochrane Database of Systematic Reviews

are the UK Working Party Diagnostic Criteria for Atopic Dermatitis
(Williams  1994).  Prevalence  of  eczema  is  reported  at  up  to  20%
in  children,  and  may  be  increasing  (Flohr  2014).  Eczema  has  a
significant  impact  on  the  patient  and  the  family.  In  childhood,
eczema is often associated with sleep disturbance and behavioural
difficulties. Eczema also significantly impacts the quality of life of
parents  of  affected  children.  Partaking  in  their  child's  treatment
can  take  up  to  two  hours  per  day,  and  their  own  sleep  is  often
disturbed along with their child's, thereby exacerbating the distress
experienced  (Carroll  2005).  The  impact  of  moderate  to  severe
eczema on family dynamics is comparable to that of other chronic
health conditions such as type 1 diabetes (Su 1997). The financial
cost of childhood eczema incorporates both the direct cost of the
child's  care  and  the  indirect  costs  of  parental  time  off  work  and
decreased  productivity  due  to  decreased  sleep  and  increased
stress. The total cost of eczema care in the USA has been estimated
at over USD 5 billion per annum (Drucker 2017).

Eczema  often  improves  during  childhood,  with  more  than  50%
of  childhood  eczema  resolving  by  adolescence  (Williams  1998).
Recent  studies  suggest  that  some  aspects  of  skin  barrier  and
immune dysfunction may persist into adulthood (Abuabara 2018).
Adult  eczema  is  estimated  at  approximately  5%  in  the  USA  and
2% in Japan (Barbarot 2018). Adults with eczema have significantly
decreased  social  functioning  and  greater  psychological  distress
than  both  the  general  population  and  adults  with  some  other
long-term conditions (Carroll 2005). In a recent systematic review,
a  positive  association  was  seen  between  eczema  and  suicidal
ideation  in  adults  and  adolescents.  It  was  proposed  that  chronic
itch, sleep disturbance, and the social stigma of a visible disease
contribute to mental health effects (Ronnstad 2018).

As  seen 
in  most  disease  prevalence  studies,  the  reported
prevalence  of  eczema  may  vary  depending  on  the  location  of
the  trial  and  variation  in  measurements  used  for  classification
and diagnosis. Using consistent measurements, the International
Study  of  Asthma  and  Allergies  in  Childhood  (ISAAC)  has  shown
an  increase  in  the  reporting  of  eczema  across  different  settings
and  in  different  populations  apart  from  those  with  already  high
prevalence  (Asher  2006).  Admittedly,  the  youngest  children  in
this  cohort  were  six  to  seven  years  old  -  not  preschool  age,  at
which eczema prevalence can be higher. This variation in reported
prevalence between different regions and over time suggests that
environmental  influences  may  contribute  significantly  to  disease
prevalence.  Eczema  has  been  associated  with  smaller  families,
higher social class, and urban living. Children of immigrants moving
from  a  country  with  low  eczema  prevalence  to  a  country  with
higher  eczema  prevalence  have  a  relatively  higher  prevalence  of
eczema,  providing  support  for  a  role  of  environmental  factors
acting  during  early  life  (Martin  2013).  Family  history  of  eczema,
that  is  genetics,  is  the  strongest  determinant  of  eczema,  and
it cannot be modified (Apfelbacher 2011). However, interaction of
genes with environmental factors may be influenced by skin barrier
interventions.

Food allergy has been defined as an adverse health effect arising
from  a  specific  immune  response  that  occurs  reproducibly  on
exposure  to  a  given  food  (Boyce  2010).  Food  allergy  can  further
be  classified  into  IgE-mediated,  non-IgE-mediated,  and  mixed
types.  IgE-mediated  food  allergy  typically  occurs  within  two
hours  of  exposure  to  the  offending  food,  and  symptoms  are
well  characterised,  ranging  from  minor  oral  or  gastrointestinal

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

8

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

symptoms,  urticaria,  or  angioedema,  to  more  severe  symptoms
such as anaphylaxis, which can occasionally result in death (Boyce
2010). IgE-mediated reactions involve degranulation of mast cells,
and  the  condition  is  diagnosed  by  a  clinical  history  supported
by  skin  prick  or  serum-specific  IgE  testing.  A  positive  test  alone
indicates  sensitisation  to  the  food  but  does  not  always  predict
clinical reactivity. The titre of IgE or the size of the skin prick test
wheal is a predictor of clinical reactivity, although not an indication
of  the  severity  of  a  reaction.  Oral  food  challenges  -  either  open
or  blinded,  placebo-controlled  challenges  -  are  used  to  confirm
the  diagnosis  in  cases  where  clinical  history  and  test  results
are  inconclusive  (Sicherer  2018  ).  Non-IgE-mediated  food  allergy
and  mixed  food  allergies  have  a  slower  onset  and  less  specific
symptoms. Diagnosis is more difficult and relies on clinical history
supported  by  exclusion  or  reintroduction  of  suspected  foods,  or
both  (Johansson  2003).  It  is  unclear  whether  non-IgE-mediated
allergies have the same association with skin barrier function and
eczema,  therefore  we  did  not  consider  non-IgE-mediated  food
allergies in this review.

Exact  prevalence  rates  for  food  allergy  are  difficult  to  ascertain
and are largely dependent on the method used to diagnose food
allergy  and  the  population  studied.  Self-reported  food  allergy
rates are generally higher than those confirmed by specific allergy
testing  (Woods  2002).  Previous  population-based  studies  have
suggested that IgE-mediated food allergy affects around 3% to 10%
of children (Kelleher 2016; Osborne 2011; Venter 2008). For some
people, food allergy can resolve spontaneously during childhood,
particularly for foods such as milk and egg. However, a recent US
survey study identified a history suggestive of IgE-mediated food
allergy  in  over  10%  of  adults,  demonstrating  that  it  is  not  just
a  disease  of  childhood  (Gupta  2019).  Like  eczema,  food  allergy
is  thought  to  have  increased  in  prevalence  in  recent  decades,
although epidemiological data from the 1990s onwards in England
and Australia suggest that food allergy prevalence in young children
may be stable (Peters 2018 ; Prescott 2013; Sicherer 2003; Venter
2008).  Food  allergy  also  varies  in  prevalence  across  different
regions, with lower prevalence in areas with lower overall rates of
allergic  disease,  such  as  rural  settings  in  Asia  and  Africa  (Botha
2019; Prescott 2013).

Food allergy is a considerable burden on the individual, family, and
wider  society.  Acute  reactions  can  cause  significant  anxiety  and
when  severe  may  rarely  result  in  a  fatal  outcome  within  minutes
of  food  ingestion  (Umasunthar  2013).  The  continuous  vigilance
required  to  avoid  potential  triggers  has  an  adverse  impact  on
quality  of  life  of  allergic  children  and  adults  and  their  families
(Cummings 2010). People with food allergy and their carers report
a  negative  impact  of  dietary  restrictions,  limitations  to  social
activities,  and  an  emotional  and  financial  burden  of  living  with
food  allergy.  For  example,  in  the  USA,  the  financial  cost  of  food
allergy  for  affected  families  and  healthcare  providers  has  been
estimated  as  at  least  USD  25  billion  per  annum  (Gupta  2013).  In
recent  decades,  numbers  of  hospital  admissions  for  food-related
anaphylaxis  have  increased.  It  is  unclear,  however,  whether  this
represents a true increase in incidence or a greater recognition of
the  potential  for  acute  food  allergy  as  a  cause  of  symptoms,  as
there  reassuringly  has  not  been  a  concomitant  increase  in  fatal
anaphylaxis (Jerschow 2014; Poulos 2007; Turner 2015).

Eczema  and  food  allergy  are  closely  associated.  Both  conditions
typically begin during the first year of life. Genetic variations that

Cochrane Database of Systematic Reviews

damage  skin  barrier  function  are  associated  with  both  eczema
and food allergy (Palmer 2006; Van den Oord 2009). In particular,
FLG  is  the  most  widely  studied  of  the  genes  associated  with
atopy. FLG codes for filaggrin, a filament aggregating protein that
contributes  to  the  structure  and  function  of  the  outer  epidermis.
Those  with  one  or  more  FLG  loss-of-function  mutations  have
significantly  increased  prevalence  of  eczema  and  food  allergy
(Irvine  2011).  An  intergenic  locus  on  chromosome  11q13.5  has
non-coding  variants  associated  with  multiple  atopic  disorders
including  eczema  (Esparza-Gordillo  2009),  allergic  sensitisation
(Bønnelykke  2013),  and  food  allergy  (Asai  2018).  Animal  studies
demonstrate  that  exposure  to  food  allergen  across  a  damaged
skin  barrier  predisposes  to  food  sensitisation  (Strid  2004;  Strid
2005).  Human  observational  studies  support  an  onset,  timing,
and  severity-dependent  relationship  between  childhood  eczema
and  risk  of  food  allergy.  In  Martin  2015,  over  50%  of  infants  who
needed  prescription  topical  steroids  before  three  months  of  age
for  treatment  of  eczema  were  IgE-sensitised  to  one  or  more
of  egg  white,  peanut,  or  sesame.  This  study  was  included  in  a
systematic review, which demonstrated a strong dose-dependent
relationship between eczema, food sensitisation, and food allergy,
and  suggested  that  eczema  may  be  an  important  cause  of  food
allergy (Tsakok 2016).

With  regard  to  the  primary  prevention  of  eczema,  some  studies
have  suggested  that  maternal  supplementation  with  a  probiotic
supplement during pregnancy and breastfeeding may reduce the
risk  of  eczema  (Garcia-Larsen  2018).  However,  the  mechanism  of
action of such an intervention is unclear; findings are inconsistent
between trials; and few relevant studies have published protocols
that confirm the absence of selective reporting.

With regard to the primary prevention of food allergy, it has been
shown that the early introduction of allergenic foods such as egg
and peanut can decrease the risk of allergy to those foods (Du Toit
2015;  Ierodiakonou  2016;  Natsume  2017;  Perkin  2016).  However,
it  is  unclear  whether  this  approach  will  reduce  the  prevalence  of
food allergy at a population level because applying the intervention
to multiple foods is likely to be too onerous for parents (Voorheis
2019), and some children already have allergy to the food before
the age when complementary foods are usually introduced (Du Toit
2015). 

New  approaches  are  therefore  required  for  the  prevention  of
eczema and food allergy; simple interventions designed to promote
skin barrier function represent one potential approach.

Description of the intervention

In this review we included all interventions designed to improve the
skin barrier in infants, either by enhancement or by promotion of
the barrier through hydration via directly applied topical products,
such  as  emollients  or  moisturisers,  or  through  the  reduction  of
potential  damage  to  the  skin  barrier  and  consequent  dryness
through various means such as avoiding soaps or reducing water
hardness. We expected that promotion of the skin barrier and skin
hydration  through  topical  emollients  would  be  the  most  widely
used intervention. Emollients are described as mainly lipid-based
products that smooth the skin, whereas moisturisers give water and
moisture to the skin (Penzer 2012). However, sometimes 'emollient'
is referred to as an ingredient of 'moisturisers' (Lodén 2012). There
is not yet a clear nomenclature for topical preparations for the skin.
The terms 'moisturiser' and 'emollient' are used interchangeably in

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

9

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

different  settings  to  describe  directly  applied  topical  products.
Several  different  'classes'  or  'formulations'  of  emollients  and
moisturisers are available, including oil-in-water creams, water-in-
oil  creams,  ointments,  lotions,  oils,  gels,  sprays,  and  emulsions
(Van  Zuuren  2017).  However,  these  may  not  accurately  reflect
the  format,  ingredient,  and  effects  of  the  product.  Further
complicating  this  is  the  fact  that  many  skin  care  products
are  classed  as  cosmetics  and  are  therefore  not  subjected
to  the  same  regulations  as  medicines.  A  recently  proposed
classification  includes  considering  the  vehicle,  formulation,  and
active ingredients (Surber 2017).

Emollients  themselves  may  be  categorised  by  their  mode  of  use,
as  leave-on  emollients  that  are  directly  applied  to  the  skin  and
allowed to dry in; as soap substitutes whereby an emollient may
be used instead of a soap to clean; and as bath oils or emollients
by which a product is added to the bath water (Van Zuuren 2017).
We  expected  most  intervention  trials  to  use  leave-on  emollients,
although the characteristics of emollients may vary.

As  part  of  treatment  for  established  eczema,  emollients  are
recommended  to  be  applied  two  to  three  times  a  day,  at  up
to  150  g  to  200  g  per  week  in  young  children  and  up  to  500
g  in  adults  (Eichenfield  2014;  Ring  2012).  Overall,  emollients
are  regarded  as  safe,  with  few  adverse  effects.  However,  daily
application  of  sufficient  emollient  can  be  time-consuming  and
unpleasant, potentially having a negative impact on the child and
the  family  (Carroll  2005).  Certain  emollients  can  cause  stinging,
especially to skin with established eczema (Oakley 2016). There is
concern  that  emollients  can  actively  sensitise  to  their  individual
components,  leading  to  cutaneous  reactions  (Danby  2011),  and
even  systemic  allergic  reactions  (Voskamp  2014).  Slippage  of
infants  covered  in  emollient  from  the  hands  of  carers  is  a  stated
potential  adverse  reaction  in  emollient  prevention  studies  such
as  the  Barrier  Enhancement  for  Eczema  Prevention  (BEEP)  study
(Chalmers 2017).

Protection  of  the  skin  barrier  could  also  be  achieved  by
limiting  water  loss  across  the  skin,  or  by  limiting  skin  contact
with  potentially  harmful  substances  or  irritants.  Activities  and
substances that may harm the skin barrier, at least in people with
established eczema, include excessive bathing, wash products, and
hard  water  (Cork  2002).  Ameliorating  any  of  these  factors  in  the
first months of life may thus potentially improve hydration and skin
barrier function, thereby reducing subsequent eczema prevalence.

Neonatal  skin  is  different  from  the  skin  of  children  and  adults,
as  it  takes  time  to  adjust  to  the  dry  extrauterine  environment
during  the  postnatal  period  (Cooke  2018).  Postnatal  maturation
of  skin  structure  and  physiology  can  take  up  to  a  year,  with
regional differences in maturation, with cheek skin maturing more
slowly  than  skin  at  other  sites  (McAleer  2018).  However,  very
early  neonatal  skin  has  decreased  water  permeability  compared
to  the  skin  of  older  children  and  adults,  along  with  decreased
surface  pH  and  stratum  corneum  formation,  demonstrating  an
effective  skin  barrier  in  the  first  two  days  of  life,  which  changes
rapidly  (Yosipovitch  2000).  It  was  previously  thought  that  infant
skin  beyond  the  first  few  weeks  following  birth  was  structurally
and  functionally  equivalent  to  the  skin  of  adults;  however,  skin
undergoes  a  maturation  process  that  can  last  for  several  years
after birth (Chiou 2004; Stamatas 2011; Visscher 2017). This process
involves  higher  keratinocyte  proliferation  and  desquamation
rates  with  impaired  keratinocyte  differentiation  compared  to

Cochrane Database of Systematic Reviews

adults  (Liu  2018;  Stamatas  2010).  The  increased  keratinocyte  cell
turnover  results  in  smaller  corneocytes  and  a  thinner  stratum
corneum (Stamatas 2010). These changes in  the stratum corneum
create  a  shorter  path  for  penetration  of  irritants  and  allergens
through the skin of normal babies. The increased permeability of a
baby's stratum corneum compared to that of an adult is reflected
in higher transepidermal water loss (TEWL) rates (Nikolovski 2008).
This  higher  stratum  corneum  permeability  is  likely  to  be  an
important factor in the development of eczema early in life. Infants,
with  their  thinner  skin  and  an  increased  body  surface  area-to-
volume  ratio  compared  with  adults,  may  be  more  susceptible
to  percutaneous  uptake  of  any  potentially  harmful  substances
(Mancini 2008).

and 

care 

infant 

for  neonatal 

skin  differs
Standard 
internationally and is affected by cultural factors. The World Health
Organization (WHO) recommends not bathing newborn infants in
the first 24 hours after birth, but does not recommend any specific
method  of  infant  skin  care  beyond  this  time  (WHO  2015).  In  the
UK,  standard  skin  care  advice  given  to  parents  of  newborns  is  to
wash  in  plain  water  for  the  first  month,  and  to  use  a  mild  non-
perfumed  soap  if  one  is  required.  What  constitutes  a  'mild  soap'
is not described, and there is no set recommendation for bathing
frequency or use of moisturisers (NICE 2006). Few emollient studies
have  included  term  infants;  most  have  incorporated  premature
infants, whose skin is different from the skin of term infants (Irvin
2015).  Application  of  an  emollient  or  oil  to  the  skin  of  newborn
infants  is  practised  in  some  regions  and  cultures  for  a  variety  of
reasons often unrelated to allergy prevention (Amare 2015).

Timing  of  the  first  bath  in  neonates  may  be  important.  In  some
areas  of  the  world,  infants  are  washed  immediately  after  birth,
but  the  WHO  recommends  leaving  the  vernix  caseosa  intact  and
allowing  it  to  wear  off  with  normal  handling  (WHO  2015).  When
modes of washing were compared, a comparison of infant bathing
with  water  versus  washing  with  a  cotton  wash  cloth  did  not
demonstrate  a  significant  difference  in  skin  barrier  properties
after four weeks, but did show regional differences in skin barrier
properties and demonstrated dynamic adaption of the skin barrier
over  the  first  four  weeks  of  life  (Garcia  Bartels  2009).  Amongst
neonates  bathed  twice  weekly,  those  washed  in  age-appropriate
liquid  cleanser  with  added  cream  had  lower  TEWL  than  those
washed with water only, whereas stratum corneum hydration was
similar.  Whether  this  shows  improvement  in  the  skin  barrier  is
unclear  (Garcia  Bartels  2010).  Although  specific  wash  products
or  moisturiser  ingredients  such  as  sodium  laureth  sulfate  are
thought  to  be  harmful,  plain  water  or  wash  products  without
known  skin  irritants  are  thought  to  be  safe,  other  than  the
risk  of  slippages  with  oil-based  products  (Blume-Peytavi  2016).
Some  groups  recommend  pharmaceutical-grade  oils  or  specially
formulated baby skin products over locally produced oils that are
traditionally used in many parts of the world (Blume-Peytavi 2016).
However, such recommendations sometimes come from industry-
funded  groups,  and  there  is  little  direct  evidence  to  suggest  that
traditional local oils are inferior to commercial products. Frequency
and timing of infant bathing may vary by culture and region, and
although  excessively  frequent  infant  bathing  is  thought  to  harm
skin  barrier  function  and  physiology,  the  optimal  frequency  of
infant washing or bathing is not known.

Hard water is relatively rich in calcium and magnesium, and water
hardness  varies  depending  on  geographical  location.  Water  of

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

a  certain  hardness  will  cause  limescale  and  may  corrode  pipes
(Ewence  2011).  Hard  water  is  associated  with  increased  eczema
prevalence (Engebretsen 2017). It is thought that the skin barrier
disruption  associated  with  hard  water  is  due  to  the  interaction
between surfactants in wash products and hard water itself (Danby
2018).

This review covers all potential skin care interventions designed to
promote, or reduce damage to, the skin barrier and to enhance skin
hydration for the primary prevention of eczema and food allergy.

How the intervention might work

Emollients, as one intervention, are the mainstay of treatment for
those with already established eczema, as detailed in a Cochrane
Review  (Van  Zuuren  2017),  because  dry  skin  (xerosis)  is  a  key
feature  of  eczema,  and  topical  moisturisers  have  an  integral  role
in the standard treatment of eczema of all severities (Eichenfield
2014).  Emollients  can  decrease  TEWL,  increase  stratum  corneum
hydration,  improve  comfort,  and  reduce  itch  when  used  on  skin
that already has active eczema (Lodén 2012; Rawlings 2004), and
are therefore a key component in the treatment of eczema (Ring
2012). They may be more effective than interventions such as less
frequent bathing or use of water softeners for eczema prevention.

All  moisturisers  contain  varying  amounts  of  active  ingredients
such  as  humectant  or  ceramide,  as  well  as  excipient  ingredients
such  as  emulsifiers  (Lodén  2012).  Humectants,  such  as  glycerol
or  urea,  aid  retention  and  attraction  of  water  by  the  stratum
corneum.  Ceramides  are  intracellular  lipids  found  in  the  stratum
corneum that are reduced in lesional eczematous skin (Meckfessel
2014).  Occlusives  such  as  petrolatum  form  a  layer  on  the  skin
surface  that  may  prevent  TEWL  across  the  stratum  corneum  and
can soften the skin (Eichenfield 2014; Rawlings 2004). Moisturisers
can  be  hydrophilic  or  lipophilic.  Hydrophilic  moisturisers  attract
water  and  are  important  for  skin  hydration,  whereas  lipophilic
moisturisers  tend  to  stay  on  the  surface  to  aid  the  skin  barrier
(Caussin 2009).

Van Zuuren 2017 showed that regular use of emollients for those
with  eczema  can  prolong  time  to  eczema  flare  and  reduce  the
number  of  flares  and  need  for  topical  corticosteroids.  In  infants,
skin barrier dysfunction is seen before the development of clinical
eczema  (Danby  2011;  Flohr  2010).  Applying  moisturisers  before
eczema  is  noted  may  therefore  offer  a  route  for  the  primary
prevention of eczema. Three published pilot studies suggest that
applying  moisturisers  to  infant  skin  might  reduce  the  prevalence
of  eczema  during  the  application  period  (Horimukai  2014;  Lowe
2018a; Simpson 2014). These pilot studies were small-scale studies
testing the feasibility of the intervention or looking for signals of a
preventative effect, or both. They were insufficiently powered for
confirming a preventative effect. It is not known whether applying
moisturisers  could  lead  to  a  programming  effect  on  the  skin,
causing  longer-term  effects  on  skin  physiology,  immunology,  or
clinical manifestations of eczema.

The  strong  association  between  eczema  and  food  allergy  would
suggest  that  reduced  clinical  manifestations  of  eczema  could
potentially  reduce  the  risk  of  food  allergy,  even  if  it  were  just  to
delay the onset of eczema from early infancy, where the association
with  development  of  food  allergy  is  strongest  (Martin  2015).  In
a  small  pilot  study  of  a  ceramide-dominant  emollient  with  an
action described as a lipid replacement, evidence suggests reduced

Cochrane Database of Systematic Reviews

allergic  sensitisation  to  foods  in  the  per-protocol  analysis  of  the
intervention group (Lowe 2018a).

Mechanistic studies within the clinical trials suggest that emollients
can  increase  stratum  corneum  hydration  when  used  in  healthy
infants;  however,  trials  have  not  consistently  identified  changes
in  skin  pH  or  TEWL  (Yonezawa  2018).  It  is  unclear  whether  this
increase  in  stratum  corneum  hydration  will  lead  to  reduced  skin
inflammation and associated allergic sensitisation.

Why it is important to do this review

The first version of this Cochrane Review (Kelleher 2021), published
in February 2021, found that skin barrier interventions probably do
not prevent eczema. For the co-primary outcome of food allergy,
only one study was included with food allergy outcome (Chalmers
2020). The review found weak evidence that skin care interventions
may  slightly  increase  food  allergy  rates,  but  without  significant
evidence to support or refute this from other included trials. The
largest  included  trial  was  affected  by  the  COVID-19  pandemic
(Skjerven 2020), resulting in delays to data sharing and publication
for  the  food  allergy  outcomes.  It  is  important  to  clarify  whether
or not skin care interventions may cause harm by increasing food
allergy, so that appropriate advice can be given to carers of young
infants. Observational data published since the first version of this
Cochrane Review have reported an association between frequency
of  emollient  application  during  early  infancy  and  risk  of  food
allergy (Perkin 2021). The potential mechanism for this association
is  the  facilitation  of  transcutaneous  passage  of  environmental
food  allergens,  leading  to  food  sensitisation  and  food  allergy.
The purpose of this update was to include food allergy and food
sensitisation data from Skjerven 2020 in order to provide increased
information about the relationship between skin care interventions
during infancy and the risk of developing IgE-mediated food allergy.
In  this  update,  we  also  incorporated  subgroup  analyses  using
new information from trials that had undertaken FLG genotyping
or  genotyping  of  the  non-coding  variants  in  the  intergenic  locus
on  chromosome  11q13.5  subsequent  to  the  first  version  of  this
Cochrane Review (Kelleher 2021).

O B J E C T I V E S

Primary objective

To assess the effects of skin care interventions such as emollients
for the primary prevention of eczema and food allergy in infants.

Secondary objective

To  identify  features  of  study  populations  such  as  age,  hereditary
risk, and adherence to interventions that are associated with the
greatest  treatment  benefit  or  harm  for  both  eczema  and  food
allergy.

M E T H O D S

Criteria for considering studies for this review

Types of studies

Parallel-group  or  factorial  randomised  controlled  trials  (RCTs),
including  both 
individual  and  cluster-randomised  trials.  We
excluded quasi-RCTs and controlled clinical trials. We also excluded
cross-over  trials,  as  the  design  is  inappropriate  to  the  clinical
context.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Types of participants

Infants (age 12 months or younger). As this is a primary prevention
review,  we  did  not  include  studies  on  infants  who  already  had
diagnosed eczema or food allergy at the time of randomisation. We
excluded study populations defined by a pre-existing health state in
the infant, such as preterm birth (less than 37 weeks' gestation) or
congenital skin conditions, because findings in these populations
may not be generalisable.

We  attempted  to  obtain  individual  participant  data  (IPD)  for  all
included studies. If IPD were not available, we obtained aggregate
data instead. For studies with only aggregate data, we excluded the
whole study if some participants were not eligible, unless ineligible
participants made up an insignificant proportion of the total group,
that  is  less  than  5%.  In  trials  with  IPD,  we  planned  to  include
only data on participants who met our eligibility criteria; however,
no exclusions were necessary, as all obtained IPD were eligible.

Types of interventions

All  skin  care 
interventions  that  could  potentially  enhance
skin  barrier  function,  reduce  dryness,  or  reduce  subclinical
inflammation. These include:

1. moisturisers/emollients;
2. bathing products (these may include oils or emollients);
3. advice  regarding  reducing  soap  exposure  and  bathing

frequency; and

4. use of water softeners.

Interventions  could  be  simple  single  interventions,  or  complex
interventions  that  utilised  a  combination  of  measures  to
protect  or  promote  skin  barrier  function  and  hydration  or  to
reduce subclinical inflammation. Comparators were no treatment
intervention  or  advice,  or  standard  care,  in  the  study  setting.
We  excluded  multifaceted  interventions,  whereby  the  skin  care
component  was  only  a  small  part  of  the  study,  if  the  skin  care
component was likely trivial or irrelevant to the outcome. We also
planned  to  separately  assess  those  interventions  that  primarily
aimed  to  enhance  the  skin  barrier  through  direct  application  of
emollient or moisturiser (skin care intervention A) and those that
aimed to protect the skin barrier from irritation, that is through the
use of water softeners (skin care intervention B). However, we did
not find any eligible studies for skin care intervention B.

Types of outcome measures

No  minimum  follow-up  was  required.  However,  we  separately
analysed  outcomes  that  related  to  symptoms  during  the
intervention period and outcomes that occurred and were reported
after the intervention period, when appropriate and feasible.

Primary outcomes

1. Eczema. When multiple measures were reported, the hierarchy
of  diagnosis  was  investigator  assessment  as  described  by  the
Hanifin and Rajka criteria in their original form (Hanifin 1980),
or by the UK Working Party refinement of them (Williams 1994),
other  modifications  of  the  Hanifin  and  Rajka  criteria,  doctor
diagnosis of eczema, then patient or parent report of eczema.
2. Food  allergy.  When  multiple  measures  of  food  allergy  were
reported,  the  hierarchy  of  diagnosis  was  confirmed  IgE-
mediated  food  allergy  diagnosed  via  oral  food  challenge,

Cochrane Database of Systematic Reviews

with  eligibility  for  oral  food  challenge  decided  as  per  study
protocol, although ideally based on current recommendations
(Grabenhenrich 2017). If oral food challenge was not available,
then food allergy was as diagnosed by investigator assessment
using  a  combination  of  clinical  history  and  allergy  testing:
skin  prick  testing  and  serum-specific  IgE.  We  defined  IgE
sensitisation as skin test to a food of 3 mm or more, or specific
IgE of 0.35 kUa/L or higher. The primary foods of interest were
milk, egg, and peanut; however, we collected data on any foods
that were available from each study.

The time point for all food allergy and eczema outcome analyses
was by age one to three years, using the closest available time point
to  two  years,  from  each  included  trial.  Adverse  event  outcomes
were measured during the intervention period only. When pooling
data from different trials, we considered the relationship between
timing of the intervention and timing of the outcome measure, for
example we separately pooled measures of eczema taken during
the  intervention  period  and  measures  of  eczema  taken  after  the
intervention period had ceased.

As  we  identified  multiple  measures  of  eczema  across  trials,
we  conducted  sensitivity  analysis  to  look  separately  at  eczema
measured  using  the  Hanifin  and  Rajka  criteria  in  their  original
form  (Hanifin  1980),  or  the  UK  Working  Party  refinement  of
them (Williams 1994), and other modifications of the Hanifin and
Rajka criteria only. We planned to look separately at food allergy
measured  using  secure  diagnosis  of  food  allergy  by  oral  food
challenge in a sensitivity analysis, if necessary.

Secondary outcomes

1. Adverse events, including skin infection during the intervention
period; stinging or allergic reactions to moisturisers; or slippage
accidents around the time of bathing or application of emollient.
We planned to report all serious adverse events.

2. Eczema  severity:  clinician-assessed  using  EASI  (Eczema  Area
and  Severity  Index)  or  a  similarly  validated  method  (Hanifin
2001).

3. Parent-reported  eczema  severity  using  POEM 

(Patient-
Orientated  Eczema  Measure)  or  a  similarly  validated  patient-
reported measure (Charman 2004).

4. Time to onset of eczema.
5. Parent report of immediate (less than two hours) reaction to a
known food allergen: milk, soya, wheat, fish, seafood, peanut,
tree nut, egg, or local common food allergen.

6. Allergic sensitisation to foods and inhalants via skin prick test

(or, if not available, via serum-specific IgE).

Initiative 

We  analysed  any  relevant  core  outcomes  identified  as  part
of  the  Cochrane  Skin  Core  Outcomes  Set 
(CS-
COUSIN) and Harmonising Outcome Measures for Eczema (HOME)
initiatives  when  this  information  was  available  from  each  trial
(www.homeforeczema.org).  Relevant  HOME  domains 
include
clinician signs measured using the Eczema Area and Severity Index
(EASI)  instrument,  patient-reported  symptoms  using  the  POEM
instrument,  long-term  disease  control,  and  quality  of  life.  These
outcomes were designed for trials involving those with established
eczema.  There  is  not  yet  a  set  of  core  outcomes  for  defining
eczema or food allergy in prevention studies; however, for eczema,
a  modified  version  of  the  UK  Hanifin  and  Rajka  criteria  has  been
proposed to differentiate between an incident diagnosis of eczema

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

and transient eczematous rashes of infancy (Simpson 2012). When
feasible, we contacted trial authors early in the design or set-up of
their trial to encourage sharing of outcome assessment methods,
instruments used, and timing. We did not include long-term disease
control or quality of life outcomes in this review.

Search methods for identification of studies

We  aimed  to  identify  all  relevant  RCTs  regardless  of  language
or  publication  status  (published,  unpublished,  in  press,  or  in
progress).

Electronic searches

For  this  update  Cochrane  Skin  Information  Specialist  Liz  Doney
searched the following databases up to 16 September 2021, using
strategies created for the previous version of this review (Kelleher
2021).

1. Cochrane Skin Specialised Register 2021 (Appendix 1).
2. Cochrane Central Register of Controlled Trials (CENTRAL; 2021,

Issue 8), in the Cochrane Library (Appendix 2).

3. MEDLINE via Ovid (from 1946 to 16 September 2021) (Appendix

3).

4. Embase via Ovid (from 1974 to 16 September 2021) (Appendix 4).

Trials registers

For  this  update,  two  review  authors  (MK  and  RJB)  searched  the
following trials registers on 31 July 2021.

1. ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 5).
2. World  Health  Organization  (WHO)  International  Clinical  Trials
Registry Platform (ICTRP) (apps.who.int/trialsearch/) (Appendix
6).

Retractions and errata

We undertook a search to identify retraction statements or errata
related  to  the  studies  included  in  the  review  in  MEDLINE  and
Embase  on  13  October  2021.  No  new  relevant  records  were
retrieved.

Searching other resources

Conference proceedings

We  reviewed  the  proceedings  of  the  Asia  Pacific  Association
of  Pediatric  Allergy,  Respirology  &  Immunology  Conferences
(APAPARI) for 2018, 2019, and 2020.

Searching reference lists

We  checked  the  bibliographies  of  included  trials  and  identified
relevant systematic reviews to obtain further references to relevant
RCTs.

Adverse effects

We  did  not  perform  a  separate  search  for  adverse  effects  of
interventions used for the prevention of eczema and food allergy.
We only considered adverse effects described in the included trials.

Data collection and analysis

We undertook the review according to the methods recommended
in  Chapter  26  of  the  Cochrane  Handbook  for  Systematic  Reviews

Cochrane Database of Systematic Reviews

of Interventions (Tierney 2021). A summary record of prospectively
planned  components  of  the  meta-analysis  was  registered  on
PROSPERO (reference 42017056965; registered 10 February 2017)
(Boyle 2017).

Selection of studies

For  this  update  of  the  review,  two  review  authors  (from  MK,
SC,  and  RJB)  independently  carried  out  title,  abstract,  and
full-text  screening,  with  arbitration  by  a  third  review  author
(RP)  when  necessary.  We  combined  both  retrospective  and
prospectively  acquired  data  in  the  meta-analysis.  Retrospective
data are outcome data acquired, analysed, unblinded, and known
to  the  trial  investigators  before  registration  of  the  systematic
review protocol (PROSPERO reference 42017056965; registered 10
February 2017) (Boyle 2017). Prospectively acquired data are those
data  known  to  the  trial  investigators,  in  analysed  and  unblinded
form, before 10 February 2017. We used participant-level data from
all  trials  when  possible.  We  invited  the  authors  of  each  included
trial to collaborate in accordance with Chapter 26 of the Cochrane
Handbook  for  Systematic  Reviews  of  Interventions  (Tierney  2021).
We asked all trial authors to provide IPD. One review team member
(MK or SC) sent a data request email to the first and corresponding
authors  of  the  associated  trial  listing  the  variables  required  for
the analysis (Appendix 7). Following completion of a data sharing
agreement, selected variables, or full data sets when appropriate
permissions were obtained, were exchanged between researchers
along  with  a  data  dictionary.  If  study  authors  were  unable  to
provide participant-level data, we accepted appropriate summary
data.

Data extraction and management

We  conducted  data  collection  and  handling  in  accordance  with
the  guidance  provided  in  Chapter  26  of  the  Cochrane  Handbook
for  Systematic  Reviews  of 
Interventions  (Tierney  2021).  We
extracted descriptive data on trial setting, methods, participants,
interventions,  comparator,  length  of  follow-up,  instruments  used
for measuring outcomes, funding source, and conflicts of interest
for  each  included  trial.  Two  review  authors  (MK,  SC,  RP,  or  VC)
independently extracted data using a standardised data collection
form.  Any  disagreements  were  resolved  through  discussion  or
by  consulting  a  third  review  author  (RJB)  when  necessary.  We
requested that trial authors who agreed to provide information or
data beyond those available in the public sphere share protocol and
statistical analysis plan details, along with details of available data
fields. For a trial in which MK and RJB were investigators (Chalmers
2020), SC or VC performed data extraction, and RP acted as arbiter.

All  IPD  data  used  in  the  review  were  de-identified.  The  list  of
variables that we requested from each trial is provided in Appendix
7. We transferred specific data fields and then cleaned and coded
data for analysis for those trials willing to provide IPD. Data sources
from  previously  published  trials  were  provided  as  anonymised
whole databases when trial authors preferred. We carried out range
and  consistency  checks  for  all  data.  Any  missing  data,  obvious
errors, inconsistencies between variables, or extreme values were
queried  and  rectified  with  individual  trial  authors  as  necessary.
We also cross-checked summaries of provided data with those in
published reports of the trial and contacted original trial authors
to resolve identified inconsistencies. We kept a secure record of all
correspondence, agreements and data transfers with trial authors,
and the review database.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

For  included  trials  that  were  unable  to  provide  IPD,  we  recorded
the  reason  for  data  unavailability  and  requested  aggregate  data
on our outcomes. If aggregate data could not be obtained directly
from the trial authors, two review authors assessed whether any
relevant  appropriate  aggregate-level  data  were  available  in  the
trial  publication  or  other  sources  (e.g.  clinical  trials  registries).
We  recorded  aggregate  data  on  a  standardised  data  extraction
form. Two review authors (MK, RP or SC) independently extracted
data.  Any  disagreements  on  extracted  aggregate  data  were
discussed  and  resolved  by  consensus,  with  no  requirement  for  a
third review author to arbitrate.

The  detailed  statistical  analysis  plan  for  this  review  was  written
when data to be collected for the trials providing IPD were known,
but  before  any  grouped  outcome  data  from  prospective  trials
had been evaluated (Cro 2020a). The statistical analysis plan was
therefore written with consideration of the nature and limitations
of the data recorded in trials known to be eligible for inclusion, and
the statistician remained blind to intervention and control group
outcomes for each data field, so that bias was not introduced by
exploring the possible impact of different data analyses and coding
decisions on findings.

Assessment of risk of bias in included studies

We  assessed  risk  of  bias  using  version  2  of  the  Cochrane  tool  for
assessing  risk  of  bias  in  randomised  trials  (RoB  2)  (Higgins  2018;
Higgins 2021b), which is designed specifically for RCTs and assesses
bias based on the following five domains.

1. Bias arising from the randomisation process.
2. Bias due to deviations from intended interventions.
3. Bias due to missing outcome data.
4. Bias in measurement of the outcome.
5. Bias in selection of the reported result.

We  assessed  risk  of  bias  separately  for  eczema  (by  age  one  to
three years using the closest time point to two years), food allergy
(by  age  one  to  three  years  using  the  closest  time  point  to  two
years),  slippage  accidents  (during  the  intervention  period),  skin
infection (during the intervention period), allergic reactions (during
the intervention period), time to onset of eczema, parent report of
food  allergy  reaction  (at  age  one  to  three  years  using  the  closest
time point to two years), and allergic sensitisation (at age one to
three years using the closest time point to two years). The RoB 2
tool  is  outcome-specific,  and  we  rated  each  domain  as  'low  risk
of  bias',  'some  concerns',  or  'high  risk  of  bias'.  For  bias  due  to
deviations from intended interventions, we were interested in the
effects of assignment to the interventions at baseline, regardless of
whether interventions were received as intended, by an intention-
to-treat analysis that included all randomised participants. Bias in
selection  of  the  reported  result  was  low  risk  for  all  prospectively
identified studies, as we obtained the full data set for these trials.
We did not perform risk of bias assessments for qualitative narrative
information.

At the time of writing of this review, the RoB 2 tool for cluster-RCTs
was  under  development.  For  cluster-RCTs,  we  therefore  similarly
assessed  risk  of  bias  using  RoB  2  as  outlined  above  (Higgins
2018), but included an additional cluster-RCT-specific domain from
the  archived  version  of  the  RoB  2  tool  for  cluster-RCTs  (Eldridge
2016): 'Domain 1b - Bias arising from the timing and identification
and recruitment of participants'.

Cochrane Database of Systematic Reviews

We  used  the  following  criteria  to  reach  an  overall  risk  of  bias
judgement for a specific outcome.

1. Overall low risk of bias: all domains considered at low risk for the

specific result.

2. Some concerns: some concerns have been raised in at least one
domain for the specific result, but no domains are considered at
high risk of bias.

3. High risk of bias: at least one domain is considered at high risk
for the specific result, or there are some concerns for multiple
domains, which substantially lowers confidence in the result.

Two review authors (MK, SC, VC, or RP) independently conducted
risk of bias assessments, with any disagreements resolved through
discussion or through arbitration with a third review author (RJB).
For a trial in which MK and RJB were investigators (Chalmers 2020),
SC and VC independently conducted risk of bias assessments with
RP acting as arbiter.

Measures of treatment effect

For  binary  outcomes  when  meta-analysis  was  considered
appropriate,  we  calculated  risk  ratios  (RRs).  For  continuous
outcomes  when  trials  used  the  same  measurement  scale,
we  calculated  mean  differences  (MDs);  when  trials  used  different
measurement scales, we calculated standardised mean differences
(SMDs). For time-to-event outcomes, we expressed the intervention
effect  as  a  hazard  ratio  (HR).  We  computed  a  95%  confidence
interval (CI) for each outcome.

Unit of analysis issues

This  review  included  RCTs  only.  As  discussed  below  (see  Data
synthesis),  we  adopted  a  two-stage  approach  for  this  IPD  meta-
analysis. In stage 1, we separately estimated the treatment effect
of interest for each included trial. In stage 2, we pooled treatment
effects using methods for meta-analyses of aggregate data.

included  factorial  RCTs  and  cluster-RCTs.  For  factorial
We 
randomised  trials,  if  we  noted  a  significant  interaction  between
the two active interventions with respect to our primary outcome,
we included only the arms ‘skin care intervention/control’ versus
‘control/control’.  We  explored  through  sensitivity  analysis  the
impact  of  including  data  from  all  arms  of  factorial  trials  when
an  interaction  was  present,  with  adjustment  for  non-skin  care
interventions.

For  other  trials  with  more  than  two  treatment  arms  (excluding
factorial  trials,  which  were  handled  as  described  above),  which
could  have  multiple  intervention  groups  in  a  particular  meta-
analysis, we combined all relevant intervention groups into a single
intervention  group  and  all  relevant  control  groups  into  a  single
control group.

For  all  stage  1  analyses  for  cluster-RCTs  providing  IPD,  we
used  mixed  models  that  permit  analysis  at  the  level  of  the
individual whilst accounting for clustering in the data. Treatment
effects from cluster-RCTs were therefore appropriately adjusted for
correlation within clusters before inclusion in the stage 2 (pooled)
analysis,  following  recommendations  for  the  analysis  of  cluster-
RCTs (Higgins 2021a).

For  cluster-RCTs  providing  non-IPD,  we  planned  to  extract  data
from  trial  reports  that  had  taken  into  account  the  clustering  in

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

these  data,  and  then  analyse  the  data  using  the  generic  inverse-
variance  method  in  Review  Manager  Web  (RevMan  Web  2022).  If
data were not adjusted for clustering, we would attempt to estimate
the  intervention  effect  by  calculating  an  intracluster  correlation
coefficient (ICC), whilst following the recommendations provided
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2021a).

Dealing with missing data

We  dealt  with  missing  data  according  to  the  recommendations
provided  in  the  Cochrane  Handbook  for  Systematic  Reviews  of
Interventions  (Deeks  2021).  We  contacted  trial  authors  to  resolve
missing information about methodological properties of identified
trials.  When  trial  authors  were  unable  to  provide  the  required
information,  we  rated  the  relevant  risk  of  bias  criterion  using
the  Cochrane  RoB  2  tool  (Higgins  2018).  We  did  not  anticipate
substantial  quantities  of  missing  data  for  the  primary  outcomes.
For trials providing IPD, we naturally handled missing participant
data under the assumption of missing-at-random within each trial
analysis.

We  planned  that  for  trials  that  did  not  provide  IPD  and  reported
an  MD  but  no  standard  deviation  (SD)  or  other  statistic  that
could be used to derive the SD, we would use imputation (Furlan
2009).  Specifically,  we  planned  to  impute  SDs  for  each  outcome
using the pooled SD across all other trials within the same meta-
analysis  by  treatment  group.  This  is  an  appropriate  method  of
analysis  if  a  majority  of  the  trials  do  not  have  missing  SDs  in
the meta-analysis. If a large proportion of trials (e.g. ≥ 20%) were
missing  data  on  parameter  variability  for  a  particular  outcome,
imputation would not have been appropriate, and we would have
conducted analysis using only trials providing complete data, and
discussed the implications of this alongside the results. However,
such imputation did not prove necessary.

In  risk  of  bias  assessments,  to  address  the  impact  of  non-
negligible  missing  data  (≥  5%)  on  individual  trial  outcomes,  we
conducted sensitivity analyses using IPD and best-case/worst-case
scenarios, that is we conducted analysis by imputing a best-case
scenario of response in both treatment groups, followed by analysis
under  a  worst-case  scenario  of  no  response  in  both  treatment
groups. Results of sensitivity analyses under these scenarios were
compared  to  primary  complete-case  analyses  (conducted  under
the  missing-at-random  assumption)  to  assess  risk  of  bias  due  to
missing data.

We  included  trials  with  substantial  quantities  of  missing  data
(e.g.  rated  as  high  risk  of  bias  or  some  concerns  due  to  missing
data) in meta-analysis, but to investigate the robustness of pooled
results,  we  performed  sensitivity  analysis  whilst  excluding  trials
rated  overall  at  high  risk  of  bias  or  with  some  concerns,  which
included excluding trials rated at high risk of bias or some concerns
due to missing data.

Assessment of heterogeneity

We examined both clinical and statistical heterogeneity, combining
data in meta-analysis only when we judged that evaluation would
yield  a  meaningful  summary.  We  assessed  clinical  heterogeneity
by  examining  the  characteristics  of  included  participants,  types
of  interventions,  primary  and  secondary  outcomes,  and  follow-
up  period.  We  used  the  I2  statistic  and  the  Chi2  test  to  quantify
the degree of statistical heterogeneity of trials judged as clinically

Cochrane Database of Systematic Reviews

homogeneous  (Higgins  2003).  We  interpreted  the  I2  statistic  as
follows:

• 0% to 40%: might not be important heterogeneity;
• 30 to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• greater  than  75%:  indicative  of  considerable  heterogeneity

(Deeks 2021).

The observed I2 value was judged against this guide in combination
with its 95% CI, the P value from the Chi2 test, and the magnitude
and  direction  of  effect.  When  the  magnitude  and  direction  of
effects  and  the  strength  of  evidence  for  heterogeneity  based  on
the  P  value  from  the  Chi2  confidence  intervals  for  I2  revealed
heterogeneity,  or  if  we  observed  considerable  heterogeneity,
we  explored  reasons  for  heterogeneity,  and  when  appropriate
conducted sensitivity analysis whilst excluding any trials identified
as outlying.

Assessment of reporting biases

By including as many prospective trials as possible in this review,
as  well  as  IPD,  the  risks  of  reporting  bias  and  publication  bias
should  have  been  reduced.  However,  we  planned  that  if  at  least
10  trials  were  included  in  the  meta-analysis,  we  would  formally
assess  reporting  bias  using funnel  plots  to  explore  the  likelihood
of  any  reporting  bias  or  small-study  effects.  We  planned  to
assess  funnel  plot  asymmetry  visually  and  to  use  formal  tests
for funnel plot asymmetry. For continuous outcomes, we planned
to use the test proposed by Egger (Egger 1997). For dichotomous
outcomes,  we  planned  to  use  the  test  proposed  by  Rucker  when
estimated between-study heterogeneity variance of log odds ratios,
Tau2,  was  greater  than  0.1  (Rucker  2008).  Otherwise,  when  the
heterogeneity variance Tau2 was less than 0.1, we would use one
of  the  tests  proposed  by  Harbord  (Harbord  2006).  We  planned
that  if  asymmetry  was  detected  in  any  of  these  tests  or  was
suggested by a visual assessment, we would explore and discuss
possible  explanations.  However,  we  did  not  conduct  a  meta-
analysis including 10 or more trials, therefore we did not undertake
any formal assessment of reporting bias.

Data synthesis

We  conducted  an  IPD  meta-analysis  of  both  prospective  and
retrospectively  acquired  data.  Primary  meta-analysis  used  IPD
only.  We  did  not  use  aggregate  data  in  the  primary  meta-
analysis when IPD could not be provided, as the total proportion
of  participants  that  made  up  aggregate  data  was  less  than  10%
of  the  overall  number  of  participants  across  all  trials  (i.e.  total
aggregate data represented a negligible proportion of the data set).
We performed a sensitivity analysis by adding in the aggregate data,
as described below, to explore the impact of data availability bias.
We undertook a prospectively planned meta-analysis (PPMA) of a
more limited number of trials as a sensitivity analysis. PPMA was
limited to those trials in which trial authors were not aware of trial
outcomes at the time of PPMA protocol registration on PROSPERO
(Boyle 2017).

The main analyses estimated the effect of being assigned to receive
the  intervention,  according  to  the  intention-to-treat  principle.
We  retained  all  eligible  participants  in  the  treatment  group  to
which  they  had  originally  been  assigned  who  had  an  outcome,
irrespective of the treatment they actually received. To understand

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

the  effect  of  compliance,  we  included  pre-planned  secondary
supplementary  analysis  to  estimate  the  complier  average  causal
effect.

We  planned  to  perform  all  analyses  stratified  by  type  of
intervention group. Our planned comparisons were therefore:

1. skin care intervention versus no treatment or standard care;
2. skin care intervention 'A' versus no treatment or standard care;
3. skin care intervention 'B' versus no treatment or standard care.

We  planned  to  consider  interventions  in  two  broad  categories:  A
interventions promoting hydration and skin barrier mainly through
emollients, and B interventions that would protect from harm, such
as  water  softeners  or  avoidance  of  irritants.  Because  our  search
did  not  reveal  any  completed  eligible  trials  of  B-type  skin  care
interventions,  it  did  not  prove  necessary  to  stratify  comparisons
by  type  of  skin  care  intervention,  therefore  we  undertook  only
comparisons  of  type  A.  For  each  outcome,  when  we  judged  a
sufficient number of trials (two or more) to be clinically similar, we
pooled results in a meta-analysis. When we did not undertake meta-
analyses owing to clinical heterogeneity or to insufficient data, we
discussed the results from individual trials narratively.

We  adopted  a  two-stage  approach  to  analysis  for  all  primary
and  secondary  analyses.  In  the  first  stage,  we  derived  individual
trial  treatment  effect  estimates  from  IPD.  For  analyses  of  binary
outcomes,  including  both  primary  outcomes  (eczema  and  food
allergy),  the  stage  1  model,  fitted  to  each  trial  providing  IPD
separately,  was  a  binomial  regression  model.  For  analyses  of
continuous  outcomes,  the  stage  1  model  fitted  to  each  trial
providing  IPD  was  a  linear  regression  model.  For  time-to-event
outcomes,  the  stage  1  model  fitted  to  each  trial  providing  IPD
was  a  binomial  regression  model  with  a  complementary  log-log
link, where follow-up time was split into appropriate intervals for
the  obtained  data  (3  months,  6  months,  12  months,  18  months,
and  24  months).  This  model  was  appropriate  for  time-to-event
data  of  a  discrete  nature.  In  addition  to  the  treatment  group
variable indicating use of a skin care intervention, we included the
important  prognostic  factors  of  sex  and  family  history  of  atopic
disease within the stage 1 models.

In the second stage, we combined derived treatment effects using
methods  for  meta-analyses  of  aggregate  data.  We  used  random-
effects  models  in  stage  2  to  derive  the  pooled  treatment  effect
(DerSimonian  1986;  Riley  2010).  We  planned  to  use  random-
effects  models  because  we  anticipated  some  level  of  variability
across  trials,  for  example  by  types  of  interventions,  length  of
follow-up, and methods of measurement. A random-effects model
incorporates  heterogeneity  amongst  trials  and  allows  the  true
treatment effect to be different in each trial. In sensitivity analysis,
the  second  stage  also  included  aggregate  data  from  trials  whose
authors did not provide IPD.

We  performed  residual  analysis  for  all  IPD  meta-analyses  and
PPMAs  to  assess  model  assumptions  and  fit.  Meta-analyses  also
included trial sequential analysis, using two-sided 5% significance
and  80%  power  to  estimate  optimum  heterogeneity-adjusted
information  sizes  needed  to  identify  relative  risk  reductions  of
20% and 30% (Wetterslev 2008). We estimated control event rates
using  random-effects  meta-analyses  of  pooled  proportions  from
the largest trials included in the meta-analyses and compared them
with  event  rates  from  large  population-based  studies.  We  used

Cochrane Database of Systematic Reviews

trial sequential analysis to identify when the optimum information
size  or  futility  boundaries  for  predefined  effect  sizes  in  relation
to primary outcomes would be reached. We performed stage 1 of
the IPD meta-analysis in Stata 15 or above (Stata), with summary
results of these analyses added to RevMan Web 2022.

To  explore  the  impact  of  compliance,  we  estimated  the  effect
of  complying  with  the  intended  intervention.  For  the  subgroup
of  trials  providing  compliance  data,  we  estimated  the  complier
average causal effect (CACE) for each primary outcome. As in the
primary  analysis,  we  followed  a  two-stage  approach  to  analysis.
For each trial, we estimated the CACE using instrumental variable
(IV)  analysis.  We  used  randomisation  as  an  instrumental  variable
for intervention received, and we estimated the CACE using a two-
stage  residual  inclusion  estimator  approach  (2SRI)  (Cook  2018).
Randomisation  meets  the  criteria  for  an  adequate  instrument
in  that  (i)  randomisation  predicts  the  treatment  receipt;  (ii)
randomisation  is  unconfounded  with  the  outcome;  and  (iii)  we
assume  no  direct  effect  of  randomisation  on  the  outcome  (other
than  via  treatment  receipt):  'the  exclusion  restriction'.  Here,
we  initially  defined  a  ‘complier’  as  an  individual  who  used  the
prescribed  intervention  for  three  or  more  days  a  week  over
the  intervention  period.  When  interventions  and  the  quality  of
compliance  data  were  sufficiently  comparable,  we  used  random-
effects  models  in  stage  2  to  derive  the  pooled  CACE  effect.  We
repeated the primary analysis for each of the trials in the subgroup
of trials with compliance data to compare pooled CACE estimates
against  the  primary  treatment  effect  (RR)  whilst  estimating  the
effect  of  being  assigned  to  the  intervention  for  the  subgroup  of
trials  for  which  compliance  data  were  available.  Subsequently,
we explored the impact of different threshold values for defining
compliance  (≥  5  days  a  week  over  the  intervention  period,  7
days over the intervention period, ≥ 3 days a week over the first 3
months of the intervention period, ≥ 5 days a week over the first 3
months of the intervention period, and 7 days a week over the first
3 months of the intervention period).

The detailed statistical analysis plan, which set out all comparisons
to be made and the precise model forms and fitting strategy to be
used, may be consulted for additional information (Cro 2020a). For
trials providing only narrative information, or incomplete measures
of  effect  (i.e.  no  denominators  available)  when  meta-analysis
could not be performed, we summarised available effect estimates
or  narrative  information  alongside  meta-analyses  for  the  same
groupings  of  populations,  interventions,  outcomes,  and  study
design as were used in the quantitative meta-analysis.

Subgroup analysis and investigation of heterogeneity

We  identified  the  following  subgroups  of  interest  a  priori  for
analysis in this update.

1. By participant-level characteristics

a. Comparing  effects  of  the  intervention  on  'high'  or  'not
high'  genetic  risk  for  atopy  based  on  FLG  genotype  or  the
chromosome 11 intergenic variant rs2212434, or both.

b. Comparing effects of the intervention on 'high' or 'not high'
risk for atopy based on family history of allergic disease.

2. By study-level characteristics

a. Comparing  effects  of  interventions  aimed  at  preventing
damage  to  the  skin  (e.g.  reduced  exposure  to  soaps,
wipes,  bathing,  hard  water)  versus  interventions  aimed  at

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

promoting skin hydration or barrier function (e.g. emollient
cream, lotion, ointment, oil) versus combined treatment.
b. Intervention  timing:  comparing  effects  of  intervention  on
participants advised to commence the skin care intervention
within  the  first  four  weeks  of  life  versus  those  who
commenced intervention after four weeks.
Intervention  duration:  comparing  duration  of  intended
treatment,  when  'short'  is  regarded  as  up  to  six  months  of
treatment,  and  'longer'  is  six  months'  duration  or  longer.
When feasible, we planned to undertake modelling to assess
the  relationship  between  study  outcome  and  timing  or
duration of intervention.

c.

We calculated subgroup effects for participant-level characteristics
on  the  two  primary  outcomes  by  first  estimating  treatment  by
covariate  interaction  terms  within  studies  using  IPD.  We  then
combined  interaction  terms  across  studies  in  the  same  way  as
for  the  main  intervention  effects,  using  a  random-effects  meta-
analysis.  For  study-level  characteristics,  we  pooled  treatment
effects separately for each characteristic, and performed a test for
subgroup differences using a Chi2 test.

Sensitivity analysis

We conducted the following a priori planned sensitivity analyses for
the co-primary outcomes when relevant.

1. By overall risk of bias: in primary analysis, we included all trials
regardless  of  overall  risk  of  bias,  and  undertook  a  sensitivity
analysis  of  trial  outcomes  assessed  as  having  an  overall  low
risk of bias. The 'low risk of bias' sensitivity analysis excluded
trial outcomes at overall high risk or those with some concerns,
as  assessed  via  the  Cochrane  RoB  2  tool  (Higgins  2018).  This
included omitting trial outcomes with high risk of bias and those
with  some  concerns  due  to  missing  data,  because  inclusion
would have led to the trial receiving an overall rating that was
not low risk of bias.

2. By outcome measures: we explored the impact of using different
definitions  of  outcome  measures  by  undertaking  sensitivity
analyses  of  outcomes  that  had  previously  been  validated.  For
the primary outcome of eczema, in the absence of agreed-upon
core  outcomes,  we  undertook  sensitivity  analysis  of  eczema
evaluated  using  only  the  UK  Working  Party  Criteria  (Williams
1994),  or  other  variations  of  the  Hanifin  and  Rajka  criteria
(Hanifin  1980).  For  the  primary  outcome  of  food  allergy,  we
undertook  sensitivity  analysis  for  secure  diagnosis  of  food
allergy by oral food challenge or investigator decision using an
algorithm  developed  for  the  Barrier  Enhancement  for  Eczema
Prevention (BEEP) study.

3. Including  aggregate  data  from  trials  that  did  not  provide  IPD:
as aggregate data made up less than 10% of the total number
of  participants  across  all  trials,  our  primary  analysis  included
IPD  only,  and  we  conducted  a  sensitivity  analysis  including
aggregate data from trials that did not provide IPD.

4. Excluding  any  data  that  were  not  prospectively  acquired:
prospectively  acquired  data  are  data  that  were  not  known  to
the  study  chief  investigator,  in  analysed  and  unblinded  form,
before  10  February  2017.  PPMA  reduces  bias  related  to  the
knowledge of existing trial outcomes, which might influence trial
selection  in  a  retrospective  study,  because  trials  are  included
without  any  knowledge  of  outcome.  Additionally,  outcomes
across  prospectively  planned  trials  were  more  closely  aligned

Cochrane Database of Systematic Reviews

due  to  awareness  of  being  included  in  this  IPD  meta-analysis.
We conducted sensitivity analysis of prospectively acquired data
using the same approach to the primary analysis (i.e. using IPD
only; see Data synthesis).

5. To  explore  heterogeneity:  when  considerable  statistical
heterogeneity  was  observed  (I2  >  75%),  we  explored  reasons
for heterogeneity, and when appropriate conducted sensitivity
analysis  whilst  excluding  any  trials  identified  as  outlying.
Outlying  trials  are  those  with  very  different  trial  findings
from others reporting comparable interventions/outcomes. We
identified outliers from inspection of individual trial treatment
estimates and 95% CIs in forest plots.

6. Including data from all arms of factorial trials with a significant
interaction:  for  factorial  trials,  when  there  was  a  significant
interaction  between  the  two  active  interventions  with  respect
to our primary outcome, we included only the arms ‘skin care
intervention/control’ versus ‘control/control’. In such scenarios,
we  performed  an  additional  sensitivity  analysis  exploring  the
impact  of  including  data  from  all  arms  of  factorial  trials,  with
adjustment for the non-skin barrier intervention in stage 1 of the
analysis.

Summary of findings and assessment of the certainty of the
evidence

We planned to include the following summary of findings tables.

1. Summary of findings table 1: Skin care intervention versus no

treatment or standard care only.
a. This table includes primary estimates of treatment effects in
addition to key sensitivity analyses for primary outcomes.

2. Summary  of  findings  table  2:  Skin  care  intervention  A  versus
no treatment or standard care only. Intervention A = skin care
interventions that aim to promote hydration or barrier function.
a. This  table  would  include  subgroup  analyses  of  low  risk  of
eczema and food allergy versus high risk of eczema and food
allergy, either by FLG mutation or by family history of allergic
disease.

3. Summary  of  findings  table  3:  Skin  care  intervention  B  versus
no treatment or standard care only. Intervention B = skin care
interventions that aim to prevent damage.
a. This  table  would  include  subgroup  analyses  of  low  risk  of
eczema and food allergy versus high risk of eczema and food
allergy, either by FLG mutation or by family history of allergic
disease.

It did not prove necessary to stratify comparisons by types of skin
care interventions because we did not identify any eligible trials of
skin care intervention type B. We therefore included only Summary
of findings 1.

Outcomes for summary of findings tables

Primary outcomes

1. Eczema diagnosis
2. IgE-mediated food allergy

Key secondary outcomes

1. Adverse events during the intervention period, such as slippage,

skin infection, stinging, or allergic reaction to moisturiser

2. Time to onset of eczema

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

3. Parental  report  of  immediate  reaction  to  a  common  food

R E S U L T S

allergen

4. Allergic sensitisation to a food allergen

We  included  outcomes  for  sensitivity  analyses  by  method  of
outcome assessment and by risk of bias in the 'Comments' section
of Summary of findings 1.

Certainty of the evidence

We  applied  the  GRADE  approach  to  our  main  comparisons  listed
above (Andrews 2013; Schünemann 2021). The outcomes included
in  our  summary  of  findings  table  are  the  primary  outcomes  of
eczema  and  food  allergy,  along  with  key  secondary  outcomes
of  adverse  events,  time  to  onset  of  eczema,  parental  report
of  immediate  food  allergy,  and  allergic  sensitisation  to  a  food
allergen.  Two  review  authors  (MK,  SC,  VC,  or  RJB)  independently
assessed each outcome for risk of bias, imprecision, inconsistency,
indirectness,  and  publication  bias,  downgrading  the  certainty  of
evidence when appropriate. For assessing a trial for which MK and
RJB were investigators (Chalmers 2020), SC and VC independently
performed  GRADE  assessment  for  that  study.  We  graded  each
outcome as high, moderate, low, or very low certainty.

Description of studies

We included 33 RCTs in the review.

Results of the search

For  this  update,  we  re-ran  our  searches  of  four  databases
and  two  trials  registers  (see  Electronic  searches).  Across  this
update  and  the  previous  version  of  this  review,  we  retrieved
a  total  of  10,884  records  from  these  sources.  Our  searches  of
other resources (conference proceedings, scanning bibliographies)
identified  no  further  relevant  records.  After  de-duplication,  9964
records  remained.  We  excluded  9676  records  based  on  title  and
abstract and obtained the full texts of the remaining 288 records.
We  excluded  191  studies  reported  in  194  references,  of  which
15  were  duplicates.  Reasons  for  excluding  the  176  studies  are
provided  in  Characteristics  of  excluded  studies.  We  identified  11
ongoing  studies  reported  in  14  references  (see  Characteristics
of  ongoing  studies),  and  4  studies  reported  in  5  references  are
awaiting  classification  (see  Characteristics  of  studies  awaiting
classification). We included 33 studies reported in 75 references in
the review (see Characteristics of included studies). Our screening
process is illustrated in a study flow diagram (Figure 1).

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

18

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Study flow diagram.

Cochrane Database of Systematic Reviews

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

19

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   (Continued)

Cochrane Database of Systematic Reviews

Included studies

Participant characteristics

We  included  33  studies  involving  a  total  of  25,827  participants
in  the  review.  For  details  on  each  trial,  see  Characteristics  of
included studies. Of the 33 included studies, 17 trials randomising
5823 participants reported outcome data relevant to eczema, food
allergy, or the adverse events of interest; these data were IPD, either
aggregate or narrative. Of the 17 studies, 11 studies randomising
5217 participants (of which 10 studies provided IPD) were included
in one or more meta-analysis.

The remaining 16 included studies did not report any outcome data
relevant to the review (Abraham 2019; Baldwin 2001; Duan 2019;
Garcia Bartels 2010; Garcia Bartels 2011; Garcia Bartels 2012; Garcia
Bartels 2014; Lavender 2011; Lavender 2012; Lavender 2013; Lund
2020;  Raisi  Dehkordi  2010;  Rush  1986;  Sankaranarayanan  2005;
Tielsch 2007; Zhao 2005). Ten of these studies assessed the impact
of  short-term  application  of  skin  care  products  in  term  infants  in
the first few weeks of life on physiological skin outcomes (Abraham
2019; Duan 2019; Garcia Bartels 2010; Garcia Bartels 2012; Garcia
Bartels 2014; Lavender 2011; Lavender 2012; Lavender 2013; Lund
2020; Raisi Dehkordi 2010). Rush 1986 evaluated the impact of daily
bathing  on  Staphylococcus  aureus  colonisation  levels.  Baldwin
2001 assessed diaper products to prevent diaper dermatitis. Garcia
Bartels 2011 assessed the effects of swimming and lotion on infant
skin, whilst Zhao 2005 evaluated the impact of swimming alone on
neonatal skin barrier. Tielsch 2007 was a cluster-randomised trial
including more than 17,000 participants that evaluated the effects
of chlorhexidine wipes on neonatal mortality and infection in rural
Nepal.  Sankaranarayanan  2005  evaluated  the  effects  of  coconut
and  mineral  oil  on  weight  velocity.  The  longest  follow-up  period
for these trials was four weeks, and outcomes were physiological
skin measures or non-skin-related outcomes. These trials met the
criteria for inclusion; however, they did not include eczema or food
allergy outcomes, or any useable adverse event outcomes.

For  studies  included  in  the  meta-analysis,  almost  all  participants
were enrolled in the study before 14 days of age.

Female sex ranged from 43% of participants in Cooke 2015 to 56%
in  NCT03376243.  Vaginal  delivery  ranged  from  26%  in  Simpson
2014 to 83% in Cooke 2015.

Design

As  per  the  inclusion  criteria,  all  trials  were  RCTs  comparing  a
skin  barrier  intervention  versus  standard  care  or  no  skin  care
intervention.  Most  trials  (25/33)  recruited  infants  before  one
month  of  age  and  randomised  them  to  a  'control'  group,  which
provided  standard  care  for  infant  skin  in  the  locality,  or  an
'intervention'  group.  Both  intervention  and  control  groups  were
then followed up at specified intervals for assessment of outcomes.
Because  the  most  common  intervention  was  the  application
of  emollients  or  changes  to  skin  care,  in  almost  all  studies
participants  were  not  blinded  to  their  allocation  status.  All  trials
apart  from  Skjerven  2020  and  Tielsch  2007  were  individually
randomised.

Two  studies  were  factorial  RCTs:  Skjerven  2020  was  a  cluster-
randomised  trial  evaluating  both  a  skin  barrier  intervention
and early introduction of solid foods. Due to significant interaction
between  interventions,  only  the  skin  care  and  control  arms  of
the  study  were  used  for  IPD  analysis.  Dissanayake  2019  was
an  individually  randomised  factorial  trial  evaluating  both  a  skin
barrier intervention and an oral synbiotic. Eight studies had more
than two arms but included a control arm (Abraham 2019; Cooke
2015;  Dizon  2010;  Duan  2019;  Garcia  Bartels  2010;  Garcia  Bartels
2014; Raisi Dehkordi 2010; Sankaranarayanan 2005).

Simpson  2014  was  the  pilot  study  for  Chalmers  2020.  Lowe
2018a was the pilot study for an ongoing study, Lowe 2019.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

20

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sample sizes

three 

largest  studies  contributing 

The 
to  data  analysis
were  Skjerven  2020  (n  =  2397),  Chalmers  2020  (n  =  1394),
and  Dissanayake  2019  (n  =  549).  Eight  studies  enrolled  between
100 and 250 participants (Bellemere 2018; Cooke 2015; Da Cunha
2008;  Dizon  2010;  Horimukai  2014;  McClanahan  2019;  Simpson
2014;  Yonezawa  2018),  and  six  studies  included  fewer  than  100
participants  (Amer  2017;  Kataoka  2010;  Lowe  2018a;  Migacheva
2018; NCT03376243; Thitthiwong 2019).

Setting

In  most  of  the  included  trials,  women  were  approached  during
pregnancy  or  in  the  first  few  weeks  after  birth  and  were  offered
participation.  Most  studies  were  conducted  from  tertiary  referral
hospitals.  All  studies  that  contributed  to  the  meta-analysis  were
conducted  in  well-resourced  settings.  Visits  mainly  took  place
at  children's  hospitals,  apart  from  Chalmers  2020,  which  was  a
pragmatic study, and a majority of end-of-study assessments were
conducted  in  participants'  homes.  Chalmers  2020  recruited  from
multiple  sites  across  England.  Skjerven  2020  recruited  mainly
in  Oslo,  Norway,  but  also  in  Sweden.  Four  studies  were  based
in  Japan  (Dissanayake  2019;  Horimukai  2014;  Kataoka  2010;
Yonezawa  2018).  The  remaining  trials  were  based  in  Australia,
France, Germany, and the United States.

Participants

All trials set their own inclusion and exclusion criteria. The review
protocol  set  inclusion  criteria  as  infants  under  the  age  of  one
year;  however,  the  vast  majority  of  studies  in  the  review  that
contributed  data  to  meta-analyses  enrolled  newborns  up  to
three  weeks  of  age.  The  exceptions  to  this  were  Garcia  Bartels
2011 (infants 3 to 6 months), Dizon 2010 (mean age approximately
5.4  months),  Duan  2019  (mean  age  3  months),  and  Garcia
Bartels  2014  (infants  enrolled  at  9  months  of  age).  As  this  was
a  primary  prevention  review,  infants  who  already  had  eczema
diagnosed  were  excluded,  along  with  infants  with  a  known  skin
condition. Studies that focused on a prespecified population such
as  preterm  infants  were  excluded,  as  their  findings  may  not  be
generalisable. Most studies contributing to meta-analyses enrolled
participants  with  a  family  history  of  allergy,  although  this  was
defined in different ways across studies. Horimukai 2014 included
infants  with  high  risk  of  atopic  dermatitis  from  family  history,
and  Kataoka  2010  included  infants  with  "family  history  of  AD
in  second  degree  of  kinship".  Four  studies  included  infants  with
at  least  one  first-degree  relative  with  eczema,  hay  fever,  or
asthma (Chalmers 2020; McClanahan 2019; NCT03376243; Simpson
2014).  Lowe  2018a  and  Thitthiwong  2019  included  infants  with
a  self-reported  family  history  in  parent  or  sibling  of  any  allergic
disease, whereas Bellemere 2018 required two atopic first-degree
relatives. Dissanayake 2019, Skjerven 2020, and Yonezawa 2018 did
not  require  family  history  of  atopy  for  enrolment.  Key  baseline
characteristics  of  participants  included  in  the  meta-analyses  are
summarised in Table 2 and Table 3.

Interventions

The included studies evaluated any skin barrier intervention that
could  alter  the  skin  barrier  in  the  infant.  We  did  not  identify  any
completed trials of interventions to reduce exposure to substances
that might damage the skin barrier, although we did identify one
ongoing trial of a water softener with this aim (Jabbar-Lopez 2019).

Cochrane Database of Systematic Reviews

Some included trials used a single intervention, whilst others used
a package of skin care interventions, and two studies were factorial
trials. The intervention was compared to standard infant care in the
country of the study setting.

i. Emollients

The  most  common  intervention,  used  in  13  of  33  trials,  was
emollient  with  standard  care.  The  type  of  emollient  and  the
treatment regimen varied across trials.

Five trials compared a commercial daily emollient for a treatment
duration  of  three  to  six  months  with  standard  care  (Bellemere
2018;  Kataoka  2010;  Lowe  2018a;  Simpson  2014;  Yonezawa
2018).  Bellemere  2018  compared  the  use  of  a  "French  cosmetic
in  neonates  twice  daily  for  the  first  six
brand"  emollient 
months  of  life  versus  control,  with  outcomes  measured  at  six
months  of  age.  Kataoka  2010  randomised  newborn  infants  to
an  unspecified  daily  emollient  "more  than  once  a  day",  or  to
control, for six months, with outcome measured at six months of
age.  Lowe  2018a  randomised  80  newborn  infants  to  a  ceramide
dominant  emollient  (EpiCeram;  PuraCap  Pharmaceutical  LLC,
South Plainfield, NJ, USA) or control (no intervention); participants
were  advised  to  apply  the  emollient  all  over  twice  a  day
for  six  months.  Outcomes  were  measured  at  12  months  of
age.  Simpson  2014  was  the  pilot  study  for  Chalmers  2020  and
randomised 124 infants to once-daily all-over emollient or standard
care  for  six  months,  starting  within  three  weeks  of  birth,  with
outcomes  measured  at  24  weeks.  The  emollient  was  chosen
from  sunflower  oil,  Doublebase  Gel,  or  paraffin  in  UK-based
participants,  and  from  sunflower  oil,  Aquaphor,  or  Cetaphil  in
US-based  participants.  In  Yonezawa  2018,  newborn  infants  were
randomised  to  an  emollient  one  or  more  times  per  day  and
reduced  bathing  to  every  second  day  or  standard  care  for  the
control  group.  Soap  for  washing  was  provided  by  the  team.  The
intervention  period  lasted  from  week  1  to  week  12  after  birth;
outcomes were measured at three months of age.

Five  trials  compared  the  use  of  commercial  emollients  with
standard care over a longer intervention period, between 32 weeks
and 12 months (Chalmers 2020; Horimukai 2014; McClanahan 2019;
NCT03376243; Thitthiwong 2019). Chalmers 2020 was a pragmatic
RCT  of  all-over  body,  once-daily  emollient  from  enrolment  to
one  year,  with  outcome  assessment  one  year  after  end  of
treatment.  This  trial  used  Doublebase  Gel  or  Diprobase  Cream,
with  participants  being  able  to  choose  between  them  and  to
swap  during  the  study.  In  Horimukai  2014,  infants  younger  than
one  week  were  randomised  to  an  all-over,  once-daily  emulsion-
type emollient (2e (Douhet) Emulsion; Shiseido, Tokyo, Japan) or
to  control  for  32  weeks.  Participants  in  the  control  group  were
allowed  to  use  petroleum  jelly  if  they  wished.  Outcomes  were
measured at 32 weeks. McClanahan 2019 randomised 100 infants
under  three  weeks  of  age  to  Cetaphil  Restoraderm  emollient  or
to an emollient of choice on an as-needed basis. The intervention
group  was  advised  to  apply  the  emollient  all  over  the  baby
once  daily  until  12  months  of  age,  with  outcomes  recorded
at  two  years  of  age.  Thitthiwong  2019  randomised  54  infants
less  than  10  weeks  old  to  once-daily,  all-over-body  cold  cream
or  control.  The  skin  outcome  was  assessed  at  nine  months
of  age;  however,  it  was  unclear  when  the  intervention  period
was  completed.  NCT03376243  randomised  newborn  infants  to
once-daily all-over Lipikaur Baume or control. Both groups received

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

21

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

general skin care advice for infants. The intervention was given for
12 months, and outcome was assessed at two years of age.

Skjerven  2020  evaluated  skin  care 
intervention  and  early
introduction  of  allergenic  food.  As  Skjerven  2020  reported  a
significant  interaction  between  interventions  for  the  primary
eczema outcome, we only used data from the skin care and control
arms for our primary analysis, where infants were bathed using an
oil emulsion and had cream applied to the face once daily from age
two weeks to eight months. Eczema outcome was measured at 12
months of age, and food allergy was assessed at three years of age.

Two  trials  compared  the  use  of  emollient  and  synbiotic  with
standard  care  (Dissanayake  2019;  Migacheva  2018).  Dissanayake
2019 was a factorial trial of skin care intervention plus a synbiotic
versus  normal  care  for  the  prevention  of  eczema  in  infants.  The
skin  care  intervention  was  a  lipid-based  emollient,  which  was
advised  to  be  put  on  the  cheeks  twice  daily  and  on  the  body  if
wished. The synbiotic was a combination of 0.5 g (7 × 109 colony-
forming  units  (CFUs)/g)  of  Bifidobacterium  bifidum  and  fructo-
oligosaccharides twice a day. The intervention period lasted from
birth  to  six  months,  with  outcome  assessment  at  12  months  of
age. Migacheva 2018 compared an emollient and an oral synbiotic
versus control. Sixty-three infants younger than three weeks of age
were randomised to twice-daily all-over emollient for six months
and  two  supplements  of  synbiotic  at  three  and  six  months,  or
control.

ii. Topical oils 

Cooke  2015  was  a  three-armed  trial  evaluating  the  effect  of
sunflower oil or olive oil versus control on neonatal skin. Parents
were  advised  to  apply  4  drops  of  oil  to  their  baby's  left  forearm,
left  thigh,  and  abdomen,  twice  a  day.  All  groups  were  advised
not  to  use  any  other  skin  care  products.  The  intervention  period
lasted  four  weeks,  with  outcomes  measured  at  four  weeks.  Raisi
Dehkordi 2010 randomised 120 infants who were 10 to 15 days old
to massage with sunflower oil, sesame oil, or no oil. Mothers were
advised to massage the oil into infants twice daily for 28 days, with
outcomes measured at the end of the 28 days. Sankaranarayanan
2005 randomised 224 babies to coconut oil, mineral oil, or control
with four times daily oil massage from birth until 31 days of age;
outcomes were measured at 31 days of age.

iii. Bathing products and frequency 

In Abraham 2019, 102 children were randomly assigned to bathing
with one of chlorhexidine, saline, or standard bath, with outcomes
assessed  up  to  24  hours  after  the  intervention.  In  Dizon  2010,
children  younger  than  one  year  were  randomly  assigned  to  one
of  three  groups  to  be  bathed  for  two  weeks:  Group  I:  Johnson's
Baby Top-to-Toe Wash, Group II: Sebamed Baby Liquid Cleanser, or
Group III: clear water. Assessment was done at one and two weeks
of treatment. In Duan 2019, 150 infants were randomised to Group
I commercial baby wash (Johnson's Baby Wash) and commercial
baby lotion (Johnson's Baby Lotion), and Group II water wash and
commercial baby lotion, or water only. Parents were asked to wash
their infant daily in the wash and apply the lotion, or to wash their
infant daily with water and apply the lotion daily, or to wash their
infant  daily  with  water  only.  This  intervention  was  administered
for 12 weeks, with outcomes assessed at the end of the 12-week
period. In Garcia Bartels 2010, 64 newborn infants were randomised
to twice-weekly washing for the first eight weeks of life in one of
four groups: Group WG: bathing with wash gel (Top-To-Toe Baby Gel

Cochrane Database of Systematic Reviews

Penaten, Johnson & Johnson); Group C: bathing with clear water
and  afterwards  topical  cream  (Baby  Caring  Facial  &  Body  Cream
Penaten, Johnson & Johnson); Group WG + C: bathing with wash
gel  and  topical  cream;  or  Group  C:  bathing  with  wash  only  (i.e.
control).  Outcome  assessment  was  conducted  at  eight  weeks  of
age.  Lavender  2011  randomised  newborn  infants  to  be  washed
with  Johnson's  Baby  Top-To-Toe  or  water,  at  least  three  times  a
week,  for  the  first  eight  weeks  of  life.  Skin  was  assessed  at  four
and eight weeks, the first during and the second at the end of the
intervention  period.  This  was  a  pilot  trial;  the  full  trial,  Lavender
2013, randomised 307 infants to washing with commercial product
or  water  alone  at  least  three  times  a  week.  The  intervention
period lasted for four weeks only, with outcome assessment at four
weeks (the end of the intervention period). Lund 2020 randomised
100  newborn  infants  to  be  washed  with  Johnson's  Baby  Top-To-
Toe  or  water,  in  the  first  hours  of  life.  Skin  was  assessed  before
and "after" this bath. Rush 1986 randomised healthy term newborn
infants to daily washing with soap and water versus dry skin care
and no bath. The outcome was measured on day 4 of bathing, or
immediately before discharge.

iv. Combined skin interventions 

Amer 2017 compared detailed instructions to use a combined skin
intervention  for  parents  of  newborn  infants  involving  delaying
the  first  bath  and  using  daily  baby  oil  on  scalp  and  body
or  chlorhexidine  wash  for  umbilical  cord  bathing  twice  per
week  versus  study  shampoo  versus  standard  care.  The  cream,
wash,  shampoo,  and  wipes  used  were  provided  to  parents  for  a
four-week  interval,  with  outcomes  measured  at  the  end  of  the
treatment  period.  Skjerven  2020  was  a  factorial  randomised  trial
of 2396 infants evaluating the effects of a skin barrier intervention
of emollient and bath oil and early introduction of allergenic food
on the development of eczema and food allergy. Those randomised
to  the  skin  barrier  intervention  were  advised  to  bathe  daily  with
bath oil and to apply emollient to the infant's face from two weeks
to  eight  months  of  age.  Outcomes  were  assessed  at  12  months
to three years of age. Garcia Bartels 2011 evaluated the effects of
infant swimming and applying an emollient after swimming versus
swimming  alone  in  three-  to  six-month-old  infants.  Both  groups
participated in the swimming classes once a week for four weeks.
The intervention group was instructed to apply a simple emollient
all  over  after  swimming.  The  final  outcome  was  assessed  at
one  week  after  the  end  of  the  intervention  period.  In  another
swimming-related  intervention,  Zhao  2005  evaluated  the  impact
of  daily  infant  swimming  in  the  maternity  hospital  compared  to
control.  Infants  in  the  swimming  group  had  twice-daily,  10-  to
15-minute  swimming  sessions  whilst  in  the  maternity  hospital.
Outcomes were measured on discharge.

v. Diapers 

Baldwin 2001 compared a new zinc oxide diaper to a commercially
available  diaper  for  prevention  of  diaper  dermatitis.  Previously
well  children  without  diaper  dermatitis  were  randomly  assigned
to  control  diaper  or  zinc  oxide-based  diaper  for  four  weeks.  The
outcome  of  diaper  dermatitis  was  measured  at  the  end  of  the
treatment period.

vi. Cleansing products

In  Da  Cunha  2008,  newborn  infants  were  randomised  to  receive
chlorhexidine liquid soap bath versus control liquid soap. Outcome
was  measured  at  24  hours  after  bath.  In  Garcia  Bartels  2012,

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

22

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

newborn  infants  were  randomised  to  washing  of  the  diaper  area
with  commercial  wipes  or  water-moistened  cloths  (control)  for
four  weeks.  Skin  was  assessed  at  four  weeks  (the  end  of  the
intervention  period).  In  Lavender  2012,  280  newborn  infants
were  also  randomised  to  washing  of  the  diaper  area  with  a
commercial wipe (Johnson's Baby Skincare Fragrance Free Wipe)
or cotton wool and water for four weeks postbirth, with outcome
assessed at four weeks (the end of the intervention period). Tielsch
2007 was a cluster-randomised study of 17,530 infants in rural Nepal
that  compared  all-over  cleansing  at  birth  with  a  chlorhexidine
wipe  versus  a  wipe  without  chlorhexidine.  This  was  a  one-time
intervention provided at birth. Outcome was measured at 28 days.

Follow-up

Our  specified  primary  and  secondary  outcomes  were  measured
from  one  to  three  years,  apart  from  adverse  events,  which  were
measured  during  the  intervention  period.  The  included  studies
evaluating emollients and the Skjerven 2020 study were the only
studies with follow-up long enough to meet this outcome timing.
Most  of  the  other  studies  followed  infants  up  to  a  maximum  of
four weeks, which was too soon to assess whether eczema or food
allergy was present.

Comparators

All  trials  included  a  comparison  arm  that  provided  'routine'  skin
care for their country. We did not specify the comparator, as daily
practices on how to treat infant skin vary between countries and
within  countries  according  to  cultural  norms.  We  excluded  any
trials that had an active comparator such as an emollient.

Outcomes

Of  the  33  included  studies,  17  studies  provided  data  on  one  or
more  outcomes  relevant  to  this  review,  of  which  11  could  be
included  in  the  meta-analysis.  Ten  trials  provided  IPD,  including
nine  studies  that  provided  IPD  for  the  primary  outcome  eczema
or food allergy. Cooke 2015 provided IPD for adverse events only.
Prespecified  outcome  timings  were  one  to  three  years  for  both
primary  and  secondary  outcomes  related  to  eczema  and  food
allergy.  Adverse  events  were  measured  during  the  intervention
period.

Eczema data were measured between one and three years of age
in  eight  trials  (Chalmers  2020;  Dissanayake  2019;  Lowe  2018a;
McClanahan 2019; Migacheva 2018; NCT03376243; Skjerven 2020;
Yonezawa 2018). Two trials had eczema outcomes before one year
(Horimukai  2014;  Simpson  2014).  A  further  four  trials  recorded
some  data  on  eczema  outcomes  that  were  not  useable  in
the  meta-analysis  (Amer  2017;  Bellemere  2018;  Kataoka  2010;
Thitthiwong 2019); however, these data were included in narrative
format  in  the  results.  The  primary  outcome  of  eczema  was
measured by Hanifin and Rajka or by UK Working Party methods
in  all  trials  except  one,  which  used  parental  report  of  a  doctor
diagnosis  of  eczema  (Yonezawa  2018).  Three  studies  measured
eczema  severity  between  one  and  three  years  by  clinician
assessment:  Chalmers  2020  and  NCT03376243  used  the  Eczema
Area  and  Severity  Index  (EASI)  at  two  years  and  one  year,
respectively,  whilst  Lowe  2018a  used  the  objective  SCORAD
(SCORing Atopic Dermatitis) (a clinical tool used to assess the extent
and severity of eczema) at one year. Only Chalmers 2020 recorded
parental report of eczema severity based on the Patient-Orientated
Eczema Measure (POEM) at two years. Nine studies measured time

Cochrane Database of Systematic Reviews

to onset of eczema (Chalmers 2020; Dissanayake 2019; Horimukai
2014; Lowe 2018a; McClanahan 2019; NCT03376243; Simpson 2014;
Skjerven 2020; Yonezawa 2018).

The primary outcome of IgE-mediated food allergy diagnosed by
oral  food  challenge  between  one  and  three  years  was  measured
in  Chalmers  2020  and  Skjerven  2020,  although  only  Chalmers
2020  provided  data  for  oral  food  challenge  alone,  whereas  both
trials  provided  data  for  a  composite  outcome  of  food  allergy
diagnosed  by  oral  food  challenge  or  expert  panel  assessment
at  two  or  three  years,  respectively.  Three  trials  provided  data
on  parental  report  of  doctor  diagnosis  of  food  allergy  between
one  and  three  years:  Dissanayake  2019  (by  one  year),  Yonezawa
2018  (by  two  years),  and  Chalmers  2020  (by  two  years).  Two
trials  provided  data  on  parental  report  of  an  immediate  (<  2
hours)  reaction  to  a  common  food  allergen:  Chalmers  2020  (at
two  years)  and  NCT03376243  (by  one  year).  Data  on  allergic
sensitisation to foods between one and three years were provided
in  Chalmers  2020  (at  two  years),  Lowe  2018a  (at  one  year),
and Skjerven 2020 (three years). Two trials provided data on allergic
sensitisation to foods at eight months, Horimukai 2014, and nine
months, Dissanayake 2019, which were used in sensitivity analysis
only.  Kataoka  2010  and  Thitthiwong  2019  provided  narrative
information on food allergy that could not be used in meta-analysis
but that was included in narrative format in the results.

Ten  studies  provided  data  for  the  prespecified  adverse  events  of
interest (Amer 2017; Chalmers 2020; Cooke 2015; Da Cunha 2008;
Dizon 2010; Lowe 2018a; McClanahan 2019; NCT03376243; Simpson
2014;  Skjerven  2020).  Nine  studies  contributed  some  narrative
data  on  non-specific  adverse  events,  which  were  not  included  in
the  meta-analysis  but  are  presented  descriptively  in  the  Effects
of  interventions  section  (Dissanayake  2019;  Garcia  Bartels  2011;
Horimukai  2014;  Lavender  2012;  Migacheva  2018;  Raisi  Dehkordi
2010; Sankaranarayanan 2005; Thitthiwong 2019; Tielsch 2007).

Funding

Of the 11 trials contributing data to one or more meta-analyses, two
trials did not specify funding (McClanahan 2019; Migacheva 2018);
the other nine contributing trials were funded through higher-level
institutions.

Of the six trials contributing aggregate data that were considered
not  relevant  for  inclusion  in  one  or  more  meta-analyses,  three
studies  did  not  specify  funding;  two  were  supported  by  local
hospitals; and one was commercially sponsored.

Of the 16 trials that did not contribute any data on outcomes, two
trials  did  not  report  on  funding;  two  were  sponsored  by  local
hospitals;  one  was  sponsored  by  a  local  hospital  and  the  Gates
Foundation; and 11 were commercially sponsored.

Excluded studies

We excluded a total of 191 studies (see Characteristics of excluded
studies  for  selected  reasons  for  exclusion).  Overall,  we  excluded
these studies for the following reasons.

• Wrong  patient  population  (96  studies).  The  aim  of  this  review
was  to  evaluate  the  prevention  of  eczema  and  food  allergy
in  infants,  therefore  any  population  already  diagnosed  with
eczema was excluded, along with participants over the age of
12 months. We also excluded any studies primarily evaluating

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

preterm  infants,  as  these  infants  did  not  have  a  'normal'
neonatal course; most were cared for in neonatal intensive care
units, where skin care practices are inherently different.

• Wrong study design (62 studies). Studies were excluded mainly

if they were not RCTs.

• Wrong comparator (18 studies). Studies were excluded if there

was no standard control in the study design.

• Wrong  intervention  (15  studies).  Some  interventions  included

oral probiotics.

Studies awaiting classification

We 
classification 
classification).

assessed 

four 

trials 

(see 

Characteristics 

of 

as 
studies 

awaiting
awaiting

is  a  World  Health  Organization 

ISRCTN38965585 
(WHO)-
sponsored  cluster-randomised  trial  including  over  40,000  infants
and assessing the effects of newborn massage with cold-pressed
olive  oil  on  newborn  survival  in  rural  India.  This  study  was
registered initially in 2014 and is marked as "recruitment complete".
This  study  could  only  have  contributed  information  for  adverse
events;  no  results  are  recorded  at  the  clinical  trial  registry  or  in
our search. We received no response from study authors when we
contacted them via the email addresses provided. For the update
of  this  review,  we  again  attempted  to  contact  the  team,  with  no
response.

JPRN-UMIN000026877  is  a  small  trial  of  50  infants  evaluating
the  efficacy  of  a  foam  body  cleanser  and  "lotion"  on  infant
skin;  it  was  sponsored  by  a  Japanese  cosmetics  company  and  is
marked as "complete" at the clinical trial register. We received no
response from study authors when we contacted them via the email
addresses provided, and again for this update.

NCT03640897 is a commercial trial of a wipe for infants (n = 133).
It does meet our criteria for efficacy outcomes; however, it could
potentially  contribute  information  for  adverse  events.  This  study
has  been  marked  as  "complete"  at  the  trial  register  since  March
2019. No data have been published. We received no response from
study  authors  when  we  contacted  them  through  their  website
at www.labogilbert.com/.

Ng  2021 
is  a  recently  published  study  from  Singapore  of
twice-daily Cetaphil Restoraderm moisturiser along with Cetaphil
Restoraderm wash in 200 infants with at least two primary relatives
with atopy. The primary outcome was moderate to severe eczema
at 12 months. This moisturiser contains ceramides and 2 filaggrin
breakdown products: arginine and sodium pyrrolidone carboxylic
acid. This study was not previously registered and was published
in  August  2021,  therefore  we  were  unable  to  incorporate  it  into
this  update  as  the  extensive  analysis  was  complete  by  then  and
there  was  insufficient  time  to  arrange  a  data  sharing  agreement.
However, this study should be included in any future updates of the
review.

Cochrane Database of Systematic Reviews

pilot RCT at King's College London of 80 infants that is evaluating
whether  families  would  be  willing  to  be  randomised  to  have
domestic ion exchange water softener installed, with a secondary
outcome of prevention of eczema in infants. NCT03808532 is an RCT
by MYOR Corporation of 290 infants that is evaluating the effect of
daily  emollient  for  the  prevention  of  eczema.  Eichner  2020  is  an
RCT of 1250 infants conducted in the USA to evaluate the impact of
daily lipid-rich emollient from birth to two years on the cumulative
incidence  of  eczema  at  24  months.  ChiCTR2000035585  is  an  RCT
conducted in China comparing different lengths of intervention of
daily emollient for the prevention of eczema in high-risk children
(target sample size of 752 infants). TCTR20200630006 is an RCT of
154  Thai  infants  comparing  moisturiser  versus  control  in  infants
with a family history of atopic disease.

For  the  prevention  of  eczema  and  food  allergy,  NCT03871998  is
an  RCT  in  Ireland  of  242  infants  that  is  evaluating  the  effect  of
twice-daily  all-over  emollient  in  the  first  two  months  of  life  on
incidence of eczema at 12 months and of IgE-mediated food allergy
at  24  months.  Lowe  2019  is  an  RCT  of  760  infants  undertaken
in  Melbourne,  Australia,  to  evaluate  the  impact  of  a  twice-daily
ceramide-dominant  emollient  for  the  prevention  of  eczema  and
food allergy. NCT04398758 is an RCT that is under way in Germany
to  evaluate  twice-daily  paraffin-based  cream  on  infants  with  a
family  history  of  diagnosed  eczema.  The  primary  outcome  is
eczema  at  six  months,  with  food  sensitisation  at  12  months  a
secondary outcome.

For  evaluation  of  the  skin  barrier  in  infants  without  recording
eczema  or  food  allergy  outcomes,  and  so  limited  to  contributing
adverse  event  outcome  data,  NCT03142984  is  a  study  of  160
infants  assessing  skin  barrier  effects  of  a  new  baby  wash  and
baby  lotion  in  the  UK.  CTRI/2020/03/023963  is  a  registered  study
exploring the impact of sesame oil on the skin barrier function of
newborn  infants  in  a  hospital  in  India  (target  sample  size  of  60
children),

Trialists leading the following ongoing trials are all involved in the
IPD  collaboration  and  are  willing  to  contribute  IPD  to  any  future
update of this review: NCT02906475, NCT03142984, Jabbar-Lopez
2019, NCT03871998, Lowe 2019, and Eichner 2020.

Risk of bias in included studies

We  assessed  risk  of  bias  using  the  Cochrane  RoB  2  tool  for  trials
providing outcome data on one or more of eczema, food allergy,
slippage  accidents,  skin  infections,  stinging  or  allergic  reactions,
serious  adverse  events,  time  to  eczema  onset,  parent  report  of
immediate  reaction  to  a  common  allergenic  food,  and  allergic
sensitisation (Higgins 2018). Detailed risk of bias assessment data,
with  consensus  responses  to  each  RoB  2  signalling  question,
are  available  at  Cro  2020b.  Risk  of  bias  assessments  by  analysis
are  also  summarised  in  the  risk  of  bias  tables.  Risk  of  bias
assessments  were  not  performed  for  trials  providing  qualitative
narrative information.

Ongoing studies

Risk of bias summary by domain

We  classified  11  studies  as  ongoing  studies  (see  Characteristics
of  ongoing  studies).  Specifically  for  the  prevention  of  eczema  in
infants, NCT02906475 is an RCT of 160 infants undertaken by HIPP
Pharmaceuticals to evaluate the impact of use of daily milk lotion
in  infants  for  the  prevention  of  eczema.  Jabbar-Lopez  2019  is  a

Most studies (12/17) were at low risk of bias for the randomisation
process;  we  rated  five  studies  as  some  concerns  for  risk  of  bias,
as  insufficient  information  on  allocation  concealment  or  balance
in  baseline  characteristics  was  provided  (Amer  2017;  Bellemere
2018; Dizon 2010; Kataoka 2010; Migacheva 2018).

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

24

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Most  studies  (12/17)  providing  outcome  data  were  judged  to  be
at  low  risk  of  bias  for  deviations  from  intended  interventions  for
all outcomes, as whilst it was not possible to blind participants or
carers in the individual studies due to the nature of the intervention
under study, no evidence indicates that deviations arose because
of  the  trial  context.  Control  group  rates  of  skin  care  application
were  consistent  with  those  of  other  trials  and  observational
studies, which have reported that up to 75% of individuals apply
a  skin  care  intervention  (Rendell  2011).  Additionally,  analyses
were appropriately performed according to the intention-to-treat
principle to identify the effect of assignment to the intervention.

We  assessed  three  studies  as  at  some  concerns  of  bias
for deviations from intended interventions for all outcomes (Amer
2017;  Migacheva  2018;  Thitthiwong  2019),  as  they  provided  no
information to permit an assessment of whether deviations arose
because of trial context. In two other studies, analysis populations
were unclear, therefore we rated these studies as having high risk
of bias (Bellemere 2018; Kataoka 2010).

For  missing  data  on  our  outcomes  of  interest,  studies  were
predominantly  at  low  risk  of  bias  or  at  some  concerns  if
they  included  a  non-negligible  quantity  of  missing  data,  and  if
sensitivity  analysis  using  the  individual  participant  revealed  that
trial conclusions changed (point estimate changed by at least 20%
of the complete-case estimate). However, across most outcomes,
whilst  missingness  could  have  depended  on  the  true  value,  we
judged  it  unlikely  that  missingness  in  the  outcome  depended  on
its  true  value  due  to  trial  circumstances  and  the  fact  that  rates
of  missingness  did  not  vary  considerably  by  intervention  groups.
The one exception to this was a single trial that provided outcome
data  on  food  allergy  as  assessed  by  oral  food  challenge  and  was
rated  as  having  high  risk  of  bias  for  missing  data  (see  Risk  of
bias  table  for  Analysis  1.33)  (Chalmers  2020).  Data  were  missing
for  398/1394  (29%)  of  randomised  participants.  Results  varied  in
missing data sensitivity analyses performed using the IPD, and it
was  judged  potentially  likely  that  missingness  depended  on  the
value  of  the  outcome  (because  there  was  a  difference  between
treatment groups in the proportion of participants who underwent
oral  food  challenge),  and  recorded  reasons  for  missingness
included  decline  in  oral  food  challenge  and  unwillingness  to
participate, which could have depended on the outcome.

For  measurement  of  the  outcome,  outcomes  reported  by  carers
(e.g.  adverse  events,  report  of  reaction,  POEM,  eczema  for  one
study)  were  judged  at  some  concerns  for  risk  of  bias,  as  carers
were  unblinded  due  to  the  nature  of  the  intervention.  However,
whilst  knowledge  of  the  intervention  could  have  influenced
the  measurement,  it  was  judged  unlikely  to  have  impacted
measurement. For other outcome measurements, if no information
was  available  on  the  blinding  status  of  assessors,  these  were
rated as some concerns. One trial supplied no information on how
eczema was measured or by whom it was measured and was rated
as having high risk of bias for this outcome.

Selection of the reported result

Of the 17 studies providing data on one or more of our outcomes
assessed  for  risk  of  bias,  10  were  rated  at  low  risk  of  bias  for
selection of reported results; these studies supplied IPD (Chalmers
2020; Cooke 2015; Dissanayake 2019; Horimukai 2014; Lowe 2018a;
McClanahan  2019;  Simpson  2014;  Skjerven  2020;  NCT03376243;
Yonezawa  2018).  For  each  of  these  trials,  for  each  outcome,  we

Cochrane Database of Systematic Reviews

performed  the  required  analysis  using  the  supplied  trial  data
set  in  keeping  with  a  prespecified  statistical  analysis  plan  that
was  finalised  before  unblinded  outcome  data  were  available  for
analysis (Cro 2020a).

Seven  trials  contributing  some  aggregated  outcome  data  were
rated  as  some  concerns  for  selection  of  reported  results  (Amer
2017;  Bellemere  2018;  Da  Cunha  2008;  Dizon  2010;  Kataoka
2010;  Migacheva  2018;  Thitthiwong  2019).  Of  these  studies,
only Migacheva 2018 was included in the meta-analysis. All seven
trials  provided  no  information  on  whether  a  prespecified  statical
analysis plan, finalised before unblinding, was followed.

Overall risk of bias

In  summary,  we  assessed  most  of  the  evidence  included  in
this  review  as  low  risk  or  some  concern  of  risk  of  bias.  Over
all  RoB  2  domains,  3/17  studies  were  rated  as  low  risk  of  bias
across  all  included  outcomes  (Cooke  2015;  Dissanayake  2019;
Horimukai  2014);  eight  were  rated  as  some  concerns  for  risk
of  bias  across  all  included  outcomes  (Da  Cunha  2008;  Dizon
2010; McClanahan 2019; Migacheva 2018; NCT03376243; Simpson
2014;  Thitthiwong  2019;  Yonezawa  2018);  and  one  was  at  high
risk  of  bias  for  its  sole  included  outcome  (Bellemere  2018).  Two
trials  were  predominantly  rated  as  some  concerns  of  risk  of  bias
across all included outcomes due to measurement of the outcome
or missing data  (5/6 and 4/6 outcomes for Skjerven 2020 and Lowe
2018a,  respectively),  but  also  included  outcomes  at  low  risk  of
bias  (1/6  and  2/6  outcomes  for  Skjerven  2020  and  Lowe  2018a,
respectively).  We  assessed  one  study  as  at  high  risk  of  bias  for
eczema and as at some concerns for risk of bias for the skin infection
outcome  overall  (Amer  2017).  Another  study  was  at  high  risk  of
bias  for  allergic  sensitisation  and  some  concerns  for  risk  of  bias
for the eczema outcome overall (Kataoka 2010). Finally, one study
was  at  low  risk  of  bias  for  2/7  outcomes;  some  concerns  for  4/7
outcomes due to unblinded measurement; and high risk of bias for
food allergy due to missing data (Chalmers 2020).

Effects of interventions

See: Summary of findings 1 Skin care intervention compared to
standard skin care or no skin care intervention for the prevention
of eczema and food allergy

Primary outcomes

Primary  and  secondary  outcome  results  are  presented  for
comparison  1:  skin  care  intervention  versus  no  treatment  or
standard  care  only.  We  did  not  evaluate  comparison  2:  skin
care  intervention  B  versus  no  treatment  or  standard  care  only
because  our  search  did  not  identify  any  eligible  studies  of  skin
care interventions type B. Results are summarised in Summary of
findings 1.

Eczema 

Individual  participant  data  on  eczema  diagnosis  by  age  one
to  three  years  were  available  from  seven  studies  including
4800 randomised participants (Chalmers 2020; Dissanayake 2019;
Lowe  2018a;  McClanahan  2019;  NCT03376243;  Skjerven  2020;
Yonezawa  2018).  Eczema  was  measured  using  the  Hanifin  and
Rajka criteria (Hanifin 1980), or the UK Working Party refinement of
these criteria (Williams 1994), or other modifications of the Hanifin
and  Rajka  criteria  in  six  trials  (Chalmers  2020;  Dissanayake  2019;
Lowe  2018a;  McClanahan  2019;  NCT03376243;  Skjerven  2020),

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

and  eczema  was  doctor  diagnosed  in  one  trial  (Yonezawa  2018).
Eczema  was  diagnosed  cumulatively  up  to  12  months  in  three
trials  (Dissanayake  2019;  Lowe  2018a;  NCT03376243);  up  to  24
months in three trials (Chalmers 2020; McClanahan 2019; Yonezawa
2018);  and  up  to  both  12  months  and  36  months  in  one  trial
(Skjerven  2020).  Pooled  IPD  available  from  3075  participants  in
these  studies  showed  no  benefit  of  skin  care  intervention  (risk
ratio (RR) 1.03, 95% confidence interval (CI) 0.81 to 1.31; Analysis
1.1).  However,  the  95%  CI  for  the  pooled  RR  indicates  that  we
cannot rule out potential benefit or harm, extending from 0.81 to
1.31. Results showed moderate statistical heterogeneity between
studies  for  this  outcome  (I2  =  41%,  P  =  0.12).  This  was  driven
by  one  trial  with  an  RR  favouring  standard  care  (RR  1.57,  95%
CI  1.10  to  2.23)  (Skjerven  2020),  and  may  be  due  to  the  type  of
intervention  (bathing  with  oil  and  emollient  applied  to  the  face
only) or by timing of outcome assessment, or both. When this study
was excluded, pooled IPD available from 2004 participants in the
remaining  six  studies  continued  to  show  no  benefit  of  skin  care
intervention (RR 0.95, 95% CI 0.81 to 1.12; I2 = 0%; Analysis 1.12).
When three-year data instead of one-year data were used from this
study (Skjerven 2020), there was also no evidence for a benefit of
skin  care  intervention  and  no  statistical  heterogeneity  (RR  1.00,
95% CI 0.88 to 1.14; I2 = 0%; Analysis 1.5).

study 

supply 

that  did  not 

We  conducted  a  series  of  preplanned  sensitivity  analyses
including  aggregate  data
(see  Table  4).  Sensitivity  analysis 
from  one  additional 
IPD
involving 63 randomised participants, of which 60 completed the
study  (Migacheva  2018),  did  not  change  the  pooled  result  (RR
0.97, 95% CI 0.75 to 1.25; Analysis 1.2). When only the six studies
that  used  the  Hanifin  and  Rajka  criteria  (Hanifin  1980),  or  the
UK  Working  Party  refinement  of  them  (Williams  1994),  or  other
modifications  of  the  Hanifin  and  Rajka  criteria  to  assess  eczema
were  included,  the  pooled  result  remained  consistent  (RR  1.02,
95% CI 0.78 to 1.34; Analysis 1.3). The pooled result also remained
consistent in sensitivity analyses that included data from all four
arms  of  Skjerven  2020  (RR  1.03,  95%  CI  0.81  to  1.31;  Analysis
1.4);  using  three-year  in  place  of  the  one-year  eczema  outcome
for  Skjerven  2020  (RR  1.00,  95%  CI  0.88  to  1.14;  Analysis  1.5);
including  only  studies  at  low  risk  of  bias  (RR  0.97,  95%  CI  0.81
to  1.17;  Analysis  1.6);  excluding  non-prospectively  acquired  data
(RR  1.08,  95%  CI  0.84  to  1.37; Analysis  1.7);  incorporating  studies
assessing  eczema  by  six  months  to  three  years  (RR  0.89,  95%  CI
0.70 to 1.14; Analysis 1.8); and considering eczema only after the
intervention period (i.e. at one year or beyond) (RR 1.00, 95% CI 0.87
to 1.16; Analysis 1.9).

Four  additional  studies  randomising  a  total  of  314  participants
provided  aggregate  data  on  eczema  at  four  weeks,  Amer
2017,  six  months,  Bellemere  2018;  Kataoka  2010,  and  nine
months, Thitthiwong 2019, that were not eligible for meta-analysis
because  IPD  were  not  supplied,  and  data  were  only  reported
from  the  short  follow-up  period.  Amer  2017  reported  eczema
in  0/35  (0%)  participants  randomised  to  skin  care  intervention
and  2/35  (5.7%)  randomised  to  standard  care  over  a  four-week
follow-up period. At six months, Bellemere 2018 reported eczema
in  9.8%  of  the  intervention  arm  versus  18.3%  of  the  control
arm  (60  participants  were  randomised  to  each  treatment  group,
but  the  analysis  population  was  not  clear);  after  follow-up  of
24  months,  seven  new  cases  of  atopic  dermatitis  were  observed
in  the  intervention  group  and  six  new  cases  in  the  control
group. Kataoka 2010 reported 5/35 (14%) versus 6/32 (19%) cases of

Cochrane Database of Systematic Reviews

eczema in the intervention and control arms, respectively.  At nine
months,  Thitthiwong  2019  reported  0/26  (0%)  versus  4/27  (15%)
cases of eczema in the intervention and control arms, respectively.

Subgroup  analysis  did  not  suggest  any  differences  in  treatment
effects  by  intervention  type  or  intervention  duration.  For  basic
emollients  (Chalmers  2020;  McClanahan  2019;  Skjerven  2020),
there  was  a  pooled  RR  of  1.04  (95%  CI  0.66  to  1.65),  and  for
complex emollients (Dissanayake 2019; Lowe 2018a; NCT03376243;
Yonezawa  2018),  there  was  a  pooled  RR  of  1.01  (95%  CI  0.75
to  1.37)  (Analysis  1.10).  Only  one  study  reported  a  prescribed
intervention period of less than six months (Yonezawa 2018), with
an RR of 1.01 (95% CI 0.45 to 2.26; Analysis 1.11). For the six studies
with an intervention period of six months or more (Chalmers 2020;
Dissanayake  2019;  Lowe  2018a;  McClanahan  2019;  NCT03376243;
Skjerven 2020), there was a pooled RR of 1.02 (95% CI 0.78 to 1.34)
(Analysis 1.11). One study initiated the intervention after the first
week  of  life  (Skjerven  2020),  with  an  RR  of  1.57  (95%  CI  1.10  to
2.23),  which  differed  significantly  from  studies  that  initiated  the
intervention  during  the  first  week  of  life  (RR  0.95,  95%  CI  0.81  to
1.12; Analysis 1.12). Another clear difference in this study was that
the intervention was emollient applied to the face only, with a daily
bath using a bath oil.

The  interaction  effect  between  treatments  and  actual  age  of
treatment  initiation  (<  4  days,  ≥  4  days)  for  eczema  by  one  to
three years could be estimated for two trials (Chalmers 2020; Lowe
2018a), which randomised a total of 1474 participants. Pooled IPD
available  from  1284  participants  in  these  two  studies  showed  no
impact  of  age  of  treatment  initiation  on  treatment  effect  (RR
1.05,  95%  CI  0.64  to  1.73;  Analysis  1.13).  In  one  additional  study
randomising  118  participants  (Horimukai  2014),  the  interaction
between  treatment  and  actual  age  of  treatment  initiation  for
eczema  by  eight  months  could  be  estimated  for  99  participants.
When data from this study were incorporated, pooled IPD available
from  1383  participants  continued  to  show  no  impact  of  age  of
treatment initiation (RR 1.59, 95% CI 0.56 to 4.51; Analysis 1.14).

The  interaction  effect  between  treatment  and  FLG  genotype  on
eczema  by  one  to  three  years  could  be  estimated  for  three
trials  (Chalmers  2020;  McClanahan  2019;  Skjerven  2020).  Pooled
individual  data  available  from  1716  participants  in  these  studies
showed no impact of having the 1/2 FLG mutations on treatment
effect (RR 1.08, 95% CI 0.69 to 1.70; Analysis 1.15). In one additional
study randomising 124 participants (Simpson 2014), the interaction
between treatment and FLG mutations for eczema by six months
could be estimated for 63 participants. When data from this study
were  incorporated,  pooled  IPD  available  from  1779  participants
continued  to  show  an  uncertain  impact  of  FLG  mutations  on
treatment effect (RR 1.03, 95% CI 0.66 to 1.61; Analysis 1.16).

The  interaction  effect  between  treatment  and  family  history  of
atopic disease on eczema by one to three years could be estimated
for three trials (Dissanayake 2019; Skjerven 2020; Yonezawa 2018),
which randomised 3172 participants. Based on available data from
1663  participants,  the  pooled  RR  of  eczema  by  two  years  for
having one or more family members in the skin care intervention
group versus zero did not indicate a notable interaction (RR 0.95,
95% CI 0.35 to 2.61; Analysis 1.19).

The  interaction  effect  between  treatment  and  FLG  genotype  or
family  history  of  atopic  disease  on  eczema  by  one  to  three  years
could be estimated for one trial (Skjerven 2020). Based on available

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

26

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

data from 1065 participants in Skjerven 2020, the RR of eczema by
one year for having 1/2 FLG mutations or family history of atopic
disease in the skin care intervention group versus zero mutations
and  no  family  history  was  RR  0.62  (95%  CI  0.16  to  2.44;  Analysis
1.20).  The  wide  95%  CI  indicates  uncertainty  surrounding  the
direction  and  magnitude  of  any  effect  of  FLG  or  family  history  of
atopic disease on treatment effect from this one study.

The  interaction  effect  between  treatment  and  the  chromosome
11  intergenic  variant  rs2212434  on  eczema  by  one  to  three  years
could be estimated for two trials (Skjerven 2020; Chalmers 2020).
Pooled  individual  data  available  from  1807  participants  in  these
studies showed no impact of C:T or T:T genotype (where T is the
risk  allele)  versus  C:C  genotype  on  the  treatment  effect  (RR  1.31,
95%  CI  0.85  to  2.03;  Analysis  1.17)  The  wide  95%  CI  indicates
uncertainty surrounding the direction and magnitude of any effect
of chromosome 11 variants on the treatment effect from these two
studies.

There  is  evidence  of  a  multiplicative  effect  of  FLG  null  genotype
and  variants  at  the  chromosome  11q13.5  locus  on  eczema  risk
(O'Regan  2010).  The  interaction  effect  between  treatment  and
FLG  genotype  and  the  chromosome  11  variant  on  eczema  by
one  to  three  years  was  available  for  two  trials  (Chalmers  2020;
Skjerven 2020). Based on available data on 1644 participants, the
RR  for having eczema by one to three years in those with one or
two  FLG  mutation(s)  and/or  C:T  or  T:T  genotype  at  chromosome
11  locus  in  the  skin  care  intervention  group  versus  no  FLG
mutation and no chromosome 11 variant was 1.24 (95% CI 0.72 to
2.12; Analysis 1.18).

The complier average causal effect (CACE) for an individual using
skin  care  intervention  for  three  or  more  days  a  week  could  be

Figure 2.   Trial sequential analysis for eczema (RR of 30%).

Cochrane Database of Systematic Reviews

estimated  for  three  trials  providing  adequate  compliance  and
eczema  outcome  data  (Chalmers  2020;  Lowe  2018a;  Yonezawa
2018).  The  pooled  CACE  for  an  individual  using  skin  care
intervention for three or more days a week from 1440 participants
in  these  studies  was  on  average  more  in  favour  of  the  skin  care
intervention (RR 0.65, 95% CI 0.29 to 1.45; Analysis 1.21) compared
with  the  pooled  intention-to-treat  effect  for  these  same  three
studies (RR 0.93, 95% CI 0.77 to 1.12; Analysis 1.27). However, the
95% CI for the CACE estimate was considerably wider than for the
intention-to-treat effect and was consistent with the intention-to-
treat effect of no difference, a decreased or an increased risk ratio,
therefore we could not infer any difference in treatment effects for
a complier. Additional CACE estimates for alternative definitions of
a complier are displayed in Table 5, and similarly do not reveal an
impact of compliance on treatment effect.

Trial  sequential  analysis  shows  that  a  target  sample  size  of
5534 would be necessary to demonstrate a minimum relative risk
reduction  of  30%  (assuming  a  control  rate  of  15%  versus  skin
care  intervention  10.5%)  with  90%  power  (Figure  2).  However,
based  on  the  data  accumulated  to  date  and  included  within  the
primary eczema meta-analysis (3075 participants), the Z value falls
on  the  boundary  of  the  inner  wedge  and  is  well  within  the  two-
sided significance testing boundaries, indicating that a conclusion
can  be  made:  the  intervention  effect  is  not  greater  than  30%.  A
target sample size of 13,072 would be necessary to demonstrate a
minimum relative risk reduction of 20% (assuming a control rate
of 15% versus skin care intervention 12%) with 90% power (Figure
3). The meta-analysis is currently inconclusive for an effect size of
20 because it has not yet crossed the upper or lower boundary for
statistical significance or non-superiority.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

27

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 3.   Trial sequential analysis for eczema (RR of 20%).

Food allergy

IgE-mediated 

Individual  participant  data  on 
food  allergy,
confirmed by oral food challenge, by age one to three years were
recorded  in  one  study  (Chalmers  2020).  Data  on  oral  food
challenge,  conducted  at  two  years,  were  available  for  976
participants in one study (Chalmers 2020), and favoured standard
care  (RR  2.53,  95%  CI  0.99  to  6.49;  Analysis  1.33).  The  95%  CI  for
the  RR  is  wide,  and  is  consistent  with  both  no  effect  or  small  to
large  harm  of  skin  care  intervention  in  this  one  study.  Data  were
available for food allergy evaluated by a combination of oral food
challenge  and  investigator  assessment  based  on  clinical  history
or  allergy  tests,  or  both,  for  2030  participants  in  two  studies  and
favoured standard care (RR 1.45, 95% CI 0.98 to 2.15; Analysis 1.34)
(Chalmers 2020; Skjerven 2020). The width of the 95% CI for the RR
was reduced, but still included both no difference and small to large
harm of skin care intervention. These data are also shown in Table
6.

For  food  allergy  measured  by  a  parental  report  of  a  doctor
diagnosis,  IPD  were  available  for  three  studies  including  2170
randomised  participants  (Chalmers  2020;  Dissanayake  2019;
Yonezawa 2018). Food allergy diagnosis was cumulative up to 12
months for one trial (Dissanayake 2019), and up to 24 months for
two  trials  (Chalmers  2020;  Yonezawa  2018).  Pooled  IPD  available
from  1614  participants  in  these  studies  showed  no  effect  of  skin
care intervention (RR 1.02, 95% CI 0.80 to 1.31; I2 = 0; Analysis 1.35).

One  additional  trial  randomising  53  participants  reported  some
narrative information on food allergy for only the control group that
was not suitable for inclusion in meta-analysis (Thitthiwong 2019).
It was narratively reported that "none of the 4 IAD [infantile atopic
dermatitis]  infants  developed  cow’s  milk  protein  allergy  or  any
other food allergy".

As  only  one  study  reported  the  primary  food  allergy  outcome
(Chalmers 2020), and the two studies that reported IgE-mediated
food allergy confirmed by oral food challenge or via an investigator
assessment  based  on  clinical  history  and/or  skin  prick  tests
fell  within  the  same  groups  for  each  of  the  planned  subgroup
analysis (intervention type: basic emollients, intervention period:
≥  6  months;  and  intervention  duration:  long)  (Chalmers  2020;
Skjerven 2020), we did not conduct planned subgroup analysis at
the study level for food allergy.

Access  to  IPD  did  allow  us  to  assess  the  interaction  between
actual  age  of  treatment  initiation  and  treatment.  Based  on  data
available  for  976participants  in  Chalmers  2020,  the  RR  of  food
allergy for starting skin care treatment at four or more days of age,
in  comparison  to  initiation  of  skin  care  treatment  less  than  four
days,  was  0.49  (95%  CI  0.07  to  3.40).  The  wide  95%  CI  indicates
uncertainty surrounding the direction and magnitude of any effect
of age of treatment initiation.

The  interaction  effect  between  treatment  and  FLG  genotype  on
food allergy (provided by IgE-mediated food allergy confirmed by
oral  food  challenge  only)  was  available  for  one  trial  (Chalmers
2020),  but  was  not  estimable.  The  interaction  effect  between
treatment  and  FLG  genotype  on  food  allergy  (provided  by  IgE-
mediated food allergy confirmed by oral food challenge or via an
investigator assessment based on clinical history or skin prick tests
data,  or  both)  by  one  to  three  years  could  be  estimated  for  two
trials  (Chalmers  2020;  Skjerven  2020).  Based  on  individual  data
from  1517  participants,  the  RR  of  food  allergy  by  three  years  for
having one or two FLG null mutations in the skin care intervention
group  versus  no  FLG  mutations  was  RR  1.29  (95%  CI  0.41  to
4.08; Analysis 1.36).

The  interaction  effect  between  treatment  and  the  chromosome
11  variant  on  food  allergy  (provided  by  IgE-mediated  food

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

28

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

allergy  confirmed  by  oral  food  challenge  only)  was  available  for
one trial (Chalmers 2020), but was not estimable. The interaction
effect between treatment and the chromosome 11 variant on food
allergy (provided by IgE-mediated food allergy confirmed by oral
food challenge or via an investigator assessment based on clinical
history  or  skin  prick  tests  data,  or  both)  by  one  to  three  years
could be estimated for two trials (Chalmers 2020; Skjerven 2020).
Based  on  available  data  from  1650  participants,  the  RR  of  food
allergy  by  three  years  for  having  C:T  or  T:T  genotype  in  the  skin
care intervention group versus C:C mutation was RR 1.59 (95% CI
0.63 to 4.01; Analysis 1.37). The wide 95% CIs indicate uncertainty
surrounding  the  direction  and  magnitude  of  any  effect  of  the
chromosome 11 variant mutations on treatment effect from these
studies.

The  interaction  effect  between  treatment  and  the  combination
of  FLG  genotype  and  the  chromosome  11  variant  on  food  allergy
(provided  by  IgE-mediated  food  allergy  confirmed  by  oral  food
challenge  only)  was  available  for  one  trial  (Chalmers  2020),  but
was not estimable.  The interaction effect between treatment and
the combination of FLG genotype and the chromosome 11 variant
on food allergy (provided by IgE-mediated food allergy confirmed
by oral food challenge or via an investigator assessment based on
clinical history or skin prick tests data, or both) by one to three years
could be estimated for two trials (Chalmers 2020; Skjerven 2020).
Based  on  available  data  from  1492  participants,  the  RR  of  food
allergy by three years in those with one or two FLG mutations and/or
C:T or T:T genotype at the chromosome 11 locus versus no FLG null
mutations and C:C genotype was 1.67 (95% CI 0.57 to 4.93; Analysis
1.38).

Cochrane Database of Systematic Reviews

The CACE for an individual using a skin care intervention for three
or more days a week could be estimated for one study providing
adequate  compliance  and  food  allergy  outcome  data  (Chalmers
2020).  The  CACE  on  food  allergy  assessed  (confirmed  by  oral
food challenge or via an investigator assessment based on clinical
history  or  skin  prick  tests  data,  or  both)  for  an  individual  using
a  skin  care  intervention  for  three  or  more  days  a  week  based
on 1115 participants was accompanied by a considerable level of
uncertainty, as reflected by very wide 95% CI (RR 4.06, 95% CI 0.59
to  27.68;  Analysis  1.39).  Whilst  the  point  estimate  for  the  RR  was
more  in  favour  of  standard  care  compared  with  the  intention-to-
treat effect of RR 2.53 (95% CI 0.99 to 6.49) (Analysis 1.33), the 95% CI
for the CACE estimate is considerably wider than for the intention-
to-treat effect and is consistent with the intention-to-treat effect of
no difference. We therefore cannot infer any difference in treatment
effect  for  a  complier.  Additional  CACE  estimates  for  alternative
definitions of a complier are displayed in Table 7, and similarly do
not demonstrate an impact of compliance on the treatment effect
due to a large amount of uncertainty in estimation.

Trial  sequential  analysis  shows  that  a  target  sample  size  of  7602
would  be  necessary  to  demonstrate  a  minimum  relative  risk
reduction of 30% (assuming a control rate of 5% versus skin care
intervention  3.5%)  with  90%  power  (Figure  4).  A  target  sample
size  of  18,063  would  be  necessary  to  demonstrate  a  minimum
relative  risk  reduction  of  20%  (assuming  a  control  rate  of  5%
versus skin care intervention 4%) with 90% power (Figure 5). Based
on  the  data  accumulated  to  date  included  within  the  primary
food allergy meta-analysis (976 participants), the meta-analysis is
inconclusive  for  a  relative  effect  size  of  30  or  smaller,  because  it
has  not  yet  crossed  the  upper  or  lower  boundary  for  statistical
significance or non-superiority.

Figure 4.   Trial sequential analysis for food allergy (RR of 30%).

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

29

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 5.   Trial sequential analysis for food allergy (RR of 20%).

Secondary outcomes

Adverse effects

Our  adverse  events  of  interest  for  which  we  separately  reported
meta-analysis  below  were  skin  infections,  stinging  or  allergic
reactions, slippages, and serious adverse events recorded over the
study intervention period. Ten trials reported some data on one or
more of these specific adverse events, seven trials of which could be
included in one or more meta-analyses.

An  additional  nine  trials  randomising  18,869  participants  (one
trial  randomised  17,530  participants)  provided  a  short  general
qualitative  narrative  on  adverse  events  not  eligible  for  inclusion
in  the  meta-analysis  (Dissanayake  2019;  Garcia  Bartels  2011;
Horimukai  2014;  Lavender  2012;  Migacheva  2018;  Raisi  Dehkordi
2010; Sankaranarayanan 2005; Thitthiwong 2019; Tielsch 2007). Of
these  nine  trials,  six  trials  randomising  18,593  participants

  (9412  control,  9181 

intervention)  narratively  reported  no

intervention-related adverse events (Dissanayake 2019; Horimukai
2014;  Lavender  2012;  Migacheva  2018;  Thitthiwong  2019;
Tielsch  2007).  Of  the  remaining  three  trials,  Sankaranarayanan
2005 (randomised 112 term babies to groups of 38 coconut oil, 37
mineral oil, and 37 placebo) reported "3 in the coconut oil group, 3
in the mineral oil group and 2 in the placebo group developed mild
rash  that  did  not  require  discontinuation  of  application";  Garcia
Bartels 2011 (randomised 44; 20 lotion and 24 no lotion) reported
"the overall occurrence of adverse events (AEs) was lower in group
L (lotion) (n = 18) than in group WL (without lotion) (n = 33, Table 3)";
and Raisi Dehkordi 2010 (randomised 120) reported "some adverse
events  in  the  oil  massage  groups;  however  they  were  mild  rash,
which required no cessation".

Skin infections

Individual  participant  data  on  skin  infections  were  available
from  six  studies  (Chalmers  2020;  Cooke  2015;  Lowe  2018a;

McClanahan 2019; Simpson 2014; Skjerven 2020), including a total
of 4209 randomised participants. Pooled IPD available from 2728
participants  in  these  studies  were  in  favour  of  standard  care  (RR
1.33, 95% CI 1.01 to 1.75; Analysis 1.45), with I2 = 0 (P = 0.95).

One  additional  trial  that  randomised  70  participants  (35  to  each
group) reported weekly infection rates over four weeks of 0 (0%), 3
(8.6%), 7 (20%), and 5 (14.3%) in the control group versus 0 (0%), 0
(0%), 1 (2.9%), and 0 (0%) in the skin care group (Amer 2017).

Stinging or allergic reactions

Individual  participant    data  on  stinging  or  allergic  reactions
to  moisturisers  were  available  from  four  studies  (Cooke  2015;
Lowe  2018a;  McClanahan  2019;  NCT03376243),  including  a  total
of  349  randomised  participants.  Pooled  IPD  available  from
343 participants in these studies were in favour of standard care (RR
2.24, 95% CI 0.67 to 7.43; Analysis 1.46), with I2 = 0 (P = 0.99), but
with some uncertainty about the true effect, the 95% CI including
no difference and a benefit of skin care intervention.

One study randomising 120 participants to Johnson's Baby Top-To-
Toe wash (Group 1, n = 60), Sebamed Baby Liquid Cleanser (Group
2, n = 60), and lukewarm tap water (Group 3, n = 60) reported "in
group I, 1/60 subjects had mild rashes and redness on the neck and
arms that appeared around 4 days after use. The irritation appeared
2-3  hours  after  bathing  and  lasted  for  a  few  minutes.  In  group  II,
2/60 subjects had irritation in the first week. These were mild rashes
on  the  back  and  leg  and  lasted  for  1-  2  days.  For  group  II,  1/60
subjects had mild rashes and dryness 3 days after starting use of the
product. No irritation was noted with any of the three compounds
in  the  second  week"  (Dizon  2010).    It  was  also  reported  that  "no
statistically significant irritation was visible to the clinician for all
three groups of the study".

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

30

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

One additional study randomised 93 participants to receive the first
bath with chlorhexidine (n = 44) or neutral liquid soap in the control
group (n = 49) (Da Cunha 2008). No adverse effects were reported
for the use of chlorhexidine, including skin irritation.

Slippage accidents

Individual  participant  data  on  slippage  accidents  were  available
from  four  studies  (Chalmers  2020;  Lowe  2018a;  Simpson  2014;
Skjerven 2020), involving a total of 3994 randomised participants.
Two studies recorded no slippage events in both treatment groups
(Simpson  2014;  Skjerven  2020).  Pooled  IPD  analysis  from  2538
participants  in  these  studies  showed  that  the  treatment  effect
favoured  standard  care  (RR  1.42,  95%  CI  0.67  to  2.99;  Analysis
1.47), with I2 = 0 (P = 0.68), but with some uncertainty about the true
effect, the 95% CI including no difference and a benefit of skin care
intervention (Chalmers 2020; Lowe 2018a).

Skjerven 2020 provided data on slippage accidents and was a 2 x
2 factorial trial. Because significant interaction was noted between
the two interventions in this trial (food intervention and skin care
intervention), we only included in our analysis data from the skin
care  intervention  group  versus  the  control  group,  as  was  in  line
with  our  prespecified  statistical  analysis  plan  (Cro  2020a).  One
accident connected with bathing was reported for a participant in
the 'food and skin care' intervention group (1/583, 0.2%); however
the 'food and skin care' group was not included in the analysis as a
significant interaction between skin care and early introduction of
food allergens was identified.

Serious adverse events

Individual  participant  data  on  serious  adverse  events  were
available from three studies including a total of 2591 randomised
participants  (Cooke  2015;  Lowe  2018a;  Skjerven  2020).  Pooled
IPD  available  from  1367  participants  in  these  studies  favoured
standard care (RR 1.80, 95% CI 0.45 to 7.18; Analysis 1.48), but with
some  uncertainty  about  the  true  effect,  the  95%  CI  including  no
difference  and  a  benefit  of  skin  care  intervention.  The  evidence
showed some heterogeneity (I2 = 51, P = 0.13); however, only three
trials  were  included  in  this  comparison,  each  of  which  had  wide
confidence intervals for the effect size, including no difference and a
benefit of standard care and a benefit of skin care intervention due
to  small  numbers  of  events.  A  description  of  reported  serious
adverse events is provided in Table 8.

Eczema severity 

Individual  participant  data  on  eczema  severity  as  assessed  by  a
clinician  at  one  to  three  years  were  available  from  three  studies
including  1528  randomised  participants  (Chalmers  2020;  Lowe
2018a;  NCT03376243).  Eczema  severity  was  measured  using  the
EASI  at  24  months  for  Chalmers  2020;  the  EASI  at  12  months
for NCT03376243; and the objective SCORAD at 12 months for Lowe
2018a. When no eczema was present, two studies had recorded an
eczema severity rating of 0 (Chalmers 2020; NCT03376243). For one
study, we imputed an eczema severity rating of 0 for the purpose of
analysis when no eczema was reported (Lowe 2018a).

We  first  assessed  the  risk  of  moderate/severe/very  severe
eczema  versus  clear/mild  eczema.  Two  studies  did  not  record
any  incidences  of  moderate/severe/very  severe  eczema  in  either
treatment  group  amongst  a  total  of  108  participants  (58
skin  care  intervention  versus  50  standard  care)  (Lowe  2018a;

Cochrane Database of Systematic Reviews

NCT03376243). In the third study (Chalmers 2020), data on eczema
severity, measured  by  a  clinician at  two  years,  were  available for
1120  participants,  and  showed  no  difference  between  treatment
groups  (RR  0.92,  95%  CI  0.37  to  2.27;  Analysis  1.49).  The  95%  CI
for the RR is wide, indicating no difference or small to large harm,
and benefit of the skin care intervention for moderate/severe/very
severe eczema cannot be ruled out based on this one study.

We  subsequently  assessed  the  pooled  standardised  mean
for  clinician-assessed  eczema
treatment  group  difference 
severity.  Pooled  IPD  available  from  1228  participants  in  the
three  studies  providing  participant  data  on  clinician-assessed
eczema  severity  showed  no  difference  between  treatment
groups (standardised mean difference (SMD) −0.02, 95% CI −0.17 to
0.12; Analysis 1.50), with I2 = 7% (P = 0.34) (Chalmers 2020; Lowe
2018a; NCT03376243). When the SMD was re-expressed on the EASI,
this  was  equivalent  to  a  mean  difference  (MD)  of  −0.035  (95%  CI
−0.296 to 0.209), using the pooled standard deviation (SD) of 1.74
for EASI as observed in the largest study (Chalmers 2020).

An additional study randomising 63 participants (31 intervention,
32  control)  that  did  not  provide  IPD  narratively  reported  that  60
infants completed the study (29 intervention, 31 control), and the
severity of eczema measured using the SCORAD in the control group
was significantly greater than in the intervention group: "(22.6 +/-
12.9  vs  17.6  +/-  5.3  respectively,  U  =  348,  P  <  0.058)"  (Migacheva
2018).  Bellemere  2018  reported  that  amongst  120  randomised
participants (60 intervention, 60 control), the frequency of atopic
dermatitis  during  the  first  six  months  of  life  was  9.8%  in  the
prevention group, 18.3% in the control group, and 6.7% in the no-
risk group. Mean SCORAD scores were 24.1 and 23.3 in the at-risk
groups.

Parent-assessed eczema severity

Individual  participant  data  on  eczema  severity  as  assessed  by  a
parent were available from one study including 1394 randomised
participants (Chalmers 2020). Eczema severity was measured using
the POEM at 24 months. We first evaluated the risk of moderate/
severe/very severe eczema versus clear/mild eczema as assessed
by  the  parent.  Data  on  eczema  severity  as  assessed  by  a  parent
at  two  years  were  available  for  1171  participants,  and  showed
no difference between treatment groups (RR 1.17, 95% CI 0.82 to
1.67; Analysis 1.51 ). The width of the 95% CI for the RR indicates
that we cannot rule out no difference or small to large favouring of
standard care or skin care intervention for moderate/severe/very
severe eczema based on this one study.

We  subsequently  assessed  the  MD  for  parent-assessed  eczema
severity  for  the  only  study  with  available  data  (Chalmers  2020).
Individual  participant  data  available  from  1171  participants
showed no difference between treatment groups (MD 0.07, 95% CI
−0.38 to 0.52; Analysis 1.52).

Time to onset of eczema

Individual  participant  data  on  time  to  eczema  onset  were
available from nine studies including 5042 randomised participants
(Chalmers 2020; Dissanayake 2019; Horimukai 2014; Lowe 2018a;
McClanahan  2019;  Simpson  2014;  Skjerven  2020;  NCT03376243;
Yonezawa  2018).  Eczema  was  measured  using  the  Hanifin  and
Rajka criteria (Hanifin 1980), or the UK Working Party refinement
of them (Williams 1994), or other modifications of the Hanifin and
Rajka  criteria  in  six  studies  (Dissanayake  2019;  Horimukai  2014;

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lowe  2018a;  McClanahan  2019;  NCT03376243;  Skjerven  2020);
was  doctor  diagnosed  in  two  studies  (Simpson  2014;  Yonezawa
2018); and was assessed by first parent report of a clinical diagnosis
in one study (Chalmers 2020). Eczema onset was assessed up to six
months in one study (Simpson 2014); up to 8 months (32 weeks)
in  one  study  (Horimukai  2014);  up  to  12  months  in  four  studies
(Dissanayake 2019; Lowe 2018a; NCT03376243; Skjerven 2020); and
up to 24 months in three studies (Chalmers 2020; McClanahan 2019;
Yonezawa  2018).  For  each  trial,  data  were  censored  at  the  trial-
specific last measured time point for individuals not experiencing
eczema.

Pooled IPD available from 3349 participants in these nine studies
showed no benefit of skin care intervention (hazard ratio (HR) 0.86,
95%  CI  0.65  to  1.14;  Analysis  1.53).  However,  the  95%  CI  for  the
pooled  HR  indicates  that  we  cannot  rule  out  potential  benefit  or
harm,  extending  from  0.65  to  1.14.  The  median  time  to  eczema
onset  across  the  included  studies  in  the  control  group  was  six
months. The pooled HR corresponds to a median time to eczema
onset of 6.98 months in the skin care intervention group. Results
show  moderate  statistical  heterogeneity  between  studies  for  this
outcome (I2 = 53%, P = 0.03). Post hoc subgroup analysis conducted
to  explore  heterogeneity  showed  a  significant  interaction  effect
(P  =  0.03)  of  trial  follow-up  (<  1  year  versus  ≥  1  year).  The
pooled  HR  from  the  two  studies  with  follow-up  of  less  than  a
year  was  0.55  (95%  CI  0.35  to  0.87)  (I2  =  0%,  P  =  0.67)  (Analysis
1.54).  However,  as  this  result  was  based  on  a  total  of  only  224
participants  from  two  studies  that  followed  up  participants  for
only  six  or  eight  months,  there  is  uncertainty  as  to  whether  the
skin  care  intervention  delays  eczema.  The  pooled  HR  from  the
seven  studies  with  follow-up  of  at  least  one  year  was  1.00  (95%
CI 0.75 to 1.33; I2 = 44%; Analysis 1.54). Remaining heterogeneity
amongst studies with follow-up of at least one year was driven by
one  trial  (Skjerven  2020).  When  Skjerven  2020  was  excluded,  the
pooled HR with follow-up of at least one year was 0.91 (95% CI 0.78
to 1.07) (I2 = 0%, P = 0.67), which continues to show no benefit of
skin  care  intervention.  This  heterogeneity  may  be  driven  by  type
of intervention (bathing and oil and emollient applied to the face
only)  or  by  timing  of  intervention  initiation  (from  two  weeks),  or
both.

One  additional  study  that  did  not  provide  IPD,  with  a  follow-
up  period  of  nine  months,  reported  no  diagnoses  of  eczema
in  the  skin  care  intervention  group,  and  four  (14.8%)  atopic
dermatitis  diagnoses  in  the  control  group,  for  whom  "the  mean
age  of  the  4  infants  at  the  onset  of  IAD  was  5.5  ±  0.55
months" (Thitthiwong 2019).

Parent report of immediate reaction to food allergen

Individual  participant  data  on  parental  report  of  an  immediate
reaction (within two hours) to a known common food allergen at
one to three years were available from two studies including 1448
randomised  participants  (Chalmers  2020;  NCT03376243).  In  one
study,  no  immediate  reactions  were  reported in  either  treatment
group from a total of 41/54 participants who were followed up to
one  year  (NCT03376243).  In  the  other  study,  data  were  available
for  1171/1394  participants  who  were  followed  up  to  two  years
(Chalmers 2020); reactions were reported in 118/574 infants (21%)
in the skin care intervention group and 96/597 infants (16%) in the
standard care group, favouring standard care (RR 1.27, 95% CI 1.00
to 1.61; Analysis 1.55).

Cochrane Database of Systematic Reviews

For  one  trial  (Chalmers  2020),  we  were  able  to  examine  parental
reports  of  an  immediate  reaction  (within  two  hours)  separately
for  milk,  egg,  and  peanut.  Reactions  to  milk  were  reported
for  61/575  (11%)  of  the  skin  care  intervention  group  and
46/598  (8%)  of  the  standard  care  group,  favouring  standard  care
on  average,  but  with  some  uncertainty  regarding  the  true  effect,
with  the  95%  CI  including  no  difference  (RR  1.38,  95%  CI  0.95  to
2.00;  Analysis  1.56).  Reactions  to  egg  were  reported  for  44/575
(8%)  of  the  skin  care  intervention  group  and  41/598  (7%)  of  the
standard  care  group,  favouring  standard  care  on  average,  but
with  some  uncertainty  regarding  the  true  effect,  with  the  95%  CI
including no difference and a benefit of skin care intervention (RR
1.12,  95%  CI  0.74  to  1.68;  Analysis  1.57).  Reactions  to  peanuts
were reported for 8/574 (1.4%) of the skin care intervention group
and  10/598  (2%)  of  the  standard  care  group,  favouring  skin  care
intervention on average, but with some uncertainty regarding the
true effect, with the 95% CI including no difference and a benefit of
standard care (RR 0.84, 95% CI 0.33 to 2.10; Analysis 1.58).

Allergic sensitisation to foods or inhalants

Allergic  sensitisation  data  on  foods  or  inhalants  at  one  to  three
years were available from two studies including 1474 randomised
participants (Chalmers 2020; Lowe 2018a). In one study (Chalmers
2020),  data  were  available  for  988/1394  participants  who  were
followed  up  at  two  years;  sensitisation  was  reported  for  88/490
(18%)  of  the  skin  care  intervention  group  and  74/498  (15%)  of
the  standard  care  group.  In  the  second  study  (Lowe  2018a),  data
were  available  for  70/80  participants  who  were  followed  up  at
one  year;  sensitisation  was  reported  for  6/34  (18%)  of  the  skin
care  intervention  group  and  8/36  (22%)  of  the  standard  care
group. Pooled IPD available from 1058 participants in these studies
showed no evidence of a difference between groups, but there is
uncertainty regarding the true effect, with the 95% CI including a
benefit of skin care intervention and no difference (RR 1.09, 95% CI
0.72 to 1.66; Analysis 1.59).

For  allergic  sensitisation  to  food  only,  data  were  available  for
985/1394  participants  in  Chalmers  2020  who  were  followed  up
at  two  years;  sensitisation  was  reported  for  58/487  (12%)  of  the
skin care intervention group and 44/498 (9%) of the standard care
group. In the second study (Lowe 2018a), data were available for
70/80 participants who were followed up at one year; sensitisation
was  reported  for  3/34  (9%)  of  the  skin  care  intervention  group
and  7/36  (19%)  of  the  standard  care  group.  In  the  third  study
(Skjerven 2020), data were available for 739/1171 participants who
were  followed  up  at  three  years;  food  sensitisation  was  reported
for  18/341  (5.3%)  of  the  skin  care  intervention  group  and  21/398
(5.3%) of the standard care group. Pooled IPD available from 1794
participants in these three studies showed no difference between
groups.  The  95%  CI  for  the  pooled  RR  indicates  that  we  cannot
rule  out  potential  benefit  or  harm  of  skin  care  intervention  and
no  difference  (RR  1.05,  95%  CI  0.64  to  1.71;  Analysis  1.60).  There
was a moderate level of statistical heterogeneity across the three
included trials (I2 = 44%), which could not be explained. We pooled
results separately for milk, egg, and peanut across the three trials
providing allergic sensitisation data on foods at one to three years.
Pooled  results  for  milk  were  based  on  estimates  from  Chalmers
2020 and Lowe 2018a only (RR 1.16, 95% CI 0.55 to 2.43; Analysis
1.61). Pooled results included all three studies for egg (RR 0.92, 95%
CI  0.42  to  2.00;  Analysis  1.62)  and  for  peanut  (RR  1.08,  95%  CI
0.68 to 1.71; Analysis 1.63). Milk and peanut analysis also showed

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

32

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

a  low  level  of  heterogeneity,  although  the  egg  analysis  revealed
moderate levels of heterogeneity across the included trials.

Two  additional  studies  reported  allergic  sensitisation  to  foods  at
eight  and  nine  months  (Dissanayake  2019;  Horimukai  2014).
When  data  from  these  two  studies  were  included  in  sensitivity
analyses,  the  pooled  treatment  effect  was  RR  1.08  (95%  CI  0.92
to 1.27; Analysis 1.65). Pooled results for milk were RR 0.84 (95%
CI  0.59  to  1.21;  Analysis  1.66);  for  egg  RR  1.11  (95%  CI  0.94
to  1.30;  Analysis  1.67);  and  for  peanut  RR  1.08  (95%  CI  0.68  to
1.71; Analysis 1.68).

One  additional  study  that  did  not  provide  IPD,  with  a  follow-up
period  of  six  months,  reported  eczema  onset  for  "5/35  of  the
intervention group and 6/32 of the control group. And eczema onset
ratio among infants who reacted positive to a prick test were 5/1 vs.
6/8" (Kataoka 2010).

D I S C U S S I O N

Summary of main results

A summary of the main results is shown in Summary of findings 1.

Our key results as presented here were based on 10 trials providing
individual participant data (IPD). These studies assessed skin care
interventions  that  aim  to  promote  hydration  or  barrier  function:
eight  studies  assessed  emollients;  one  study  assessed  combined
skin  interventions,  including  emollients;  and  one  study  assessed
topical  oils,  although  this  study  only  provided  IPD  for  adverse
events.

For  our  primary  outcome  of  eczema,  we  identified  data  from
3075 participants in seven randomised controlled trials (RCTs) and
found  that  skin  care  interventions  probably  do  not  influence  the
development  of  eczema  by  age  one  to  three  years  in  healthy
term  infants  when  compared  with  standard  care.  The  certainty
of  the  evidence  was  moderate.  One  trial,  Skjerven  2020,  showed
an  increase  in  eczema  in  the  intervention  group  at  age  one  year,
leading  to  some  statistical  heterogeneity  in  the  main  eczema
analysis.  This  was  a  factorial  randomised  trial  with  skin  care
interventions  and  early  allergenic  food  introduction.  Due  to
significant  interaction  between  interventions,  only  the  skin  care
and  control  arms  of  the  trial  could  be  utilised  in  the  primary
analysis.  The  skin  care  intervention  was  a  combination  of  daily
facial  emollient  with  daily  baths  with  paraffin-based  bath  oil,
which differs somewhat to the interventions evaluated in the other
trials providing data towards the primary analysis. This difference
in  intervention  may  explain  the  statistical  heterogeneity  seen  in
the  main  eczema  analysis,  with  daily  baths  potentially  having
an  adverse  effect  on  skin  barrier  function  and  risk  of  eczema
development  compared  with  direct  emollient  application.  Our
preplanned subgroup analyses showed that the following factors
did  not  influence  the  effect  of  intervention  on  risk  of  developing
eczema:  family  history  of  atopy  or  FLG  mutation,  classification
of  intervention  type,  duration  of  intervention,  and  age.  In  this
update  we  included  chromosome  11  analysis,  which  was  newly
available  data;  however,  there  was  similarly  no  effect  of  the
intervention  on  eczema  dependent  on  genetic  status.  We  also
found  that  the  skin  care  interventions  used  probably  do  not
change  time  to  onset  of  eczema  when  compared  with  standard
care (based on 3349 participants in nine trials; moderate-certainty
evidence).  This  is  thought  to  be  important  in  the  interaction

Cochrane Database of Systematic Reviews

between  eczema  and  food  allergy  because  increased  length  of
time with eczema is associated with increased likelihood of food
sensitisation  (Tsilochristou  2019).  Overall,  the  evidence  from  this
review  demonstrates  with  moderate  certainty  that  the  skin  care
interventions used in these RCTs do not impact the development
of  eczema  (Chalmers  2020;  Dissanayake  2019;  Horimukai  2014;
Lowe  2018a;  McClanahan  2019;  NCT03376243;  Simpson  2014;
Skjerven 2020; Yonezawa 2018).

For our co-primary outcome of food allergy, we found that skin care
interventions using emollients may increase the risk of developing
an  immunoglobulin  (Ig)E-mediated  food  allergy  when  compared
with standard care. Two trials (2081 participants) had food allergy
diagnosed  by  oral  food  challenge  as  an  outcome.  Only  one  trial
reported this separately (Chalmers 2020), and both trials reported
a  combined  outcome  of  food  allergy  by  oral  food  challenge  or
investigator  assessment  (Chalmers  2020;  Skjerven  2020).  Both
analyses suggested that skin care interventions may increase the
risk  of  food  allergy;  however,  the  certainty  of  the  evidence  is
low,  thus  we  are  uncertain  as  to  whether  skin  care  interventions
influence  risk  of  food  allergy  by  age  one  to  three  years  when
compared with standard care.

The evidence for allergic sensitisation to food was of low certainty
due to statistical heterogeneity and imprecision, with no difference
in  allergic  sensitisation  to  food  by  age  one  to  three  years
between treatment groups in pooled analysis of three trials (1797
participants).

Data from one trial (1171 participants) suggest that when compared
with  standard  care,  skin  care  interventions  may  slightly  increase
the risk of parent-reported immediate reaction to a common food
allergen at two years, but this association was seen only for parent-
reported  immediate  reaction  to  cow's  milk,  which  is  thought  to
be an unreliable measure of IgE-mediated cow's milk allergy due
to commercially influenced over-reporting of cow's milk allergy in
infants (Munblit 2020). Hence, we also judged the certainty of this
evidence to be low.

Complier  average  causal  effect  (CACE)  analysis  was  utilised
to  assess  whether  compliance  with  the  assigned  intervention
influenced  outcomes.  For  both  >  3  days  per  week  and  >  5  days
per  week,  although  the  CACE  favoured  the  intervention  for  the
eczema  outcome,  the  CI  ranged  from  large  benefit  to  moderate
harm, therefore we were unable to demonstrate whether increased
adherence  to  the  assigned  interventions  was  associated  with
different  outcomes.  Insufficient  evidence  meant  that  we  were
unable to ascertain whether treatment adherence affected the risk
of developing food allergy with any confidence.

Our  key  adverse  events  of  interest  were  local  infection,  stinging
or  allergic  reactions  to  moisturisers,  and  slippage  accidents.  We
found  that  compared  to  standard  care,  skin  care  interventions
probably  increase  the  risk  of  skin  infection  in  an  analysis  that
included IPD from 2728 infants participating in six trials (moderate-
certainty  evidence).  There  may  be  an  increase  in  stinging  and
allergic  reactions  (four  trials  including  343  participants)  and
slippage accidents (four trials including 2538 participants) with the
intervention; however, the certainty of these findings was low due
to  very  small  numbers  of  events,  yielding  very  wide  confidence
intervals that included the possibility of no effect or reduced risk.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

33

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Overall completeness and applicability of evidence

Only 17 of 33 included studies reported outcomes relevant to this
review.

age, FLG genotype, chromosome 11 risk variant, or family history
of atopy, we found no evidence for an interaction between these
factors and the intervention on eczema risk.

Of  these  17  studies,  seven  reported  our  primary  outcome
cumulative incidence of eczema by one to three years, and three
of  these  studies  measured  eczema  severity  between  one  and
three  years  by  clinician  assessment,  with  one  of  these  studies
also  reporting  parent  report  of  eczema  severity.  Nine  studies
measured  time  to  onset  of  eczema.  Two  studies  reported  parent
report of immediate food allergy, and two studies reported allergic
sensitisation  to  food  or  inhalant  allergen.  Ten  studies  reported
adverse event data for our prespecified adverse events of interest.

Only  10  trials  provided  IPD  analysis.  Most  of  the  other  identified
trials  included  types  of  skin  barrier  interventions  other  than
emollients, such as change in bath routine, but they did not provide
follow-up  long  enough  after  intervention  to  allow  measurement
of  our  predefined  primary  outcomes,  and  they  were  limited  to
contributing some narrative data on safety outcomes. As a result,
the impact of non-emollient interventions on the development of
eczema or food allergy, rather than their short-term impact on skin
barrier physiology or safety outcomes, is unknown.

All  of  the  trials  reporting  eczema  as  an  outcome  used  an
emollient either on its own, or within a combination of skin care
interventions, as the intervention and commenced within the first
month of life. Eczema was largely evaluated by a blinded trained
assessor  using  widely  accepted  tools  such  as  Hanifin  and  Rajka
or  UK  Working  Party  criteria  for  diagnosis.  We  can  therefore  be
confident in the diagnosis of eczema in these studies. Interventions
mainly  focused  on  emollients,  with  each  study  using  a  different
emollient  with  different  constituents.  Trials  also  had  variable
regimens and durations of emollient therapy. The emollients used
were  a  combination  of  so-called  simple  emollients  and  more
complex  emollients  that  contained  lipids.  Emollient  regimens
varied  in  intensity  from  twice-daily  all-over  body  emollient  to
once  daily  on  cheeks  in  combination  with  other  skin  care
interventions. Skin care for infants varies by country and culture,
and  there  is  no  standard  recommendation.  Our  comparison  of
control (standard skin care or no skin care intervention) may thus
have varied between studies.

We analysed data based on assignment to intervention rather than
on  adherence  to  intervention.  Compliance  with  daily  emollient,
when  reported,  was  low  but  may  have  been  higher  in  smaller
pilot studies, in which potentially greater input from the research
team could have aided compliance. Complier average causal effect
was  utilised  to  assess  whether  compliance  with  the  assigned
intervention  influenced  outcomes.  However,  we  were  unable  to
identify  whether  or  not  adherence  to  skin  care  interventions
influences risk of eczema.

The  prospective  portion  of  this  meta-analysis,  planned  in  2017,
ensured  that  the  two  largest  trials  in  the  series  had  aligned
outcomes  and  used  similar  methods  of  outcome  evaluation
(Chalmers 2020; Skjerven 2020). Meta-analysis of these two studies
and  another  five  studies  providing  IPD  on  the  development  of
eczema  by  one  to  three  years  allowed  us  to  assess  both  study
factors  and  individual  participant  factors  that  may  influence
results. When we evaluated study factors such as type of emollient
used  and  duration  of  intervention  and  individual  factors  such  as

Ongoing  studies  are  randomising  newborn  healthy 
infants
intervention,  half  of  which  are  assessing
to  a  skin  care 
emollients.  NCT03871998  is  designed  to  address  whether  the
emollient intervention applied from day one or two of life for a short
(two-month) time period influences eczema and IgE-mediated food
allergy development. Lowe 2019 and Eichner 2020 are evaluating
daily complex emollients, and are expected to report in 2022. It is
possible that the use of more complex emollient interventions may
have different effects on risk of eczema.

We  identified  16  eligible  studies  that  did  not  have  outcome
measures relevant to this review (i.e. they did not record eczema
or  food  allergy  at  one  to  three  years  or  at  any  time,  and  they
did not comment on adverse events). Infants in these trials were
followed  up  to  a  maximum  of  four  weeks,  which  was  too  soon
to  assess  whether  eczema  or  food  allergy  was  present.  These
trials mainly involved different timings and mechanisms of bathing
infants, along with different types of bathing products. Follow-up
was four weeks or less, and outcomes were skin physiology, such as
transepidermal water loss. It is possible that had these infants been
followed up for longer, and had eczema outcome been measured,
these skin care practices would have been shown to have an effect
on eczema. Furthermore, although "skin care intervention type B:
any skin care interventions that aimed to protect the skin barrier
from  irritation  such  as  water  softeners"  was  prespecified  in  our
search, it could not be assessed, as no suitable trials were found. A
trial of water softeners is currently ongoing (Jabbar-Lopez 2019).

Evidence  for  the  effects  of  skin  care  interventions  in  infants  on
risk  of  food  allergy  has  increased  due  to  this  update.  We  were
able to analyse data from two trials (2081 participants) reporting
food allergy diagnosed by oral food challenge, although only one
of  these  trials  reported  oral  food  challenge  outcomes  separately.
Both  trials  reported  a  combined  outcome  of  food  allergy  by  oral
food challenge or investigator assessment. Data from more trials
reporting food allergy are needed in order to increase the certainty
of evidence around effects of skin care interventions on food allergy
development.

Quality of the evidence

Our confidence in the findings for eczema was moderate. Sensitivity
analysis including only studies with low risk of bias was consistent
with  the  primary  analysis.  We  downgraded  the  certainty  of
evidence  for  eczema  due  to  statistical  heterogeneity  that  could
not  be  explained.  For  the  primary  eczema  outcome,  the  source
of  this  heterogeneity  was  one  trial  that  found  increased  eczema
in  the  intervention  group  compared  with  the  control  group  at
age  one  year,  but  not  at  age  three  years  (Skjerven  2020).  One
potential  cause  of  this  heterogeneity  was  the  nature  of  the
intervention.  Skjerven  2020  used  a  bathing  intervention,  whilst
other trials contributing to the primary eczema analysis used direct
application of a moisturiser to the infant's skin. However, for the
outcome time to onset of eczema, we downgraded the certainty of
evidence due to statistical heterogeneity, and heterogeneity in this
analysis was due to more than one trial.

Our  confidence  in  the  findings  for  food  allergy  was  low,  and
reliant on a small number of studies reporting robust food allergy

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

34

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

outcomes.  We  downgraded  the  certainty  of  evidence  for  food
allergy  due  to  imprecision,  with  small  numbers  of  studies  and
events and wide confidence intervals encompassing both a harmful
effect and no effect. We also downgraded the primary food allergy
outcome,  due  to  risk  of  bias  related  to  missing  outcome  data.
In  the  only  trial  that  reported  oral  food  challenge  outcomes
separately  (Chalmers  2020),  participants  who  were  invited  for
an  oral  food  challenge  due  to  suspected  food  allergy  frequently
declined to attend an oral food challenge, and the proportion that
did attend differed between intervention group (29%) and control
group  (17%),  suggesting  a  high  risk  of  bias  related  to  missing
outcome data. Although the findings were similar if all those with
missing  outcome  data  were  assumed  to  not  have  food  allergy,
they  differed  if  participants  were  assumed  to  have  food  allergy.
However,  findings  for  food  allergy  assessed  by  the  combined
outcome of oral food challenge and investigator assessment also
suggested  that  skin  care  interventions  may  increase  risk  of  food
allergy  (Analysis  1.34).  We  also  downgraded  the  secondary  food
allergy  outcome,  allergic  sensitisation  to  a  food  allergen,  due  to
statistical heterogeneity that could not be explained.

Our confidence in the findings for adverse events was moderate or
low. We downgraded the certainty of evidence for skin infection due
to imprecision, with wide confidence intervals including a harmful
effect  and  no  effect.  We  downgraded  the  certainty  of  evidence
for  slippages  and  stinging/allergic  reactions  to  moisturisers  due
to  severe  imprecision,  with  small  numbers  of  events  and  wide
confidence  intervals  that  included  both  a  harmful  effect  and  a
beneficial effect. We assessed risk of bias for all studies included
in  the  adverse  events  analyses  except  one  as  some  concerns  for
the  specific  adverse  events  assessed;  this  was  due  to  the  nature
of adverse events being self-recalled by carers, who could not be
blinded because of the type of intervention under study.

Potential biases in the review process

The  meta-analysis  collaboration  group  for  this  review,  SCiPAD
(Skin  Barrier  Interventions  for  Prevention  of  Allergic  Disease),
was  formed  in  2017  through  collaboration  between  the  two
largest  trials,  Chalmers  2020  and  Skjerven  2020.  The  purpose  of
the  prospective  collaboration  was  to  increase  the  alignment  of
outcomes  measured  in  the  two  individual  trials  and  to  enhance
the power of individual trials to identify effects of the interventions
on  the  outcome  of  food  allergy,  which  is  less  prevalent  than
eczema.  Other  trial  groups  were  invited  to  join  the  collaboration
between  2017  and  2020,  and  their  data  formed  the  basis  of
the  prospective  portion  of  the  meta-analysis.  Prospective  meta-
analysis  allows  for  alignment  of  outcomes  before  completion
of  the  trial,  so  that  comparisons  and  analysis  are  more  readily
conducted  between  trials.  Within  this  collaborative  group,  trials
mainly  involved  emollients  as  an  intervention  and  eczema  as
an  outcome.  We  attempted  to  reduce  any  availability  bias
by  conducting  a  sensitive  search,  which  identified  over  6000
potentially  eligible  studies,  and  by  contacting  authors  of  eligible
studies  to  request  their  collaboration  in  the  IPD  meta-analysis;
however, follow-up for most studies was too short for inclusion.

We  classified  collaborating  trials  when  trial  outcome  data  were
not  analysed  and  known  to  study  authors  before  February  2017
as  contributing  'prospectively  acquired  data'.  Data  from  some  of
these  trials  became  known  to  the  investigators  or  to  the  public
before the statistical analysis plan (SAP) for this meta-analysis was
locked, so that, in theory, findings could have influenced the design

Cochrane Database of Systematic Reviews

of  the  statistical  analysis  plan.  Development  of  the  SAP  was  led
by  a  statistician  (SC)  with  no  detailed  knowledge  of  eligible  trial
publications at the time of finalisation of the SAP, and the principles
of the SAP and the review protocol were aligned with the February
2017  PROSPERO  registration  of  the  prospective  meta-analysis
(Boyle  2017).  The  SAP  was  signed  off  before  any  unblinding  of
individual participant data sets received from individual trials. Our
close  collaboration  with  trial  investigators  meant  that  they  were
involved  in  protocol  and  SAP  development  and  in  interpretation
of  meta-analysis  findings.  A  strength  of  this  approach  is  that
collaborating trialists had the opportunity to review our analyses
of  their  data  sets  before  stage  2  of  the  IPD  meta-analysis  and  to
correct  any  misinterpretation  of  data  coding.  Review  authors  MK
and  RJB  were  very  involved  in  the  Chalmers  2020  trial,  with  RJB
the principal investigator for food allergy, and MK involved in food
allergy  diagnosis;  these  two  review  authors  were  therefore  not
involved in data extraction or risk of bias assessment for this trial,
other than as investigators commenting on meta-analysis findings.

Use of IPD in this review allowed us to (i) fit a consistent analysis
model  to  trial  data  sets  for  each  outcome  to  ensure  that  we
compared  treatment  effects  adjusted  for  the  same  covariates
across  trials;  (ii)  fully  explore  the  risk  of  bias  due  to  missing
data  by  conducting  additional  sensitivity  analyses  that  had  not
previously  been  reported;  (iii)  obtain  more  reliable  and  powerful
subgroup analyses including estimation of treatment interactions
with  participant  characteristics  that  had  not  previously  been
reported;  and  (iv)  evaluate  the  relationship  between  compliance
with  the  intervention  and  outcomes  of  interest.  However,  the
method of sharing IPD can result in availability bias. We attempted
to limit this by offering all trials administrative assistance in working
with their individual institutions for data agreement development
and sign-off and for data sharing and extraction. Overall, trials with
relevant  outcomes  from  which  we  did  not  manage  to  access  IPD
were generally small (fewer than 100 participants) or were industry
funded,  and  researchers  were  concerned  about  the  commercial
impact  of  data  sharing.  Only  one  trial,  with  60  participants,  had
primary  outcome  data  eligible  for  inclusion  in  the  meta-analysis
and  did  not  supply  IPD;  sensitivity  analysis  including  aggregate
data  from  this  one  trial  showed  similar  findings  to  the  main
analysis.  One  industry-funded  trial  was  involved  in  the  SCiPAD
collaboration  (NCT02906475  );  however,  this  trial  is  ongoing,  and
results are expected in 2022.

Overall,  the  close  relationship  between  trialists  and  systematic
reviewers  in  this  project  carries  risk  of  availability  bias  and
academic  bias  towards  individual  clinical  trial  findings,  which  is
mitigated only in part by the prospectively planned nature of the
meta-analysis for most studies contributing data.

The  interventions  used  in  the  included  trials  varied  in  their
composition,  and  there  is  no  standard  classification  system  for
emollients  (Surber  2017).  This  led  to  difficulty  in  classification
of  the  intervention  for  the  purpose  of  subgroup  analysis,  as
different  emollients  have  overlapping  constituents,  which  may
have  differential  effects  on  the  skin  barrier  or  on  skin  health.
We  took  advice  from  a  member  of  our  collaboration  (MC)  with
expertise  in  emollient  formulation  and  effects  on  skin  barrier,
who  classified  the  interventions  used  before  seeing  the  meta-
analysis  results.  These  were  used  for  the  subgroup  analysis  of
'basic' versus 'complex' skin care interventions, which showed no
evidence of an interaction. We acknowledge that other groups may

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

35

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

have  classified  the  interventions  differently.  Similarly,  although
we  planned  to  stratify  interventions  as  skin  care  intervention  A:
those that primarily aim to enhance the skin barrier through direct
application of emollient or moisturiser, and skin care intervention
B:  those  that  aim  to  protect  the  skin  barrier  from  damage,  we
did  not  find  any  trial  results  where  intervention  B  had  been
used.  Jabbar-Lopez  2019  would  be  classified  as  an  intervention
B, but is still ongoing. Similarly, there is no standard recommended
skin  care  for  infants,  with  practices  varying  by  country  and  by
culture, therefore the comparison of control, taken as standard skin
care or no skin care intervention, may have varied between studies.

Several  trials  did  not  contribute  data  to  the  meta-analysis,  or
contributed  only  narrative  data  on  non-specific  adverse  events.
We  had  some  difficulty  in  deciding  whether  these  trials  should
be  included  based  on  the  type  of  intervention  and  the  type
of  comparator  evaluated.  For  example,  we  excluded  trials  that
compared one way of bathing to another (Bryanton 2004), but we
included a trial that used a different product in the bath compared
to the control group bath, because this might influence skin barrier
function (Lund 2020). We concentrated on a normal healthy term
population  so  that  our  findings  were  generalisable  and  were  not
impacted by the unique structure of preterm skin and the different
skin care practices to which preterm infants are exposed.

Agreements and disagreements with other studies or
reviews

in  term 

intervention 

is  an  update  of  the  first  Cochrane  Review  of  skin
This 
barrier 
infants.  A  previous  Cochrane
Review  looked  at  topical  emollients  for  preventing  infection
in  preterm  infants  (Cleminson  2016).  That  review  concluded
that  there  was  no  evidence  that  emollients  prevent  invasive
infection  in  preterm  infants  in  high-,  middle-,  or  low-income
countries.  Cleminson  2016  also  evaluated  topical  oils  (mainly
vegetable oils), finding some evidence that preterm infants treated
with  topical  vegetable  oils  had  increased  growth  compared  to
those given control treatment, although long-term growth was not
measured.  Cleminson  2016  had  invasive  infection  as  a  primary
outcome.  The  review  did  not  discuss  or  report  on  cutaneous
infection, so it is unclear whether this was not seen as an adverse
effect of the interventions studied, or if it just was not measured. If
skin care interventions increase risk of cutaneous infection in term
infants,  but  not  in  preterm  infants,  the  reason  for  this  difference
is  unclear.  Preterm  infants  have  more  permeable  skin  than  term
infants and have specific vulnerability to serious bacterial infection.
It is possible that hand hygiene for those who apply emollients or
oils to the skin of preterm infants may be more thorough than hand
hygiene for those who apply emollients or oils to the skin of healthy
term infants. If this were the case, then differences in effects on risk
of cutaneous infection could potentially be explained by differences
in hand hygiene practice.

A  previous  Cochrane  overview  of  interventions  for  the  primary
prevention of eczema in children identified systematic reviews of
trials  evaluating  dietary  interventions  such  as  maternal  dietary
antigen  avoidance,  exclusive  breastfeeding  for  a  defined  period
of  time,  omega-3  and  omega-6  fatty  acid  supplementation,
hydrolysed  protein  formula,  soya  formula,  and  prebiotics  and
probiotics.  The  overview  did  not  identify  trials  of  skin  care
interventions or an intervention that effectively prevents the onset
of eczema (Foisy 2011).

Cochrane Database of Systematic Reviews

A  systematic  review  of  interventions  for  the  prevention  of  food
allergy  was  undertaken  by  a  European  Academy  of  Allergy
and  Clinical  Immunology  committee  to  inform  an  update  of
their  guidance  on  food  allergy  prevention  (De  Silva  2020).  This
systematic  review  included  Dissanayake  2019  in  its  section  on
emollients for food allergy prevention, as other studies reporting
eligible food allergy outcomes had not been published at the time
this systematic review was conducted. Review authors concluded
that emollients may not reduce risk of food allergy (low-certainty
evidence).  Our  review  included  the  larger  and  more  recently
completed trials using oral food challenge for outcome assessment
(Chalmers 2020; Skjerven 2020), and did not include food challenge
outcomes  from  Dissanayake  2019  in  the  primary  food  allergy
analysis because oral food challenge was not used for food allergy
assessment in this trial. We rated the evidence for this outcome as
low certainty and found that skin care interventions may increase
risk of food allergy. However, this was not supported by the findings
for parent report of doctor diagnosis of food allergy or for allergic
sensitisation to foods, where we found skin care interventions such
as emollients may not change these outcomes.

Two  pilot  studies,  Simpson  2014  and  Horimukai  2014,  were
reported as showing significant reductions in eczema risk. Larger,
more definitive trials published subsequently found no reduction
in  eczema,  and  our  meta-analysis  results  are  consistent  with  the
findings  from  these  larger  trials  (Chalmers  2020;  Skjerven  2020).
The  reason  for  the  difference  in  findings  between  small  pilot
studies and larger trials is not clear, but differences in adherence to
treatment, methods and timing of outcome assessment, and study
population may all be relevant.

Finally,  a  previous  Cochrane  Review  has  evaluated  emollients  as
treatment for already established eczema (Van Zuuren 2017). That
review concluded that although the evidence was weak, emollients
reduce disease severity compared to no treatment - reducing flares,
prolonging time between flares, and decreasing the need for topical
corticosteroids. Our new review concerns the primary prevention of
eczema and does not directly impact the well-established and well-
accepted intervention of emollients for people who already have
eczema.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

We found, based on low- to moderate-certainty evidence, that skin
care  interventions  such  as  emollients  probably  do  not  influence
the  development  or  time  to  onset  of  eczema  in  healthy  term
infants by age one to three years; may increase risk of food allergy;
and  probably  increase  the  risk  of  skin  infection.  This  suggests
that  regular  application  of  emollients  or  other  similar  skin  care
interventions is probably not beneficial for healthy infants, unless
there  are  other  specific  reasons  for  using  such  products.  This
information should be taken into account by guideline developers
in  this  field.  Given  the  probable  increase  in  local  skin  infection
risk, it may be important for carers to practise appropriate hygiene
measures when applying emollients to the skin of infants.

We  were  unable  to  draw  any  firm  conclusions  about  the  impact
of  skin  care  interventions  on  immunoglobulin  E  (IgE)-mediated
food allergy by age one to three years, but the available evidence
suggests  that  they  may  increase  risk  of  food  allergy  based  on
low-certainty  evidence.  Low-certainty  evidence  from  one  trial

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

36

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

suggests that skin care interventions may slightly increase parent
reports of immediate food allergy (to a common allergen) at two
years.  However,  this  outcome  was  only  detected  for  cow’s  milk,
which  may  be  unreliable  as  a  measure  due  to  the  commercially
influenced over-reporting of cow's milk allergy in infants. Evidence
suggests  that  skin  care  interventions  may  not  change  risk  of
food  sensitisation  by  age  one  to  three  years  (low-certainty
evidence).  The  gold  standard  for  diagnosing  food  allergy  is  an
oral food challenge; however, these are costly and time-consuming
for  participants  and  trialists.  Alternative  modes  of  diagnosis  of
food  allergy,  by  standardised  questionnaires  and  documented
sensitisation, or even by more complex methods such as basophil
activation test, may be considered in further trials.

Infant  slippages  and  stinging/allergic  reactions  to  moisturisers
may  increase  with  the  use  of  skin  care  interventions  during
infancy (low-certainty evidence), although confidence intervals for
slippages and stinging/allergic reactions were wide and included
the possibility of no effect or reduced risk. All results presented here
are in comparison to standard care.

Subgroup  analysis  showed  that  age,  hereditary  risk,  filaggrin
(FLG)  mutation,  duration  of  intervention,  and  classification  of
intervention type did not affect the risk of developing eczema. We
could  not  evaluate  these  effects  for  food  allergy  risk.  We  do  not
know  if  adherence  to  treatment  affects  the  relationship  between
skin  care  interventions  and  risk  of  developing  eczema  or  food
allergy.

The  common  clinical  practice  of  applying  emollients  to  the  skin
of people who already have eczema is not directly affected by our
findings.

Implications for research

In this review, the trials with eczema as an outcome were mainly
emollient trials. Other methods of skin barrier intervention in this
review  had  very  short  follow-up  and  did  not  measure  eczema
as  an  outcome,  so  their  impact  on  eczema  remains  unclear.
Potential  future  studies  on  bathing  practices  should  have  longer
follow-up  of  clinical  outcomes  and  use  standard  methods  of
eczema measurement. Trialists may wish to consider using novel
interventions that impact skin barrier function, rather than those
that have already been evaluated in these trials.

We  were  unable  to  identify  with  confidence  whether  skin  care
interventions such as emollients affect the risk of developing food
allergy.  More  research  is  needed  to  identify  whether  food  allergy
risk is influenced by early skin care practices. Future trials should
measure  food  allergy  using  a  robust  outcome  assessment  (Asai
2020),  and  researchers  may  wish  to  consider  applying  published
algorithms to evaluate food allergy outcomes in participants who
do not undergo oral food challenge (Kelleher 2020b). We can infer
from  the  paucity  of  oral  food  challenge-diagnosed  food  allergy
outcomes  in  this  meta-analysis  that  oral  food  challenges  are
difficult  to  conduct  and  are  infrequently  attended  in  prevention
studies. We suggest that future studies incorporate Core Outcome
Measures for Food Allergy (COMFA).

We  were  unable  to  draw  any  conclusions  on  adherence  to
intervention,  and  would  suggest  that  future  studies  carefully
document  adherence  and  compliance  with  interventions.  Also,

Cochrane Database of Systematic Reviews

collaboration  between  groups  regarding  future  potential  studies
may allow for larger numbers with less imprecision.

This  review  focused  on  the  primary  prevention  of  eczema  and
food allergy, preventing the diagnosis of eczema and food allergy
in  infants.  Given  the  strong  links  between  early-onset  eczema
and  food  allergy,  another  body  of  work  has  begun  on  secondary
prevention  of  food  allergy  amongst  infants  already  diagnosed
with  eczema.  These  trials,  NCT03742414  and  UMIN000028043,
include infants younger than 13 weeks with diagnosed eczema who
are  randomised  to  active  eczema  management  from  onset  with
emollient  and  topical  corticosteroids.  Both  studies  have  IgE-
mediated food allergy as a primary outcome and are ongoing.

A C K N O W L E D G E M E N T S

We are grateful to Emma Thomas, Boaz Gaventas, Alexa Baracaia,
and the Centre of Evidence Based Dermatology patient panel for
feedback on prioritisation of outcomes and outcome measures for
this systematic review.

The  draft  search  strategy  for  the  World  Health  Organization
International  Clinical  Trials  Registry  Platform  was  developed
with  advice  from  Douglas  Grindlay,  Information  Specialist  at  the
Centre of Evidence Based Dermatology, University of Nottingham,
Nottingham, UK. We are extremely grateful to Liz Doney, Business
Manager and Information Specialist at Nottingham University, who
ran the search of the Cochrane Skin Specialised Register, CENTRAL,
MEDLINE, and Embase in October 2019 and for updates through to
August 2021.

We  gratefully  acknowledge  all  members  of  the  wider  Skin  Care
intervention  for  Prevention  of  Atopic  Disease  (SCiPAD)  group,
especially  those  who  contributed  to  discussion  and  input  at  the
annual meetings in Munich 2018 and Lisbon 2019, or at the online
results  meeting  in  2020,  including  Daniel  Munblit,  Carsten  Flohr,
Elisabeth  Harberl,  Jonathan  Hourihane,  and  Michael  Perkin.  We
acknowledge the work of Lien Tran in co-ordination of the initial
review, and the work of Christian Surber for advice on classification
of emollients for the initial review.

This  systematic  review  is  supported  by  an  award  of  an  National
Institute for Health and Care Research (NIHR) Transitional Research
Fellowship  to  MK  hosted  by  Imperial  College  London,  and  an
award of an NIHR Research for Patient Benefit grant to Nottingham
University Hospitals NHS Trust.

Cochrane  Skin  supported  the  authors  in  the  development  of
this  update.  Robert  Boyle  and  Emma  Axon  are  members  of
Cochrane  Skin,  but  were  not  involved  in  the  editorial/decision-
making  process  for  this  update.  The  following  people  conducted
the editorial process for this update.

• Sign-off  Editor  (final  editorial  decision):  Michael  Brown,

Cochrane Editorial Board

• Managing  Editor  (selected  peer  reviewers,  collated  peer-
reviewer  comments,  provided  editorial  guidance  to  authors,
edited the article): Joey Kwong, Cochrane Evidence Production
& Methods Directorate

• Editorial  Assistant  (conducted  editorial  policy  checks  and
supported editorial team): Leticia Rodrigues, Cochrane Evidence
Production & Methods Directorate

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

37

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• Copy  Editor  (copy-editing  and  production):  Lisa  Winer,  c/o

Cochrane Copy Edit Support

• Peer  reviewers  (provided  comments  and  recommended  an
editorial decision): Motohiro Ebisawa, Clinical Research Center
for  Allergy  and  Rheumatology,  NHO  Sagamihara  National
Hospital  (clinical  review);  Sigrun  Schmidt,  Departments  of
Clinical  Epidemiology  and  Dermatology,  Aarhus  University
Hospital  (clinical  review);  Sayantani  B  Sindher,  Department
of  Medicine,  Division  of  Pulmonary,  Allergy  and  Critical  Care,
Department  of  Pediatrics,  Division  of  Allergy,  Immunology
and  Rheumatology,  Sean  N.  Parker  Center  for  Allergy  and

Asthma  Research,  Stanford  University  School  of  Medicine
(clinical  review);  Sandra  Lawton,  Rotherham  NHS  Foundation
Trust  (clinical  review);  NML  Zeeuw  van  der  Laan  (consumer
review);  Jennifer  Hilgart,  Cochrane  Evidence  Production  &
Methods  Directorate  (methods  review);  Kerry  Dwan,  Cochrane
Evidence Production & Methods Directorate (statistical review);
Robin Featherstone, Cochrane Evidence Production & Methods
Directorate (search review)

We  are  also  indebted  to  all  participants  of  the  individual  studies
whose contributions have furthered our knowledge on skin care in
infants.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

38

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Abraham 2019 {published data only (unpublished sought but not
used)}10.5958/0976-5506.2019.01945.4

*  Abraham D,  Ravindran V,  Joseph M. Effectiveness of
chlorhexidine bath, saline bath and standard bath on skin
health status. Indian Journal of Public Health Research
and Development 2019;10(8):563-8. [DOI: 10.37506/
ijphrd.v10i8.7446]

Amer 2017 {published data only}

Amer M, Amer A. Neonatal skin care. A four-week
follow up randomized controlled trial. European
Journal of Pediatric Dermatology 2015;25(2):93-9. [DOI:
10.26326/2281-9649.25.2.1106]

*  Amer M, Diab N,  Soliman M, Amer A. Neonatal skin care: what
should we do? A four-week follow-up randomized controlled
trial at Zagazig University Hospitals. International Journal of
Dermatology 2017;56(11):1198-203. [DOI: 10.1111/ijd.13735]

Baldwin 2001 {published data only}

*  Baldwin S,  Odio MR,  Haines SL, O'Connor RJ,  Englehart JS,
Lane AT. Skin benefits from continuous topical administration
of a zinc oxide/petrolatum formulation by a novel
disposable diaper. Journal of the European Academy of
Dermatology and Venereology 2001;15(s1):5-11. [DOI: 10.1046/
j.0926-9959.2001.00002.x]

Bellemere 2018 {published data only}

Bellemere G, Boyer G, De Belilovsky C,  Baudouin C. Prevention
of atopic dermatitis using emollients for 6 months - follow-
up for 24 months. Journal of Investigative Dermatology
2019;139(5):S97. [DOI: 10.1016/j.jid.2019.03.639]

Bellemere G, Boyer G, De Belilovsky C,  Baudouin C. Prevention
of atopic dermatitis using emollients for 6 months - follow-up
for 24 months. Pediatric Dermatology 2019;36:S9. [DOI: 10.1111/
pde.13846]

Bellemere G, Boyer G, De Belilovsky C,  Moga A,  Fontanie M,
 Baudouin C. Early atopic dermatitis: prevention biological
data 1. Pediatric Dermatology 2017;34:S106-7. [DOI: 10.1111/
pde.13196]

Bellemere G, Boyer G, De Belilovsky C,  Moga A,  Fontanie M,
 Baudouin C. Early atopic dermatitis: prevention study. Pediatric
Dermatology 2018;35:S4-5. [DOI: 10.1111/pde.13502]

*  Bellemere G, Boyer G, de Belilovsky C,  Moga A, Fontaine M.
Early atopic dermatitis: prevention biologic data. Journal of
the American Academy of Dermatology 2018;79(3):AB115. [DOI:
10.1016/j.jaad.2018.05.487]

Chalmers 2020 {published and unpublished data}

*  Chalmers JR,  Haines RH, Bradshaw L, Montgomery AA,
Thomas KS, Brown SJ, et al. Daily emollient during infancy
for prevention of eczema: the BEEP randomised controlled
trial. Lancet 2020;395(10228):962-72. [DOI: 10.1016/
S0140-6736(19)32984-8]

Chalmers JR,  Haines RH, Mitchell EJ, Thomas KS, Brown SJ,
 Ridd M, et al. Effectiveness and cost-effectiveness of daily
all-over-body application of emollient during the first year
of life for preventing atopic eczema in high-risk children (the
BEEP trial): protocol for a randomised controlled trial. Trials
2017;18(1):343. [DOI: 10.1186/s13063-017-2031-3]

Chalmers JR, Thomas KS, Montgomery A,  Sach T, Boyle RJ,
 Ridd MJ, et al. A protocol for a randomized controlled trial
to determine whether application of emollient from birth
can prevent eczema in high-risk children (BEEP Trial) (PP01).
British Journal of Dermatology 2014;170(6):e32. [DOI: 10.1111/
bjd.13064]

ISRCTN21528841. Barrier enhancement for eczema prevention.
www.isrctn.com/ISRCTN21528841 (first received 25 July 2014).
[DOI: 10.1186/ISRCTN21528841]

Cooke 2015 {published and unpublished data}

Cooke A, Cork M, Victor S, Campbell M, Danby S,  Chittock J,
et al. A pilot, assessor-blinded, randomized controlled trial of
topical oils for neonatal skin. British Journal of Dermatology
2015;173:153. [DOI: 10.1111/bjd.13819]

*  Cooke A, Cork MJ, Victor S, Campbell M, Danby S,  Chittock J,
et al. Olive oil, sunflower oil or no oil for baby dry skin or
massage: a pilot, assessor-blinded, randomized controlled trial
(the Oil in Baby SkincaRE (OBSeRvE) Study). Acta Dermato-
Venereologica 2016;96(3):323-30. [DOI: 10.2340/00015555-2279]

ISRCTN37373893. The use of oil in baby skincare trial.
www.isrctn.com/ISRCTN37373893 (first received 22 August
2013). [DOI: 10.1186/ISRCTN37373893]

Da Cunha 2008 {published data only}

*  Da Cunha M,  Procianoy R,  Franceschini D, De Oliveira L,
 Cunha ML. Effect of the first bath with chlorhexidine on skin
colonization with Staphylococcus aureus in normal healthy
term newborns. Scandinavian Journal of Infectious Diseases
2008;40(8):615-20. [DOI: 10.1080/00365540801932447]

Dissanayake 2019 {published and unpublished data}

*  Dissanayake E,  Tani Y,  Nagai K, Sahara M,  Mitsuishi C,
 Togawa Y, et al. Skin care and synbiotics for prevention
of atopic dermatitis or food allergy in newborn infants:
a 2 x 2 factorial, randomized, non-treatment controlled
trial. International Archives of Allergy & Immunology
2019;180(3):202-11. [DOI: 10.1159/000501636]

Dissanayake E,  Tani Y, Sahara M,  Mitsuishi C,  Nagai K,
Sato Y, et al. Skincare and synbiotics for the prevention of
atopic dermatitis or food allergy in newborn infants: a 2 x 2
factorial randomized non-treatment controlled trial. Allergy
2018;73(105):692-3. [DOI: 10.1111/all.13539]

JPRN-UMIN000010838. Skin care and synbiotics for prevention
of atopic dermatitis or food allergy in newborn infants:
a 2 x 2 factorial, randomized, non-treatment controlled
trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-
UMIN000010838 (first received 31 May 2013).

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

39

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Dizon 2010 {published data only}

*  Dizon MV,  Galzote C, Estanislao R, Mathew N,  Sarkar R.
Tolerance of baby cleansers in infants: a randomized controlled
trial. Indian Pediatrics 2010;47(11):959-63. [DOI: 10.1007/
s13312-010-0161-8]

Duan 2019 {published data only}

*  Duan Y, Ma L,  Galzote C, Kong FQ,  Shen CP. A randomized
pilot clinical assessment of three skincare regimens on skin
conditions in infants. Clinical, Cosmetic and Investigational
Dermatology 2019;12:895-909. [DOI: 10.2147/CCID.S204216]

NCT02981056. A clinical assessment of the efficacy and effects
of different skincare regimens on infants. clinicaltrials.gov/ct2/
show/NCT02981056 (first received 2 December 2016).

Garcia Bartels 2010 {published data only}

*  Garcia Bartels N,  Scheufele R,  Prosch F,  Schink T,
 Proquitté H,  Wauer RR, et al. Effect of standardized skin care
regimens on neonatal skin barrier function in different body
areas. Pediatric Dermatology 2010;27(1):1-8. [DOI: 10.1111/
j.1525-1470.2009.01068.x]

Garcia Bartels 2011 {published data only}

*  Garcia Bartels N,  Rosler S,  Martus P,  Stroux A,  Lonnfors S,
 Reisshauer A, et al. Effect of baby swimming and baby lotion
on the skin barrier of infants aged 3-6 months. Journal of the
German Society of Dermatology 2011;9(12):1018-26. [DOI:
10.1111/j.1610-0387.2011.07710.x]

Garcia Bartels 2012 {published data only}

*  Garcia Bartels N,  Massoudy L,  Scheufele R, Dietz E,
 Proquitté H,  Wauer R, et al. Standardized diaper care regimen:
a prospective, randomized pilot study on skin barrier function
and epidermal IL-1α in newborns. Pediatric Dermatology
2012;29(3):270-6. [DOI: 10.1111/j.1525-1470.2011.01590.x]

NCT01131403. Clinical analysis of the influence of using the
skin care products on the diaper area in comparison with using
a cotton wool cloth, moistened with clear water on the skin
physiology of the newborns from the 1st day to the 4th week of
life. clinicaltrials.gov/ct2/show/NCT01131403 (first received 27
May 2010).

Garcia Bartels 2014 {published data only}

*  Garcia Bartels N,  Lunnemann L,  Stroux A,  Kottner J,
Serrano J,  Blume-Peytavi U. Effect of diaper cream
and wet wipes on skin barrier properties in infants: a
prospective randomized controlled trial. Pediatric Dermatology
2014;31(6):683-91. [DOI: 10.1111/pde.12370]

Horimukai 2014 {published and unpublished data}

*  Horimukai K,  Morita K,  Narita M,  Kondo M,  Kitazawa H,
 Nozaki M,  et al. Application of moisturizer to neonates prevents
development of atopic dermatitis. Journal of Allergy and
Clinical Immunology 2014;134(4):824-30.e6. [DOI: 10.1016/
j.jaci.2014.07.060]

JPRN-UMIN000004544. Effect of emollients on the prevention
of infantile eczema and atopic dermatitis. apps.who.int/
trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004544 (first
received 1 November 2010).

Morita K. Application of moisturizer to neonates prevents
development of atopic dermatitis. World Allergy Organization
Journal 2014;8(Suppl 1):764. [DOI: 10.1186/1939-4551-8-S1-
A252]

Ohya Y, Morita K,  Narita M,  Futamura M,  Kondo M,  Kitazawa H,
et al. Primary prevention of atopic dermatitis by skin care
with emollient: a randomized controlled study (OP02).
British Journal of Dermatology 2014;170(6):e9. [DOI: 10.1111/
bjd.13064]

Kataoka 2010 {published data only}

*  Kataoka Y, Yoshida N,  Nishino H,  Maeda N,  Sarumaru T,
 Kijima A, et al. Can skin care from neonatal period prevent the
onset of atopic dermatitis? Allergo Journal 2010;19:338-9. [DOI:
10.1007/s40629-019-00114-5]

Lavender 2011 {published data only}

ISRCTN72285670. Baby Skin Care Trial: a study comparing an
infant skin-cleansing product with water. www.isrctn.com/
ISRCTN72285670 (first received 17 March 2009). [DOI: 10.1186/
ISRCTN72285670]

*  Lavender T,  Bedwell C, O'Brien E, Cork MJ, Turner M, Hart A.
Infant skin-cleansing product versus water: a pilot randomized,
assessor-blinded controlled trial. BMC Pediatrics 2011;11:35.
[DOI: 10.1186/1471-2431-11-35]

Lavender 2012 {published data only}

ISRCTN86207019. Baby skin care research programme: Baby
Wipes study. www.isrctn.com/ISRCTN86207019 (first received
17 February 2010). [DOI: 10.1186/ISRCTN86207019]

*  Lavender T,  Furber C, Campbell M, Victor S, Roberts I,
 Bedwell C, et al. Effect on skin hydration of using baby wipes
to clean the napkin area of newborn babies: assessor-blinded
randomised controlled equivalence trial. BMC Pediatrics
2012;12:59. [DOI: 10.1186/1471-2431-12-59]

Lavender T,  Furber C, Cork M, Campbell M, Victor S. Baby
skin care research programme: assessor-blinded randomised
controlled trial comparing impregnated cleansing wipes
with water in infants. Archives of Disease in Childhood:
Fetal and Neonatal Edition 2011;1:Fa43-4. [DOI: 10.1136/
archdischild.2011.300164.91]

Lavender 2013 {published data only}

*  Lavender T,  Bedwell C, Roberts SA, Hart A, Turner MA,
Carter LA, et al. Randomized, controlled trial evaluating a
baby wash product on skin barrier function in healthy, term
neonates. Journal of Obstetric, Gynaecologic, and Neonatal
Nursing 2013;42(2):203-14. [DOI: 10.1111/1552-6909.12015]

Lowe 2018a {published and unpublished data}

ACTRN12609000727246. Prevention of eczema by a barrier
lipid equilibrium strategy (PEBBLES) pilot study - testing
the compliance and safety of a strategy for improving
infant skin function. www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?ACTRN=12609000727246 (first received 19
August 2009).

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

40

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ACTRN12613000472774. The PEBBLES study: Prevention
of Eczema By a Barrier Lipid Equilibrium Strategy.
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?
id=364115 (first received 23 April 2013).

*  Raisi Dehkordi Z. A comparative study of the effect of
massage with sunflower oil or sesame oil on infants' crying and
sleep times: a randomized control trial. European Psychiatry
2014;29(Suppl 1):1. [DOI: 10.1016/S0924-9338(14)78247-1]

ACTRN12617001380381. The PEBBLES study – testing a strategy
for preventing eczema and food allergy in high risk infants.
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?
id=373506 (first received 20 September 2017).

Rush 1986 {published data only}

*  Rush J. Does routine newborn bathing reduce Staphylococcus
aureus colonization rates? A randomized controlled trial. Birth
1986;13(3):176-80.

Lowe A, Su J, Allen K,  Abramson M,  Cranswick N, Robertson C,
et al. A randomized trial of a barrier lipid replacement
strategy for the prevention of atopic dermatitis and allergic
sensitization: the PEBBLES pilot study NCD. Pediatric
Dermatology 2017;34(S1):S35-6. [DOI: 10.1111/pde.13195]

Lowe A. A randomized trial of a barrier lipid replacement
strategy for the prevention of atopic dermatitis and allergic
sensitisation: the PEBBLES pilot study NCD. Journal of
Investigative Dermatology 2017;137:S72. [DOI: 10.1016/
j.jid.2017.02.436]

*  Lowe AJ, Su JC, Allen KJ,  Abramson MJ,  Cranswick N,
Robertson CF, et al. A randomized trial of a barrier lipid
replacement strategy for the prevention of atopic dermatitis
and allergic sensitization: the PEBBLES pilot study. British
Journal of Dermatology 2018;178(1):e19-21. [DOI: 10.1111/
bjd.15747]

Lund 2020 {published data only}https://onlinelibrary.wiley.com/
doi/full/10.1111/pde.14037

*  Lund C,  Kuller J, Durand DJ. Baby's first bath: changes in skin
barrier function after bathing full-term newborns with water vs
liquid baby cleanser. Pediatric Dermatology 2019;37:115-9. [DOI:
10.1111/pde.14037]

McClanahan 2019 {published and unpublished data}

*  McClanahan D, Wong A,  Kezic S,  Samrao A,  Hajar T, Hill E, et
al. A randomized controlled trial of an emollient with ceramide
and filaggrin-associated amino acids for the primary prevention
of atopic dermatitis in high-risk infants. Journal of the European
Academy of Dermatology & Venereology 2019;33(11):2807-94.
[DOI: 10.1111/jdv.15786]

NCT01375205. Comparing Cetaphil Restoraderm System versus
standard skin care in infants. clinicaltrials.gov/ct2/show/
NCT01375205 (first received 17 June 2011).

Migacheva 2018 {published data only}

*  Migacheva N,  Zhestkov A. Combined approach to primary
prevention of atopic dermatitis. Allergy 2018;73:331. [DOI:
10.1111/all.13537]

NCT03376243 {unpublished data only}

*  NCT03376243. EARLYEMOLLIENT - Feasibility of early
emollient use in children with atopic eczema. clinicaltrials.gov/
ct2/show/NCT03376243 (first received 18 December 2017).

Raisi Dehkordi 2010 {published data only}

IRCT201102265912N1. The effect of massage with sunflower
oil and sesame oil. www.who.int/trialsearch/Trial2.aspx?
TrialID=IRCT201102265912N1 (first received 8 January 2012).

Sankaranarayanan 2005 {published data only}

*  Sankaranarayanan K,  Mondkar JA,  Chauhan MM,
 Mascarenhas BM,  Mainkar AR,  Salvi RY. Oil massage in
neonates: an open randomized controlled study of coconut
versus mineral oil. Indian Pediatrics 2005;42(9):877-84. [PMID:
16208048]

Simpson 2014 {published and unpublished data}

Chalmers JR, Simpson EL, Chen YY,  Cork MJ, Brown SJ,
Thomas KS, et al. Feasibility study of barrier enhancement
for eczema prevention (BEEP). British Journal of Dermatology
2014;170:e8-9. [DOI: 10.1186/ISRCTN84854178]

Glatz M, Jo J, Kennedy EA, Polley EC, Simpson EL, Kong HH.
Emollient therapy alters barrier function and skin microbes
in infants at risk for developing atopic dermatitis. Allergy
2017;72:311. [DOI: 10.1111/all.13251]

Glatz M, Polley EC,  Schmid-Grendelmeier P, Simpson EL,
Kong HH. Emollient therapy alters barrier function and skin
microbes in infants at risk for developing atopic dermatitis.
Swiss Medical Weekly 2017;147(Suppl 228):53S.

Glatz M, Polley EC, Simpson EL, Kong HH. Emollient therapy
alters skin barrier and microbes in infants at risk for developing
atopic dermatitis. Journal of Investigative Dermatology
2015;135:S31. [DOI: 10.1038/jid.2015.69]

Glatz M, Jo JH, Kennedy EA, Polley EC,  Segre JA,  Simpson EL,
et al. Emollient use alters skin barrier and microbes in
infants at risk for developing atopic dermatitis. PLOS ONE
2018;13(2):0192443. [DOI: 10.1371/journal.pone.0192443]

ISRCTN84854178. Feasibility study of barrier enhancement for
eczema prevention. www.isrctn.com/ISRCTN84854178 (first
received 8 January 2010).

NCT01291940. The effects of emollient therapy on the skin
barrier. clinicaltrials.gov/ct2/show/NCT01291940 (first received
9 February 2011).

Simpson E, Chalmers JR, Irvine AD, Cork MJ, McLean WHI,
Williams HC. Barrier enhancement for eczema prevention; the
BEEP feasibility study. Allergo Journal 2010;19(5):340. [DOI:
10.1007/BF03362342]

Simpson EL, Chalmers JR,  Hanifin JM, French ME,  Lubianski T,
 Samrao A, et al. Barrier enhancement for eczema prevention -
the BEEP feasibility study. Journal of Investigative Dermatology
2012;132(Suppl 1):S90. [DOI: 10.1038/jid.2012.86]

*  Simpson EL, Chalmers JR,  Hanifin JM, Thomas KS, Cork MJ,
McLean WH, et al. Emollient enhancement of the skin barrier

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

from birth offers effective atopic dermatitis prevention. Journal
of Allergy and Clinical Immunology 2014;134(4):818-23. [DOI:
10.1016/j.jaci.2014.08.005]

2 years of age, among infants of the general population. Allergy,
Asthma & Clinical Immunology 2019;15(74):1552. [DOI: 10.1186/
s13223-019-0385-7]

Skjerven 2020 {published and unpublished data}

Zhao 2005 {published data only}

Carlsen L, Rehbinder EM, Skjerven HO, Hauger Carlsen M,
 Aspelund Fatnes T,  Fugelli P,  et al. Preventing Atopic
Dermatitis and ALLergies in Children - the PreventADALL study.
Allergy 2018;73(10):2063-70. [DOI: 10.1111/all.13468]

*  Zhao S,  Xie L, Hu H, Xia J, Zhang W, Ye N, et al. A study
of neonatal swimming (water therapy) applied in clinical
obstetrics. Journal of Maternal-Fetal & Neonatal Medicine
2005;17(1):59-62. [DOI: 10.1080/14767050400028782]

Skjerven HO,  Rehbinder EM,  Vettukattil R,  LeBlanc M,
 Granum B, Haugen G,  et al. Department of Error: Skin
emollient and early complementary feeding to prevent infant
atopic dermatitis (PreventADALL): a factorial, multicentre,
cluster-randomised trial (Lancet (2020) 395(10228) (951-61)
(S0140673619329836)). Lancet 2020;395(10228):e53. [DOI:
10.1016/S0140-6736(20)30422-0]

*  Skjerven HO,  Rehbinder EM,  Vettukattil R, LeBlanc M,
 Granum B, Haugen G, et al. Skin emollient and early
complementary feeding to prevent infant atopic dermatitis
(PreventADALL): a factorial, multicentre, cluster-randomised
trial. Lancet 2020;395(10228):951-61. [DOI: 10.1016/
S0140-6736(19)32983-6]

Thitthiwong 2019 {published data only}

TCTR20161208001. The good skin care practices and emollient
using since early infancy as the primary prevention of
infantile atopic dermatitis in infants at risk: a randomized
controlled trial. apps.who.int/trialsearch/Trial2.aspx?
TrialID=TCTR20161208001 (first received 4 December 2016).

*  Thitthiwong P, Koopitakkajorn T. The good skin care
practices and emollient using since early infancy as the
primary prevention of infantile atopic dermatitis in infants
at risk: a randomized controlled trial. Siriraj Medical Journal
2019;72(1):41-6. [DOI: 10.33192/Smj.2020.06]

References to studies excluded from this review

ACTRN12607000466448 {published data only}

ACTRN12607000466448. An intervention to reduce the
prevalence and impact of asthma and food allergies occurring
in association with atopic dermatitis through improved skin
care in infants and young children. www.anzctr.org.au/Trial/
Registration/TrialReview.aspx?id=82278 (first received 11
September 2007).

Ahmed 2007 {published data only}

Ahmed AS,  Saha SK,  Chowdhury MA, Law PA, Black RE,
Santosham M, et al. Acceptability of massage with skin barrier-
enhancing emollients in young neonates in Bangladesh. Journal
of Health, Population, and Nutrition 2007;25(2):236-40. [PMID:
17985826]

Alonso 2013 {published data only}

Alonso C, Larburu I, Bon E, Gonzalez MM, Iglesias MT, Urreta I, et
al. Efficacy of petrolatum jelly for the prevention of diaper rash:
a randomized clinical trial. Journal for Specialists in Pediatric
Nursing 2013;18(2):123-32. [DOI: 10.1111/jspn.12022]

ISRCTN00356649. Efficacy of petroleum jelly in the prevention
of irritant diaper dermatitis. www.isrctn.com/ISRCTN00356649
(first received 8 October 2010).

Tielsch 2007 {published data only}

Arline Diana 2020 {published data only}

NCT00109616. Community trial of newborn skin and umbilical
cord cleansing on neonatal mortality in Nepal. clinicaltrials.gov/
ct2/show/NCT00109616 (first received 2 May 2005).

*  Tielsch JM,  Darmstadt GL,  Mullany LC,  Khatry SK,  Katz J,
LeClerq SC, et al. Impact of newborn skin-cleansing with
chlorhexidine on neonatal mortality in Southern Nepal:
a community-based, cluster-randomized trial. Pediatrics
2007;119(2):e330-40. [DOI: 10.1542/peds.2006-1192]

Yonezawa 2018 {published and unpublished data}

JPRN-UMIN000013260. Effects of moisturizing skin care from
the neonatal stage for improving skin barrier function and
preventing skin trouble. www.who.int/trialsearch/Trial2.aspx?
TrialID=JPRN-UMIN000013260 (first received 1 March 2014).

*  Yonezawa K,  Haruna M,  Matsuzaki M,  Shiraishi M,  Kojima R.
Effects of moisturizing skincare on skin barrier function and
the prevention of skin problems in 3-month-old infants:
a randomized controlled trial. Journal of Dermatology
2018;45(1):24-30. [DOI: 10.1111/1346-8138.14080]

Yonezawa K, Haruna M. Short-term skin problems in infants
aged 0-3 months affect food allergies or atopic dermatitis until

*  Arline Diana I, Gondokaryono SP, Lestari Sugito T, Devita
Lokanata M, Agustin T, Rahmayunita G, et al. A randomized,
controlled, cross-over study of the safety and efficacy of super-
absorbent diaper for babies with mild-to-moderate diaper
rash. Medical Journal of Indonesia 2020;29(3):283-9. [EMBASE:
2005360896]

Ayalew 2021 {published data only}

*  Ayalew T, Asmare E. Colostrum avoidance practice among
primipara mothers in urban Northwest Ethiopia. A cross-
sectional study. BMC Pregnancy Childbirth 2021;21(1):123.
[MEDLINE: 33573612]

Azor-Martinez 2020 {published data only}

*  Azor-Martinez E, Garcia-Fernandez L, Strizzi JM, Cantarero-
Vallejo MD, Jimenez-Lorente CP, Balaguer-Martinez JV, et
al. Effectiveness of a hand hygiene program to reduce acute
gastroenteritis at child care centers: a cluster randomized trial.
American Journal of Infection Control 2020;48(11):1315-21.
[EMBASE: 2005576267]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

42

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Baer 2006 {published data only}

Baer EL, Davies MW,  Easterbrook K. Disposable nappies for
preventing napkin dermatitis in infants. Cochrane Database
of Systematic Reviews 2006, Issue 3. Art. No: CD004262. [DOI:
10.1002/14651858.CD004262.pub2]

Barria 2004 {published data only}

Barría K,  Muñoz C,  Pérez-Cotapos ML,  Fehlmann E,
 Brockmann P, Tapia JL. Comparison of 2 models for the
initial skin care in the healthy full term newborn infant.
Pediatric Dermatology 2004;21:317-8. [DOI: 10.1111/
j.0736-8046.2004.21332.x]

Baudouin 2014a {published data only}

Baudouin C, De Belilovsky C, Lachmann N, Bredif S,  Menu F,
Msika P. Tolerance assessment of baby's skin products:
innovative approaches using stinging test and infant epidermis
model. Journal of Investigative Dermatology 2014;2:S51.

Baudouin 2014b {published data only}

Baudouin C, De Belilovsky C, Menu F,  Lachmann N,  Msika P,
 Bredif S. Tolerance assessment of cosmetic products dedicated
to baby's skin: innovative approaches using stinging test and
infant epidermis model. Journal of the American Academy of
Dermatology 2014;1:AB149. [DOI: 10.1016/j.jaad.2014.01.619]

Berger 2009 {published data only}

Berger C, Inzinger R. Study of skin care in premature and
newborn infants. Kinderkrankenschwester 2009;28(3):116-25.

Bhakoo 1969 {published data only}

Bhakoo ON, Lall JC, Agarwal KC. Prevention of hospital
infections in neonates: an evaluation of no bath regimen. Indian
Pediatrics 1969;6(1):697-700.

Blume Peytavi 2010 {published data only}

Blume-Peytavi U, Garcia Bartels N. Neonatal skin care influence
of standardized skin care regimen on skin barrier function.
Aktuelle Dermatologie 2010;36(6):214-6.

Blume Peytavi 2012 {published data only}

Blume-Peytavi U, Hauser M,  Stamatas GN, Pathirana D, Garcia
Bartels N. Skin care practices for newborns and infants: review
of the clinical evidence for best practices. Pediatric Dermatology
2012;29:1-14.

Blume Peytavi 2014 {published data only}

Blume-Peytavi U, Hauser M, Lunnemann L, Stamatas GN,
Kottner J, Garcia Bartels N. Prevention of diaper dermatitis
in infants - a literature review. Pediatric Dermatology
2014;31(4):413-29.

Blume Peytavi 2016 {published data only}

Blume-Peytavi U. Improved understanding of infant skin
physiology, maturation and skin care. European Journal of
Pediatric Dermatology 2016;26(3):166.

Brandon 2010 {published data only}

Brandon DH, Coe K, Hudson-Barr D, Oliver T, Landerman LR.
Effectiveness of no-sting skin protectant and Aquaphor on

Cochrane Database of Systematic Reviews

water loss and skin integrity in premature infants. Journal of
Perinatology 2010;30(6):414-9. [DOI: 10.1038/jp.2009.174]

Bryanton 2004 {published data only}

Bryanton J, Walsh D, Barrett M, Gaudet D. Tub bathing versus
traditional sponge bathing for the newborn. Journal of
Obstetric, Gynecologic, and Neonatal Nursing 2004;33(6):704-12.
[DOI: 10.1177/0884217504270651]

Bryce 2020 {published data only}

*  Bryce E, Mullany LC, Khatry SK, Tielsch JM, LeClerq SC, Katz J.
Coverage of the WHO's four essential elements of newborn care
and their association with neonatal survival in southern Nepal.
BMC Pregnancy and Childbirth 2020;20(1):540. [DOI: 10.1186/
s12884-020-03239-6]

Chaithirayanon 2016 {published data only}

Chaithirayanon S. Comparative study between talcum and
zinc oxide cream for the prevention of irritant contact diaper
dermatitis in infants. Journal of the Medical Association of
Thailand 2016;99(Suppl 8):S1-6. [PMID: 29901362]

Chasekwa 2019 {published data only}

*  Chasekwa B, Prendergast A, Evans C, Mutasa K, Mbuya M,
Stoltzfus RJ, et al. Impact of improved nutrition/sanitation on
stunting and anemia in HIV-exposed infants. Topics in Antiviral
Medicine 2019;27 Suppl:305-6s. [EMBASE: 634221047]

Chen 2009 {published data only}

Chen HY. The clinic effect of Chinese medicine bath and
massage on pathological jaundice of newborn. China Foreign
Medical Treatment 2009;28(18):128.

Cleminson 2015 {published data only}

Cleminson J, McGuire W. Topical emollient for prevention
of infection in preterm infants: a systematic review. Lancet
2015;385:S31. [PMID: 26312853]

Cleminson 2016 {published data only}

Cleminson J, McGuire W. Topical emollient for preventing
infection in preterm infants. Cochrane Database of
Systematic Reviews 2016, Issue 1. Art. No: CD001150. [DOI:
10.1002/14651858.CD001150.pub3]

Conner 2004 {published data only}

Conner JM, Soll RF, Edwards WH. Topical ointment for
preventing infection in preterm infants. Cochrane Database
of Systematic Reviews 2004, Issue 1. Art. No: CD001150. [DOI:
10.1002/14651858.CD001150.pub2]

Cooke 2014 {published data only}

Cooke A, Victor S, Cork M, Lavender T. Topical oils for the
prevention or treatment of dry skin in term infants. Cochrane
Database of Systematic Reviews 2014, Issue 5. Art. No:
CD011100. [DOI: 10.1002/14651858.CD011100]

Cooke 2018 {published data only}

Cooke A, Bedwell C, Campbell M, McGowan L, Ersser SJ,
Lavender T. Skin care for healthy babies at term: a systematic
review of the evidence. Midwifery 2018;56:29-43. [PMID:
29055852]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cowan 1986 {published data only}

Cowan ME, Frost MR. A comparison between a detergent
baby bath additive and baby soap on the skin flora of
neonates. Journal of Hospital Infection 1986;7(1):91-5. [DOI:
10.1016/0195-6701(86)90033-2]

CTRI201208002876 {unpublished data only}http://
ctri.nic.in/Clinicaltrials/showallp.php?
mid1=5054&EncHid=&userName=A%20clinical%20trial
%20to%20find%20the%20efficacy%20and%20safety%20of
%20Tubby%20nutririch%20lotion

*  CTRI201208002876. A prospective, open label clinical trial to
evaluate the efficacy and safety of Tubby Nutririch lotion for
the treatment of dry skin with or without atopic tendency in
infants and children. ctri.nic.in/clinicaltrials/pmaindet2.php?
trialid=5054 (first received 9 August 2012).

CTRI201709009890 {published data only}http://
ctri.nic.in/Clinicaltrials/showallp.php?
mid1=19272&EncHid=&userName=Comparing%20the
%20effect%20of%20three%20different%20skin%20antiseptic
%20preparations%20in%20neonates

CTRI/2017/09/009890. Comparing the effect of three different
skin antiseptic preparations in neonates (first 28 days of life)
- randomized trial. ctri.nic.in/clinicaltrials/pmaindet2.php?
trialid=19272 (first received 22 September 2017).

Da Cunha 2005a {published data only}

da Cunha ML, Procianoy RS. Effect of bathing on skin flora of
preterm newborns. Journal of Perinatology 2005;25(6):375-9.
[DOI: 10.1038/sj.jp.7211332]

Cochrane Database of Systematic Reviews

infants in Bangladesh: a randomised controlled trial. Lancet
2005;365(9464):1039-45. [DOI: 10.1016/S0140-6736(05)71140-5]

Darmstadt 2007 {published data only}

Darmstadt GL, Saha SK, Ahmed AS, Choi Y, Chowdhury MA,
Islam M, et al. Effect of topical emollient treatment of preterm
neonates in Bangladesh on invasion of pathogens into the
bloodstream. Pediatric Research 2007;61(5 Pt 1):588-93. [DOI:
10.1203/pdr.0b013e3180459f75]

Darmstadt 2008 {published data only}

Darmstadt GL, Saha SK, Ahmed  AS,   Ahmed S, Chowdhury MA,
Law PA, et al. Effect of skin barrier therapy on neonatal
mortality rates in preterm infants in Bangladesh: a randomized,
controlled, clinical trial. Pediatrics 2008;121(3):522-9. [DOI:
10.1542/peds.2007-0213]

Darmstadt 2014 {published data only}

Darmstadt GL, Ahmed S, Ahmed AS, Saha SK. Mechanism
for prevention of infection in preterm neonates by topical
emollients: a randomized, controlled clinical trial. Pediatric
Infectious Disease Journal 2014;33(11):1124-7. [DOI: 10.1097/
INF.0000000000000423]

De Belilovsky 2020 {published data only}

*  De Belilovsky C, Boyer G, Bellemere G, Baudouin C.
Evaluation of tolerability and cleansing properties of liniment in
comparison to water in the diaper area skin care in a pediatric
population. Journal of the American Academy of Dermatology
2020;83(Suppl 6):AB116. [EMBASE: 2010133394]

De Lima 2020 {published data only}

Da Cunha 2005b {published data only}

Da Cunha ML,  Procianoy RS. Skin microflora and bathing of
preterm newborn infants. In: Pediatric Academic Societies
Annual Meeting. Washington, DC, 2005.

*  de Lima RO, Estevam LD, Leite FMC, Almeida MVS,
Nascimento L, Amorim MHC, et al. Nursing intervention-first
bath of the NB: a randomized study on neonatal behavior. Acta
Paulista de Enfermagem 2020;33(1):1-10.

Damron 2020 {published data only}

De Silva 2020 {published data only}

*  Damron JM, Shaker M. Frequent versus infrequent bathing
in pediatric atopic dermatitis: a randomized clinical trial.
Pediatrics 2020;146:s340. [DOI: 10.1542/peds.2020-023861FF]

*  De Silva D, Halken S, Singh C, Muraro A, Angier E, Arasi S, et
al. Preventing food allergy in infancy and childhood: systematic
review of randomised controlled trials. Pediatric Allergy &
Immunology 2020;31(7):813-26. [PMID: 32396244]

Darmstadt 2004 {published data only}

Darmstadt GL, Badrawi N, Law PA, Ahmed S, Bashir M,
Iskander I, et al. Topically applied sunflower seed oil
prevents invasive bacterial infections in preterm infants
in Egypt: a randomized, controlled clinical trial. Pediatric
Infectious Disease Journal 2004;23(8):719-25. [DOI:
10.1097/01.inf.0000133047.50836.6f]

Darmstadt 2005a {published data only}

Darmstadt GL, Saha SK,  Nawshad Uddin Ahmed ASM, Azad
Chowdhury MAK, Law PA, Ahmed S, et al. Skin barrier-
enhancing emollients prevent nosocomial infections in preterm
infants in Bangladesh. In: Pediatric Academic Societies Annual
Meeting. Washington DC, 2005.

Darmstadt 2005b {published data only}

Darmstadt GL, Saha SK, Ahmed AS, Chowdhury MA, Law PA,
Ahmed S, et al. Effect of topical treatment with skin barrier-
enhancing emollients on nosocomial infections in preterm

Duggan 2015 {published data only}

Duggan C. Eczema on trial. Journal of Family Health
2015;25(3):10-2. [PMID: 26118287]

Erdemir 2015 {published data only}

Erdemir A, Kahramaner Z, Yuksel Y, Cosar H,  Turkoglu E,
Sutcuoglu S, et al. The effect of topical ointment on neonatal
sepsis in preterm infants. Journal of Maternal-Fetal & Neonatal
Medicine 2015;28(1):33-6. [DOI: 10.3109/14767058.2014.900037]

Ernest 1995 {published data only}

Ernest E. Complementary therapies, the baby, and the bath
water. British Journal of Rheumatology 1995;34(5):479-80. [DOI:
10.1093/rheumatology/34.5.479-a]

EUCTR2005-001269-32-AT {published data only}

EUCTR2005-001269-32-AT. Clinical trial on skin care in
neonatology. A comparison between two skin care products

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

44

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

and no skin care. www.clinicaltrialsregister.eu/ctr-search/
search?query=2005-001269-32 (first received 22 November
2005).

Fernandez 2018 {published data only}

Fernandez D, Antolin-Rodriguez R. Bathing a premature
infant in the intensive care unit: a systematic review.
Journal of Pediatric Nursing 2018;42:e52-7. [DOI: 10.1016/
j.pedn.2018.05.002]

Field 2008 {published data only}

Field T, Field T, Cullen C, Largie S, Diego M, Schanberg S, et
al. Lavender bath oil reduces stress and crying and enhances
sleep in very young infants. Early Human Development
2008;84(6):399-401.

Fluhr 2012 {published data only}

Fluhr JW, Darlenski R, Lachmann N, Baudouin C, Msika P, De
Belilovsky C, et al. Infant epidermal skin physiology: adaptation
after birth. British Journal of Dermatology 2012;166(3):483-90.
[DOI: 10.1111/j.1365-2133.2011.10659.x]

Foisy 2011 {published data only}

Foisy M, Boyle RJ, Chalmers JR, Simpson EL, Williams HC.
Overview of reviews: the prevention of eczema in infants and
children: an overview of Cochrane and non-Cochrane reviews.
Evidence-Based Child Health: A Cochrane Review Journal
2011;6(5):1322-39. [DOI: 10.1002/ebch.827]

Franck 2000 {published data only}

Franck LS, Quinn D, Zahr L. Effect of less frequent bathing
of preterm infants on skin flora and pathogen colonization.
Journal of Obstetric, Gynecologic, and Neonatal Nursing
2000;29(6):584-9.

Friscia 2019 {published data only (unpublished sought but not
used)}

Friscia D,  Telofski L,  Nikolovski J. Effects of emollient use on
the developing infant skin microbiome. Journal of the American
Academy of Dermatology 2019;4 Suppl 1:AB4422019.

Gao 2008 {published data only}

Gao Y. Effectiveness observation on moisturizer for infant
eczema. Chinese Journal of Leprosy and Skin Disease
2008;24(4):294.

Garcia Bartels 2009 {published data only}

Garcia Bartels N, Mleczko A, Schink T, Proquitte H, Wauer RR,
 Blume-Peytavi U. Influence of bathing or washing on skin
barrier function in newborns during the first four weeks of life.
Skin Pharmacology & Physiology 2009;22(5):248-57.

Gezon 1964 {published data only}

Gezon HM, Thompson DJ, Rogers KD, Hatch TF, Taylor PM.
Hexachlorophene bathing in early infancy. New England Journal
of Medicine 1964;270:379-86.

Gfatter 1997 {published data only}

Gfatter R, Hackl P, Braun F. Effects of soap and detergents
on skin surface pH, stratum corneum hydration and fat

Cochrane Database of Systematic Reviews

content in infants. Dermatology 1997;195(3):258-62. [DOI:
10.1159/000245955]

Gleiss 1965 {published data only}

Gleiss J, Sommerkamp B. Comparative study of soapless
skin cleansing of infants. Archiv fur Kinderheilkunde
1965;172(2):154-60.

Gunt 2018 {published data only}

Gunt HB, Levy SB, Lutrario CA. A natural cream-to-powder
formulation developed for the prevention of diaper dermatitis
in diaper-wearing infants and children: barrier property and
in-use tolerance studies. Journal of Drugs in Dermatology
2018;17(5):566-70.

Hauk 2008 {published data only}

Hauk PJ. The role of food allergy in atopic dermatitis. Current
Allergy and Asthma Reports 2008;8(3):188-94.

Hawkins 2017 {published data only}

Hawkins S, Edmunds M, Foy V, Vincent C, Cox E, O'Shea S, et al.
Superior skin care for infants with a new nourishing regimen
containing stearic acid, petrolatum, and fatty acids: tip-to-toe-
wash and lotion. Pediatric Dermatology 2017;34(S1):S34. [DOI:
10.1111/pde.13195]

Hawkins 2020 {published data only}

*  Hawkins SS, Dasgupta A, Kumaran S, Salgaonkar N,
Mallemala P, Majumdar A. Evaluating prebiotic effects of
glycerol: moving toward enhancing the care of infant skin.
Journal of the American Academy of Dermatology 2020;83(6
Suppl):AB59. [EMBASE: 2010132360]

Hnatko 1977 {published data only}

Hnatko SI. Alternatives to hexachlorophene bathing of
newborn infants. Canadian Medical Association Journal
1977;117(3):223-6.

Horimukai 2016 {published data only}

Horimukai K, Morita K, Narita M, Kondo M, Kabashima S,
Inoue E, et al. Transepidermal water loss measurement during
infancy can predict the subsequent development of atopic
dermatitis regardless of filaggrin mutations. Allergology
International 2016;65(1):103-8.

Hu 2014 {published data only}

Hu X, Zhang Y. Effect of topically applied sunflower seed oil in
preterm infants. Pediatric Critical Care Medicine 2014;15(4 Suppl
1):144-5. [DOI: 10.1097/01.pcc.0000449366.67893.84]

IRCT201306164617N {published data only}

IRCT201306164617N. Effect of bath on clinical outcomes in
preterm infants: a randomized controlled trial. www.who.int/
trialsearch/Trial2.aspx?TrialID=IRCT201306164617N7 (first
received 28 June 2013).

IRCT201306164617N7 {published data only}

IRCT201306164617N7. Effect of bath on clinical outcomes
in preterm infants: a randomized controlled trial. en.irct.ir/
trial/4950 (first received 28 June 2013).

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

IRCT2013090814594N1 {published data only}

JPRN-UMIN000018110 {published data only}

IRCT2013090814594N1. A comparison between the effects of
swaddled bathing and conventional bathing on physiological
and behavioral parameters among the preterm neonates.
en.irct.ir/trial/14191 (first received 3 January 2014).

IRCT2016111530903N {published data only}

IRCT2016111530903N. The efficacy of Chamomile oil
on infantile colic. www.who.int/trialsearch/Trial2.aspx?
TrialID=IRCT2016111530903N1 (first received 4 April 2017).

IRCT20170911036118N1 {published data only}

IRCT20170911036118N1. Effect of massage and washing in
physiological jaundice. en.irct.ir/trial/27093 (first received 17
January 2018).

ISRCTN69836999 {published data only}

*  ISRCTN69836999. A pilot study to understand the best way of
applying antiseptic, with or without sunflower oil, to low birth
weight newborn babies who are in hospital. www.isrctn.com/
ISRCTN69836999 (first received 7 April 2020).

ISRCTN71423189 {published data only}

ISRCTN71423189. Multi-centre randomised controlled
trial of ion-exchange water softeners for the treatment of
atopic eczema in children (Softened Water Eczema Trial).
www.isrctn.com/ISRCTN71423189 (first received 8 January
2007). [DOI: 10.1186/ISRCTN71423189]

ISRCTN89579779 {published data only}

JPRN-UMIN000018110. Preliminary study on the skin cleaning
method without cleaning agent during bathing in the
NICU - comparison with the case of using a skin cleaning
agent. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-
UMIN000018110 (first received 26 June 2015).

JPRN-UMIN000025302 {published data only}

JPRN-UMIN000025302. Open test of skin care products for
newborns. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-
UMIN000025302 (first received 16 November 2017).

JPRN-UMIN000032181 {published data only}

JPRN-UMIN000032181. Study of neonates on the intestinal
bacterial flora and skin conditions. upload.umin.ac.jp/cgi-open-
bin/icdr_e/ctr_view.cgi?recptno=R000036709 (first received 10
April 2018).

JPRN-UMIN000032798 {published data only}

JPRN-UMIN000032798. Baby diaper study (No.2016-001).
upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?
recptno=R000037416 (first received 31 May 2018).

JPRN-UMIN000035357 {published data only}

JPRN-UMIN000035357. Effect of moisturizer application
on perianal area in neonates; comparison of effects on
erythema and skin barrier function at 1-month checkup.
upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?
recptno=R000040287 (first received 25 December 2018).

ISRCTN89579779. The use of Aquaphor to prevent
transepidermal water loss and to maintain electrolyte
balance in preterm newborn infants in the first week of life.
www.isrctn.com/ISRCTN89579779 (first received 30 September
2004). [DOI: 10.1186/ISRCTN89579779]

JPRN-UMIN000035412 {published data only}

JPRN-UMIN000035412. Effect of change in bathing and skin
care in infancy on the incidence of eczema at 6 months of age.
rctportal.niph.go.jp/en/detail?trial_id=UMIN000035412 (first
received 7 January 2019).

Jabbar-Lopez 2020 {published data only}

Kadar 1974 {published data only}

*  Jabbar-Lopez ZK, Craven J, Logan K, Greenblatt D, Marrs T,
Radulovic S, et al. Longitudinal analysis of the effect of water
hardness on atopic eczema: evidence for gene–environment
interaction. British Journal of Dermatology 2020;183(2):285-93.
[PMID: 31599965]

Jabraeile 2016 {published data only}

Jabraeile M, Rasooly AS, Farshi MR,  Malakouti J. Effect
of olive oil massage on weight gain in preterm infants: a
randomized controlled clinical trial. Nigerian Medical Journal
2016;57(3):160-3.

Jensen 1971 {published data only}

Jensen JP. Transcutaneous absorption of boron from a baby
ointment used prophylactically against diaper dermatitis.
Nordisk Medicin 1971;86(48):1425-9.

JPRN-UMIN000005158 {published data only}

JPRN-UMIN000005158. Randomized controlled trial to
evaluate clinical efficacy of once- or twice-daily skincare with
emollient for prevention of atopic dermatitis exacerbation.
upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?
recptno=R000005803 (first received 3 July 2011).

Kadar V,  Osbourn R. The mildness of soaps in the care of
infants' skin: a comparative study. Current Therapeutic Research
- Clinical and Experimental 1974;16(5):452-6. [PMID: 4275656]

Kanti 2014 {published data only}

Kanti V, Grande C, Stroux A, Buhrer C, Blume-Peytavi U, Garcia
Bartels N. Influence of sunflower seed oil on the skin barrier
function of preterm infants: a randomized controlled trial.
Dermatology 2014;229(3):230-9.

Kanti 2017 {published data only}

Kanti V, Gunther M, Stroux A, Sawatzky S, Henrich W,  Abou-
Dakn M, et al. Influence of sunflower seed oil or baby lotion on
the skin barrier function of newborns: a pilot study. Journal of
Cosmetic Dermatology 2017;16(4):500-7.

Kiechl Kohlendorfer 2008 {published data only}

Kiechl-Kohlendorfer U, Berger C,  Inzinger R. The effect of
daily treatment with an olive oil/lanolin emollient on skin
integrity in preterm infants: a randomized controlled trial.
Pediatric Dermatology 2008;25(2):174-8. [DOI: 10.1111/
j.1525-1470.2008.00627.x]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

46

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Konar 2019 {published data only}

Ling 2011 {published data only}

Konar MC,  Islam K, Roy A,  Ghosh T. Effect of virgin coconut oil
application on the skin of preterm newborns: a randomized
controlled trial. Journal of Tropical Pediatrics 2019;66:129-35.
[DOI: 10.1093/tropej/fmz041]

Koplin 2019 {published data only}

Koplin JJ, Allen KJ, Tang MLK. Important risk factors for
the development of food allergy and potential options
for prevention. Expert Review of Clinical Immunology
2019;15(2):147-52.

Ling L, Bi XY. Swimming and bathing with Chinese herbal
medicine in treatment of neonatal jaundice: clinical analysis of
50 cases. Journal of Qilu Nursing 2011;17(1):42-3.

Linnamaa 2010 {published data only}

Linnamaa P, Savolainen J, Koulu L, Tuomasjukka S,  Kallio H,
Yang B, et al. Blackcurrant seed oil for prevention of atopic
dermatitis in newborns: a randomized, double-blind,
placebo-controlled trial. Clinical and Experimental Allergy
2010;40(8):1247-55. [DOI: 10.1111/j.1365-2222.2010.03540.x]

Kottner 2017 {published data only}

Lowe 2012 {published data only}

Kottner J, Kanti V, Dobos G, Hahnel E,  Lichterfeld-Kottner A,
Richter C, et al. The effectiveness of using a bath oil to reduce
signs of dry skin: a randomized controlled pragmatic study.
International Journal of Nursing Studies 2017;65:17-24.

Kvenshagen 2014 {published data only}

Lowe AJ, Tang MLK, Dharmage SC, Varigos G, Forster D,
Gurrin LC, et al. A phase I study of daily treatment with a
ceramide-dominant triple lipid mixture commencing in
neonates. BMC Dermatology 2012;12(3):no pagination. [DOI:
10.1186/1471-5945-12-3]

Kvenshagen BK,  Mowinckel P, Carlsen KH, Carlsen KL. Intensive
oil baths from six weeks of age reduce xerosis and possibly
atopic eczema in infancy. European Respiratory Journal
2012;40(Suppl 56):424s.

Lowe 2018b {published data only}

Lowe AJ, Leung DYM, Tang MLK,  Su JC, Allen KJ. The skin as
a target for prevention of the atopic march. Annals of Allergy,
Asthma, & Immunology 2018;120(2):145-51.

Kvenshagen BK, Carlsen KH, Mowinckel P, Berents TL,
Carlsen KC. Can early skin care normalise dry skin and
possibly prevent atopic eczema? A pilot study in young infants.
Allergologia et Immunopathologia 2014;42(6):539-43. [DOI:
10.1016/j.aller.2014.06.003]

Lane 1993 {published data only}

Lane AT, Drost SS. Effects of repeated application of emollient
cream to premature neonates' skin. Pediatrics 1993;92(3):415-9.

Larson 2005 {published data only}

Larson AA,  Dinulos JG. Cutaneous bacterial infections in the
newborn. Current Opinion in Pediatrics 2005;17(4):481-5.

Lee 2018 {published data only}

Lee JC, Lee Y, Park HR. Effects of bathing interval on skin
condition and axillary bacterial colonization in preterm
infants. Applied Nursing Research 2018;40:34-8. [DOI: 10.1016/
j.apnr.2017.12.012]

LeFevre 2010 {published data only}

LeFevre A,  Shillcutt SD, Saha SK, Ahmed AS, Ahmed S,
Chowdhury MA, et al. Cost-effectiveness of skin-barrier-
enhancing emollients among preterm infants in Bangladesh.
Bulletin of the World Health Organization 2010;88(2):104-12.
[DOI: 10.2471/BLT.08.058230]

Leung 2015 {published data only}

Leung DYM. Prophylactic emollient use beginning at
birth prevents atopic dermatitis. Journal of Pediatrics
2015;166(3):777-8.

Li 2016 {published data only}

Li X, Zhong Q, Tang L. A meta-analysis of the efficacy and safety
of using oil massage to promote infant growth. Journal of
Pediatric Nursing 2016;31(5):e313-22.

Lund 2001a {published data only}

Lund CH, Kuller J, Lane AT, Lott JW, Raines DA, Thomas KK.
Neonatal skin care: evaluation of the AWHONN/NANN research-
based practice project on knowledge and skin care practices.
Journal of Obstetric, Gynecologic, and Neonatal Nursing
2001;30(1):30-40.

Lund 2001b {published data only}

Lund CH, Osborne JW, Kuller J, Lane AT, Lott JW, Raines DA.
Neonatal skin care: clinical outcomes of the AWHONN/NANN
evidence-based clinical practice guideline. Association of
Women's Health, Obstetric and Neonatal Nurses and the
National Association of Neonatal Nurses. Journal of Obstetric,
Gynecologic, and Neonatal Nursing 2001;30(1):41-51.

Manios 2019 {published data only}

Manios Y, Karaglani E, Thijs-Verhoeven I,
Vlachopapadopoulou E, Papazoglou A, Maragoudaki E,
et al . Milk fat-based formula reduced palmitic acid soaps
and excretion of calcium in healthy term infants: Two
double-blind, randomized, cross-over trials. Proceedings
of the Nutrition Society 2019;79(OCE2):E268. [DOI: 10.1017/
S0029665120002165]

Mardini 2020 {published data only}

*  Mardini J, Rahme C, Matar O, Abou Khalil S, Hallit S, Fadous
Khalife MC. Newborn's first bath: any preferred timing? A pilot
study from Lebanon. BMC Research Notes 2020;13(1):430.
[CENTRAL: CN-02176018]

Marenholz 2015 {published data only}

Marenholz I,  Esparza-Gordillo J, Lee YA. The genetics of the skin
barrier in eczema and other allergic disorders. Current Opinion
in Allergy & Clinical Immunology 2015;15(5):426-34.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

47

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Melo 2020 {published data only}

Melo PS, Barbieri M, Westphal F, Fustinoni SM, Henrique AJ,
Francisco AA, et al. Maternal and perinatal parameters after
non-pharmacological interventions: a randomised, controlled
clinical trial. Acta Paulista de Enfermagem 2020;33(3):1-9.
[CENTRAL: CN-02199203]

Muggli 2009 {published data only}

Muggli R. Natural management of napkin rash. European
Journal of Pediatric Dermatology 2009;19(1):43-6.

Nangia 2015 {published data only}

Nangia S, Paul VK, Deorari AK, Sreenivas V, Agarwal R, Chawla D.
Topical oil application and trans-epidermal water loss in
preterm very low birth weight infants - a randomized trial.
Journal of Tropical Pediatrics 2015;61(6):414-20. [DOI: 10.1093/
tropej/fmv049]

Natsume 2018 {published data only}

Natsume O, Ohya Y. Recent advancement to prevent the
development of allergy and allergic diseases and therapeutic
strategy in the perspective of barrier dysfunction. Allergology
International 2018;67(1):24-31.

oil massage. Biomedicine Hub 2021;6(1):17-34. [EMBASE:
634019153]

NCT01364948 {published data only}

NCT01364948. Effect of coconut oil application in reducing
water loss from skin of premature babies in first week of life
(TEWL) (TopOilTewl). clinicaltrials.gov/ct2/show/NCT01364948
(first received 3 June 2011).

NCT01396642 {published data only}

NCT01396642. Topical emollient therapy. clinicaltrials.gov/ct2/
show/NCT01396642 (first received 19 July 2011).

NCT01758068 {published data only}

NCT01758068. Effect of twice daily application of coconut oil in
reducing water loss from skin of premature babies in first week
of life. clinicaltrials.gov/ct2/show/NCT01758068 (first received
31 December 2012).

NCT02120833 {published data only}

NCT02120833. A test to determine the usefulness and safety of a
cream used on babies with dry itchy skin. clinicaltrials.gov/ct2/
show/NCT02120833 (first received 7 September 2015).

NCT00162747 {published data only}

NCT02403999 {published data only}

NCT00162747. Topical therapy for prevention of infections in
preterm infants. clinicaltrials.gov/ct2/show/NCT00162747 (first
received 13 September 2005).

NCT02403999. A tolerability assessment study of three wash
products in infants. clinicaltrials.gov/ct2/show/NCT02403999
(first received 31 March 2015).

NCT00257569 {published data only}

NCT02404493 {published data only}

NCT00257569. Study of atopic dermatitis in pediatrics.
clinicaltrials.gov/ct2/show/NCT00257569 (first received 23
November 2005).

NCT00806221 {published data only}

NCT00806221. An open-label study investigating the effects
of early skin barrier protection on the development of atopic
dermatitis. clinicaltrials.gov/ct2/show/NCT00806221 (first
received 10 December 2008).

NCT02404493. Test to determine the effectiveness of
moisturizing balm used on babies with dry, itchy skin.
clinicaltrials.gov/ct2/show/NCT02404493 (first received 31
March 2015).

NCT02557698 {published data only}

NCT02557698. Effectiveness of using an oil bath additive.
clinicaltrials.gov/ct2/show/NCT02557698 (first received 23
September 2015).

NCT00917085 {published data only}

NCT02614248 {published data only}

NCT00917085. Is skin-to-skin care helpful for preterm infants
and their mothers after birth? clinicaltrials.gov/ct2/show/
NCT00917085 (first received 10 June 2009).

NCT01131403 {published data only}

NCT01131403. Clinical analysis of the influence of using the
skin care products on the diaper area in comparison with using
a cotton wool cloth, moistened with clear water on the skin
physiology of the newborns from the 1st day to the 4th week of
life. clinicaltrials.gov/ct2/show/NCT01131403 (first received 27
May 2010).

NCT01177111 {published data only}

NCT01177111. Impact of sunflower seed oil massage on
neonatal mortality and morbidity in Nepal. clinicaltrials.gov/
ct2/show/NCT01177111 (first received 6 August 2010).

NCT02614248. The use of coconut oil for the prevention
and treatment of diaper dermatitis in the NICU population.
clinicaltrials.gov/ct2/show/NCT02614248 (first received 25
November 2015).

NCT02857062 {published data only}

To evaluate the in use tolerance of E45 eczema repair
emollient in babies and children with (very(dry/atopic skin.
clinicaltrials.gov/ct2/show/NCT02857062 (first received 5
August 2016).

NCT03089476 {published data only}

NCT03089476. Evaluating skin barrier dysfunction in infants
at high risk of atopy. clinicaltrials.gov/ct2/show/NCT03089476
(first received 24 March 2017).

NCT03112876 {published data only}

*  Visscher MO, Summers A, Narendran V, Khatry S, Sherchand J,
LeClerq S, et al. Birthweight and environmental conditions
impact skin barrier adaptation in neonates receiving natural

NCT03112876. Sebum collection and skin barrier function
analysis (Sebum). clinicaltrials.gov/ct2/show/NCT03112876
(first received 13 April 2017).

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

48

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03143504 {published data only}

Nesmiyanov 2018 {published data only}

NCT03143504. A longitudinal investigation of skin barrier
development from birth and the validation of early predictors
of atopic eczema risk: the Skin Testing for Atopic eczema Risk
(STAR) Study (STAR). clinicaltrials.gov/ct2/show/NCT03143504
(first received 8 May 2017).

Nesmiyanov P, Gutov M, Strygin A, Tolkachev B, Morkovin E,
 Dotsenko A. M. vaccae-based formulation for the primary
prevention of atopic dermatitis. Allergy 2018;73:107. [DOI:
10.1111/all.13535]

Nopper 1996 {published data only}

NCT03719742 {published data only}

NCT03719742. A clinical study to evaluate the safety and
efficacy of a baby cleanser and a moisturizer. clinicaltrials.gov/
ct2/show/NCT03719742 (first received 25 October 2018).

Nopper AJ, Horii KA,  Sookdeo-Drost S, Wang TH, Mancini AJ,
Lane AT. Topical ointment therapy benefits premature infants.
Journal of Pediatrics 1996;128(5 Pt 1):660-9. [DOI: 10.1016/
s0022-3476(96)80132-6]

NCT03738163 {published data only}

Noviello 2005 {published data only}

NCT03738163. A clinical investigation with Epaderm®
cream (PD-539878). clinicaltrials.gov/ct2/show/NCT03738163
(first received 13 November 2018).

NCT03742414 {published data only}

NCT03742414. Seal, stopping atopic dermatitis and allergy
study. clinicaltrials.gov/ct2/show/NCT03742414 (first received
15 November 2018).

NCT03813472 {published data only}

NCT03813472. Hydration sensor for atopic dermatitis.
clinicaltrials.gov/ct2/show/results/NCT03813472 (first received
23 January 2019).

NCT04001855 {published data only}

NCT04001855. Evaluating the effect of bathing additives in
atopic dermatitis. clinicaltrials.gov/ct2/show/NCT04001855
(first received 28 June 2019).

NCT04099602 {published data only}

NCT04099602. The effect of massage on bilirubin level in
infants. clinicaltrials.gov/ct2/show/NCT04099602 (first received
  23 September 2019).

NCT04231799 {published data only}

*  NCT04231799. Delaying first bathing and skin barrier function
on infant (TEWL). clinicaltrials.gov/ct2/show/NCT04231799 (first
received 18 January 2020).

NCT04619758 {published data only}

*  NCT04619758. Emollient therapy in preterm & low birth
weight neonates: a randomized clinical trial. clinicaltrials.gov/
ct2/show/NCT04619758 (first received 6 November 2020).

NCT04720989 {published data only}

*  NCT04720989. The effect of cleansing product used in the
first bathing on transepidermal water loss and skin Ph in late
preterm and term infants: a multicenter, evaluative blind
randomized controlled study. clinicaltrials.gov/ct2/show/
NCT04720989 (first received 22 January 2021).

NCT04842786 {published data only}

*  NCT04842786. Topical coconut oil application and incidence
of sepsis in neonates. clinicaltrials.gov/ct2/show/NCT04842786
(first received 13 April 2021).

Noviello MR. Effects after daily use of washing products on
infants aged 0-52 weeks. Minerva Pediatrica 2005;57(6):411-8.

PACTR202004705649428 {published data only}

*  PACTR202004705649428. A cluster randomised trial to
evaluate the effectiveness of household alcohol-based handrub
for the prevention of sepsis, diarrhoea and pneumonia in
Ugandan infants. www.who.int/trialsearch/Trial2.aspx?
TrialID=PACTR202004705649428 (accessed 13 October 2021).

Perkin 2021 {published data only}

*  Perkin MR, Logan K, Marrs T, Radulovic S, Craven J, Boyle RJ,
et al. Association of frequent moisturizer use in early infancy
with the development of food allergy. Journal of Allergy &
Clinical Immunology 2021;147(3):967-76. [PMID: 33678253]

Pupala 2017 {published data only}

Pupala S, Rao S, Strunk T, Patole S. Topical application of
coconut oil to the skin of preterm infants - a systematic review.
Journal of Paediatrics and Child Health 2017;53 Suppl 2:82.

Pupala 2018 {published data only}

Pupala S, Strunk T, Patole S, Doherty D, Hibbert J. Topical
coconut oil to improve skin condition in very preterm infants: a
pilot randomised clinical trial. Journal of Paediatrics and Child
Health 2018;54:103-4. [DOI: 10.1111/jpc.13882_280]

Pupala 2019 {published data only}

Pupala SS, Rao S, Strunk T, Patole S. Topical application of
coconut oil to the skin of preterm infants: a systematic review.
European Journal of Pediatrics 2019;178(9):1317-24.

Qiu 2008 {published data only}

Qiu HM, Zhou L. The clinic effect of Chinese medicine
bath therapy on 132 neonates with hyperbilirubinemia.
Shaanxi Journal of Traditional Chinese Medicine
2008;29(11):1479-80.

Quinn 2005 {published data only}

Quinn D, Newton N, Piecuch R. Effect of less frequent
bathing on premature infant skin. Journal of Obstetric,
Gynecologic, and Neonatal Nursing 2005;34(6):741-6. [DOI:
10.1177/0884217505282021]

Ram 2020 {published data only}

*  Ram PK, Begum F, Crabtree-Ide C, Uddin MR, Weaver AM,
Dostogir Harun MG, et al. Waterless hand cleansing with
chlorhexidine during the neonatal period by mothers and other

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

49

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

household members: findings from a randomized controlled
trial. American Journal of Tropical Medicine and Hygiene
2020;103(5):2116-26. [PMID: 32959761]

RBR-93996y {published data only}

RBR-93996y. Effect of liquid and bar soap in healthy
term newborns. www.who.int/trialsearch/Trial2.aspx?
TrialID=RBR-93996y (first received 13 July 2018).

Rehbinder 2018 {published data only}

Rehbinder EM, Winger AJ, Landro L, Carlsen KH, Carlsen MH,
Fatnes TA,  et al. Is dry skin in infants 3 months of age
associated with increased transepidermal water loss? British
Journal of Dermatology 2018;179(1):e59. [DOI: 10.1111/
bjd.16718]

Rosenstock 2007 {published data only}

Rosenstock. The impact of emollient therapy during
the neonatal period on neurodevelopmental outcomes.
Pediatric Academic Society 2007;8315:no pagination.

Sach 2019 {published data only}

Sach TH, McManus E, Levell NJ. Understanding economic
evidence for the prevention and treatment of atopic eczema.
British Journal of Dermatology 2019;181(4):707-16. [DOI:
10.1111/bjd.17696]

Salam 2013 {published data only}

Salam RA, Das JK, Darmstadt GL, Bhutta ZA. Emollient therapy
for preterm newborn infants - evidence from the developing
world. BMC Public Health 2013;13 Suppl 3:S31.

Salam 2015 {published data only}

Salam RA, Darmstadt GL, Bhutta ZA. Effect of emollient therapy
on clinical outcomes in preterm neonates in Pakistan: a
randomised controlled trial. Archives of Disease in Childhood.
Fetal and Neonatal Edition 2015;100(3):F210-5. [DOI: 10.1136/
archdischild-2014-307157]

Sarkar 2010 {published data only}

Sarkar R, Basu S, Agrawal RK, Gupta P. Skin care for the
newborn. Indian Pediatrics 2010;47(7):593-8.

Sawatzky 2016 {published data only}

Sawatzky S, Schario M, Stroux A, Lunnemann L, Zuberbier T,
 Blume-Peytavi U, et al. Children with dry skin and atopic
predisposition: outcome measurement with validated
scores for atopic dermatitis. Skin Pharmacology & Physiology
2016;29(3):148-56.

Solanki 2005 {published data only}

Solanki K, Matnani M, Kale M,  Joshi K, Bavdekar A, Bhave S,
et al. Transcutaneous absorption of topically massaged oil in
neonates. Indian Pediatrics 2005;42(10):998-1005.

Cochrane Database of Systematic Reviews

Soriano 2000 {published data only}

Soriano CR, Martinez FE, Jorge SM. Cutaneous application of
vegetable oil as a coadjutant in the nutritional management
of preterm infants. Journal of Pediatric Gastroenterology and
Nutrition 2000;31(4):387-90.

Summers 2017 {published data only}

Summers A, Visscher M, Khatry S, Sherchand J, LeClerq S,
Katz J, et al. Neonatal skin integrity: impact of mustard seed
versus sunflower oil massage among newborns in rural Nepal.
Pediatric Dermatology 2017;34:S85. [DOI: 10.1111/pde.13195]

Tasdemir 2021 {published data only}

Taşdemir Hİ, Efe E. The effect of delaying first bathing on skin
barrier function in late preterm infants: a study protocol for
multi-centre, single-blind RCT. Journal of Advanced Nursing
2021;77(2):1051-61. [PMID: 33210328]

Tasker 2020 {published data only}

Tasker F, Brown A, Grindlay DJC, Rogers NK, Harman KE. What's
new in atopic eczema? An analysis of systematic reviews
published in 2018. Part 1: prevention and topical therapies.
Clinical & Experimental Dermatology 2020;45(8):974-9. [PMID:
32852805]

TCTR20161209001 {published data only}

TCTR20161209001. Efficacy of breast milk application on skin
condition in preterm infants: a randomized controlled trial.
www.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20161209001
(first received 9 December 2016).

Telofski 2020 {published data only}

Telofski L, Capone KA, Friscia D, Nikolovski J. Effects
of emollient use on the developing infant skin
microbiome. Pediatrics 2020;146:128. [DOI: 10.1542/
peds.146.1_MeetingAbstract.128]

Thomas 1979 {published data only}

Thomas WR. The prevention of superficial infection in neonates.
Journal of Antimicrobial Chemotherapy 1979;5(2):235-6. [DOI:
10.1093/jac/5.2.235]

Vaivre Douret 2009 {published data only}

Vaivre-Douret L, Oriot D, Blossier P, Py A,  Kasolter-Pere M,
Zwang J. The effect of multimodal stimulation and cutaneous
application of vegetable oils on neonatal development in
preterm infants: a randomized controlled trial. Child: Care,
Health & Development 2009;35(1):96-105.

Visscher 2009 {published data only}

Visscher M, Odio M, Taylor T, White T, Sargent S, Sluder L,
et al. Skin care in the NICU patient: effects of wipes versus
cloth and water on stratum corneum integrity. Neonatology
2009;96(4):226-34.

Soll 2000 {published data only}

Wananukul 2001 {published data only}

Soll RF, Edwards WH. Emollient ointment for preventing
infection in preterm infants. Cochrane Database of
Systematic Reviews 2000, Issue 2. Art. No: CD001150. [DOI:
10.1002/14651858.CD001150]

Wananukul S, Praisuwanna P, Kesorncam K. Effects of
clear topical ointment on transepidermal water loss in
jaundiced preterm infants receiving phototherapy. Chotmaihet
thangphaet [Journal of the Medical Association of Thailand]
2001;84(6):837-41.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

50

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wananukul 2002 {published data only}

JPRN-UMIN000026877 {published data only}

Wananukul S, Praisuwanna P. Clear topical ointment decreases
transepidermal water loss in jaundiced preterm infants
receiving phototherapy. Chotmaihet thangphaet [Journal of the
Medical Association of Thailand] 2002;85(1):102-6.

Wang 2009 {published data only}

Wang YL, Tan P, Wu SY, Gao GE, Chen B. The effect of Chinese
medicine bath therapy on the levels of neonatal bilirubin. China
Pharmacist 2009;12(11):1622-3.

JPRN-UMIN000026877. Use test of skin care goods.
www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-
UMIN000026877 (first received 5 April 2017).

NCT03640897 {published data only}

NCT03640897. Evaluation of the safety and performance
of LiNiDERM® in the prevention of infant diaper rash.
clinicaltrials.gov/ct2/show/NCT03640897 (first received 21
August 2018).

Waserman 2016 {published data only}

Ng 2021 {published data only}

Waserman S. Doctor, can we prevent food allergy and eczema
in our baby? Current Opinion in Allergy & Clinical Immunology
2016;16(3):265-71.

Xatzopoulou 2010 {published data only}

Xatzopoulou S, Liosis G, Giannouli O, Grigoriadou D, Kyriacou M.
Olive oil as a potential prebiotic in infants' skin. Early Human
Development 2010;1:S20.

Xiao 2009 {published data only}

Xiao DM, Wu CL, Liu QL. Traditional Chinese medicine bath
with the sun on the prevention of neonatal jaundice. Chinese
Medicine Modern Distance Education of China 2009;7(3):19.

Yamamoto 1996 {published data only}

Yamamoto K. Soaps and detergents in children. Clinics in
Dermatology 1996;14(1):81-4.

Zhang 2016 {published data only}

Zhang SZ, Xu ZH, Zhao LH. Observation on the effect of Shule
liniment for neonatal touch combined with acupoint massage
in the treatment of neonatal rash. Guang Ming Zhong Yi Za Zhi
[Guangming Journal of Chinese Medicine] 2016;31(1):63-4.

Zheng 2019 {published data only}

*  Zheng Y, Wang Q, Ma L, Chen Y, Gao Y, Zhang G, et al. Shifts
in the skin microbiome associated with diaper dermatitis
and emollient treatment amongst infants and toddlers in
China. Experimental Dermatology 2019;28(11):1289-97. [PMID:
31472099]

References to studies awaiting assessment

ISRCTN38965585 {published data only}

CTRI/2014/12/005282. Can an intervention involving
improvements in community-based newborn massage
practice with promotion of cold-pressed sunflower oil
as preferred emollient improve newborn survival in
rural North India? www.who.int/trialsearch/Trial2.aspx?
TrialID=CTRI/2014/12/005282 (first received 11 December 2014).

ISRCTN38965585. Can an intervention involving improvements
in community-based newborn massage practice with
promotion of cold-pressed sunflower oil as preferred
emollient improve newborn survival in rural North India?
www.isrctn.com/ISRCTN38965585 (first received 8 July 2014).
[DOI: 10.1186/ISRCTN38965585]

*  Ng PSM, Wee LWY, Ho VPY, Tan WC, Bishnoi P, Alagappan U, et
al. Moisturisers from birth in at-risk infants of atopic dermatitis -
a pragmatic randomised controlled trial. Australasian Journal of
Dermatology 2021 Aug 23 [Epub ahead of print]. [DOI: 10.1111/
ajd.13703]

References to ongoing studies

ChiCTR2000035585 {published data only}

*  ChiCTR2000035585. A multi-center, randomized, single-
blind controlled study on the regular use of medical emollients
in early birth to reduce the incidence and severity of atopic
dermatitis in infants and young children. www.who.int/
trialsearch/Trial2.aspx?TrialID=ChiCTR2000035585 (first
received 14 August 2020).

CTRI/2020/03/023963 {published data only}

*  CTRI/2020/03/023963. Topical oil for skin protection
in neonates. ctri.nic.in/Clinicaltrials/showallp.php?
mid1=41652&EncHid=&userName=Topical%20oil (first received
13 March 2020).

Eichner 2020 {published data only}

Eichner B, Michaels LAC,  Branca K, Ramsey K, Mitchell J,
 Morris CD, et al. A Community-based Assessment of Skin
Care, Allergies, and Eczema (CASCADE): an atopic dermatitis
primary prevention study using emollients - protocol for
a randomized controlled trial. Trials 2020;21(1):243. [DOI:
10.1186/s13063-020-4150-5]

NCT03409367. A Community-based Assessment of Skin Care,
Allergies, and Eczema (CASCADE). clinicaltrials.gov/ct2/show/
NCT03409367 (first received 24 January 2018).

Jabbar-Lopez 2019 {published data only}

Jabbar-Lopez ZK, Gurung N,  Greenblatt D,  Briley A,
Chalmers JR, Thomas KS, et al. Protocol for an outcome
assessor-blinded pilot randomised controlled trial of an
ion-exchange water softener for the prevention of atopic
eczema in neonates, with an embedded mechanistic study: the
Softened Water for Eczema Prevention (SOFTER) trial. BMJ Open
2019;9(8):e027168. [DOI: 10.1136/bmjopen-2018-027168]

NCT03270566. Softened water for eczema prevention pilot
trial. clinicaltrials.gov/ct2/show/NCT03270566 (first received 1
September 2017).

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

51

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lowe 2019 {published data only}

ACTRN12617001380381. The PEBBLES Study - testing
a strategy for preventing eczema and food allergy in
high risk infants. www.who.int/trialsearch/Trial2.aspx?
TrialID=ACTRN12617001380381 (first received 28 September
2017).

Lowe A, Su J, Tang M, Lodge CJ, Matheson M, Allen KJ,  et al.
PEBBLES study protocol: a randomised controlled trial to
prevent atopic dermatitis, food allergy and sensitisation in
infants with a family history of allergic disease using a skin
barrier improvement strategy. BMJ Open 2019;9(3):e024594.
[DOI: 10.1136/bmjopen-2018-024594]

NCT02906475 {published data only}

NCT02906475. Atopic dermatitis in atopy predisposed infants.
clinicaltrials.gov/ct2/show/NCT02906475 (first received 20
September 2016).

NCT03142984 {published data only}

NCT03142984. UK BABY study using a baby wash and lotion
regimen (BOND). clinicaltrials.gov/ct2/show/NCT03142984 (first
received 8 May 2017).

NCT03808532 {published data only}

NCT03808532. Moisturizer to prevent atopic dermatitis (ACE-
AD). clinicaltrials.gov/ct2/show/NCT03808532 (first received 17
January 2019).

NCT03871998 {published data only}

*  NCT03871998. Short-term topical application to prevent
atopic dermatitis (STOP AD). clinicaltrials.gov/ct2/show/
NCT03871998 (first received 12 March 2019).

Cochrane Database of Systematic Reviews

Additional references

Abuabara 2018

Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The
prevalence of atopic dermatitis beyond childhood: a systematic
review and meta-analysis of longitudinal studies. Allergy
2018;73(3):696-704.

Abuabara 2019

Abuabara K, Ye M, McCulloch CE, Sullivan A, Margolis DJ,
Strachan DP, et al. Clinical onset of atopic eczema: results
from 2 nationally representative British birth cohorts followed
through midlife. Journal of Allergy and Clinical Immunology
2019;144(3):710-9.

Amare 2015

Amare Y, Shamba DD, Manzi F, Bee MH, Omotara BA, Iganus RB,
et al. Current neonatal skin care practices in four African sites.
Journal of Tropical Pediatrics 2015;61(6):428-34. [DOI: 10.1093/
tropej/fmv053]

Andrews 2013

Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ,
Coello PA, et al. GRADE guidelines: 15. Going from evidence
to recommendation - determinants of a recommendation's
direction and strength. Journal of Clinical Epidemiology
2013;66(7):726-35. [DOI: 10.1016/j.jclinepi.2013.02.003]

Apfelbacher 2011

Apfelbacher CJ, Diepgen TL, Schmitt J. Determinants of eczema:
population-based cross-sectional study in Germany. Allergy
2011;66(2):206-13.

Asai 2018

Ni Chaoimh C, Lad D, Nico C, Puppels GJ, Caspers PJ, Irvine AD,
et al. Neonatal natural moisturising factor concentrations in
a high-risk cohort with parental history of atopy compared
to a reference cohort. Allergy: European Journal of Allergy
and Clinical Immunology 2020;75 Suppl 109:91. [EMBASE:
633542472]

Asai Y, Eslami A, van Ginkel CD, Akhabir L, Wan M, Ellis G, et
al. Genome-wide association study and meta-analysis in
multiple populations identifies new loci for peanut allergy
and establishes C11orf30/EMSY as a genetic risk factor
for food allergy. Journal of Allergy & Clinical Immunology
2018;141(3):991-1001. [DOI: 10.1016/j.jaci.2017.09.015.]

Ni Chaoimh C, Lad D, Stamatas GN, Oddos T, Irvine AD, O'B
Hourihane J. Parental compliance with an infant moisturization
protocol in the first 2 months of life. Allergy 2020;75 Suppl
109:596. [EMBASE: 633545599]

NCT04398758 {unpublished data only}

*  NCT04398758. Moisturizer mediated Prevention of
symptoms of Atopic Dermatitis in early childhood (MOPAD).
clinicaltrials.gov/ct2/show/NCT04398758 (first received 21 May
2020).

TCTR20200630006 {published data only}

*  TCTR20200630006. Effect of emollient on newborn skin
from birth in the prevention of atopic eczema: a randomized
control study in Thai neonates. www.thaiclinicaltrials.org/
show/TCTR20200630006 (first received 30 June 2020).

Asai 2020

Asai J, Martino D, Eiwegger T, Nadeau K, Koppelman GH,
Clarke AE, et al. Phenotype consensus is required to enable
large-scale genetic consortium studies of food allergy. Allergy
2020;75:2383-7. [DOI: 10.1111/all.14333]

Asher 2006

Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP,
Weiland SK, et al. Worldwide time trends in the prevalence of
symptoms of asthma, allergic rhinoconjunctivitis, and eczema
in childhood: ISAAC phases one and three repeat multicountry
cross-sectional surveys. Lancet 2006;368(9537):733-43.

Bai 2017

Bai G, Herten MH, Landgraf JM, Korfage IJ, Raat H. Childhood
chronic conditions and health-related quality of life:
findings from a large population-based study. PLOS ONE
2017;12(6):e0178539.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

52

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Barbarot 2018

Charman 2004

Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L,
Simpson EL, et al. Epidemiology of atopic dermatitis in adults:
results from an international survey. Allergy 2018;73(6):1284-93.

Blume-Peytavi 2016

Blume-Peytavi U, Lavender T, Jenerowicz D, Ryumina I,
Stalder JF, Torrelo A, et al. Recommendations from a European
roundtable meeting on best practice healthy infant skin care.
Pediatric Dermatology 2016;33(3):311-21.

Botha 2019

Botha M, Basera W, Facey-Thomas HE, Gaunt B, Gray CL,
Ramjith J, et al. Rural and urban food allergy prevalence from
the South African Food Allergy (SAFFA) study. Journal of Allergy
and Clinical Immunology 2019;143(2):662-8. [DOI: 10.1016/
j.jaci.2018.07.023]

Boyce 2010

Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA,
Wood RA, et al. Guidelines for the diagnosis and management of
food allergy in the United States: report of the NIAID-sponsored
expert panel. Journal of Allergy and Clinical Immunology
2010;126(6):S1-58.

Boyle 2017

Boyle R, Williams H, Askie L, Lodrup-Carlsen K, Montgomery A,
Chalmers J, et al. Prospectively planned meta-analysis
of skin barrier studies for the prevention of eczema and
associated health conditions. www.crd.york.ac.uk/prospero/
display_record.php?RecordID=56965 (first received 10 February
2017).

Bønnelykke 2013

Bønnelykke K, Matheson MC, Pers TH, Granell R, Strachan DP,
Alves AC, et al. Meta-analysis of genome-wide association
studies identifies ten loci influencing allergic sensitization.
Nature Genetics 2013;45(8):902-6. [DOI: 10.1038/ng.2694]

Carroll 2005

Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB, Manuel JC.
The burden of atopic dermatitis: impact on the patient, family,
and society. Pediatric Dermatology 2005;22(3):192-9.

Caussin 2009

Caussin J, Rozema E, Gooris GS, Wiechers JW, Pavel S,
Bouwstra JA. Hydrophilic and lipophilic moisturizers
have similar penetration profiles but different effects on
SC water distribution in vivo. Experimental Dermatology
2009;18(11):954-61.

Chalmers 2017

Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ,
Ridd M, et al. Effectiveness and cost-effectiveness of daily all-
over-body application of emollient during the first year of
life for preventing atopic eczema in high-risk children (the
BEEP trial): protocol for a randomised controlled trial. Trials
2017;18(1):343.

Charman CR, Venn AJ, Williams HC. The Patient-Oriented
Eczema Measure: development and initial validation of a new
tool for measuring atopic eczema severity from the patients’
perspective. Archives of Dermatology 2004;140(12):1513-9.

Chiou 2004

Chiou YB,  Blume-Peytavi U. Stratum corneum maturation.
A review of neonatal skin function. Skin Pharmacology &
Physiology 2004;17(2):57-66. [DOI: 10.1159/000076015]

Cochrane Skin Specialised Register 2021

Cochrane Skin. More about the Cochrane Skin Specialised
Register. skin.cochrane.org/search-methods (accessed 12
October 2021).

Cook 2018

Cook JA, MacLennan GS, Palmer T, Lois N, Emsley R.
Instrumental variable methods for a binary outcome were used
to informatively address noncompliance in a randomized trial in
surgery. Journal of Clinical Epidemiology 2018;96:126-32.

Cork 2002

Cork MJ, Murphy R, Carr J, Buttle D, Ward S, Båvik C, et al. The
rising prevalence of atopic eczema and environmental trauma
to the skin. Dermatology in Practice 2002;10(3):22-6.

Cro 2020a

Cro S, Boyle R, Kelleher M, Tran L, Cornelius V. Skin care
interventions for preventing eczema and food allergy:
a statistical analysis plan for a systematic review and
individual participant data meta-analysis. zenodo.org/
record/3610604#.XiGKU8j7SUk (accessed 16 January 2020).
[DOI: 10.5281/zenodo.3610604]

Cro 2020b

Cro S, Kelleher M, Cornelius V, Boyle R. Skin care interventions
for preventing eczema and food allergy: RoB 2 assessments
(Version 1) [Data set]. Zenodo. [DOI: 10.5281/zenodo.4288759]

Cummings 2010

Cummings AJ, Knibb RC, King RM, Lucas JS. The psychosocial
impact of food allergy and food hypersensitivity in
children, adolescents and their families: a review. Allergy
2010;65(8):933-45. [DOI: 10.1111/j.1398-9995.2010.02342.x]

Danby 2011

Danby SG, Al-Enezi T, Sultan A, Chittock J, Kennedy K, Cork MJ.
The effect of aqueous cream BP on the skin barrier in volunteers
with a previous history of atopic dermatitis. British Journal of
Dermatology 2011;165(2):329-34.

Danby 2018

Danby SG, Brown K, Wigley AM, Chittock J, Pyae PK, Flohr C, et
al. The effect of water hardness on surfactant deposition after
washing and subsequent skin irritation in atopic dermatitis
patients and healthy control subjects. Journal of Investigative
Dermatology 2018;138(1):68-77.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

53

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Deckers 2012

Deckers IA, McLean S, Linssen S, Mommers M, Van Schayck CP,
Sheikh A. Investigating international time trends in the
incidence and prevalence of atopic eczema 1990–2010: a
systematic review of epidemiological studies. PLOS ONE
2012;7(7):e39803.

Deeks 2021

Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 10:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
VA, editor(s). Cochrane Handbook for Systematic Reviews of
Interventions Version 6.2 (updated February 2021). Cochrane,
2021. Available from training.cochrane.org/handbook/archive/
v6.2.

in infants by domestic water hardness and season of birth:
cohort study. Journal of Allergy and Clinical Immunology
2017;139(5):1568-74.e1.

Esparza-Gordillo 2009

Esparza-Gordillo J, Weidinger S, Fölster-Holst R, Bauerfeind A,
Ruschendorf F, Patone G, et al. A common variant on
chromosome 11q13 is associated with atopic dermatitis. Nature
Genetics 2009;41(5):596-601. [DOI: 10.1038/ng.347 A]

Ewence 2011

Ewence A, Rumsby P, Danby S, Cork MJ, Williams HC. A review of
skin irritation and tap water. www.dwi.defra.gov.uk/research/
completed-research/reports/dwi70-2-257.pdf (accessed prior to
24 January 2019).

DerSimonian 1986

Flohr 2010

DerSimonian R, Laird N. Meta-analysis in clinical trials.
Controlled Clinical Trials 1986;7(3):177-88.

De Silva 2020

De Silva D,  Halken S,  Singh C,  Muraro A,  Angier E,  Arasi S, et
al. Preventing food allergy in infancy and childhood: systematic
review of randomised controlled trials. Paediatric Allergy and
Immunology 2020;31(7):813-26. [DOI: 10.1111/pai.13273]

Drucker 2017

Drucker AM, Wang AR, Li W-Q, Sevetson E, Block JK, Qureshi AA.
The burden of atopic dermatitis: summary of a report for
the National Eczema Association. Journal of Investigative
Dermatology 2017;137(1):26-30.

Du Toit 2015

Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S,
Santos AF, et al. Randomized trial of peanut consumption
in infants at risk for peanut allergy. New England Journal of
Medicine 2015;372(9):803-13.

Egger 1997

Egger M, Smith GD, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. BMJ
1997;315(7109):629-34.

Eichenfield 2014

Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS,
Schwarzenberger K, et al. Guidelines of care for the
management of atopic dermatitis: Part 2: Management and
treatment of atopic dermatitis with topical therapies. Journal of
the American Academy of Dermatology 2014;71(1):116-32.

Eldridge 2016

Eldridge S, Campbell M, Campbell M, Drahota A, Giraudeau B,
Higgins J, et al. Revised Cochrane risk of bias tool for
randomized trials (RoB 2.0): additional considerations for
cluster-randomized trials. www.riskofbias.info/welcome/
rob-2-0-tool/archive-rob-2-0-cluster-randomized-trials-2016
(accessed 14 October 2020).

Flohr C, England K, Radulovic S, McLean WH, Campbell LE,
Barker J, et al. Filaggrin loss-of-function mutations are
associated with early-onset eczema, eczema severity and
transepidermal water loss at 3 months of age. British Journal of
Dermatology 2010;163(6):1333-6.

Flohr 2014

Flohr C, Mann J. New insights into the epidemiology of
childhood atopic dermatitis. Allergy 2014;69(1):3-16.

Furlan 2009

Furlan AD, Pennick V, Bombardier C, Van Tulder M, Editorial
Board, Cochrane Back Review Group. 2009 updated method
guidelines for systematic reviews in the Cochrane Back Review
Group. Spine 2009;34(18):1929-41.

Garcia-Larsen 2018

Garcia-Larsen V, Ierodiakonou D, Jarrold K,  Cunha S, Chivinge J,
Robinson Z, et al. Diet during pregnancy and infancy and risk of
allergic or autoimmune disease: a systematic review and meta-
analysis. PLOS Medicine 2018;15(2):e1002507. [DOI: 10.1371/
journal.pmed.1002507]

Grabenhenrich 2017

Grabenhenrich LB, Reich A, Bellach J, Trendelenburg V,
Sprikkelman AB, Roberts G, et al. A new framework
for the documentation and interpretation of oral food
challenges in population-based and clinical research. Allergy
2017;72(3):453-61.

Gupta 2004

Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic
disease in the UK: secondary analyses of national databases.
Clinical & Experimental Allergy 2004;34(4):520-6.

Gupta 2013

Gupta R, Holdford D, Bilaver L, Dyer A, Holl JL, Meltzer D. The
economic impact of childhood food allergy in the United States.
JAMA Pediatrics 2013;167(11):1026-31.

Gupta 2019

Engebretsen 2017

Engebretsen KA, Bager P, Wohlfahrt J, Skov L, Zachariae C,
Nybo Andersen AM, et al. Prevalence of atopic dermatitis

Gupta RS, Warren CM, Smith BM, Jiang J, Blumenstock JA,
Davis MM, et al. Prevalence and severity of food allergies among
US adults. JAMA Network Open 2019;2(1):e185630.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

54

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hanifin 1980

Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis.
Acta Dermato-Venereologica 1980;60 Suppl 92:44-7.

Hanifin 2001

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M,
et al. The eczema area and severity index (EASI): assessment
of reliability in atopic dermatitis. Experimental Dermatology
2001;10(1):11-8.

demographic associations. Journal of Allergy and Clinical
Immunology 2014;134(6):1318-28 e7.

Johansson 2003

Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ,
Lockey RF, et al. Revised nomenclature for allergy for global use:
report of the Nomenclature Review Committee of the World
Allergy Organization. Journal of Allergy and Clinical Immunology
2003;113(5):832-6.

Harbord 2006

Kelleher 2016

Harbord RM, Egger M, Sterne JA. A modified test for small-
study effects in meta-analyses of controlled trials with binary
endpoints. Statistics in Medicine 2006;25(20):3443-57.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327:557-60.

Higgins 2018

Higgins JP, Savovic J, Page MJ, Sterne JA, ROB2 development
group. Revised Cochrane risk-of-bias tool for randomized trials
(RoB 2). sites.google.com/site/riskofbiastool/welcome/rob-2-0-
tool/current-version-of-rob-2 (accessed 5 February 2019).

Higgins 2021a

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
Welch VA, editor(s). Cochrane Handbook for Systematic Reviews
of Interventions Version 6.2 (updated February 2021). Cochrane,
2021. Available from training.cochrane.org/handbook/archive/
v6.2.

Higgins 2021b

Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter
8: Assessing risk of bias in a randomized trial. In: Higgins JPT,
Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA,
editor(s). Cochrane Handbook for Systematic Reviews of
Interventions Version 6.2 (updated February 2021). Cochrane,
2021. Available from training.cochrane.org/handbook/archive/
v6.2.

Ierodiakonou 2016

Ierodiakonou D, Garcia-Larsen V, Logan A, Groome A,  Cunha S,
 Chivinge J, et al. Timing of allergenic food introduction
to the infant diet and risk of allergic or autoimmune
disease: a systematic review and meta-analysis. JAMA
2016;316(11):1181-92. [DOI: 10.1001/jama.2016.12623]

Irvin 2015

Irvin EJ, Miller HD. Emollient use in the term newborn: a
literature review. Neonatal Network 2015;34(4):227-30.

Irvine 2011

Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated
with skin and allergic diseases. New England Journal of Medicine
2011;365(14):1315-27.

Jerschow 2014

Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis
in the United States, 1999-2010: temporal patterns and

Kelleher MM, Dunn-Galvin A, Gray C, Murray DM, Kiely M,
Kenny L, et al. Skin barrier impairment at birth predicts
food allergy at 2 years of age. Journal of Allergy and Clinical
Immunology 2016;137(4):1111-6.e8.

Kelleher 2020b

Kelleher MM, Jay N, Perkin MR, Haines RH, Batt R, Bradshaw LE,
et al. An algorithm for diagnosing IgE-mediated food allergy in
study participants who do not undergo food challenge. Clinical
and Experimental Allergy 2020;50:334-42.

Leung 2004

Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New
insights into atopic dermatitis. Journal of Clinical Investigation
2004;113(5):651-7.

Liu 2018

Liu Q, Zhang Y, Danby SG, Cork MJ, Stamatas GN. Infant skin
barrier, structure, and enzymatic activity differ from those of
adult in an East Asian cohort. BioMed Research International
2018;12:1-8. [DOI: 10.1155/2018/1302465]

Lodén 2012

Lodén M. Effect of moisturizers on epidermal barrier function.
Clinics in Dermatology 2012;30(3):286-96.

Mancini 2008

Mancini A, Lawley L. Structure and function of newborn skin.
In: Neonatal Dermatology. 2nd edition. Philadelphia: Elsevier
Saunders, 2008:19-31.

Martin 2013

Martin PE, Koplin JJ, Eckert JK, Lowe AJ, Ponsonby AL,
Osborne NJ, et al. The prevalence and socio-demographic
risk factors of clinical eczema in infancy: a population-
based observational study. Clinical and Experimental Allergy
2013;43(6):642-51.

Martin 2015

Martin PE, Eckert JK, Koplin JJ, Lowe AJ, Gurrin LC,
Dharmage SC, et al. Which infants with eczema are at risk of
food allergy? Results from a population-based cohort. Clinical
and Experimental Allergy 2015;45(1):255-64.

McAleer 2018

McAleer MA, Jakasa I, Raj N, O'Donnell CP, Lane ME,
Rawlings AV, et al. Early-life regional and temporal variation
in filaggrin-derived natural moisturizing factor, filaggrin-
processing enzyme activity, corneocyte phenotypes and

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

55

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

plasmin activity: implications for atopic dermatitis. British
Journal of Dermatology 2018;179(2):431-41.

Meckfessel 2014

Meckfessel MH, Brandt S. The structure, function, and
importance of ceramides in skin and their use as therapeutic
agents in skin-care products. Journal of the American Academy
of Dermatology 2014;71(1):177-84.

Munblit 2020

Munblit D, Perkin MR, Palmer DJ, Allen KJ, Boyle RJ. Assessment
of evidence about common infant symptoms and cow's milk
allergy. JAMA Pediatrics 2020;174(6):599-608. [DOI: 10.1001/
jamapediatrics.2020.0153] [PMID: 32282040]

Natsume 2017

Natsume O, Kabashima S, Nakazato J, Yamamoto-Hanada K,
 Narita M,  Kondo M, et al. Two-step egg introduction for
prevention of egg allergy in high-risk infants with eczema
(PETIT): a randomised, double-blind, placebo-controlled
trial. Lancet 2017;389(10066):276-86. [DOI: 10.1016/
S0140-6736(16)31418-0]

NICE 2006

National Institute for Health and Care Excellence. Postnatal
care up to 8 weeks after birth. www.nice.org.uk/guidance/cg37
(accessed prior to 24 January 2019).

Nikolovski 2008

Nikolovski J, Stamatas GN, Kollias N, Wiegand BC. Barrier
function and water-holding and transport properties of infant
stratum corneum are different from adult and continue to
develop through the first year of life. Journal of Investigative
Dermatology 2008;128(7):1728-36. [DOI: 10.1038/sj.jid.5701239]

O'Regan 2010

Pawankar 2014

Pawankar R. Allergic diseases and asthma: a global public
health concern and a call to action. World Allergy Organization
Journal 2014;7(1):12.

Penzer 2012

Penzer R. Best practice in emollient therapy: a statement for
healthcare professionals December 2012. Dermatological
Nursing 2012;11(4):60-79.

Perkin 2016

Perkin K, Logan K, Tseng A,  Raji B,  Ayis S, Peacock J, et al.
Randomized trial of introduction of allergenic foods in breast-
fed infants. New England Journal of Medicine 2016;374:1733-43.
[DOI: 10.1056/NEJMoa1514210]

Perkin 2021

Perkin MR, Logan K, Marrs T, Radulovic S, Craven J, Boyle RJ, et
al. Association of frequent moisturizer use in early infancy with
the development of food allergy. Journal of Allergy and Clinical
Immunology 2021;147(3):967-76. [PMID: 33678253]

Peters 2018

Peters RL, Koplin JJ, Allen KJ, Lowe AJ, Lodge CJ, Tang ML,
et al. The prevalence of food sensitization appears not to
have changed between 2 Melbourne cohorts of high-risk
infants recruited 15 years apart. Journal of Allergy and Clinical
Immunology In Practice 2018;6(2):440-8. [DOI: 10.1016/
j.jaip.2017.11.018]

Poulos 2007

Poulos LM, Waters A-M, Correll PK, Loblay RH, Marks GB. Trends
in hospitalizations for anaphylaxis, angioedema, and urticaria
in Australia, 1993-1994 to 2004-2005. Journal of Allergy and
Clinical Immunology 2007;120(4):878-84.

O'Regan GM, Campbell LE, Cordell HJ, Irvine AD, Irwin
Mclean WH, Brown SJ. Chromosome 11q13.5 variant associated
with childhood eczema: an effect supplementary to filaggrin
mutations. Journal of Allergy and Clinical Immunology
2010;125(1):170-4. [PMID: 20109745]

Prescott 2013

Prescott SL, Pawankar R, Allen KJ, Campbell DE, Sinn JKh,
Fiocchi A, et al. A global survey of changing patterns of food
allergy burden in children. World Allergy Organization Journal
2013;6(1):21.

Oakley 2016

Ramesh 2017

Oakley R, Lawton S. Views on unwanted effects of leave-on
emollients and experiences surrounding their incidence.
Dermatological Nursing 2016;15(4):38-43.

Ramesh M, Lieberman J. Adult-onset food allergies. Annals of
Allergy, Asthma & Immunology 2017;119(2):111-9. [DOI: 10.1016/
j.anai.2017.05.014]

Osborne 2011

Rawlings 2004

Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ,
Matheson MC, et al. Prevalence of challenge-proven IgE-
mediated food allergy using population-based sampling and
predetermined challenge criteria in infants. Journal of Allergy
and Clinical Immunology 2011;127(3):668-76 e1-2.

Palmer 2006

Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H,
Lee SP, et al. Common loss-of-function variants of the
epidermal barrier protein filaggrin are a major predisposing
factor for atopic dermatitis. Nature Genetics 2006;38(4):441-6.

Rawlings AV, Canestrari DA, Dobkowski B. Moisturizer
technology versus clinical performance. Dermatologic Therapy
2004;17(Suppl 1):49-56.

Rendell 2011

Rendell ME, Baig-Lewis SF, Berry TM, Denny ME, Simpson BM,
Brown PA, et al. Do early skin care practices alter the risk of
atopic dermatitis? A case-control study. Pediatric Dermatology
2011;28(5):593-5.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

56

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

RevMan Web 2022 [Computer program]

Stamatas 2010

Review Manager Web (RevMan Web). Version 4.12.0.
The Cochrane Collaboration, 2022. Available at
revman.cochrane.org.

Riley 2010

Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual
participant data: rationale, conduct, and reporting. BMJ
2010;340: c221. [PMID: 20139215]

Ring 2012

Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A,
Gelmetti C, et al. Guidelines for treatment of atopic eczema
(atopic dermatitis) part I. Journal of the European Academy of
Dermatology and Venereology 2012;26(8):1045-60.

Ronnstad 2018

Rønnstad AT, Halling-Overgaard A-S, Hamann CR, Skov L,
Egeberg A, Thyssen JP. Association of atopic dermatitis with
depression, anxiety, and suicidal ideation in children and
adults: a systematic review and meta-analysis. Journal of the
American Academy of Dermatology 2018;79(3):448-56.e30.

Rucker 2008

Rucker G, Schwarzer G, Carpenter J. Arcsine test for publication
bias in meta-analyses with binary outcomes. Statistics in
Medicine 2008;27(5):746-63.

Schünemann 2021

Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA,
Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’
tables and grading the certainty of the evidence. In: Higgins
JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
VA, editor(s). Cochrane Handbook for Systematic Reviews of
Interventions Version 6.2 (updated February 2021). Cochrane,
2021. Available from training.cochrane.org/handbook/archive/
v6.2.

Stamatas GN, Nikolovski J, Luedtke MA, Kollias N, Wiegand BC.
Infant skin microstructure assessed in vivo differs from
adult skin in organization and at the cellular level.
Pediatric Dermatology 2010;27(2):125-31. [DOI: 10.1111/
j.1525-1470.2009.00973.x]

Stamatas 2011

Stamatas GN, Nikolovski J, Mack MC, Kollias N. Infant skin
physiology and development during the first years of life: a
review of recent findings based on in vivo studies. International
Journal of Cosmetic Science 2011;33(1):17-24. [PMID: 20807257]

Stata [Computer program]

Stata. Version 15. College Station, TX, USA: StataCorp, 2017.
Available at www.stata.com.

Stone 2002

Stone KD. Atopic diseases of childhood. Current Opinion in
Pediatrics 2002;145(5):634-46.

Strid 2004

Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of
the stratum corneum allows potent epicutaneous immunization
with protein antigens resulting in a dominant systemic Th2
response. European Journal of Immunology 2004;34(8):2100-9.

Strid 2005

Strid J, Hourihane J, Kimber I, Callard R, Strobel S.
Epicutaneous exposure to peanut protein prevents oral
tolerance and enhances allergic sensitization. Clinical and
Experimental Allergy 2005;35(6):757-66.

Su 1997

Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its
impact on the family and financial cost. Archives of Disease in
Childhood 1997;76(2):159-62.

Sicherer 2003

Surber 2017

Sicherer SH, Muñoz-Furlong A, Sampson HA. Prevalence of
peanut and tree nut allergy in the United States determined
by means of a random digit dial telephone survey: a 5-year
follow-up study. Journal of Allergy and Clinical Immunology
2003;112(6):1203-7.

Sicherer 2018

Sicherer SH, Sampson HA. Food allergy: a review and update
on epidemiology, pathogenesis, diagnosis, prevention, and
management. Journal of Allergy and Clinical Immunology
2018;141(1):41-58.

Simpson 2012

Simpson EL, Keck LE, Chalmers JR, Williams HC. How should
an incident case of atopic dermatitis be defined? A systematic
review of primary prevention studies. Journal of Allergy and
Clinical Immunology 2012;130(1):137-44.

Spergel 2003

Spergel JM, Paller AS. Atopic dermatitis and the atopic
march. Journal of Allergy and Clinical Immunology 2003;112(6
Suppl):S118-27.

Surber C, Kottner J. Skin care products: what do they
promise, what do they deliver. Journal of Tissue Viability
2017;26(1):29-36.

Thomsen 2015

Thomsen SF. Epidemiology and natural history of atopic
diseases. European Clinical Respiratory Journal 2015;2(1):24642.

Tierney 2021

Tierney JF, Stewart LA, Clarke M. Chapter 26: Individual
participant data. In: Higgins JPT, Thomas J, Chandler J,
Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
6.2 (updated February 2021). Cochrane, 2021. Available from
training.cochrane.org/handbook/archive/v6.2.

Tsakok 2016

Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S, et al.
Does atopic dermatitis cause food allergy? A systematic review.
Journal of Allergy and Clinical Immunology 2016;137(4):1071-8.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

57

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tsilochristou 2019

Voorheis 2019

Tsilochristou O, du Toit G, Sayre PH, Roberts G,
Lawson K, Sever ML,  et al. Association of Staphylococcus
aureus colonization with food allergy occurs independently
of eczema severity. Journal of Allergy and Clinical Immunology
2019;144(2):494-503. [PMID: 31160034]

Voorheis P, Bell S,  Cornelsen L. Challenges experienced
with early introduction and sustained consumption of
allergenic foods in the Enquiring About Tolerance (EAT) study: a
qualitative analysis. Journal of Allergy and Clinical Immunology
2019;144(6):1615-23.

Turner 2015

Voskamp 2014

Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N,
Garcez T, et al. Increase in anaphylaxis-related hospitalizations
but no increase in fatalities: an analysis of United Kingdom
national anaphylaxis data, 1992-2012. Journal of Allergy and
Clinical Immunology 2015;135(4):956-63.e1.

Umasunthar 2013

Umasunthar T, Leonardi-Bee J, Hodes M, Turner PJ, Gore C,
Habibi P, et al. Incidence of fatal food anaphylaxis in people
with food allergy: a systematic review and meta-analysis.
Clinical and Experimental Allergy 2013;43(12):1333-41.

UMIN000028043

UMIN000028043. Early aggressive intervention for infantile
atopic dermatitis to prevent development of food allergy:
a multicenter, investigator-blinded, randomized, parallel
group controlled trial. upload.umin.ac.jp/cgi-open-bin/ctr_e/
ctr_view.cgi?recptno=R000031912 (first received 4 July 2017).

Van Cleave 2010

Van Cleave J, Gortmaker SL, Perrin JM. Dynamics of obesity
and chronic health conditions among children and youth. JAMA
2010;303(7):623-30.

Van den Oord 2009

Van den Oord RA, Sheikh A. Filaggrin gene defects and risk
of developing allergic sensitisation and allergic disorders:
systematic review and meta-analysis. BMJ 2009;339:b2433.

van der Hulst 2007 

van der Hulst AE, Klip H, Brand PL. Risk of developing asthma
in young children with atopic eczema: a systematic review.
Journal of Allergy and Clinical Immunology 2007;120(3):565-9.
[PMID: 17655920]

Van Zuuren 2017

Van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen AP,
Arents BW. Emollients and moisturisers for eczema. Cochrane
Database of Systematic Reviews 2017, Issue 2. Art. No:
CD012119. [DOI: 10.1002/14651858.CD012119.pub2]

Venter 2008

Venter C, Pereira B, Voigt K, Grundy J, Clayton CB,
Higgins B, et al. Prevalence and cumulative incidence
of food hypersensitivity in the first 3 years of life. Allergy
2008;63(3):354-9.

Visscher 2017

Visscher MO, Burkes SA, Adams DM, Hammill AM, Wickett RR.
Infant skin maturation: preliminary outcomes for color
and biomechanical properties. Skin Research & Technology
2017;23(4):545-51. [PMID: 28303612]

Voskamp AL, Zubrinich CM, Abramovitch JB, Rolland JM,
O’Hehir RE. Goat's cheese anaphylaxis after cutaneous
sensitization by moisturizer that contained goat's milk. Journal
of Allergy and Clinical Immunology 2014;2(5):629-30.

Weidinger 2016

Weidinger S, Novak N. Atopic dermatitis. Lancet
2016;387(10023):1109-22.

Wetterslev 2008

Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential
analysis may establish when firm evidence is reached in
cumulative meta-analysis. Journal of Clinical Epidemiology
2008;61(1):64-75.

WHO 2015

World Health Organization. Pregnancy, childbirth,
postpartum and newborn care: a guide for essential practice.
www.ncbi.nlm.nih.gov/books/NBK326678/ (accessed prior to 11
March 2019).

Williams 1994

Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ,
Hunter JJ, et al. The UK Working Party's diagnostic criteria
for atopic dermatitis. I. Derivation of a minimum set of
discriminators for atopic dermatitis. British Journal of
Dermatology 1994;131(3):383-96.

Williams 1998

Williams HC, Strachan DP. The natural history of childhood
eczema: observations from the British 1958 birth cohort study.
British Journal of Dermatology 1998;139(5):834-9.

Woods 2002

Woods RK, Stoney RM, Raven J, Walters EH, Abramson M,
Thien FC. Reported adverse food reactions overestimate true
food allergy in the community. European Journal of Clinical
Nutrition 2002;56(1):31-6.

Yosipovitch 2000

Yosipovitch G, Maayan-Metzger A, Merlob P, Sirota L. Skin
barrier properties in different body areas in neonates. Pediatrics
2000;106(1):105-8.

References to other published versions of this review

Kelleher 2020a

Kelleher MM, Cro S, Cornelius V, Axon E, Lodrup Carlsen KC,
Skjerven HO, et al. Skincare interventions in infants for
preventing eczema and food allergy. Cochrane Database of
Systematic Reviews 2020, Issue 2. Art. No: CD013534. [DOI:
10.1002/14651858.CD013534]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

58

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kelleher 2021

Kelleher  MM, Cro  S, Cornelius  V, Lodrup Carlsen  KC,
Skjerven  HO, Rehbinder  EM. Skin care interventions in infants
for preventing eczema and food allergy. Cochrane Database

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Abraham 2019 

Study characteristics

Cochrane Database of Systematic Reviews

of Systematic Reviews 2021, Issue 2. Art. No: CD013534. [DOI:
10.1002/14651858.CD013534.pub2]

* Indicates the major publication for the study

Methods

Study design: randomised controlled trial

Study conducted: not reported

Treatment arms: 3

Follow-up: 24 hours

Participants

Randomised: N = 102 (chlorhexidine n = 34, saline n = 34, standard n = 34)

Inclusion criteria: 

1. Admitted to the paediatric ward at a tertiary care hospital, Vellore
2. Informed consent from parents

Exclusion criteria: not reported

Interventions

Intervention: participants were bathed according to treatment group in either chlorhexidine or saline;
concentrations were not reported

Comparator: standard bath of soap and water

Outcomes

Primary outcome: skin health status of all participants before and 2 hours and 24 hours after the inter-
vention by an individual who is blinded to the intervention using neonatal skin assessment score

Adverse events: not reported

Identification

Country: India

Setting: tertiary care hospital, Vellore

Sponsorship Source: Institutional Review Board, Christian Medical College, Vellore

Declarations of interest

Nil

Notes

Amer 2017 

Study characteristics

Methods

Study design: randomised controlled trial

Study conducted: April 2014 and September 2014

Treatment arms: 2

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

59

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Amer 2017  (Continued)

AD follow-up: 4 weeks

Cochrane Database of Systematic Reviews

Participants

Randomised: N = 70 (Group A underwent care n = 35, Group B did not undergo care n = 35) 

Inclusion criteria: 

1. Healthy and full-term (determined by mothers’ obstetrician/gynaecologist)
2. 1 to 7 days old at baseline
3. Mothers of infant participants had to be older than 18 years and were told to refrain from using their

infants’ current lotion products (if applicable) for the duration of the study

4. Mothers agreed not to introduce fragrances on themselves, on their infant, or in their household for

the duration of the study

5. Mothers also agreed to avoid excessive sun exposure on their infants’ arms and legs

Exclusion criteria: 

1. Infants suffering from any known abnormal skin conditions (rash), hypersensitivity, or allergic reac-

tivity to fragrances or other ingredients

2. Infants suffering from asthma, upper respiratory tract infection, or other conditions that would affect

the evaluation of skin care regimens
3. Infants with any genetic abnormalities
4. Premature infants

Interventions

Intervention: 

Caregivers/mothers were instructed to provide a specific skin care regimen.

Caregivers (if possible) were instructed to gently dry the baby immediately after birth and to gently re-
move any blood or meconium and not to rub off the vernix (leave as intact as possible to absorb into
the skin).

During the 4 weeks of the study, neonates were bathed at variable frequencies by mothers, most often
1 to 2 times per week, using shampoo as a cleanser; baby wipes were sometimes used as an alternative
to bathing. The first bath was given only when the temperature of the newborn was stabilised, instead
of considering only the number of hours after birth, and usually during the first week. Mothers were in-
structed to apply oil to the skin and the scalp 3 to 4 times per week and after bath time, and to apply
daily when signs of dryness (flaking/scaling) were present. Mothers were instructed to keep the umbil-
ical cord clean and dry by applying chlorhexidine in the first 10 days of life until the cord fell off and 2
days after, and allowing it to be exposed to air as frequently as possible. Mothers were instructed to use
the best quality nappy available, to change soiled nappies frequently, to cleanse the nappy area with
plain water or unperfumed, alcohol-free baby wipes, to expose the nappy area as often as possible, and
to consider using a thin layer of barrier ointment or cream with nappy changes. Mothers were instruct-
ed to care for the neonatal intertrigo by keeping it clean and dry. A colourful and informative booklet
had been designed for the mothers, which clarified instructions about care of neonatal skin and benign
transient neonatal skin disorders in order to reassure parents.

Comparator: Group B: did not undergo care; no specific intervention  

Shampoo, baby oil, wipes, and cream ingredients: 

Baby shampoo, which is composed of sodium lauroamphoacetate, sodium laureth sulfate, coco gluco-
side, polyquaternium-10, and sodium benzoate. Baby oil is a mineral oil that contains paraffinum liq-
uidum, isopropyl palmitate, and parfum, which are safe. It is used as a moisturiser and for massage.
Baby wipes consist of a non-woven carrier soaked with an emulsion-type watery or oily lotion. Baby
cream consists of zinc oxide and olive oil.

Outcomes

Primary outcomes: optimal skin function, mothers' visual skin assessment questionnaire to evaluate
the presence of neonatal skin for erythema and dryness. Clinical examination for skin assessment of
appearance of erythema, dryness, and infection or any skin disorders or adverse effects on a weekly-
 basis

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Amer 2017  (Continued)

Cochrane Database of Systematic Reviews

Adverse events: adverse events were recorded when the baby's skin was assessed during weekly clini-
cal examination

The only adverse effect of this study was a case of miliaria with use of emollient because the mother
turned on the heater all night, which turns the atmosphere hot and humid; this conclusion is in agree-
ment with a study by Rocha and colleagues, which found that emollient may cause acne, folliculitis,
and prickly heat, and may aggravate pruritus when used in extremely hot and humid areas.

Identification

Country: Egypt

Setting: outpatient clinics at the Dermatology and Venereology Department, Obstetric Department,
and Pediatric Department, Faculty of Medicine, Zagazig University Hospitals

Sponsorship source: not reported 

Declarations of interest

Not reported 

Notes

Baldwin 2001 

Study characteristics

Methods

Study design: randomised clinical trial, double-blinded, parallel-group comparison trial 

Study conducted: no date of recruitment or start/end date of trial reported in the study

Treatment arms: 2 (Study C)

AD follow-up: 4 weeks (2 visits every week)

Participants

Randomised: 304 children (evaluated skin erythema and diaper rash in 268 infants over a 4-week us-
age period) 

Inclusion criteria: 

1. General good health as determined by medical history
2. No evidence of serious or chronic disease upon initial dermatological examination
3. Skin types I to IV on the Fitzpatrick Scale
4. Age range not reported - average participant age: 9.9 months

Exclusion criteria: 

1. Severe diaper rash appearing to need physician treatment

Interventions

Parents of all eligible children were given a 1-week supply of the control product and were instructed to
use only this diaper until the next scheduled visit 6 days later (‘washout’ period). At completion of the
‘washout’ period, 304 children were randomly allocated to 1 of 2 treatment groups after a baseline der-
matological examination of the diaper area. Randomisation was by gender and diaper rash grade.

All parents were instructed to diaper their child exclusively with the product assigned to him/her, and
to avoid the use of any ointments, creams, powders, or other diaper rash or skin care products on the
diapered area of their children for the entire duration of the study. Parents were allowed to maintain-
 normal bathing and hygiene routines for their children, except that they were asked to use a standard
disposable infant wipe, which was supplied to them in lieu of their usual wipe or wash cloth for diaper
changing needs.

Parents were instructed to change their child into a clean diaper approximately 2 hours before each
subsequent scheduled visit to the clinical site. Children returned to the clinical site twice per week

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

61

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Baldwin 2001  (Continued)

Cochrane Database of Systematic Reviews

(Monday/Thursday or Tuesday/Friday) over the next 4 weeks, for a total of 8 postbaseline visits. At each
of these visits, the skin in the diaper area of each child was examined for the presence of rash and ery-
thema.

Intervention: Group 2 was assigned to use the test diaper  

Comparator: Group 1 was assigned to continue on the control product

Diaper and wipes: control diaper used was a commercially available, premium-quality product con-
taining a super-absorbent (AGM)/cellulose core and a breathable outer cover, which was obtained di-
rectly from Procter & Gamble Co., Cincinnati, OH, USA

The test diaper was identical in every respect to the control except for the inclusion of a top sheet (in-
ner layer) impregnated with a proprietary formulation containing primarily petrolatum, stearyl alcohol,
and zinc oxide in combination (ZnO/Pet). The wipes used were Pampers Baby Fresh, Proctor & Gamble
Co.

Outcomes

Severity of diaper dermatitis (skin erythema and rash), scoring given by Table 1 (Baldwin 2001)

Adverse events: not reported

Identification

Country: USA

Sponsorship source: Hill Top Laboratories (Cincinnati, OH, USA, and Winnipeg, Canada), for its collab-
oration in the conduct of the clinical studies

Declarations of interest

Not reported

Notes

Bellemere 2018 

Study characteristics

Methods

Study design: randomised clinical study

Study conducted: no date of recruitment or start/end date of trial reported in study

Treatment arms: 2

AD follow-up: 6 months

Participants

Randomised: N = 120 (n = 60 in the intervention arm, n = 60 in the control arm)

Inclusion criteria:

1. Newborns at risk aged 2 to 3 weeks
2. 2 atopic first-degree relatives

Exclusion criteria: not reported

Interventions

(Days 0, 30, 90, 120, 180). 60 newborns with no familial history of atopy were followed in parallel. Swabs
were taken on forearms, face, and atopic dermatitis lesions in 45 children: quantitative PCR for Staphy-
lococcus aureus and Staphylococcus epidermidis and LC/UV + LC/MS for natural moisturising factors and
ceramides.

Intervention: use balm twice a day, cleansing cream and bath oil twice a week from the same brand for
6 months 

Comparator: control group, no specific intervention  

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

62

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellemere 2018  (Continued)

Cochrane Database of Systematic Reviews

Moisturiser/emollient: "a French cosmetic brand" dedicated to children's skin (no other details of for-
mulation reported)

Outcomes

Primary outcome:

1. Frequency of AD in the first 6 months of life

Secondary outcomes:

1. Clinical information on predictive signs and first AD flare
2. To quantify natural moisturising factors and ceramides
3. S aureus and S epidermidis colonisation from birth until first AD flare

Adverse effects: none reported in conference abstracts

Identification

Country: not reported

Setting: not reported

Sponsorship source: none reported

Declarations of interest

Not reported

Notes

Chalmers 2020 

Study characteristics

Methods

Study design: multicentre, pragmatic, parallel-group, randomised controlled trial

Recruitment: 19 November 2014 and 18 November 2016

Treatment arms: 2

AD follow-up: participant follow-up was 2 years, including follow-up at 2 weeks (by telephone), and at
3, 6, 12, and 18 months (online or postal questionnaire), and at a 2-year face-to-face appointment

FA and inhalants follow-up: 2 years

Participants

Randomised: N = 1394 (emollient n = 693, control n = 701)

Inclusion criteria: 

1. Term infants (at least 37 weeks’ gestation)
2.

 At least 1 first-degree relative with parent-reported eczema, allergic rhinitis, or asthma diagnosed by
a doctor

3. Mother aged 16 years or older
4. Consenting adult able to understand English

Exclusion criteria: 

1. Preterm birth (birth before 37 weeks’ gestation)
2. Sibling (including twin) randomly assigned in the trial
3. Severe widespread skin condition that would make detection or assessment of eczema difficult
4. Serious health issue that would make it difficult for the family to take part in the trial
5. Condition that would make use of an emollient inadvisable

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

63

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chalmers 2020  (Continued)

Interventions

Both groups received advice on general skin care in booklet and video formats at the time of randomi-
sation (Appendix pp. 11 to 21). The skin care advice was to use mild cleansers and shampoos specifical-
ly formulated for infants, and to avoid soap, bubble bath, and baby wipes. Infants were randomly as-
signed to a group within a maximum of 21 days after delivery, and randomisation was stratified by re-
cruiting centre and number of first-degree relatives with atopic disease (1, 2, or > 2).

Intervention: adherence was captured at each questionnaire time point during year 1 (3, 6, and 12
months) by asking parents about emollient use since the last questionnaire (Appendix p. 4), and was
defined in the protocol as satisfactory in the intervention group if emollients were applied at least 3 to
4 times per week to most of the child’s body (defined as at least 2 of face and neck, arms and legs, or
trunk). A similar definition was used for contamination in the control group.

Parents were advised to apply emollient to the whole body of their child at least once daily (excluding
the scalp) until the child reached 1 year of age. They were also advised to apply emollient after every
bath, even if they had already applied the emollient that day. Daily application was advised to encour-
age regular use of emollient several times a week, but because the study was designed to reflect how
the intervention might be delivered in normal practice, no prompts or reminders were sent to parents.

The guidance given to those in the emollient group also showed parents how to apply emollients cor-
rectly by dotting over the skin and using gentle downward strokes rather than rubbing in, and con-
tained warnings about the skin being slippery after application and the need to clean up spillages from
the floor to avoid slipping.

Comparator: best-practice skin care advice only

Moisturiser/emollient: Doublebase Gel (Dermal Laboratories, Herts, UK) or Diprobase Cream (Bayer,
Berks, UK)

Outcomes

Primary outcome: diagnosis of eczema over the past year (defined by the UK Working Party refine-
ment of Hanifin and Rajka diagnostic criteria for eczema) assessed by research nurses masked to treat-
ment allocation at age 2 years

Secondary outcomes: other eczema definitions, i.e. presence of eczema between birth and 2 years of
age (assessed by any parental report of a clinical diagnosis of eczema (up to 2 years) and parent com-
pletion of UK Working Party criteria at 1 and 2 years); presence of visible eczema at 2 years recorded by
a nurse who was masked to treatment allocation; time to onset of eczema (based on first parent report
of clinician diagnosis and time of first topical corticosteroid or immunosuppressant prescription); clin-
ician- and patient-reported severity of eczema (Eczema Area and Severity Index (EASI) at 2 years and
Patient-Oriented Eczema Measure (POEM) at 1 and 2 years). Other secondary outcomes were presence
of other allergic diseases (i.e. parent-reported wheezing and allergic rhinitis (between 1 and 2 years);
allergic sensitisation (masked skin prick tests) to milk, egg, peanut, cat dander, grass pollen, or dust
mite at 2 years; parent-reported food allergy and parental report of clinical diagnosis of food allergy at
1 and 2 years; and allergy to milk, egg, or peanut at 2 years confirmed by oral food challenge; for cases
in which no oral food challenge was done, an expert allergy panel was asked to allocate treatment.

Adverse events: safety outcomes were parent-reported skin infections (parents were asked what the
doctor called the infection) and emollient-related infant slippages during the intervention period (year
1). Skin infections and slippages were collected via 3-, 6-, and 12-month questionnaires. No other ad-
verse event information was collected.

Identification

Country: UK

Setting: 12 hospitals and 4 primary care sites across the UK 

Sponsorship source: this study was sponsored by the University of Nottingham, co-ordinated by the
Nottingham Clinical Trials Unit (CTU), and funded by the UK National Institute for Health Research
(NIHR) Health Technology Assessment  Programme

Declarations of interest

The main funder (NIHR Health Technology Assessment) was involved in refining the trial design
through the funding peer-review process, but had no role in data collection, data analysis, data inter-
pretation, or writing of the report. Funders of the food allergy outcomes and skin prick tests (Goldman

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

64

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chalmers 2020  (Continued)

Cochrane Database of Systematic Reviews

Sachs Gives and Sheffield Children’s Hospital Research Fund) had no role in the study design, data col-
lection, data analysis, data interpretation, or writing of the manuscript.
HCW, AAM, and LEB had full access to all data in the study, and HCW had final responsibility for the de-
cision to submit for publication.

Notes

Cooke 2015 

Study characteristics

Methods

Study design: pilot, assessor-blinded RCT

Study data collected: between September 2013 and July 2014 

Treatment arms: 3

AD follow-up: 4 weeks

Participants

Randomised: N = 115 (olive oil n = 38, sunflower oil n = 38, no oil n = 39)

Inclusion criteria: participants with or without a family history of atopic eczema

Exclusion criteria:

1. Mother 16 years of age or younger or without capacity to consent
2. Admittance to Special Care Baby Unit
3. Receiving phototherapy treatment
4. Participation in another clinical trial
5. Medical history preventing participation to endpoint
6. Limb defects
7. Non-traumatic impairment of epidermal integrity
8. Evidence of skin disorder at first assessment

Interventions

Intervention: randomisation took place within 72 hours of birth, parents were instructed from the
day after initial assessment to apply 4 drops of oil to their baby's left forearm, left thigh, and abdomen,
twice a day. Parents in all groups were asked not to use any other skin care products at the 3 study
sites; water only was advocated. Intervention period was 4 weeks.

1. Group 1: olive oil
2. Group 2: sunflower oil

Comparator: the control group was provided no oil and was asked not to use any other skin care prod-
ucts at the 3 study sites; water only was advocated 

Outcomes

Primary outcome: change in structure of the lipid lamellae, a determinant of stratum corneum perme-
ability (measured using ATR-FTIR spectroscopy) and TEWL (measured via Biox Aquaflux Model AF200)

Secondary outcome: stratum corneum hydration (measured via a Corneometer Model CM825); skin
surface pH (measured by skin pH meter Model PH 905); clinical observations around changes in the
skin using a modified Neonatal Skin Condition Score; and erythema (measured by a Mexameter Model
MX18 probe) 

Adverse effects: adverse events, including skin infections, skin reactions, and serious adverse events,
were prompted for and collected for all participants

Identification

Country: England, UK

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

65

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cooke 2015  (Continued)

Setting: St. Mary's Hospital, Manchester

Sponsorship source: AC was funded by the NIHR, and this paper was independent research arising
from the Doctoral Research Fellowship, supported by NIHR 

Declarations of interest

None reported.

Notes

Da Cunha 2008 

Study characteristics

Methods

Study design: randomised clinical trial

Recruitment date: infants delivered between 13 September 2005 and 14 March 2006 

Treatment arms: 2

AD follow-up: time points: first bath (first collection), 30 minutes after bath (second collection), and 24
hours after bath (third collection)

Participants

Randomised: N = 112 (chlorhexidine, experimental group n = 56, neutral liquid soap, control group n =
56)

Inclusion criteria: normal term newborns with gestational age between 37 and 42 weeks 

Exclusion criteria: 

1. Skin breakdown
2. Congenital infection
3. Premature rupture of membranes for over 18 hours
4. Foetid amniotic fluid
5. HIV+ mother
6. Mother with suspicion of or with bacterial infection before delivery or presenting axillary temperature

> 37.8 °C

7. Hospitalisation before the bath at 24 hours
8. Second bath before 24 hours

Interventions

Intervention: chlorhexidine liquid soap bath, admission bath between 1 and 1.5 hours after birth 

Comparator: neutral liquid soap bath, admission bath same as above 

Moisturiser/emollient: neutral liquid soap (ingredients: Texapon SBN (detergent), Dehyton KB (co-
camide), Plantaren 2000 (detergent), Glycerin (emollient), Coperlan KDB (thickener), citric acid,
 deionised water, pH = 7) 
Chlorhexidine liquid soap bath (chlorhexidine digluconate liquid soap at 0.4%, resulting from dilution
of 10 mL of chlorhexidine digluconate liquid soap at 4% in 90 mL of warm water that released 0.25%
chlorhexidine)

Outcomes

Staphylococcus aureus skin colonisation 

Adverse effects: none reported

Identification

Country: Brazil 

Setting: Obstetric Centre of Hospital de Clinicas de Porto Alegre

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

66

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Da Cunha 2008  (Continued)

Cochrane Database of Systematic Reviews

Sponsorship source: this study was supported by the Fundo de Incentivo à Pesquisa (Research Incen-
tive Fund) of Hospital de Clínicas de Porto Alegre (FIPE/HCPA), and Conselho Nacional de Desenvolvi-
mento Científico e Tecnológico (CNPQ) 

Declarations of interest

None reported in publication.

Notes

Dissanayake 2019 

Study characteristics

Methods

Study design: 2 × 2 factorial, randomised, non-treatment controlled trial 

Recruitment: October 2012 and March 2014

Treatment arms: 4

AD follow-up: 1, 6, and 9 months

Participants

Participants: N = 549 (skin care + synbiotics n = 137; synbiotics n = 137; skin care n = 138; no interven-
tion n = 137)

Inclusion criteria:  

1. Born at full term
2. Written informed consent available from parent(s)/guardian
3. Family history of atopy was not required for inclusion

Exclusion criteria: 

1. Preterm birth
2. Complications due to severe underlying disease
3. Hepatitis B virus or HIV positivity of mother at the time of birth
4. Any other appropriate status as judged by the physician

Interventions

Intervention: parents/caregivers were advised on how interventions should be applied at home.
Group 1 received a combination of synbiotics and skin care; Group 2 received synbiotics only; Group 3
received skin care only; and Group 4 received no intervention. Interventions were carried out from birth
to 6 months of age, and further observation was made for an additional 6 months. Parents/guardian
maintained a diary for 6 months of the intervention to record the number of times that the emollient
was applied, any illnesses contracted during this period, and the use of antibiotics during this period.
Parents/guardians were instructed to apply emollient 2 to 3 times/day, after a bath or on clean skin,
particularly on the cheeks and the peri-oral area. Parents/guardians were allowed to apply the emol-
lient to other parts of the body at their discretion and were not advised for or against it.

Comparator: the control group was not prevented from applying emollients for ethical reasons. A di-
ary was maintained to record the number of times and the amount of emollient that was applied each
month.

Moisturiser/emollient: all participants receiving skin care (Groups 1 and 3) were given Locobase
REPAIR Cream (Daiichi Sankyo, Japan), which contains ceramide, cholesterol, and free fatty acids

Synbiotics: groups that were given synbiotics (Groups 1 and 2) received a combination of 0.5 g (7 × 109 
CFU/g) of Bifidobacterium bifidum OLB6378 (Meiji Holdings Co. Ltd., Japan) combined with 0.5 g of fruc-
to-oligosaccharides (Meiji Food Materia Co. Ltd., Japan) twice a day 

Outcomes

Primary outcomes: the primary outcome assessed was development of AD by 1 year of age. AD was di-
agnosed according to the criteria of the Japanese Dermatological Association, when an itchy rash last-

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

67

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dissanayake 2019  (Continued)

Cochrane Database of Systematic Reviews

ing 2 months or longer was reported in questionnaires returned at 1, 6, and 9 months and 1 year of the
baby’s age. In addition, AD was diagnosed using the UK Working Party’s diagnostic criteria included in
the questionnaire at 1 year.

Secondary outcomes: prevalence of food allergy, as reported in the questionnaires at 1 year. Sensiti-
sation to food and/or inhalant allergens; total and allergen-specific IgE levels were determined in blood
sampled at 9 months of age. EASI score; babies were examined by Dr YuT (paediatrician) at 9 months of
age. If AD was diagnosed, severity was determined using the EASI score and photography of the body.
AD diagnosis was further confirmed blindly by YaT (dermatologist) and NS (paediatrician). AD was diag-
nosed based on criteria of the Japanese Dermatological Association.

Thymus- and activation-regulated chemokine (TARC) score; blood samples obtained at 9 months were
used for evaluating TARC levels of all participants

Adverse effects: no adverse effects of the interventions were reported during the study period

Identification

Country: Japan

Setting: antenatal clinic at the Japanese Red Cross Katsushika Maternity

Sponsorship source: this study was supported by the Environmental Restoration and Conservation
Agency of Japan in fiscal years 2014 to 2016 and by grants from the Japan Agency for Medical Research
and Development (AMED-CREST) (15652274)

Declarations of interest

Study authors have no conflicts of interest to disclose.

Notes

Dizon 2010 

Study characteristics

Methods

Study design: parallel, randomised controlled trial 

Recruitment date: not reported

Treatment arms: 3

Follow-up: assessment was done at baseline, and after 1 week and 2 weeks of using products

Participants

Randomised: N = 180 Filipino infants (< 1 year) (JTT n = 60; SEBAMED n = 60; water only n = 60)

Inclusion criteria: Filipino infants (age 1 day to < 1 year) in good health with normal skin 

Exclusion criteria: prematurely born infants and those with congenital problems 

Interventions

Intervention:

1. Group I: Johnson's Baby Top-To-Toe Wash
2. Group II: Sebamed Baby Liquid Cleanser (SM)

The above products (Group I) were used on the skin of participants as whole body cleansers at least
twice a week for 2 weeks.

Assessment was done at baseline and after 1 week and 2 weeks of use: (i) clinically by a dermatologist,
(ii) instrumentally, and (iii) by the consumer (parent of the participant).

Comparator: Group III: lukewarm tap water 

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

68

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Dizon 2010  (Continued)

Outcomes

Outcome measures were clinical assessment (erythema, oedema, dryness, and scaling); skin moisture
content; skin surface pH; transepidermal water loss; skin oxyhaemoglobin and deoxyhaemoglobin; and
consumer satisfaction.

Adverse effects: parents did not report any side effects

Identification

Sponsorship source: Johnson & Johnson

Country: the Philippines 

Declarations of interest

Not reported

Notes

Duan 2019 

Study characteristics

Methods

Study design: randomised, single-centre, parallel-assignment trial 

Study date: June 2013 to November 2013 

Treatment arms: 3

AD follow-up: 6 and 12 weeks

Participants

Randomised: N = 150 (wash + lotion n = 44; water + lotion n = 43; water only n = 43)

Inclusion criteria: 

1. Healthy full-term infant (0 to 6 months old)
2. Male or female
3. Parent/caregiver ≥ 18 years old
4. Willingness of parent/caregiver to follow study instructions and sign consent forms
5. Willingness of parent/caregiver to avoid prolonged exposure of infant to sun, beach, or swimming pool
6. Willingness of caregiver to attend all scheduled visits

 Exclusion criteria: 

1. Pre-existing skin conditions (dermatitis, eczema, psoriasis, rosacea), dry skin
2. Prescription or over-the-counter topical or oral medication that might impact results (except vita-

mins)

3. Parent/caregiver or participant with unusual or hypersensitive or allergic response to skin care prod-

ucts

4. Parent/caregiver or participant with asthma
5. Participant with active localised or general infection
6. Other condition that could make the patient inappropriate for trial entry

Interventions

Intervention: 

Group 1: Johnson's Baby Top-To-Toe Wash (ideally 7 times a week, at least 5 times a week) + Johnson's
Baby Lotion (at least once a day). Products/treatments were used for 3 months, and products were
placed on the skin with attention to applying them to the arms, legs, and torso.

Group 2: water (in lieu of bathing products) + Johnson's Baby Lotion (at least once a day). Prod-
ucts/treatments were used for 3 months, and products were placed on the skin with attention to apply-
ing the products to the arms, legs, and torso.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

69

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Duan 2019  (Continued)

Cochrane Database of Systematic Reviews

Comparator: water (in lieu of bathing products) only. Products/treatments were used for 3 months.
Products were placed on skin with attention to applying products to the arms, legs, and torso.

Moisturiser/emollient: Johnson’s Baby Top-To-Toe Wash and Johnson’s Baby Lotion (Johnson &
Johnson Consumer Inc, Skillman, NJ, USA); wash + lotion

Outcomes

Primary outcome: skin surface moisture [Time Frame: 3 months]

Skin surface moisture content via capacitance measurements

Secondary outcome:  

1. Skin deep hydration [Time Frame: 3 months]
2. TEWL [Time Frame: 3 months]
3. Ratio of TEWL/skin surface moisture to reflect skin barrier function [Time Frame: 3 months]
4. Skin pH value [Time Frame: 3 months]
5. Skin roughness [Time Frame: 3 months]
6. Dermatological assessments [Time Frame: 3 months]
7. Parent/caregiver assessments [Time Frame: 3 months]
8. Skin microbiome [Time Frame: 3 months]
9. Skin biomarker [Time Frame: 3 months]

Adverse effects: none reported

Identification

Country:  China

Setting: Beijing Children’s Hospital, Xicheng District

Sponsorship source: this study was funded by Johnson & Johnson International Pte Ltd (Singapore)

Declarations of interest

YYD, CG, and F-QK were employees of Johnson & Johnson at the time this study was conducted. YYD
and F-QK are no longer employed at Johnson & Johnson. C-PS and LM received research support in as-
sociation with this study. Study authors report no other conflicts of interests in this work.

Notes

Garcia Bartels 2010 

Study characteristics

Methods

Study design: monocentric, prospective, randomised study 

Study conducted: October 2006 to May 2007

Treatment arms: 4

AD follow-up: day 2; weeks 2, 4, and 8 of life

Participants

Randomised: N = 64 (WG, bathing with wash gel n = 16; C, bathing and cream n = 16; WG + C, bathing
with wash gel plus cream n = 16; B, bathing with water n = 16)

Inclusion criteria:

1. Healthy full-term newborns with 37 completed weeks of gestation, aged 48 hours

Exclusion criteria:

1. Sepsis
2. Serious congenital malformations

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

70

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Garcia Bartels 2010  (Continued)

Cochrane Database of Systematic Reviews

3. Asphyxia
4. Hydronephrosis
5. Severe intracranial haemorrhage
6. Immunodeficiency
7. Pre-existing skin disease with eruptions covering more than 50% of body surface
8. Relevant skin maceration or inflammation ⁄ irritation
9. Urticaria
10.Acute or chronic disease with temperature below 35 °C or above 40 °C

Interventions

Intervention: full-term neonates (32 girls, 32 boys) aged ≤ 48 hours were randomly assigned to 4
groups (including 1 comparator group, each n = 16) receiving treatment twice weekly from day 7 until
week 8 of life. 

1. Group WG, bathing with pH 5.5 wash gel (Top-To-Toe Baby Gel Penaten, Johnson & Johnson GmbH,

Duesseldorf, Germany)

2. Group C, bathing with clear water and afterwards topical cream (Baby Caring Facial & Body Cream

Penaten, Johnson & Johnson GmbH, Duesseldorf, Germany)

3. Group WG + C, bathing with wash gel and topical cream

All neonates were washed 3 times with a cotton wash cloth, moistened with water, until day 7.

Bathing lasted about 5 minutes using tap water at temperature 37 °C to 38 °C, pH 7.9 to 8.2, hardness
13.4 °dH (range 7 to 25). Diapers from Pampers Baby Dry for Newborns were provided. Parents were in-
structed to avoid treating skin with any other skin care products. Topical products were allowed on ar-
eas of skin trauma or diaper dermatitis, including: triclosan 1% cream, octenidin ⁄ phenoxyethanol solu-
tion, zinc paste (optional with nystatin). Oil and vaseline were allowed to remove meconium.

Comparator: Group B, bathing with clear water 

Outcomes

1. TEWL
2. Stratum corneum hydration
3. Skin pH
4. Sebum

Adverse effects: no adverse events reported

Identification

Country: Germany 

Setting: Department of Dermatology, Clinic for Neonatology CCM at Charité-Universitätsmedizin
Berlin, and Department of Gynaecology, Clinic Dahme-Spreewald

Sponsorship source: the work of Franziska Prosch was supported by an unrestricted medical grant
from Johnson & Johnson

Declarations of interest

The funders had no input regarding study design or conduct, data analysis or interpretation, manu-
script
preparation, or the decision to submit the results for publication.

Notes

Garcia Bartels 2011 

Study characteristics

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

71

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Garcia Bartels 2011  (Continued)

Cochrane Database of Systematic Reviews

Methods

Study design: monocentric, prospective, randomised, clinical non-pharmaceutical study 

Study conducted: September to December 2009

Treatment arms: 2

AD follow-up: 4 weeks

Participants

Randomised: N = 44 (Group L using lotion n = 20; Group WL without lotion n = 24)

Inclusion criteria: 

1. Healthy full-term infant (37 weeks+)
2. Aged 3 to 6 months
3. Parental consent

Exclusion criteria: 

1. Immunocompromised infant
2. Severe illness
3. Congenital skin disorder
4. Skin irritation that could affect measurements or that was contagious
5. Current or previous atopic dermatitis in both parents
6. Acute or chronic illness with increased or decreased body temperature
7. Participation in another study

Interventions

Both groups went swimming weekly for 4 weeks for 25 to 40 minutes at the Charité-Universitätsmedi-
zin Berlin physiotherapy facilities. Both groups received a standard skin care regimen: weekly bathing
in tap water, diaper care with water and cotton cloth or Bübchen Comfort sensitive wipes. No skin care
was performed 12 hours before evaluations.

Intervention: in Group L (lotion group), baby skin care lotion was applied to the entire body once
weekly after swimming, and the skin was dried with a towel

Comparator: no lotion or other skin care product was applied in Group WL (without lotion) 

Moisturiser/emollient ingredients: Bübchen Pflege Lotion: aqua, Helianthus annuus seed oil, iso-
propyl palmitate, dicaprylyl ether, ethylhexyl stearate, polyglyceryl-3 polyricinoleate, glycerin, buty-
lene glycol, octyldodecanol, polyglyceryl-3 diisostearate, parfum, zinc stearate, chamomilla-recutita
extract, tocopheryl acetate, glyceryloleate, magnesium sulfate, tocopherol 

Outcomes

1. TEWL
2. Stratum corneum hydration
3. Skin pH
4. Sebum

Measured on 4 anatomical test areas (forehead, abdomen, buttock, thigh), using the non-invasive Mul-
ti-Probe Adapter System MPA (Courage & Khazaka Electronic, GmbH, Cologne, Germany) at 6 study vis-
its. Baseline visit (V0) was within 4 weeks before the first swimming session. After baseline, visits were
performed weekly before swimming sessions (V1 to V4). No swimming took place at follow-up, 1 week
after the last swimming session (V5).

Adverse events: method of collection of adverse events is not recorded

"Neonatal skin condition score (NSCS) was found to be mainly normal (score 3). A mildly elevated NSCS
(4) was found in < 7.5% of infants per visit, and depending on area, an NSCS of 5 was found only once
at baseline visit on the thigh (data not shown). NSCS was statistically comparable at all test regions in
both groups throughout the study period (n = 44). The overall occurrence of adverse events (AEs) was
lower in group L (n = 18) than in group WL(n = 33, Table 3). The occurrence of diaper dermatitis, how-
ever, was similar in both groups (n = 9). After dichotomisation of subjects into the two groups “no AE

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

72

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Garcia Bartels 2011  (Continued)

Cochrane Database of Systematic Reviews

at all” vs “at least one AE”,  χ2 test showed significantly less occurrence of AEs in group L compared to
group WL (55.0% vs 83.3%; P = 0.04; Figure 8)"

Identification

Country: Germany

Setting: Charité-Universitätsmedizin Berlin, Germany, physiotherapy facilities

Sponsorship source: the clinical study was sponsored by Bübchen Deutschland

Declarations of interest

Prof Blume-Peytavi has received presentation fees from Bübchen Deutschland, which sponsored the
study.

Notes

Garcia Bartels 2012 

Study characteristics

Methods

Study design: monocentric, prospective, randomised pilot study

Study conducted: May 2007 to October 2007

Treatment arms: 2

AD follow-up: baseline second day of life at neonatal ward, followed by 14th and 28th days of life 

Participants

Randomised: N = 44 (skin care with baby wipes n = 21; water-moistened washcloth n = 23 at each dia-
per change)

Inclusion criteria: healthy full-term newborns with 37 completed weeks of gestation

Exclusion criteria: 

1. Sepsis
2. Congenital malformation
3. Asphyxia
4. Hydronephrosis
5. Intracranial haemorrhage
6. Immunodeﬁciency
7. Skin disease with eruptions covering more than 50% of body surface
8. Skin maceration or inﬂammation, or both
9. Urticaria
10.Acute/chronic disease with temperatures

Interventions

Treatments were applied by parents approximately 8 times per 24 hours over 4 weeks.

Both groups received a standard skin care regimen, with twice-weekly bathing in clear tap water with-
out use of a cleanser as described. No additional skin care was given, except for areas of skin trauma or
diaper dermatitis.

Intervention: skin care with baby wipes. Infants were cleansed with baby wipes during each diaper
change.

Comparator: water-moistened washcloth (cotton washcloth moistened with tap water)

Wipes and diaper ingredients: skin care with baby wipes, Penaten (Procter & Gamble Manufacturing
GmbH, Euskirchen, Germany), baby wet wipes with aloe vera (aqua, myristyl alcohol, stearyl alcohol,
propylene glycol, epilobium angustifolium extract, aloe barbadensis, PEG-4 laurate, tocopherol, citric

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

73

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Garcia Bartels 2012  (Continued)

Cochrane Database of Systematic Reviews

acid, lactic acid, tetrasodium-EDTA phenoxyethanol, iodopropyynyl butylcarbamate, parfum; Johnson
& Johnson GmbH, Duesseldorf, Germany), Pampers Diapers ‘‘newborn’’ size, cotton washcloths provid-
ed. Tap water pH 7.9 to 8.2

Outcomes

Primary outcome: TEWL

Secondary outcomes: skin pH, SCH, epidermal desquamation, Neonatal Skin Condition Score (NSCS),
IL-1 alpha level 

Adverse effects: not reported

Identification

Country: Germany

Setting: Charité -Universitätsmedizin Berlin

Sponsorship source: Lida Massoudy’s work was supported by an unrestricted medical grant from
Johnson & Johnson GmbH. We thank Dr Gaelle Bellemere (Johnson & Johnson, Research and Develop-
ment, France) for support in the IL-1a analysis and in the D-Squame technique of blinded samples.

Declarations of interest

Not reported

Notes

Garcia Bartels 2014 

Study characteristics

Methods

Study design: single-centre, prospective, randomised trial

Study conducted: November 2010 to April 2012

Treatment arms: 3

Follow-up: 4 and 8 weeks

Participants

Randomised: N = 89 (Group 1 n = 30, Group 2 n = 28, Group 3 n = 31)

Inclusion criteria: healthy infants aged 9 months (± 8 weeks)  

Exclusion criteria: 

1. Immunocompromised infant
2. Infant with severe illness
3. Congenital disorder
4. Contagious or irritated skin affecting measurements
5. Current or previous atopic dermatitis in both parents
6. Acute or chronic illness with high or low body temperature
7. Participating in another study

Interventions

Intervention: daily use of wet wipes or water-moistened washcloths and diaper cream in the diaper
area. 
Group 2 received cleansing with water-moistened washcloths and diaper cream twice per day. 
Group 3 received cleansing with wet wipes (Penaten Baby-Lotion Tucher, Johnson & Johnson) at each
diaper change and diaper cream twice per day.

In addition, all groups were advised to perform a twice-weekly skin care regimen, which included
bathing with a baby cleanser (Penaten Baby Bad & Shampoo, Johnson & Johnson) and applying baby
lotion after bathing (Penaten Baby Intensive Lotion, Johnson & Johnson), except for the diaper region.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

74

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Garcia Bartels 2014  (Continued)

Cochrane Database of Systematic Reviews

Parents were advised to wash the water-moistened washcloths at 60 °C in the washing machine with-
out fabric softener.

Clinical measurements were performed at inclusion (week 0) (W0), week 4 (W4), and week 8 (W8) at the
CRC. Diapers were removed 10 minutes before measurements. The minimum duration between last
diaper change and measurements was 1 hour; bathing or skin care was allowed 12 hours before mea-
surements. A minimum of 4 diaper changes every 24 hours was required; if DD occurred, a topical ther-
apy was allowed on affected areas as needed. Ambient conditions were standardised (temperature 22
°C to 26 °C, relative humidity 40% to 60%). During the study period, DD occurred in the perianal and
genital areas but not in investigational areas, i.e. the outer upper quadrant of the buttock (diapered
area) and the upper leg (non-diapered area). When DD occurred, extra measurements were taken in the
affected area.

Skin condition was evaluated using a modified NSCS 2, 3, 11, and in the diaper area using a modified
DRG 1 (7-point scale; none = 0, severe = 3). Clinically relevant DD was defined as DRG of 1.5 or greater.

Parents were advised to document any changes in skin care or health status of the infant in a diary,
which they were given and was explained at the inclusion visit. The investigator verified diary entries at
each visit.

Comparator: Group 1 received cleansing with water-moistened washcloths at each diaper change 

Outcomes

Primary outcome: TEWL

Secondary outcomes: 

1. Skin surface pH
2. Stratum corneum hydration
3. Interleukin-1 alpha (IL-1α)
4. Neonatal skin condition score
5. Diaper rash grade

Adverse events: no adverse events reported 

Identification

Country: Germany

Setting: Clinical Research Center for Hair and Skin Science (CRC), Charité-Universitätsmedizin Berlin

Sponsorship source: the trial was sponsored by Johnson & Johnson Consumer EMEA.
The sponsor had input into the study design and blinded analysis of interleukin. The sponsor had no in-
fluence on conduct of the trial, collection of data, or statistical evaluations.

Declarations of interest

U Blume-Peytavi is a consultant to Johnson & Johnson GmbH. N Garcia Bartels has been speaker for
Johnson & Johnson Consumer GmbH.

Notes

Horimukai 2014 

Study characteristics

Methods

Study design: randomised controlled, parallel-group, investigator-blinded trial

Recruitment date: November 2010 to November 2013

Treatment arms: 2

AD follow-up: 4 weeks, 12 weeks, 24 weeks, 32 weeks

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

75

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Horimukai 2014  (Continued)

FA follow-up: sensitisation to food and inhalants at 32 weeks 

Participants

Randomised: N = 118 (intervention n = 59; control n = 59)

Inclusion criteria: 

1. Infant within the first week after birth
2. High-risk infant from atopic dermatitis (family history)
3. Infant without treatment with corticosteroids
4. Infant whose parents gave informed consent

Exclusion criteria: 

1. Infant treated with corticosteroid ointment (except genital and anal areas)
2. Infant with skin lesions such as dyskeratosis or bullosa diagnosed by specialists in dermatology
3. Small-for-gestational-age (< 37 weeks)
4. Infant with hepatic disease, convulsion, cardiac disease, haemophilia, diabetes, or autoimmune dis-

ease

5. Inappropriate case as evaluated by doctors

Interventions

Intervention: emollient was applied each day for 32 weeks. Hanifin-Rajka criteria were used to diag-
nose AD.

Comparator: control group applied petroleum jelly if desired

Moisturiser/emollient: emulsion-type emollient (2e (Douhet) emulsion) from the first week of life; pe-
troleum jelly was prescribed to each infant in both groups on request by the institutional review board

Outcomes

Primary outcomes: the cumulative rate of incidence of AD, eczema, or both by temporal observation.
Modified UKWP criteria were applied by a dermatology specialist.

Secondary outcomes: 

1. Specific IgE antibodies
2. TEWL
3. Stratum corneum water concentration
4. Stratum corneum pH
5. Staphylococcus aureus on skin
6. Onset of allergic disease such as asthma and food allergy

Adverse events: “the dermatology specialist stopped giving the emollient to 3 infants whose skin le-
sions seemed to be the result of urticaria or contact dermatitis caused by emulsion-type emollients (re-
lated adverse events). After several days, however, the doctor judged that these skin lesions were not
adverse events because they disappeared rapidly, and similar lesions were not seen when the same
emollients were used again. These 3 infants did not have AD/eczema or skin rash when they were fol-
lowed for 32 weeks. There were no infants from families that withdrew consent who had skin lesions. In
summary, adverse events caused by this emulsion-type emollient were not observed during this RCT”

No IPD are available on adverse events.

Identification

Sponsorship source: supported in part by Health and Labour Sciences Research Grants for Research
on Allergic Diseases and Immunology from the Ministry of Health, Labour and Welfare of Japan (H22-
Men'eki-Ippan-002 to HS; H25-Nanchito-Ippan-001 to MA and HS as principal investigators) and grants
from the National Center for Child Health and Development (20S-1 to YO and 23S-3 to HS)

Country: Japan

Setting: National Center for Child Health and Development, the only national hospital for mothers and
children in Tokyo

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

76

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Horimukai 2014  (Continued)

Declarations of interest

Extensive list in the trial publication

Notes

Kataoka 2010 

Study characteristics

Methods

Study design: randomised trial

Recruitment date: not reported

Treatment arms: 2 

Follow-up: 6 months for AD, 6 months for food allergen sensitivity

Participants

Randomised: N = 71

Inclusion criteria: family history of AD in second degree of kinship 

Exclusion criteria: none reported

Interventions

Intervention: apply prescribed emollient more than once a day and do not wash infant's face with any
other detergent 

Comparator: parent preference in skin care ("do what they like")

Outcomes

1. Eczema and skin barrier function
2. Food allergen sensitivity
3. TEWL

Adverse events: adverse effects not reported

Identification

Country: Japan

Sponsorship source: not reported

Declarations of interest

Not reported

Notes

Lavender 2011 

Study characteristics

Methods

Study design: a pilot randomised, assessor-blinded controlled trial

Recruitment date: November 2008 to November 2009

Treatment arms: 2

AD follow-up: 4 and 8 weeks

Participants

Randomised: N = 80 (recruit a sample of babies with family history of atopic eczema (n = 30) and a
sample of babies without family history of atopic eczema (n = 50))

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

77

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lavender 2011  (Continued)

Inclusion criteria: 

Cochrane Database of Systematic Reviews

Interventions

1. Born at 37 weeks' gestation or later
2. Good general health (as determined by investigator)

Exclusion criteria:

1. Admittance to the neonatal unit
2. Having phototherapy
3. Limb defects
4. Non-traumatic impairment of epidermal integrity
5. Evidence of skin disorder at first visit
6. Participation in another clinical trial

For the purposes of this study, the following normal variations were not considered skin disorders: ery-
thema neonatorum, erythema toxicum, and milia.

All participating parents were supplied with written guidance on baby bathing. These instructions in-
cluded guidance on regularity of bathing and the non-use of other products (e.g. oils, sponges, flannels,
baby wipes). Participating women were requested to bathe their baby a minimum of 3 times per week.
Women recorded the number of times they bathed their babies. Women were also instructed to avoid
any rubbing of the baby's skin and were asked not to use any additional products.

A baseline assessment was made before maternal transfer into the community and before the first
bath. A second assessment was made at 4 weeks and at 8 weeks postbirth. Measurements were taken
on the upper abdomen (above nappy area), upper leg, and forearm.

Intervention: for infants allocated to the wash product (experimental) arm, parents were provided
with sufficient baby wash and were advised to use the product as per instructions

Comparator: for infants allocated to the water only (control) arm, parents were not provided with any
products and were advised to bathe their baby with water and cotton wool only

Moisturiser/emollient: bathed in water only or bathed with the baby wash product. The wash product
was the commercially available Johnson's Baby Top-To-Toe Wash (Johnson & Johnson Consumer Com-
panies, Inc). This wash is a soap-free liquid cleanser specifically designed for newborns' skin. It is sodi-
um lauryl sulphate-free and consists of a proprietary blend of non-ionic and amphoteric surfactants
that, when combined, result in large, gentle-cleansing micelles. The formula contains only strictly nec-
essary levels of well-tolerated preservatives and a very low level of fragrance; it is pH-adjusted (around
5.5) and hypoallergenic. The International Nomenclature Cosmetic Ingredients list comprised aqua, co-
co glucoside, cocamidopropyl betaine, citric acid, acrylates/C10-30 alkyl acrylate crosspolymer, sodi-
um chloride, glyceryl oleate, p-Anisic acid, sodium hydroxide, phenoxyethanol, sodium benzoate, and
parfum.

Outcomes

1. TEWL
2. Skin surface pH
3. Hydration

Adverse effects: the skin was observed and recorded by the assessing midwife at 4 and 8 weeks post-
birth using a validated rating scale that records erythema, dryness, scaling, and the need for medical
products/attention. Any skin treatments were recorded by the mother.

Identification

Country: UK

Setting: teaching hospital in the North West of England

Sponsorship source: this study was funded by Johnson & Johnson; however, the study was investiga-
tor led. TL, CB, and MC previously acted as temporary advisors to J&J.

Declarations of interest

As above

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

78

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lavender 2011  (Continued)

Notes

Lavender 2012 

Study characteristics

Methods

Study design: prospective, assessor-blinded, randomised controlled trial 

Recruitment date: February and October 2010

Treatment arms: 2

AD follow-up: 4 weeks 

Participants

Randomised: N = 280 infants (napkin area cleansed with an alcohol-free baby wipe n = 140; cotton
wool and water n = 140)

Interventions

Inclusion criteria: 

1. Infants born at 37 weeks' gestation or later and using disposable nappies

Exclusion criteria:

1. Admitted to the neonatal unit
2. Receiving phototherapy
3. Limb defects
4. Non-traumatic impairment of epidermal integrity
5. Evidence of skin disorder at first visit
6. Chromosomal abnormality or other syndromic diagnosis
7. Infant going for adoption

Intervention: napkin cleansing regimen using a specific type of baby wipe. Participating mothers were
given a cleansing demonstration by a healthcare assistant. All mothers were advised to use nappies
that were supplied by researchers for the duration of the study to ensure similar absorbency, a factor
likely to influence skin hydration. Mothers were also advised to avoid using napkin cream, other than
that supplied by the research team as a rescue treatment. Parents were provided with cotton wool or
baby wipes according to their allocated trial arm.

Comparator: napkin cleansing regimen using cotton wool and water

Wipe and emollient: Johnson's Baby Skincare Fragrance Free Wipe (Johnson & Johnson Ltd, Maiden-
head SL6 3UG, UK). The emollients contained glycerin and glyceryl oleate. The baby wipes also con-
tained citric acid, which can have dual functionality as pH adjuster and chelator. Additionally, it was
important to have a wipe with a pH close to the skin pH (around 4.9 in this case); if the pH is too low,
this could be an irritant; if too high, this would increase protease activity and inhibit lipid lamellar syn-
thesis in the skin barrier. Wipes contained 97% water and were free of alcohol, fragrance, essential
oils, soap, and other harsh detergents; they were appropriately preserved to prevent the growth of mi-
cro-organisms. Cloth material of the wipes was a rayon viscose and polyester non-woven fibre blend,
entangled in a matrix of trough water jets without chemical binders, which is designed to reduce fric-
tion when wiped across the skin surface.

Outcomes

Primary outcome: change in stratum corneum hydration scores on the buttocks from first assessment
(within 48 hours of birth) to 4 weeks postbirth, using a Corneometer

Secondary outcomes: change in erythema measurements using a Mexameter (W MX 18) (27); change
in TEWL using an Aquaflux (AF200) (28); change in skin surface pH (using a pH meter). Measurements
were taken on the babies’ buttocks at first assessment (within 48 hours of birth) and 4 weeks postbirth.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

79

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lavender 2012  (Continued)

Adverse effects: study group found no evidence of any adverse effects of using wipes

Identification

Country: UK

Setting: North West of England

Declarations of interest

None reported.

Notes

Lavender 2013 

Study characteristics

Methods

Study design: assessor-blinded, randomised controlled, non-inferiority trial

Recruitment date: between February 2010 and March 2011

Treatment arms: 2

AD follow-up: 2 and 4 weeks for AD

Participants

Randomised: N = 307 (wash product n = 159; bathing with water alone n = 148)

Inclusion criteria: 

1. Newborn infants born at 37 weeks' gestation or later

Exclusion criteria: 

1. Admitted to the neonatal unit
2. Receiving phototherapy
3. Limb defects
4. Non-traumatic impairment of epidermal integrity
5. Evidence of skin disorder at first visit
6. Chromosomal abnormality or other syndromic diagnosis
7. Infant going for adoption

Interventions

Bathing regimen using a newborn wash product or water alone before the first bath. Participating
mothers were instructed to bathe their neonate at least 3 times per week and to avoid rubbing the skin.
On the day of assessment, mothers were requested to delay bathing their neonate until measurements
had been taken.

Intervention: parents of newborns allocated to the wash product (experimental) were provided with
sufficient newborn wash and were advised to dilute the product at a ratio of 3 squirts per bath

Comparator: control group used water alone; parents were not provided with any products. If mothers
wished to use shampoo on their neonates’ hair, they were requested to do this outside of the bath, and
to ensure that the neonate’s body was wrapped in a towel to prevent contact with the skin.

Cleanser: Johnson’s Baby Top-To-Toe Bath (Johnson & Johnson Ltd, Maidenhead SL6 3UG, UK)
is a soap-free liquid cleanser designed for newborns’ skin. It is sodium lauryl sulphate-free and consists
of a proprietary blend of non-ionic and amphoteric surfactants that when combined result in large mi-
celles that clean via dispersal of fats without disrupting the skin barrier. The formula contains well-tol-
erated preservatives and a low level of fragrance; it is pH-adjusted (around 5.5) and hypoallergenic.
The International Nomenclature Cosmetic Ingredients list comprised aqua, coco glucoside, coca mi-
dopropyl betaine, citric acid, acrylates/C10-30 alkyl acrylate crosspolymer, sodium chloride, glyceryl
oleate, p-Anisic acid, sodium hydroxide, phenoxyethanol, sodium benzoate, and parfum.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

80

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lavender 2013  (Continued)

Outcomes

Primary outcomes: the average of TEWL measurements, using a closed chamber system, over
3 sites (outer forearm, midpoint between wrist and elbow; front of thigh, midpoint between knee and
groin; abdomen, midpoint between umbilicus and sternum) at 14 days following birth using AquaFlux
Model AF200 (Biox Systems Ltd, London, UK)

Secondary outcomes: TEWL at 4 weeks postbirth, skin surface pH using Courage + Khazaka Skin-pH-
MeterR PH 900, and stratum corneum hydration scores using Corneometer CM 820 (Courage + Khaza-
ka Electronic GmbH, Cologne, Germany) from baseline (within 48 hours of birth). Given the sensitivity
of neonate skin in the early weeks following birth, this is an ideal time to investigate the effects of wash
products. Any differences in these outcomes are likely to be greater than later in an infant’s life, when
the skin barrier is more stable.

Adverse events: not reported

Identification

Country: UK

Setting: teaching hospital in the North West of England

Sponsorship source: funded by Johnson & Johnson Consumer Companies, Inc

Declarations of interest

None reported.

Notes

Lowe 2018a 

Study characteristics

Methods

Study design: a pilot randomised, parallel, single-blinded (outcome assessor), controlled trial

Recruitment date: 1 May 2013 to 2 July 2014 

Treatment arms: 2

AD follow-up: 6 weeks, 6 months, and 12 months of age for AD

FA follow-up: 6 and 12 months 

Participants

Randomised: N = 80 (treatment group n = 41; control group n = 39)

Inclusion criteria: 

1. Self-reported family history (either parent or older siblings) of allergic disease (asthma, eczema/atopic

dermatitis, allergic rhinitis/hay fever, or food allergy)

2. Single birth

Exclusion criteria: 

1. Either parent had known hypersensitivity to any of the ingredients of EpiCeram
2. Born prematurely (< 36 weeks)
3. Required admission into a neonatal special or intensive care nursery
4. Parents with insufficient English language skills or not able to comply with all protocol-required visits

and procedures

5. Infant with a major birth or early-life medical complication
6. Parents not able to comply with all protocol-required visits and procedures

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

81

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lowe 2018a  (Continued)

Interventions

Intervention: parents of infants were shown how to apply the emollient to the full skin surface of their
child twice a day for the first 6 months of life. Treatment commenced within the first 3 weeks of life
(neonatal period). Approximately 6 grams per application 

1. Adherence was high. 76% applied EpiCeram ≥ 5 days per week.
2. 18% used other emollients on average ≥ 3 days per week.

Comparator: control group: no other skin care instructions were provided

Emollient: EpiCeram is a ceramide-dominant emollient cream 

Outcomes

Primary outcomes: 

1. Presence of observed eczema within the first 6 weeks and 6 months of life using UKWP criteria for

eczema and assessed by study investigators

2. Skin barrier function, TEWL at 6 weeks and 6 months
3. Measurement tools: UK Working Party criteria

Secondary outcomes: 

1. Presence of observed eczema from 6 to 12 months of age, Hanifin and Rajka standardised criteria,

assessed by study investigators

2. Presence of probable eczema (based on diagnosis in the community but not verified by the  study

investigator) up to 12 months of age

3. Parent-reported or community doctor-diagnosed eczema
4. Eczema severity assessed using SCORAD (Scoring of Atopic Dermatitis) scale
5. Skin prick test reactivity to 6 allergens (egg white, cow's milk, peanut, dust mite, cat dander, and rye

grass)
6. Skin pH
7. Skin hydration
8. Skin oiliness

Identification

Country: Australia

Setting: Royal Women's Hospital and Frances Perry House (recruitment);
Murdoch Children's Research Institute (assessment and storage of biological samples);
University of Melbourne (data storage)

Sponsorship source: this trial was supported by the Financial Markets Foundation for Children and
the Asthma Foundation of Victoria. Additional support was obtained via an NHMRC equipment grant
to purchase instruments used to measure biophysical aspects of skin. PuraCap, then manufacturer of
EpiCeram, provided the interventional product free of charge.

Declarations of interest

None declared.

Notes

Lund 2020 

Study characteristics

Methods

Study design: randomised controlled trial

Recruitment date: September 2012 to May 2013

Treatment arms: 2

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

82

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lund 2020  (Continued)

Follow-up: 1 postbath measurement

Participants

Randomisation: N = 100 (vaginal delivery n = 50, caesarean section n = 50) (intervention n = 49, control
n = 51); randomised according to a balanced block design and stratified according to delivery mode

Inclusion criteria:

1. Healthy full-term infant
2. English-speaking parents
3. Parental consent

Exclusion criteria:

1. Respiratory symptoms requiring oxygen
2. Intravenous antibiotics
3. Maternal chorioamnionitis
4. Congenital anomalies
5. Admission to the newborn intensive care unit

Interventions

All infants were bathed according to the study protocol: immersion bath with water temperature 101
°F, depth 5 inches (12.7 cm), which has been shown to be safe even with the umbilical cord in place, and
swaddle technique to reduce infant distress. The infant was stabilised under a radiant warmer with the
2 study sites - volar forearm and beneath the sternum - exposed for 10 minutes.

Intervention: bathed using cleanser

Comparator: bathed with water only

Cleanser ingredients: Johnson & Johnson's Head-To-Toe was used, as this was used at the time at this
facility. It is a soap-free liquid cleanser designed for newborn and infant skin; it is sodium lauryl sul-
fate-free and pH-adjusted.

Outcomes

Primary outcome: skin barrier function, measured by skin surface pH

Secondary outcomes: TEWL, hydration of the stratum corneum

Adverse events: not reported

Identification

Country: USA

Setting: UCSF Benioff Children’s Hospital Oakland, Oakland, CA, USA

Sponsorship Source: this study was supported by a grant from Johnson & Johnson Consumer Co Inc
and by the National Center for Advancing Translational Sciences, National Institutes of Health, through
UCSF-CTSI Grant Number UL1 TR000004

Declarations of interest

This study was supported by a grant from Johnson & Johnson Consumer Co Inc and by the National
Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant
Number UL1 TR000004.

Notes

McClanahan 2019 

Study characteristics

Methods

Study design: single-centre, investigator-blinded RCT

Recruitment dates: June 2011 and January 2014 

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

83

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McClanahan 2019  (Continued)

Treatment arms: 2

Cochrane Database of Systematic Reviews

AD follow-up: study visits occurred at 2, 6, and 12 months. 2 phone calls were performed at 18 to 24
months to discuss development of AD, provide education on emollient use, and supply additional
product. 

Participants

Randomisation: N = 100 (intervention n = 54, control n = 46)

Inclusion criteria:

1. Parent/guardian over 18 years of age
2. Newborn within 21 days considered at high risk for AD development (first-degree relative with history

of AD, asthma, or allergic rhinitis)

3. Parents/guardians of participants willing to comply with study procedures

Exclusion criteria: 

1. Premature newborn (born before 37 weeks' gestational age)
2. Diagnosed with major congenital anomaly
3. Significant dermatitis at birth (excluding seborrhoeic dermatitis)
4. Immunodeficiency disorder
5. Serious medical problem making emollient use inadvisable by increasing the risk of adverse events

or inhibiting outcomes assessment

Interventions

Intervention group: instructed to apply moisturiser daily to all body surfaces excluding the scalp and
diaper area and to use the cleanser only as needed during bathing

Comparator: control group was given no specific instructions regarding use of emollients except to
use emollients of their choice on an as-needed basis

Moisturiser/emollient: Cetaphil Restoraderm (Galderma, Baie d’Urfé, Montreal, Canada); key ingre-
dients include shea butter as a lipid source, pseudoceramide-5, and 2 FLG breakdown products. A
cleanser was also provided. No bathing frequency instructions were provided. Both products were to
be used within 21 days of birth.

Outcomes

Primary outcomes: cumulative incidence of AD at 12 months diagnosed by a blinded investigator ("in-
vestigator-confirmed AD"). UK Working Party Criteria adapted to identify incident cases of AD were
used rather than a 12-month period of prevalence. 

Secondary outcomes: a post hoc secondary analysis of the primary outcome was also performed: cu-
mulative incidence of AD defined as AD diagnosed by an investigator and/or an outside paediatrician or
chart review within 12 or 24 months (any AD)

Adverse events: intervention group vs control group: bacterial skin infections (7.4% vs 6.5%); hyper-
sensitivity reactions including irritant contact dermatitis and urticaria (14.8% vs 8.7%). No serious ad-
verse events were reported in either group.

Identification

Country: Oregon, USA

Setting: maternal hospital wards

Sponsorship source: all funding sources supported the work

Declarations of interest

Dr Simpson has received consulting fees from Galderma, which supplied the emollient for this study.

Notes

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

84

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Migacheva 2018 

Study characteristics

Methods

Study design: randomised controlled trial

Treatment arms: 2

AD follow-up: 12 months

Participants

Randomised: N = 63

Inclusion criteria:

1. Family history of allergy

Exclusion criteria: 

1. Prematurity
2. Supplementation (including short-term use of children milk formulas in the maternity hospital)
3. Appointment of probiotics
4. Use of drugs by nursing mother
5. Use of special means of baby skin care (emollients)

Interventions

Intervention: infants in the intervention group received full-body emollient therapy (cream) twice a
day starting within 3 weeks of birth in combination with supplementation of synbiotic containing LGG
and fructo-oligosaccharides at the age of 3 to 6 months

Comparator: parents in the control group were asked to use no emollients and no pro-/prebiotics dur-
ing the study period

Adherence to the application was reported as 95.2% by the end of the study, providing reassurance
that the process was feasible.

Outcomes

Cumulative incidence of AD at 12 months, as assessed by a trained investigator

Adverse events: no intervention-related adverse events occurred

Identification

Country: Russia

Sponsorship source: not reported

Declarations of interest

Not reported

Notes

NCT03376243 

Study characteristics

Methods

Study design: pragmatic, parallel-group, assessor-blind, randomised, open-label, prospective study 

Study start date: 1 February 2017 

Treatment arms: 2

Follow-up: participants were followed up until they had eczema or 12 months or were lost to follow-up

Participants

Participants: N = 54

Inclusion criteria: 

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

85

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT03376243  (Continued)

Cochrane Database of Systematic Reviews

1. Participant (i.e. the newborn baby) must have a parent or sibling with a history of atopic eczema,

allergic rhinitis, or asthma
2. Infant in overall good health
3. Term-born babies
4. Mother at least 18 years of age at delivery and capable of giving informed consent

Exclusion criteria: 

1. Preterm birth (defined as birth before 37 weeks' gestation)
2. Child previously randomised to this trial
3. Major congenital anomaly
4. Significant inflammatory skin disease at birth (except seborrhoeic dermatitis)
5. Any immunodeficiency disorder or severe genetic skin disorder
6. Any condition that would make the use of emollients inadvisable or not possible

Interventions

Intervention: daily application of Lipikar Baume AP+ emollient and structured parent education

Comparator: no emollient intervention, only structured parent education

Outcomes

Primary outcomes: 

1. Feasibility, safety, and tolerability, and preventive effectiveness
2. Willingness to participate [Time Frame: 2 years]
3. Willingness of parents to have their child randomised and to adhere to the regimen

Secondary outcomes: 

1. Development of adverse events [Time Frame: 2 years]
2. Cumulative incidence of adverse events
3. TEWL [Time Frame: 2 years]
4. Development of TEWL over time
5. Microbiome diversity [Time Frame: 2 years]
6. Development of microbiome diversity over time      

Adverse events: skin reactions with study product prompted for at follow-up visits (month 1, month 3,
month 6, and month 12)

Identification

Country: Germany

Sponsorship source: University of Schleswig-Holstein

Declarations of interest

Not reported

Notes

Raisi Dehkordi 2010 

Study characteristics

Methods

Study design: triple-blind clinical trial

Recruitment start dates: 9 April 2010 and 23 August 2010

Treatment arms: 2

Follow-up: weekly up to 4 weeks

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

86

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Raisi Dehkordi 2010  (Continued)

Participants

Randomised: 120 infants who were 10 to 15 days old, full-term, single, exclusively breastfed, and with
no history of hospitalisation 

Inclusion criteria:

1. Term infants (37 to 42 weeks)
2. Birth weight 2500 to 4000 grams
3. Singleton
4. Fed exclusively with breast milk
5. Absence of obvious disease or birth abnormalities
6. Minimal maternal education in secondary school
7. Lack of maternal disease such as hypertension, diabetes, pregnancy, postpartum depression, or any

psychiatric illness, and no history of hospitalisation due to disease

8. Lack of separation of infant from mother

Exclusion criteria:

1. Sensitivity to any of the oils used for massage
2. Disease public or skin infant during the study  [sic]
3. No intervention in 4 sessions consecutive or intermittent (48 hours)
4. Failure to complete the application form for at least 24 hours
5. Infant feeding with artificial milk
6. Mother's illness

Interventions

Mothers administered 15 minutes of massage to their infants twice per day (morning and afternoon) for
28 days. Times of crying and sleep were measured by parents’ information forms at baseline and at the
end of the first, second, third, and fourth weeks of the study.

Intervention: sunflower oil massage or sesame oil massage

Comparator: massage with no oil

Outcomes

Main outcomes: crying time and sleeping time

Adverse events: none reported

Identification

Country: Iran

Sponsorship Source: Vice Chancellor, Tehran University for Medical Sciences

Declarations of interest

None reported.

Notes

Rush 1986 

Study characteristics

Methods

Study design: randomised controlled trial

Recruitment date: 19 March to 7 May 1984

Treatment arms: 2

Follow-up: not reported

Participants

Randomised: N = 186 (Group I n = 99, Group II n = 87)

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

87

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rush 1986  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria:

1. At least 37 weeks' gestational age
2. Apgar score ≥ 9 at 5 minutes

Exclusion criteria: 

1. Neonatal intensive care unit stay longer than 24 hours

Interventions

Intervention: washed daily with soap and water 

Comparator: no bath, dry skin care

Outcomes

Staphylococcus aureus colonisation rate

Adverse events: infection rate reported, but no details regarding adverse events 

Identification

Country: Canada

Setting: Maternity Unit

Sponsorship source: not reported

Declarations of interest

Not reported

Notes

Sankaranarayanan 2005 

Study characteristics

Methods

Study design: open randomised controlled trial 

Recruitment date: 1 August 2003 to 31 January 2004

Treatment arms: 3

Follow-up: 31 days, daily during hospital stay, weekly thereafter

Participants

Randomised: a total of 224 infants (112 preterm and 112 term infants) were enrolled. In each gestation
stratum, coconut oil n = 38, mineral oil n = 37, placebo (powder) n = 37

Inclusion criteria: full-term neonates weighing 2500 grams or more were included if they fulfilled the
following inclusion criteria:

1. Apgar score > 7 at 1 and 5 minutes with no resuscitation required at birth
2. Medically  stable  with  no  requirement  for  drugs  (other  than  mineral  and  vitamin  supplements

for preterm babies) or any interventions/procedures

3. Breastfeeding or feeding with expressed breast milk (preterm)
4. Adequate family support

Exclusion criteria:

1. Congenital anomaly or neuromuscular disorder
2. Parents staying far away from the hospital and therefore less likely to follow up
3. Parents who refused consent for the study

Interventions

Sessions began an hour after a feed. The total duration of each session was 5 minutes, and sessions
were done 4 times a day. Term infants were massaged in a draught-free room. Massage was given in

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

88

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sankaranarayanan 2005  (Continued)

Cochrane Database of Systematic Reviews

prone and supine positions to include head, neck, trunk, and extremities. At completion of the mas-
sage, kinaesthetic stimulation was provided in the supine position by passive flexion and extension
movements of the limbs at each large joint (shoulder, elbow, hip, knee, and ankle) as 5 events of 2 sec-
onds. Massage was given by a trained person from day 2 of life until discharge, and thereafter by the
mother until 31 days of age, 4 times a day. Infants were followed up daily until discharge and every
week after discharge for anthropometry.

Intervention: coconut oil or mineral oil massage

Comparator: massage using baby powder; methods of application and monitoring the same as in the
oil groups 

Moisturiser/emollient: coconut oil, mineral oil, and baby powder. No details of ingredients reported.

Outcomes

Primary outcome: weight gain velocity over first 31 days of life

Secondary outcomes: length gain velocity, head growth, neurobehavioural outcome, incidence of ad-
verse events 

Adverse events: in the preterm group, adverse events occurred in 6 infants, 2 each in the coconut oil,
mineral oil, and placebo groups. All adverse events were mild rash and did not require discontinuation
of application. Amongst term infants, 3 in the coconut oil group, 3 in the mineral oil group, and 2 in the
placebo group developed mild rash that did not require discontinuation of application.

Identification

Country: India

Setting: premature unit and postnatal wards of a major tertiary care centre in a metropolitan city in
Mumbai

Sponsorship source: Marico Industries Ltd provided oils and placebo for the study 

Declarations of interest

Marico Industries Ltd is involved in the production of coconut oil. BM, AM, and RS Mohile are employees
of Marico Industries. None of the authors from Sion Hospital have any shares in the company.

Notes

Simpson 2014 

Study characteristics

Methods

Study design: multicentre, multinational, assessor-blind, randomised (1:1), controlled pilot trial (6
months)

Recruitment date: May 2010 and May 2011 

Treatment arms: 2

Follow-up: 6 months; research nurse contacted parents by telephone at 10 days and 6 weeks, with a
face-to-face visit at 12 weeks (usually at home in the UK, and as a clinic visit in the USA). A further tele-
phone call was made at 18 weeks, and final contact was a clinic visit at 24 weeks.

Participants

Randomised: N = 124 (intervention n = 64, control n = 60)

Inclusion criteria:

1. High risk of eczema with a first-degree relative with a clinical diagnosis of atopic dermatitis, asthma,

or allergic rhinitis

Exclusion criteria: 

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

89

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Simpson 2014  (Continued)

Cochrane Database of Systematic Reviews

1. Mother had taken Lactobacillus rhamnosus supplements during pregnancy
2. Infant born before 37 weeks' gestation
3. Major congenital anomaly
4. Hydrops fetalis
5. Immunodeficiency syndrome
6. Severe genetic skin disorder
7. Serious skin condition that would make use of emollients inadvisable

Interventions

All parents were given a skin care advice booklet, which reflected current guidelines. Parents were ad-
vised to:

1. avoid soap and bubble bath;
2. use a mild, fragrance-free synthetic cleanser designed specifically for babies;
3. avoid bath oils and additives;
4. use a mild, fragrance-free shampoo designed specifically for babies, and avoid washing the suds over

the baby's body; and

5. avoid using baby wipes, when possible.

Intervention: parents were offered a choice of 3 emollients of different viscosities (an oil, a cream/gel,
or an ointment)

1. In the UK, sunflower seed oil, Doublebase Gel, and liquid paraffin
2. In the USA, sunflower seed oil, Cetaphil Cream, or Aquaphor Healing Ointment

Preferred emollient used in the intervention group: cream/gel formulations (67.2%), oil (23.4%), oint-
ment (9.4%). Parents were asked to apply the emollient to the baby's entire body surface, except for
the scalp, starting as soon as possible after birth (within a maximum of 3 weeks) and continuing until
the infant was 6 months of age.

Comparator: control arm was asked to use no emollients and was given the infant skin care advice
booklet

Oil/moisturiser/emollient ingredients: sunflower seed oil (a high ratio of linoleic/oleic acid, William
Hodgson and Co, Congleton, UK), Doublebase Gel (Dermal Laboratories, Hitchin, UK), liquid paraffin
50% in white soft paraffin (Cetaphil Cream, Galderma Laboratories, Fort Worth, TX, USA), Aquaphor
Healing Ointment (Beiersdorf, Chester, OH, USA)

Outcomes

Age of onset of eczema and proportion of transient cases 

Incidence of emollient-related adverse events

Cumulative incidence of eczema at 6 months, as determined by an investigator

Adverse events: adverse events, including accidents, infections, and reactions, were prompted for at
all patient visits. 3 superficial cutaneous infections occurred in each group; all were considered mild
in nature. There were no reports of irritant or allergic contact dermatitis (p. 821). There were no emol-
lient-related adverse events, and no differences in adverse events between groups (Results section, Ab-
stract). IPD contain 2 participants who had skin infections.

Identification

Country: UK and USA

Setting: UK: acute NHS hospital trusts (Nottingham University Hospitals, Derby Hospitals, and United
Lincolnshire Hospitals) and 1 General Practice surgery (Surgery @Wheatbridge, Chesterfield)

USA: Oregon Health & Science University Hospital and Clinics (Portland, Oregon)

Sponsorship source: National Institute for Health Research under its programme grants for Applied
Research Programme (RP-PG-0407-10177). United States–based contributions were made possible
with funding from a Mentored Patient-oriented Research Career Development Award from the Nation-
al Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health (NIH)
(5K23AR057486). Support was also obtained from the Oregon Clinical and Translational Research In-

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

90

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Simpson 2014  (Continued)

Cochrane Database of Systematic Reviews

stitute (OCTRI) and by grant number 5 KL2 RR024141-04 from the National Center for Research Re-
sources (NCRR; 5 KL2 RR024141-04), a component of the NIH, and NIH Roadmap for Medical Research.
Research in the McLean Laboratory is funded by the Wellcome Trust (Programme Grant 092530/Z/10/
Z and Strategic Award 098439/Z/12/Z). SJB holds a Wellcome Trust Intermediate Clinical Fellowship:
WT086398MA.

This study was funded by the National Institute for Health Research (RPPG-0407-10177). MJ Cork has
received compensation from Almirall Pharmaceuticals for membership on its advisory board; has re-
ceived or has grants pending from Almirall Pharmaceuticals; and has received payment for delivering
lectures, as well as compensation for travel and other meeting-related expenses, from Almirall, Astel-
las Pharma, and Steifel (a GlaxoSmithKline company). WHI McLean’s institution has received funding
from the Wellcome Trust (WT086398MA), as has that of SJ Brown, who also received an honorarium for
speaking at the American Academy of Allergy, Asthma & Immunology Annual Meeting in 2012 and 2013.
The remaining study authors declare that they have no relevant conflicts of interest.

Declarations of interest

Notes

Skjerven 2020 

Study characteristics

Methods

Study design: population-based, 2 x 2 factorial, cluster-randomised clinical trial

Recruitment date: 9 December 2014 and 31 October 2016

Treatment arms: 4

Follow-up: 12 months - UK Working Party diagnostic criteria used at 3-, 6-, and 12-month follow-up in-
vestigations, with additional use of Hanifin and Rajka diagnostic criteria at age 12 months 

Participants

Randomised: N = 2396 (no intervention group n = 596, skin intervention group n = 575, food interven-
tion group n = 642, combined intervention group n = 583)

Inclusion criteria: 

1. All newborn babies of women recruited during pregnancy and born at a minimum gestational age of

> 35 weeks

Exclusion criteria: 

1. Pregnancy with more than 2 foetuses
2. Lack of sufficient Scandinavian language skills
3. Plans to move outside of a reasonable travel distance within 1 year postpartum
4. Severe maternal, foetal, or neonatal disease that could potentially influence adherence to the inter-

ventions

Interventions

Intervention characteristics: 

1. Skin intervention group: baths for 5 to 10 minutes with added emulsified oil (0.5 dL of bath oil per
8 L of water) and cream applied to the entire face after the bath at least 4 days per week, from week
2 through to age 8 months. Parents were carefully instructed at the maternity ward on safe baby han-
dling during bathing, including written instructions with illustrations. Flasks of bath oil were handed
out to participants assigned to the skin intervention, together with tubes of Ceridal every 3 months,
during the clinical investigations from time of birth. Use of soaps was discouraged.

2. Food intervention group: complementary feeding was introduced between 12 and 16 weeks of age in
breastfed or formula-fed babies as follows: peanut butter was given for the first time at the scheduled
3-month clinical follow-up investigation, followed by cow’s milk 1 week later, wheat porridge the next
week, and finally scrambled eggs in the fourth week of introduction. Parents were instructed to let the

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

91

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Skjerven 2020  (Continued)

Cochrane Database of Systematic Reviews

infant taste each of the foods from the finger of a parent or from a teaspoon at least 4 days per week
and to continue to include the foods in the infant’s diet to at least 6 months of age.

3. Combined intervention group: skin intervention + food intervention as above

Adherence: bath oil additive was used at least 4 days per week in 497 (43%) of 1158 infants assigned to
a skin intervention, and facial cream on at least 4 days per week in 514 (44%); 316 (27%) were fully pro-
tocol adherent for use of both emollients. Between age 13 weeks and 18 weeks, peanut butter was in-
troduced to 966 (79%) of 1225 infants assigned to food intervention, cow’s milk to 838 (68%), wheat to
820 (67%), and egg to 677 (55%). 431 (35%) were fully protocol adherent up to week 26 for peanut but-
ter; 530 (43%) for cow’s milk; 543 (44%) for wheat; and 289 (24%) for egg. Full protocol adherence to the
overall food intervention was reported in 387 (32%).

Comparator characteristics:

No intervention group: no specific advice on feeding practices or skin care was given to parents of in-
fants except regular advice from well-baby clinics and national guidelines for infant nutrition. Exclusive
breastfeeding is generally recommended until age 6 months.

Adherence: IPD show regular use of emollient (Ceridal cream) (≥ 3 days a week averaged over interven-
tion period) by only 1 control participant

Cream/oil/ingredients: cream (Ceridal; GlaxoSmithKline Consumer Healthcare, Philadelphia, PA, USA),
bath oil (paraffinum liquidum and trilaureth-4-phosphate only were produced specifically for the Pre-
ventADALL trial by Pharmatech (Østfold, Norway))

Food allergy: at 36 months, assessed by oral food challenge; for those participants where oral food
challenge was declined, considered unsafe or inconclusive, an expert panel assessment was undertak-
en using the available information about allergenic food intake, tolerance, and allergic sensitisation to
foods. The procedure used for panel diagnosis of food allergy was the same as that used in Chalmers
2020.

Atopic dermatitis: at 12 months and 36 months. Blinded assessment using UK Working Party criteria

Adverse events: recorded in weekly electronic diaries up to week 26, in electronic questionnaires
every 3 months, and in specific forms by personnel at the discretion of study personnel 

Outcomes

Identification

Country: Sweden

Setting: Oslo University Hospital and Østfold Hospital Trust, Norway, and Karolinska University Hospi-
tal, Stockholm

Sponsorship source: this study was funded by several public and private funding bodies: Regional
Health Board South East, Norwegian Research Council, Health and Rehabilitation Norway, Founda-
tion for Healthcare and Allergy Research in Sweden-Vårdalstiftelsen, Swedish Asthma and Allergy As-
sociation’s Research Foundation, Swedish Research Council - Initiative for Clinical Therapy Research,
Swedish Heart-Lung Foundation, SFO-V at the Karolinska Institute, Freemason Child House Foundation
in Stockholm, Swedish Research Council for Health, Working Life and Welfare - FORTE, Oslo University
Hospital, University of Oslo, and Østfold Hospital Trust

Declarations of interest

EMR has received honoraria for presentations from Sanofi Genzyme, Novartis, MEDA, and Omega Phar-
ma. KCLC has received honoraria for presentation from Thermo-Fisher Scientific. All other study au-
thors declare no competing interests.

Notes

Thitthiwong 2019 

Study characteristics

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

92

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Thitthiwong 2019  (Continued)

Methods

Study design: prospective, randomised controlled trial 

Recruitment date: January 2016 to April 2017

Treatment arms: 2

Follow-up: clinic visits at 2, 4, 6, and 9 months old

Participants

Randomised: N = 53 (intervention n = 26; control n = 27)

Inclusion criteria:

Interventions

1. Healthy term infants, less than 10 weeks old
2. Parent(s) or sibling(s) with history of any allergic disease such as atopic dermatitis, asthma, allergic

rhinitis, allergic conjunctivitis, food allergy, or other allergic condition

Exclusion criteria:

1. Congenital anomaly
2. Immunodeficiency syndrome
3. Any skin disease other than infantile seborrhoeic dermatitis or neonatal acne

Verbal advice for good skin care practice was repeatedly given to all caregivers (in both groups) during
every clinic visit. This comprised bathing for 5 to 10 minutes with tap or lukewarm water, bathing not
more than twice daily, and using only a minimal amount of gentle liquid baby cleansers of any manu-
facturer. Use of bath oil, bubble bath, or any bath additives was not allowed in either group.

Intervention: cold cream applied all over the infant's body except peri-orbital and peri-oral areas at
least once daily shortly (within 3 to 5 minutes) after bathing and padding dry baby skin 

Comparator: control group was asked not to apply any skin care products to the baby's skin except to
use gentle liquid cleansers during bathing and barrier ointment or cream on diaper areas as needed.
This group also received good skin care advice during every visit.

Moisturiser/emollient: emollient called cold cream: white petrolatum, stearyl alcohol, propylene gly-
col, and glycerin

Outcomes

Primary outcomes: 

1. Cumulative incidence of AD in both groups
2. Diagnostic criteria based on AD guidelines by Eichenfield and colleagues 2014

Study endpoints were defined when infants developed AD, or when infants were 9 months old.

Food allergy outcomes are not mentioned as part of the outcomes, but in the results, study authors re-
port: "none of the 4 IAD infants developed cows' milk protein allergy or any other food allergy".

Secondary outcome: mean onset of AD, adverse reaction to cold cream application, factors associated
with developing AD 

Adverse events: no adverse events were reported by caregivers 

Identification

Country: Thailand

Setting: Paediatric Outpatient Department of Phramongkutklao Hospital in Bangkok

Sponsorship source: Phramongkutklao Hospital 

Declarations of interest

No conflict of interest reported. 

Notes

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

93

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tielsch 2007 

Study characteristics

Methods

Study design: cluster-randomised, placebo-controlled, community-based trial

Recruitment date: between 1 September 2002 and 8 March 2005

Treatment arms: 2

Follow-up: 28 days. Assessed at 2, 3, 4, 6, 8, 10, 12, 14, 21, and 28 days since birth (not eczema or AD re-
lated, but for assessment of infant vital status and morbidity)

Participants

Randomised: N = 17,530 (intervention n = 8650, control n = 8880)

Inclusion criteria: all liveborn infants born in the study area

Exclusion criteria: newborn infants who died before study staff arrived to conduct interventions

Interventions

Intervention: 1-time skin cleansing of newborn infants, wiping of the total body excluding eyes and
ears with Pampers Infant Wipes (Procter and Gamble Co, Cincinnati, OH, USA), which released a solu-
tion containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)

Newborn skin cleansing occurred soon after delivery at a median time of 5.8 hours after birth (in-
terquartile range 2.1 to 11.8 hours); 91.4% of infants were cleansed within the first 24 hours.

Comparator: wiping with the same infant wipes that lacked chlorhexidine (placebo) 

Wipes: all wipes were alcohol-free, produced by Procter and Gamble Co, and were packaged in sterile
plastic sachets that contained 6 wipes. Pampers Infant Wipes (Procter and Gamble Co, Cincinnati, OH,
USA) released a solution containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine diglu-
conate).

Outcomes

All-cause mortality by 28 days 

Adverse events: none reported

Identification

Country: Nepal

Setting: Sarlahi District in south-central Nepal (> 95% of births delivered in the home)

Sponsorship source: this study was conducted by the Department of International Health, Bloomberg
School of Public Health, Johns Hopkins University (Baltimore, MD, USA), under grants HD 44004 and
HD 38753 from the National Institutes of Health (Bethesda, MD, USA); grant 810−2054 from the Bill and
Melinda Gates Foundation (Seattle, WA, USA); and Cooperative Agreements HRN-A-00−97−00015−00
and GHS-A-00−03−000019−00 between Johns Hopkins University and the Office of Health and Nutri-
tion, US Agency for International Development (Washington, DC, USA). Commodity support was provid-
ed by Procter and Gamble Co (Cincinnati, OH, USA).

Declarations of interest

Financial supporters and the commodity supplier played no role in the design, conduct, management,
analysis, or interpretation of results, or in preparation, review, or approval of this article.

Notes

Yonezawa 2018 

Study characteristics

Methods

Study design: randomised, parallel, controlled trial

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

94

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Yonezawa 2018  (Continued)

Study conducted: March 2014 and June 2015

Treatment arms: 2

Follow-up: 24 months (eczema, AD, and food allergy)

Participants

Randomised: N = 227 (intervention n = 113, control n = 114)

Cochrane Database of Systematic Reviews

Inclusion criteria:

1. Newborn born at the institution at minimum gestational age of 35 weeks
2. Newborn born to Asian parents
3. Newborn who received no medical treatment in the paediatric ward
4. Mother of newborn able to speak Japanese

Exclusion criteria: not reported

Interventions

Each group performed skin care from week 1 to week 12 after birth.

Intervention: moisturising skin care (bathing every 2 days and using lotion daily). The intervention
group performed moisturising skin care as follows: (i) routine bathing every 2 days; and (ii) use of a
moisturiser 1 or more times per day. If parents were resistant to reducing the frequency of bathing,
they were allowed to bathe their newborn daily, but they could use soap only every other day. Soap
was provided by researcher. Parents were also allowed to choose a moisturiser of their choice.

Comparator: the control group performed the skin care regimen commonly used in Japan as follows:
(i) routine bathing daily; and (ii) no moisturiser. Midwives recommended that all mothers routinely
bathe their newborn daily. The researcher provided soap. The control group was allowed to apply a
moisturiser to their newborn if they wanted to.

Outcomes

Primary outcomes: 3-month outcomes: skin barrier function, by measuring values of TEWL

Secondary outcomes: 3-month outcomes: skin problems and skin conditions in the diaper area, face,
and body recorded in parents'/infants' skin diaries.
Skin conditions assessed in terms of redness, erythema, dryness, and breakdown.
Presence of diaper dermatitis assessed using the diaper rash and erythema scoring scale, which rates
diaper dermatitis on 7 levels from none to severe.
Skin problems on the face or the body were assessed using an original score scale that refers to the
Neonatal Skin Condition Score, which rates a skin condition between 3 and 9 points.
Infants with skin problems for at least 1 day were considered to have skin problems (p. 25). 

2-year outcomes: parent report of diagnosis of eczema and parent report of diagnosis of food allergy

Adverse events: not formally collected

Identification

Country: Japan 

Setting: Tokyo-Kita Medical Center

Sponsorship source: this study was supported by the Mitsubishi Foundation (Grants for Social Welfare
Activities on 2013) and the Mishima Kaiun Memorial Foundation 

Declarations of interest

None declared.

Notes

Zhao 2005 

Study characteristics

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

95

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Zhao 2005  (Continued)

Methods

Study design: randomised controlled trial

Recruitment date: October 2002 and February 2003 (infants delivered between these dates)

Treatment arms: 2

Follow-up: from delivery to discharge; no further details reported

Participants

Randomised: N = 377 (Group 1 was the swimming (study) group, comprising a total of 223 newborns,
including 127 infants delivered after spontaneous vaginal delivery and 96 infants after caesarean sec-
tion. Group 2 was the bathing (control) group, comprising 154 newborns, including 109 infants deliv-
ered after spontaneous vaginal delivery and 45 infants after caesarean section.)

Inclusion criteria: no details reported

Exclusion criteria: no details reported

Interventions

Intervention: the study group (swimming) included 223 cases (127 infants delivered after spontaneous
vaginal delivery and 96 infants after caesarean section). During hospitalisation (from delivery to dis-
charge), newborns in the study group swam twice a day for 10 to 15 minutes each time.

Comparator: bathing

Outcomes

Outcomes not relevant to SCiPAD (Skin care intervention for prevention of atopic disease).

Identification

Sponsorship source: not reported

Country: China

Setting: Guangdong Provincial Maternal and Child Health Hospital

Declarations of interest

Not reported

Notes

AD: atopic dermatitis
AGM: absorbent gelling materials
ATR: attenuated total reflection
CFU: colony forming units
DD: diaper dermatitis
DRG: diaper rash grade
EASI: Eczema Area and Severity Index
FA: food allergy
FTIR: Fourier transform infrared spectroscopy
IgE: immunoglobulin E
IL-1: interleukin-1
IPD: individual participant data
LC/UV: liquid chromatography ultraviolet
LC/MS: liquid chromatography mass spectrometry
LGG: Lactobacillus rhamnosus GG
NHMRC: National Health and Medical Research Council
NIHR: National Institute for Health and Care Research
NSCS: Neonatal Skin Condition Score
PCR: polymerase chain reaction
SCH: hydration of the stratum corneum
TEWL: transepidermal water loss
UKWP: UK Working Party

Characteristics of excluded studies [ordered by study ID]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

96

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

ACTRN12607000466448

Wrong study design

Ahmed 2007

Alonso 2013

Arline Diana 2020

Ayalew 2021

Azor-Martinez 2020

Baer 2006

Barria 2004

Baudouin 2014a

Baudouin 2014b

Berger 2009

Bhakoo 1969

Blume Peytavi 2010

Blume Peytavi 2012

Blume Peytavi 2014

Blume Peytavi 2016

Brandon 2010

Bryanton 2004

Bryce 2020

Wrong patient population

Wrong patient population

Wrong study design 

Wrong study design 

Wrong intervention

Wrong study design

Wrong comparator

Wrong patient population

Wrong patient population

Wrong patient population

Wrong study design

Wrong study design

Wrong study design

Wrong study design

Wrong study design

Wrong patient population

Wrong comparator

Wrong study design 

Chaithirayanon 2016

Wrong comparator

Chasekwa 2019

Chen 2009

Cleminson 2015

Cleminson 2016

Conner 2004

Cooke 2014

Cooke 2018

Cowan 1986

Wrong intervention

Wrong patient population

Wrong study design

Wrong study design

Wrong study design

Wrong study design

Wrong study design

Wrong comparator

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

97

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

CTRI201208002876

CTRI201709009890

Da Cunha 2005a

Da Cunha 2005b

Damron 2020

Darmstadt 2004

Darmstadt 2005a

Darmstadt 2005b

Darmstadt 2007

Darmstadt 2008

Darmstadt 2014

De Belilovsky 2020

De Lima 2020

De Silva 2020

Duggan 2015

Erdemir 2015

Ernest 1995

Reason for exclusion

Wrong study design

Wrong patient population

Wrong patient population

Wrong patient population

Wrong population 

Wrong patient population

Wrong patient population

Wrong patient population

Wrong patient population

Wrong patient population

Wrong patient population

Wrong study design

Wrong intervention

Wrong study design

Wrong study design

Wrong patient population

Wrong intervention

EUCTR2005-001269-32-AT

Wrong patient population

Fernandez 2018

Field 2008

Fluhr 2012

Foisy 2011

Franck 2000

Friscia 2019

Gao 2008

Garcia Bartels 2009

Gezon 1964

Gfatter 1997

Wrong study design

Wrong intervention

Wrong study design

Wrong intervention

Wrong patient population

Wrong patient population

Wrong patient population

Wrong intervention

Wrong comparator

Wrong patient population

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

98

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Gleiss 1965

Gunt 2018

Hauk 2008

Hawkins 2017

Hawkins 2020

Hnatko 1977

Horimukai 2016

Hu 2014

Reason for exclusion

Wrong comparator

Wrong patient population

Wrong study design

Wrong patient population

Wrong patient population 

Wrong comparator

Wrong study design

Wrong patient population

IRCT201306164617N

Wrong patient population

IRCT201306164617N7

Wrong patient population

IRCT2013090814594N1

Wrong patient population

IRCT2016111530903N

Wrong patient population

IRCT20170911036118N1

Wrong patient population

ISRCTN69836999

ISRCTN71423189

ISRCTN89579779

wrong patient population 

Wrong patient population

Wrong patient population

Jabbar-Lopez 2020

Wrong study design

Jabraeile 2016

Jensen 1971

Wrong patient population

Wrong intervention

JPRN-UMIN000005158

Wrong patient population

JPRN-UMIN000018110

Wrong study design

JPRN-UMIN000025302

Wrong study design

JPRN-UMIN000032181

Wrong study design

JPRN-UMIN000032798

Wrong study design

JPRN-UMIN000035357

Wrong study design

JPRN-UMIN000035412

Wrong study design

Kadar 1974

Kanti 2014

Wrong study design

Wrong patient population

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

99

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Kanti 2017

Reason for exclusion

Wrong comparator

Kiechl Kohlendorfer 2008

Wrong patient population

Konar 2019

Koplin 2019

Kottner 2017

Wrong patient population

Wrong study design

Wrong patient population

Kvenshagen 2014

Wrong patient population

Lane 1993

Larson 2005

Lee 2018

LeFevre 2010

Leung 2015

Li 2016

Ling 2011

Wrong patient population

Wrong study design

Wrong patient population

Wrong patient population

Wrong study design

Wrong study design

Wrong patient population

Linnamaa 2010

Wrong patient population

Lowe 2012

Lowe 2018b

Lund 2001a

Lund 2001b

Manios 2019

Mardini 2020

Marenholz 2015

Melo 2020

Muggli 2009

Nangia 2015

Natsume 2018

NCT00162747

NCT00257569

NCT00806221

Wrong study design

Wrong study design

Wrong study design

Wrong study design

Wrong intervention

Wrong intervention

Wrong study design

Wrong intervention

Wrong comparator

Wrong patient population

Wrong study design

Wrong patient population

Wrong patient population

Wrong study design

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

100

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

NCT00917085

NCT01131403

NCT01177111

NCT01364948

NCT01396642

NCT01758068

NCT02120833

NCT02403999

NCT02404493

NCT02557698

NCT02614248

NCT02857062

NCT03089476

NCT03112876

NCT03143504

NCT03719742

NCT03738163

NCT03742414

NCT03813472

NCT04001855

NCT04099602

NCT04231799

NCT04619758

NCT04720989

NCT04842786

Reason for exclusion

Wrong intervention

Wrong study design

Wrong comparator

Wrong patient population

Wrong patient population

Wrong patient population

Wrong patient population

Wrong comparator

Wrong patient population

Wrong patient population

Wrong patient population

Wrong patient population

Wrong study design

Wrong study design

Wrong study design

Wrong study design

Wrong study design

Wrong patient population

Wrong patient population

Wrong patient population

Wrong patient population

Wrong patient population

Wrong patient population 

Wrong intervention

Wrong patient population 

Nesmiyanov 2018

Wrong comparator

Nopper 1996

Noviello 2005

Wrong patient population

Wrong study design

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

101

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

PACTR202004705649428

Wrong patient population 

Perkin 2021

Pupala 2017

Pupala 2018

Pupala 2019

Qiu 2008

Quinn 2005

Ram 2020

RBR-93996y

Rehbinder 2018

Rosenstock 2007

Sach 2019

Salam 2013

Salam 2015

Sarkar 2010

Sawatzky 2016

Solanki 2005

Soll 2000

Soriano 2000

Summers 2017

Tasdemir 2021

Tasker 2020

Wrong study design

Wrong study design

Wrong patient population

Wrong study design

Wrong patient population

Wrong patient population

Wrong patient population 

Wrong patient population

Wrong study design

Wrong patient population

Wrong study design

Wrong study design

Wrong patient population

Wrong study design

Wrong patient population

Wrong patient population

Wrong study design

Wrong patient population

Wrong comparator

Wrong patient population 

Wrong study design 

TCTR20161209001

Wrong patient population

Telofski 2020

Thomas 1979

Wrong comparator 

Wrong study design

Vaivre Douret 2009

Wrong patient population

Visscher 2009

Wananukul 2001

Wrong patient population

Wrong patient population

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

102

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Wananukul 2002

Wang 2009

Waserman 2016

Reason for exclusion

Wrong patient population

Wrong patient population

Wrong study design

Xatzopoulou 2010

Wrong patient population

Xiao 2009

Yamamoto 1996

Zhang 2016

Zheng 2019

Wrong patient population

Wrong patient population

Wrong patient population

Wrong patient population 

Characteristics of studies awaiting classification [ordered by study ID]

ISRCTN38965585 

Methods

Single-centre cluster-randomised controlled trial

Participants

Aim: 41,072 newborns from 276 clusters

Interventions

Intervention:

Product: cold-pressed sunflower seed oil

The directions for newborn massage further consist of the following aspects.

1. Dosage of sunflower seed oil, comprising frequency of use, quantity per use, and duration of use:

a. Dose: 10 g per application, applied 3x daily
b. Duration: 0 to 27 days of life

2. Improvements in overall massage practice:
a. Encourage handwashing before massage
b. Encourage gently massaging the vernix into the newborn skin, rather than forcefully removing

it

c. Promote gentle massage of newborns
d. Delay use of mustard oil and skin-scrubbing substances such as bukwa (coarse-grained paste

made of mustard/wheat seeds along with additives) past the newborn period

e. Ensure that the newborn is kept warm during and after massage

Comparator: control group, which will continue following the same traditional massage practices,
including the type of oil used. No further information provided.

Primary outcome: infant mortality rate.
SCiPAD outcome of interest in this study is: 1. Infections and hospitalisation: signs and symptoms
of infection during the newborn period, along with episodes of hospitalisation, would be recorded
through parent recall. These will include local infections such as pyoderma and umbilical cord in-
fection.

Skin barrier function: barrier property of stratum corneum (assessed as TEWL)

Outcomes

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

103

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ISRCTN38965585  (Continued)

Cochrane Database of Systematic Reviews

Adherence to intervention: information on continued oil use and adherence to massage technique
would be obtained from families (mothers). This would also be applicable to a subsample (5%) of
the population.

Notes

No response from study author, emailed on 14 January 2020. 

No response from study author when emailed for update or when emailed through dataverse.har-
vard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/TGNC9H.

Link to trial: www.isrctn.com/ISRCTN38965585

JPRN-UMIN000026877 

Methods

Factorial randomised 

Participants

Target sample size: 50

Interventions

Use the foaming cleanser and lotion every single day for 4 weeks

Use the foaming cleanser and cream every single day for 4 weeks

Outcomes

Change in skin symptoms by dermatological diagnosis before and after 4-week topical application

Change in water content, TEWL, skin pH, and composition of stratum corneum before and after 4-
week topical application

Notes

Clinical trial link: apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000026877

NCT03640897 

Methods

Monocentric, prospective, randomised, comparator-controlled, parallel-group study 

Participants

133 participants

Interventions

Experimental: Liniderm

Oleocalcareous liniment Liniderm. The product will be applied on the diaper area by parents/care-
givers at each diaper change.

Active comparator: wipes

Free-fragrance baby wipes. The product will be used on the diaper area by parents/caregivers at
each diaper change.

Active comparator: water

Water and cotton pads. The product will be used on the diaper area by parents/caregivers at each
diaper change.

Outcomes

Primary outcomes: 

Number of infants who had at least 1 episode of diaper rash [Time Frame: 28 days]

Every day parents/caregivers will report in a daily log the presence or not of diaper rash.

At the end of follow-up, the investigator must identify infants who have had at least 1 episode of di-
aper rash.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

104

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT03640897  (Continued)

Secondary outcomes: 

Cochrane Database of Systematic Reviews

1. Severity of diaper rash episodes: rating [Time Frame: continuously for 28 days]
2. Severity of diaper rash episodes: extent [Time Frame: continuously for 28 days]
3. Safety of the cleaning method [Time Frame: continuously for 28 days]
4. Skin evaluation on the genital area [Time Frame: 0, 14, and 28 days]
5. Paediatrician satisfaction [Time Frame: 14 and 28 days]
6. Wellbeing [Time Frame: 0, 14, and 28 days]
7. Parent satisfaction [Time Frame: 14 and 28 days]

Notes

Ng 2021 

Methods

Participants

Interventions

Single-centre, prospective, parallel-group, randomised study

Healthy term infants, less than 2 weeks old, with at least 2 first-degree family members with atopy
(n = 200)

Intervention: to apply Cetaphil Restoraderm (Pro AD Derma) skin-restoring moisturiser twice dai-
ly, and wash with Cetaphil Restoraderm wash

Comparator: not provided with moisturiser or wash

Outcomes

Primary outcome:

Evaluate the difference in incidence of moderate or severe AD in at-risk infants treated with mois-
turisers within the first 2 weeks of life, compared to those without moisturisers at 2, 6, and 12
months

Secondary outcome:

Overall incidence of AD, TEWL, stratum corneum hydration, skin pH, incidence of food and environ-
mental sensitisation
and allergies, and filaggrin (FLG) mutation. #Side effect profiles of the prescribed moisturisers and
wash 

Notes

Trial not registered.

AD: atopic dermatitis
TEWL: transepidermal water loss

Characteristics of ongoing studies [ordered by study ID]

ChiCTR2000035585 

Study name

Methods

Participants

A multi-center, randomized, single-blind controlled study on the regular use of medical emollients
in early birth to reduce the incidence and severity of atopic dermatitis in infants and young chil-
dren

Parrallel randomised controlled trial 

Target sample size: early intervention group: 188; long-term intervention group: 188; late interven-
tion group: 188; non-intervention group: 188

1. Newborn within 3 days of birth

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

105

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ChiCTR2000035585  (Continued)

Cochrane Database of Systematic Reviews

2. At least 1 first-degree relative (parent or sibling) diagnosed with atopic dermatitis, allergic rhinitis

or allergic asthma by clinical physician

3. Postnatal Apgar score at 10
4. Vital signs stable
5. Informed consent signed

Interventions

Early intervention arm: use medical emollients at least once a day from 3 days of birth until 6
months of age

Long-term intervention group: use medical emollients at least once a day from 3 days of birth until
12 months of age

Delayed intervention group: after 3 weeks of birth, use medical emollients at least once a day until
12 months of age

Non-intervention group: do not emphasise the use of emollients, use as needed

Outcomes

Starting date

Cumulative prevalence of atopic dermatitis within 1 year of age

Contact information

zryaoxh@sina.com 

Notes

CTRI/2020/03/023963 

Study name

Methods

Assessing the impact of topical sesame oil application on skin barrier function in neonates: a pilot
randomised controlled trial in Pune, India

Participants

Target sample size: 60

"All neonates born at the delivery unit of the study hospital will be eligible for this study except for
the defined exclusions"

Interventions

Topical application of sesame oil treated with herb Sida cordifolia within 2 hours after birth

Control: standard care is to not apply anything to the infant skin

Outcomes

Primary outcome: reduction in TEWL. Measured twice daily 12-hourly, until 7 days, or discharge if
earlier

Secondary outcome: the trend in change in bacterial colonisation at axillary, periumbilical, and
groin sites measured in log CFU/mL after intervention compared to baseline levels will be the sec-
ondary outcome at 2 hours after oil application, 24 hours, 48 hours

Starting date

Contact information

Unavailable 

Notes

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

106

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Eichner 2020 

Study name

A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE)

Methods

Pragmatic, multisite, randomised, community-based trial

Participants

Estimated enrolment: 1250

Interventions

Experimental: daily emollient

Parents assigned to the intervention arm will receive a lipid-rich emollient and educational mate-
rials promoting once-daily full-body emollient use until the infant is 24 months old. Parents will
select 1 of 5 emollients to be mailed to the dyad's home at enrolment and approximately every 6
months for the duration of the study. These emollients include (1) CeraVe Healing Ointment, (2)
Vaseline, (3) Cetaphil Cream, (4) CeraVe Cream, and (5) Vanicream.

Intervention: other: participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe
Healing Ointment, CeraVe Cream, Cetaphil Cream

Comparator: no intervention, natural skin

Parents assigned to the control arm will receive educational materials promoting general infant
skin care guidelines only and will be asked to refrain from emollient use unless dry skin develops
(current standard-of-care guidelines).

Outcomes

Primary outcome

Cumulative incidence of AD [Time Frame: 24 months]

Secondary outcomes

1. Parental report [Time Frame: 3, 6, 9, 12, 15, 18, and 24 months]
2. Children's Eczema Questionnaire [Time Frame: 12 and 24 months]
3. Sleep loss [Time Frame: 12 and 24 months]
4. Prescription topical skin medication [Time Frame: 3, 6, 9, 12, 15, 18, 21, and 24 months]
5. Asthma risk [Time Frame: 12 and 24 months]
6. Food allergy symptoms [Time Frame: 12 and 24 months]
7. Food allergy clinician diagnosed [Time Frame: 12 and 24 months]
8. Global Health Status [Time Frame: 12 and 24 months]
9. Atopic dermatitis severity 1 [Time Frame: 12 and 24 months]
10.Atopic dermatitis severity 2 [Time Frame: 12 and 24 months]
11.Atopic dermatitis severity 3 [Time Frame: 12 and 24 months]
12.Atopic dermatitis severity 4 [Time Frame: 12 and 24 months]
13.Atopic dermatitis severity 5 [Time Frame: 12 and 24 months]

Starting date

3 July 2018

Contact information

LeAnn Michaels; michaell@ohsu.edu
Clara Stemwedel; stemwedc@ohsu.edu

Notes

Jabbar-Lopez 2019 

Study name

Softened Water for Eczema Prevention Pilot Trial (SOFTER)

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

107

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jabbar-Lopez 2019  (Continued)

Methods

Assessor-blinded pilot randomised controlled trial

Participants

Estimated enrolment: N = 80

Interventions

Intervention group will have a domestic ion-exchange water softener installed before birth.

Comparator: usual hard water supply; control group will receive the usual domestic water supply

Outcomes

Primary outcome: 

1. Proportion of eligible families screened who are willing and able to be randomised [Time Frame:

before birth]

Secondary outcomes: 

1. Proportion with patient-reported, doctor-diagnosed eczema [Time Frame: by 6 months of age]
2. Proportion with visible eczema according to UK diagnostic criteria-based photographic protocol

[Time Frame: 4 weeks, 3 and 6 months]

3. Severity of eczema (if present) using Eczema Area and Severity Index (EASI) [Time Frame: 4 weeks,

3 and 6 months]

4. Patient-reported eczema symptoms (Patient-Orientated Eczema Measure (POEM)) [Time Frame:

monthly from 4 weeks to 6 months of age]

5. Time to onset of patient-reported doctor-diagnosed eczema [Time Frame: from birth to end of

follow-up (6 months of age)]

6. Proportion of participants with visible eczema status (yes/no) recorded [Time Frame: baseline, 4

weeks, 3 and 6 months]

7. Proportion with filaggrin (FLG) null mutations [Time Frame: at birth, 4 weeks, 3 and 6 months of

age]

8. Effect of FLG gene mutation status on TEWL, cytokine levels, natural moisturising factors levels,

and skin microbiota diversity [Time Frame: at birth, 4 weeks, 3 and 6 months of age]

Starting date

12 February 2018 to June 2019

Update July 2021. Still ongoing 

Contact information

Carsten Flohr; carsten.flohr@kcl.ac.uk

Notes

Lowe 2019 

Study name

PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy
and sensitisation in infants with a family history of allergic disease using a skin barrier improve-
ment strategy

Methods

Multicentre, phase III, outcome assessor-blinded, randomised controlled trial

Participants

Aim: to recruit 760 

Interventions

Intervention: 2 times per day treatment with EpiCeram (intervention group). EpiCeram has been
approved for use by patients with AD or eczema by the US Food and Drug Administration (FDA) but
does not yet have Australian Therapeutic Goods Administration (TGA) approval and is not currently
available in Australia. Parents will be instructed to apply approximately 6 g of EpiCeram per appli-
cation 2 times per day from birth until the infant is 6 months of age.

Comparator: standard skin care advice (control group) 

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

108

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lowe 2019  (Continued)

Cochrane Database of Systematic Reviews

Parents of children in the control group will be managed as per existing practice and will not be
given any emollients. For ethical reasons, parents of children in the control group will not be told to
withhold skin care from their infant, and information related to use of emollients will be collected
from all participants.

Compliance: a weekly diary will be completed online by parents, who will document the frequency
of EpiCeram application and use of any other creams 

Outcomes

Primary outcomes:

1. Presence of AD in the first 12 months of life assessed using UK Working Party criteria or visible AD

at the time of examinations, or both

2. Food allergy, based on skin prick tests, history of reactions, and food challenge at 12 months

Secondary outcomes: 

1. Adverse reaction to EpiCeram
2. Skin barrier function as assessed by TEWL at 6 weeks and 12 months
3. Food sensitisation (positive skin prick test) at 12 months of age
4. Presence of observed AD that first presents from 6 to 12 months (incident after intervention pe-

riod)

5. Presence of probable AD within first year of life based on parent report of doctor-diagnosed AD
6. IgE-associated AD (AD in the context of a positive skin prick test)
7. AD severity assessed using the Eczema Area and Severity Index (EASI)

Starting date

October 2015

Update July 2021. Delays secondary to COVID-19, results due end of 2022

Contact information

Adrian Lowe; lowea@unimelb.edu.au

Notes

NCT02906475 

Study name

Atopic Dermatitis in Atopy Predisposed Infants (ADAPI)

Methods

Randomised, pragmatic, parallel-group trial 

Participants

Aim: N = 160

Interventions

Compilation: standardised skin care regimen

Intervention: milk lotion will be applied once daily on the total body including the face by parents
or caregivers at home. If bathing is needed, the bathing addendum is used in addition to water.

Comparator: for the control group, no predetermined or standardised skin care regimen is pre-
scribed

Outcomes

Primary outcomes: 

1. Cumulative incidence of atopic dermatitis [Time Frame: 12 months]
2. Cumulative incidence of AD at week 52, with AD diagnosis based on criteria by Simpson and col-

leagues 2012

Secondary outcomes: 

1. Cumulative incidence of atopic dermatitis [Time Frame: 24 months]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

109

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02906475  (Continued)

Cochrane Database of Systematic Reviews

2. AD incidence density [Time Frame: 12 months]
3. AD incidence density [Time Frame: 24 months]
4. Eczema Area and Severity Index (EASI) [Time Frame: 12 months]
5. Eczema Area and Severity Index (EASI) [Time Frame: 24 months]
6. Infant Dermatitis Quality of Life (IDQoL) [Time Frame: 12 months]
7. Infant Dermatitis Quality of Life (IDQoL) [Time Frame: 24 months]
8. TEWL on the midvolar forearm [Time Frame: at ages 14 days, 1, 3, 6, 12 months, and 2 years]
9. Skin surface pH on the midvolar forearm [Time Frame: at ages 14 days, 1, 3, 6, 12 months, and 2

years]

10.Stratum corneum hydration on the forearm [Time Frame: at ages 14 days, 1, 3, 6, 12 months, and

2 years]

Starting date

Study start date: October 2016

Estimated study completion date: December 2020

Update July 2021. Delays secondary to COVID-19

Contact information

Stephanie Meyer; stephanie.meyer@hipp.de

Notes

NCT03142984 

Study name

Randomized controlled trial of gentle touch/early massage with a new wash and lotion regimen for
improved skin barrier strength, parental bonding, and physical development in newborn babies:
The Barrier Optimizing Skincare for Newborn Development (BOND) Trial

Methods

Randomised, single-group assignment 

Participants

150 participants

Interventions

Experimental: phase 1

An open-use test in a cohort of newborn babies to confirm tolerability and evaluate acceptability of
a new Baby Wash & Shampoo product and Baby Lotion

Baby Wash & Shampoo (F# 13217-070), Baby Lotion (F# 13217-071)

Experimental: phase 2

An evaluator-blind, randomised controlled trial to determine whether a wash and lotion regimen
used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skin
care practices without massage

Baby Wash & Shampoo (F# 13217-070), Baby Lotion (F# 13217-071), Alternative Baby Wash & Sham-
poo (GTIN/UPC # 5011451106260)

Outcomes

Primary outcomes: 

1. Change in neonatal skin condition score from baseline to 3 weeks [Time Frame: 3 weeks]
2. Change in TEWL from baseline to 12 weeks [Time Frame: 12 weeks]
3. Change in stratum corneum hydration (Corneometer) from baseline to 12 weeks [Time Frame: 12

weeks]

4. Number of adverse events reported related to investigational products [Time Frame: 3 weeks]

Secondary outcomes: 

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

110

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT03142984  (Continued)

Cochrane Database of Systematic Reviews

1. Product questionnaires [Time Frame: 3 weeks]
2. Change in neonatal skin condition score from baseline to 12 weeks [Time Frame: 12 weeks]
3. Change  in  stratum  corneum  surface  water  content  (ATR-FTIR)  from  baseline  to  12  weeks

[Time Frame: 12 weeks]

4. Change in stratum corneum lipid structure (ATR-FTIR) from baseline to 12 weeks [Time Frame: 12

weeks]

5. Change in stratum corneum carboxylate levels (ATR-FTIR, marker of natural moisturising factor

levels and filaggrin (FLG) expression) from baseline to 12 weeks [Time Frame: 12 weeks]

Starting date

4 July 2017 to 17 March 2021

Update July 2021. Estimated completion end of December 2022

Contact information

No contact details on clinical trials 

Notes

clinicaltrials.gov/ct2/show/NCT03142984

NCT03808532 

Study name

Moisturizer to Prevent Atopic Dermatitis (ACE-AD)

Methods

Randomised parallel assignment 

Participants

290 participants

Interventions

Experimental: high risk with moisturiser

No intervention: high risk without moisturiser

Outcomes

Primary outcomes:

1. Cumulative incidence of AD at 12 months of age in the intervention group compared to the control
group [Time Frame: 12 months]. Evaluated using UK refinement of Hanifin and Rajka diagnostic
criteria for atopic eczema and by parental report of a medical diagnosis of AD by the infant's pae-
diatrician and/or dermatologist

Secondary outcomes: 

1. Cumulative incidence of AD at 6 months of age in the intervention group compared to the control

group [Time Frame: 6 months]

2. Cumulative incidence of AD at 24 months of age in the intervention group compared to the control

group [Time Frame: 24 months]

3. Timing of onset of AD in the intervention group compared to the control group [Time Frame: 12

months]

4. Severity of AD in the intervention group compared to the control group [Time Frame: 12 months]
5. Cumulative incidence of food allergies at 12 months of age in the intervention group compared

to the control group [Time Frame: 12 months]

6. Cumulative incidence of food allergies at 24 months of age in the intervention group compared

to the control group [Time Frame: 24 months]

Starting date

June 2020

Update July 2021. Study withdrawn due to lack of funding.

Contact information

Michael Brandwein; michael@myor.me

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

111

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03808532  (Continued)

Notes

NCT03871998 

Study name

Short-term Topical Application to Prevent Atopic Dermatitis (STOP AD)

Methods

Single-centre, randomised, open-label, controlled study 

Participants

242 participants

Interventions

Experimental: intervention arm

Skin barrier protection in the first 2 months of life

No intervention: control arm

Standard skin care advice. No moisturiser in the first 2 months of life

Outcomes

Primary outcomes:

1. Cumulative incidence of atopic dermatitis at 12 months [Time Frame: 12 months]
2. Cumulative incidence of IgE-mediated food allergy at 2 years [Time Frame: 2 years]

Secondary outcomes:

1. Longitudinal changes in TEWL from birth to 12 months [Time Frame: birth to 12 months]
2. Longitudinal changes in natural moisturising factor (NMF) in the stratum corneum from birth to

12 months [Time Frame: birth to 12 months]

3. Microbial  diversity  and  richness  of 

(study  sub-
set) [Time Frame: skin swabs for microbiome analysis will be taken at baseline (0 to 4 days), 8
weeks, and 12 months]

the  cheek  and  antecubital 

fossa 

4. Changes in skin microbial diversity and richness over the first year of life [Time Frame: skin swabs

for microbiome analysis will be taken at baseline (0 to 4 days), 8 weeks, and 12 months]

5. Comparison  of  microbial  diversity  and  richness  between  intervention  and  control  groups
[Time Frame: skin swabs for microbiome analysis will be taken at baseline (0 to 4 days), 8 weeks,
and 12 months]

6. Skin  biomarker  profile  analysis  of 

(study  sub-
set) [Time Frame: skin swabs for biomarker analysis will be taken at baseline (0 to 4 days), 8 weeks,
and 12 months]

the  cheek  and  antecubital 

fossa 

7. Changes in skin biomarker profile between studies over the first year of life [Time Frame: skin
swabs for biomarker analysis will be taken at baseline (0 to 4 days), 8 weeks, and 12 months]
profiles 

control
groups [Time Frame: skin swabs for biomarker analysis will be taken at baseline (0 to 4 days), 8
weeks, and 12 months]

8. Comparison 

intervention 

biomarker 

between 

skin 

and 

of 

Starting date

12 March 2019

Update July 2021. Recruitment completed, study ongoing.

Contact information

Carol Ní Chaoimh; cnichaoimh@ucc.ie

Mairead Murray; mairead.murray@ucc.ie

Notes

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

112

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT04398758 

Study name

Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood (MOPAD)

Methods

Randomised controlled trial 

Participants

Healthy newborns, < 3 weeks of age, 1 first-degree relative with medically diagnosed AD

N = 360

Interventions

"SanaCutan Basiscreme" applied all over body twice daily for 6 months (main phase) or 12 months
(follow-up phase)

Outcomes

Cumulative incidence of children with atopic dermatitis at 6 months of age

Starting date

21 May 2020

Update 2021. Estimated completion date December 2023

Contact information

Dr Wehran; studien@infectopharm.com  

PI Dr Kristen Beyer, Charité University, Berlin, Germany

Notes

TCTR20200630006 

Study name

Effect of emollient on newborn skin from birth in the prevention of atopic eczema: a randomized
control study in Thai neonates

Methods

Randomised controlled trial 

Participants

154 infants between 1 and 21 days old 

Inclusion criteria:

1. 1st degree relative with 1 of allergic diseases of atopic dermatitis, asthma, or allergic rhinitis
2. Full term born infant; gestational age > 37 weeks
3. Healthy full term infant with no complication after birth

Interventions

Experimental: applying moisturiser

Comparator: no treatment

Outcomes

Starting date

The occurrence of atopic dermatitis diagnosis at 6 months 

Contact information

leelawadee@kku.ac.th

Notes

AD: atopic dermatitis
ATR-FTIR: attenuated total reflectance-Fourier transform infrared
CFU: colony-forming units
IgE: immunoglobulin E
TEWL: transepidermal water loss

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

113

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

R I S K   O F   B I A S

Legend:   

  Low risk of bias    

  High risk of bias    

  Some concerns   

Risk of bias for analysis 1.1 Eczema by 1 to 3 years

Bias

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

Lowe 2018a

McClanahan 2019

NCT03376243

Skjerven 2020

Yonezawa 2018

Risk of bias for analysis 1.2 Sensitivity analysis: Eczema by 1 to 3 years including aggregate trial data

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

Lowe 2018a

McClanahan 2019

Migacheva 2018

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

114

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

NCT03376243

Skjerven 2020

Yonezawa 2018

Risk of bias for analysis 1.3 Sensitivity analysis: Eczema by 1 to 3 years (UKWP only)

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

Lowe 2018a

McClanahan 2019

NCT03376243

Skjerven 2020

Risk of bias for analysis 1.4 Sensitivity analysis: Eczema by 1 to 3 years (including data from all 4 arms of PreventADALL)

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

115

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Lowe 2018a

McClanahan 2019

NCT03376243

Skjerven 2020

Yonezawa 2018

Risk of bias for analysis 1.5 Sensitivity analysis: Eczema by 1 to 3 years (using PreventADALL 36-month outcome)

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

Lowe 2018a

McClanahan 2019

NCT03376243

Skjerven 2020

Yonezawa 2018

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

116

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias for analysis 1.6 Sensitivity analysis: Eczema by 1 to 3 years - low risk of bias

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

Lowe 2018a

Risk of bias for analysis 1.7 Sensitivity analysis: Eczema by 1 to 3 years - excluding non-prospectively acquired data

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

McClanahan 2019

NCT03376243

Skjerven 2020

Yonezawa 2018

Risk of bias for analysis 1.8 Sensitivity analysis: Eczema by 6 months to 3 years

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

117

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Horimukai 2014

Lowe 2018a

McClanahan 2019

NCT03376243

Simpson 2014

Skjerven 2020

Yonezawa 2018

Risk of bias for analysis 1.10 Subgroup analysis (study level): Eczema by 1 to 3 years by intervention type

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 1.10.1 Basic emolient

Chalmers 2020

McClanahan 2019

Skjerven 2020

Subgroup 1.10.2 Complex emolient

Dissanayake 2019

Lowe 2018a

NCT03376243

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

118

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Yonezawa 2018

Risk of bias for analysis 1.11 Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention duration 

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 1.11.1 Intervention prescribed for <6 months

Yonezawa 2018

Subgroup 1.11.2 Intervention prescribed for ≥6 months

Chalmers 2020

Dissanayake 2019

Lowe 2018a

McClanahan 2019

NCT03376243

Skjerven 2020

Risk of bias for analysis 1.12 Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention timing

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 1.12.1 Intervention prescribed to start in first week of life

Chalmers 2020

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

119

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Dissanayake 2019

Lowe 2018a

McClanahan 2019

NCT03376243

Yonezawa 2018

Subgroup 1.12.2 Intervention prescribed to start after first week of life

Skjerven 2020

Risk of bias for analysis 1.33 Food allergy by 1 to 3 years

Bias

Study

Chalmers 2020

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Risk of bias for analysis 1.34 Sensitivity analysis: Food allergy by 1 to 3 years (diagnosed by oral food challenge or investigator
assessment)

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Chalmers 2020

Skjerven 2020

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

120

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias for analysis 1.45 Adverse event: skin infection

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Cooke 2015

Lowe 2018a

McClanahan 2019

Simpson 2014

Skjerven 2020

Risk of bias for analysis 1.46 Adverse event: stinging or allergic reaction to moisturisers

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Cooke 2015

Lowe 2018a

McClanahan 2019

NCT03376243

Risk of bias for analysis 1.47 Adverse event: slippage accidents

Bias

Study

Chalmers 2020

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

121

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Lowe 2018a

Simpson 2014

Skjerven 2020

Risk of bias for analysis 1.48 Serious adverse events

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Cooke 2015

Lowe 2018a

Skjerven 2020

Risk of bias for analysis 1.53 Time to onset of eczema

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

Horimukai 2014

Lowe 2018a

McClanahan 2019

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

122

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

NCT03376243

Simpson 2014

Skjerven 2020

Yonezawa 2018

Risk of bias for analysis 1.54 Subgroup analysis: Time to onset of eczema (< 1-year follow-up versus ≥ 1-year follow-up)

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 1.54.1 Follow-up ≥ 1 year

Chalmers 2020

Dissanayake 2019

Lowe 2018a

McClanahan 2019

NCT03376243

Skjerven 2020

Yonezawa 2018

Subgroup 1.54.2 Follow-up < 1 year

Horimukai 2014

Simpson 2014

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

123

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias for analysis 1.55 Parent report of immediate (< 2 hours) reaction to a known common food allergen

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Chalmers 2020

NCT03376243

Risk of bias for analysis 1.59 Allergic sensitisation to common foods or inhalants at 1 to 3 years

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Chalmers 2020

Lowe 2018a

Risk of bias for analysis 1.60 Allergic sensitisation to common foods at 1 to 3 years

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Chalmers 2020

Lowe 2018a

Skjerven 2020

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

124

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias for analysis 1.65 Sensitivity analysis: Allergic sensitisation to common foods at 6 months to 3 years

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Chalmers 2020

Dissanayake 2019

Horimukai 2014

Lowe 2018a

Skjerven 2020

D A T A   A N D   A N A L Y S E S

Comparison 1.   Skin care intervention versus standard skin care or no skin care intervention

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1 Eczema by 1 to 3 years

1.2 Sensitivity analysis: Eczema by 1 to 3 years
including aggregate trial data

1.3 Sensitivity analysis: Eczema by 1 to 3 years
(UKWP only)

1.4 Sensitivity analysis: Eczema by 1 to 3 years
(including data from all 4 arms of Preven-
tADALL)

1.5 Sensitivity analysis: Eczema by 1 to 3 years
(using PreventADALL 36-month outcome)

1.6 Sensitivity analysis: Eczema by 1 to 3 years -
low risk of bias

1.7 Sensitivity analysis: Eczema by 1 to 3 years -
excluding non-prospectively acquired data

1.8 Sensitivity analysis: Eczema by 6 months to
3 years

7

8

6

7

7

3

6

9

3075

3135

2919

4176

3076

1739

3001

3223

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

1.03 [0.81, 1.31]

0.97 [0.75, 1.25]

1.02 [0.78, 1.34]

1.03 [0.81, 1.31]

1.00 [0.88, 1.14]

0.97 [0.81, 1.17]

1.08 [0.84, 1.37]

0.89 [0.70, 1.14]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

125

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.9 Sensitivity analysis: Eczema after the inter-
vention period (at 1 year or beyond - up to 3
years) 

1.10 Subgroup analysis (study level): Eczema
by 1 to 3 years by intervention type

1.10.1 Basic emolient

1.10.2 Complex emolient

1.11 Subgroup analysis (study level): Eczema
by 1 to 3 years by prescribed intervention dura-
tion 

1.11.1 Intervention prescribed for <6 months

1.11.2 Intervention prescribed for ≥6 months

1.12 Subgroup analysis (study level): Eczema
by 1 to 3 years by prescribed intervention tim-
ing

1.12.1 Intervention prescribed to start in first
week of life

1.12.2 Intervention prescribed to start after first
week of life

1.13 Participant-level treatment interaction:
Eczema by 1 to 3 years for treatment initiation
< 4 days versus ≥ 4 days of age

1.14 Participant-level treatment interaction:
Eczema by 6 months to 3 years for treatment
initiation < 4 days versus ≥ 4 days of age

1.15 Participant-level treatment interaction:
Eczema by 1 to 3 years by FLG genotype (0 mu-
tations versus 1/2 mutations)

1.16 Participant-level treatment interaction:
Eczema by 6 months to 3 years by FLG geno-
type (0 mutations versus 1/2 mutations)

1.17 Participant-level treatment interaction:
Eczema by 1 to 3 years by chromosome 11 sta-
tus (C:C versus C:T or T:T)

1.18 Participant-level treatment interaction:
Eczema by 1 to 3 years by FLG mutation and
chromosome 11 status (no FLG and C:C versus

4

7

3

4

7

1

6

7

6

1

2

3

3

4

2

2

2511

3075

2341

734

3075

156

2919

3075

2004

1071

1284

1383

1716

1779

1807

1644

Risk Ratio (IV, Ran-
dom, 95% CI)

1.00 [0.87, 1.16]

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

1.03 [0.81, 1.31]

1.04 [0.66, 1.65]

1.01 [0.75, 1.37]

1.03 [0.81, 1.31]

1.01 [0.45, 2.26]

1.02 [0.78, 1.34]

1.03 [0.81, 1.31]

0.95 [0.81, 1.12]

1.57 [1.10, 2.23]

1.05 [0.64, 1.73]

Risk Ratio (IV, Ran-
dom, 95% CI)

1.59 [0.56, 4.51]

Risk Ratio (IV, Ran-
dom, 95% CI)

1.08 [0.69, 1.70]

Risk Ratio (IV, Ran-
dom, 95% CI)

1.03 [0.66, 1.61]

Risk Ratio (IV, Ran-
dom, 95% CI)

1.31 [0.85, 2.03]

Risk Ratio (IV, Ran-
dom, 95% CI)

1.24 [0.72, 2.12]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

126

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

FLG mutation and/or chromosome 11 C:T or
T:T)

1.19 Participant-level treatment interaction:
Eczema by 1 to 3 years by ≥ 1 first-degree rela-
tive with history of allergic disease 

1.20 Participant-level treatment interaction:
Eczema by 1 to 3 years by ≥ 1 first-degree rela-
tive with history of allergic disease and/or FLG
genotype (0 mutations versus 1/2 mutations)

1.21 CACE: Eczema by 1 to 3 years for use over
intervention period ≥ 3 days a week

1.22 CACE sensitivity: Eczema by 1 to 3 years for
use over intervention period ≥ 5 days a week

1.23 CACE sensitivity: Eczema by 1 to 3 years for
use over intervention period 7 days  a week 

1.24 CACE sensitivity: Eczema by 1 to 3 years for
use over first 3 months  ≥ 3 days a week

1.25 CACE sensitivity: Eczema by 1 to 3 years for
use over first 3 months  ≥ 5 days a week

1.26 CACE sensitivity: Eczema by 1 to 3 years for
use over first 3 months 7 days a week

1.27 Sensitivity analysis: Eczema by 1 to 3 years
for studies included in CACE for use over inter-
vention period ≥ 3 days a week

1.28 Sensitivity analysis: Eczema by 1 to 3 years
for studies included in CACE for use over inter-
vention period ≥ 5 days a week

1.29 Sensitivity analysis: Eczema by 1 to 3 years
for studies included in CACE for use over inter-
vention period 7 days a week

1.30 Sensitivity analysis: Eczema by 1 to 3 years
for studies included in CACE for use over first 3
months ≥ 3 days a week

1.31 Sensitivity analysis: Eczema by 1 to 3 years
for studies included in CACE for use over first 3
months ≥ 5 days a week

1.32 Sensitivity analysis: Eczema by 1 to 3 years
for studies included in CACE for use over first 3
months 7 days a week

1.33 Food allergy by 1 to 3 years

3

1

3

2

3

2

2

3

3

2

3

2

2

3

1

1663

1065

1440

1366

1415

1366

1366

1415

1440

1366

1415

1366

1366

1415

Risk Ratio (IV, Ran-
dom, 95% CI)

0.95 [0.35, 2.61]

Risk Ratio (IV, Ran-
dom, 95% CI)

0.62 [0.16, 2.44]

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

0.65 [0.29, 1.45]

0.74 [0.26, 2.09]

0.78 [0.23, 2.71]

1.02 [0.79, 1.31]

0.84 [0.46, 1.52]

0.83 [0.34, 2.03]

0.93 [0.77, 1.12]

Risk Ratio (IV, Ran-
dom, 95% CI)

0.95 [0.79, 1.15]

Risk Ratio (IV, Ran-
dom, 95% CI)

0.95 [0.79, 1.15]

Risk Ratio (IV, Ran-
dom, 95% CI)

0.95 [0.79, 1.15]

Risk Ratio (IV, Ran-
dom, 95% CI)

0.95 [0.79, 1.15]

Risk Ratio (IV, Ran-
dom, 95% CI)

0.95 [0.79, 1.15]

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

127

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.34 Sensitivity analysis: Food allergy by 1 to 3
years (diagnosed by oral food challenge or in-
vestigator assessment)

1.35 Sensitivity analysis: Food allergy by 1 to 3
years (parent report of doctor diagnosis)

1.36 Participant-level treatment interaction:
Food allergy by 1 to 3 years (diagnosed by oral
food challenge or investigator assessment)
by FLG genotype (0 mutations versus 1/2 muta-
tions)

1.37 Participant-level treatment interaction:
Food allergy by 1 to 3 years (diagnosed by oral
food challenge or investigator assessment) by
chromosome 11 status (C:C versus C:T or T:T)

1.38 Participant-level treatment interaction:
Food allergy by 1 to 3 years (diagnosed by oral
food challenge or investigator assessment) by
FLG mutation and chromosome 11 status (no
FLG and C:C versus FLG mutation and/or chro-
mosome 11 C:T or T:T)

1.39 CACE: Food allergy (oral food challenge or
panel assessment) by 1 to 3 years for use over
intervention period ≥ 3 days a week

1.40 CACE sensitivity: Food allergy (oral food
challenge or panel assessment) by 1 to 3 years
for use over intervention period ≥ 5 days a
week

1.41 CACE sensitivity: Food allergy (oral food
challenge or panel assessment) by 1 to 3 years
for use over intervention period 7 days a week

1.42 CACE sensitivity: Food allergy (oral food
challenge or panel assessment) by 1 to 3 years-
 for use over first 3 months ≥ 3 days a week

1.43 CACE sensitivity: Food allergy (oral food
challenge or panel assessment) by 1 to 3 years-
 for use over first 3 months  ≥ 5 days a week

1.44 CACE sensitivity: Food allergy (oral food
challenge or panel assessment) by 1 to 3 years-
 for use over first 3 months 7 days a week

1.45 Adverse event: skin infection

1.46 Adverse event: stinging or allergic reaction
to moisturisers

2

3

2

2

2

1

1

1

1

1

1

6

4

2030

1614

1517

1650

1492

Risk Ratio (IV, Ran-
dom, 95% CI)

1.45 [0.98, 2.15]

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

1.02 [0.80, 1.31]

1.29 [0.41, 4.08]

Risk Ratio (IV, Ran-
dom, 95% CI)

1.59 [0.63, 4.01]

Risk Ratio (IV, Ran-
dom, 95% CI)

1.67 [0.57, 4.93]

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

2728

343

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

1.33 [1.01, 1.75]

2.24 [0.67, 7.43]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

128

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.47 Adverse event: slippage accidents

1.48 Serious adverse events

1.49 Clinician-assessed eczema severity at
1 to 3 years (clear/mild versus moderate/se-
vere/very severe)

1.50 Clinician-assessed eczema severity at 1 to
3 years (standardised mean difference)

1.51 Parent-reported eczema severity at 1 to 3
years (clear/mild versus moderate/severe/very
severe)

1.52 Parent-reported eczema severity at 1 to 3
years (mean difference)

1.53 Time to onset of eczema

1.54 Subgroup analysis: Time to onset of
eczema (< 1-year follow-up versus ≥ 1-year fol-
low-up)

1.54.1 Follow-up ≥ 1 year

1.54.2 Follow-up < 1 year

1.55 Parent report of immediate (< 2 hours) re-
action to a known common food allergen

1.56 Parent report of immediate (< 2 hours) re-
action to milk

1.57 Parent report of immediate (< 2 hours) re-
action to egg

1.58 Parent report of immediate (< 2 hours) re-
action to peanut

1.59 Allergic sensitisation to common foods or
inhalants at 1 to 3 years

1.60 Allergic sensitisation to common foods at
1 to 3 years

1.61 Allergic sensitisation to milk at 1 to 3 years

4

3

3

3

1

1

9

9

7

2

2

1

1

1

2

3

3

2538

1367

1228

3349

3349

3125

224

1058

1794

1794

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

1.42 [0.67, 2.99]

1.80 [0.45, 7.18]

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Std. Mean Difference
(IV, Random, 95% CI)

-0.02 [-0.17, 0.12]

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Mean Difference (IV,
Random, 95% CI)

Totals not select-
ed

Hazard Ratio (IV,
Random, 95% CI)

Hazard Ratio (IV,
Random, 95% CI)

Hazard Ratio (IV,
Random, 95% CI)

Hazard Ratio (IV,
Random, 95% CI)

0.86 [0.65, 1.14]

0.86 [0.65, 1.14]

1.00 [0.75, 1.33]

0.55 [0.35, 0.87]

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Risk Ratio (IV, Ran-
dom, 95% CI)

Totals not select-
ed

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

1.09 [0.72, 1.66]

1.05 [0.64, 1.71]

1.16 [0.55, 2.43]

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

129

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.62 Allergic sensitisation to egg at 1 to 3 years

1.63 Allergic sensitisation to peanut at 1 to 3
years

1.64 Allergic sensitisation to inhalants at 1 to 3
years

1.65 Sensitivity analysis: Allergic sensitisation
to common foods at 6 months to 3 years

1.66 Sensitivity analysis: Allergic sensitisation
to milk at 6 months to 3 years

1.67 Sensitivity analysis: Allergic sensitisation
to egg at 6 months to 3 years

1.68 Sensitivity analysis: Allergic sensitisation
to peanut at 6 months to 3 years

3

3

2

5

5

5

4

1797

1804

1061

2344

2342

2345

1892

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

Risk Ratio (IV, Ran-
dom, 95% CI)

0.92 [0.42, 2.00]

1.08 [0.68, 1.71]

1.09 [0.76, 1.57]

1.08 [0.92, 1.27]

0.84 [0.59, 1.21]

1.11 [0.94, 1.30]

1.08 [0.68, 1.71]

Analysis 1.1.   Comparison 1: Skin care intervention versus standard skin
care or no skin care intervention, Outcome 1: Eczema by 1 to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

612
223
36
29
27
572
87

32.1%
20.7%
7.1%
6.3%
4.5%
21.8%
7.4%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.60 [0.26 , 1.37]
0.54 [0.22 , 1.31]
0.86 [0.29 , 2.53]
1.57 [1.10 , 2.23]
1.01 [0.45 , 2.26]

1586

100.0%

1.03 [0.81 , 1.31]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Risk of Bias
E
B

C

D

+
+
+
+
+
+
+

+
+
+
?
?
?
?

+
+
+
+
+
+
?

+
+
+
+
+
+
+

A

+
+
+
+
+
+
+

F

+
+
+
?
?
?
?

Chalmers 2020
Dissanayake 2019
Lowe 2018a
McClanahan 2019
NCT03376243
Skjerven 2020
Yonezawa 2018

-0.05
0.14
-0.51
-0.61
-0.15
0.45
0.01

0.1
0.19
0.42
0.45
0.55
0.18
0.41

598
232
38
31
22
499
69

Total (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 10.20, df = 6 (P = 0.12); I² = 41%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable

1489

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

130

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.2.   Comparison 1: Skin care intervention versus standard skin care or no skin care
intervention, Outcome 2: Sensitivity analysis: Eczema by 1 to 3 years including aggregate trial data

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

612
223
36
29
31
27
572
87

27.2%
19.3%
7.5%
6.8%
6.3%
4.9%
20.1%
7.8%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.60 [0.26 , 1.37]
0.54 [0.22 , 1.31]
0.44 [0.18 , 1.12]
0.86 [0.29 , 2.53]
1.57 [1.10 , 2.23]
1.01 [0.45 , 2.26]

1617

100.0%

0.97 [0.75 , 1.25]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Chalmers 2020
Dissanayake 2019
Lowe 2018a
McClanahan 2019
Migacheva 2018 (1)
NCT03376243
Skjerven 2020
Yonezawa 2018

-0.05
0.14
-0.51
-0.61
-0.81
-0.15
0.45
0.01

0.1
0.19
0.42
0.45
0.47
0.55
0.18
0.41

598
232
38
31
29
22
499
69

Total (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 13.36, df = 7 (P = 0.06); I² = 48%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable

1518

Footnotes
(1) Aggregate trial data (unadjusted)

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Chalmers 2020
Dissanayake 2019
Lowe 2018a
McClanahan 2019
NCT03376243
Skjerven 2020

-0.05
0.14
-0.51
-0.61
-0.15
0.45

0.1
0.19
0.42
0.45
0.55
0.18

598
232
38
31
22
499

Total (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 10.19, df = 5 (P = 0.07); I² = 51%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable

1420

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Analysis 1.3.   Comparison 1: Skin care intervention versus standard skin care or no skin
care intervention, Outcome 3: Sensitivity analysis: Eczema by 1 to 3 years (UKWP only)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

612
223
36
29
27
572

32.3%
22.5%
8.5%
7.7%
5.5%
23.5%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.60 [0.26 , 1.37]
0.54 [0.22 , 1.31]
0.86 [0.29 , 2.53]
1.57 [1.10 , 2.23]

1499

100.0%

1.02 [0.78 , 1.34]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Risk of Bias
E
B

C

D

+
+
+
+
?
+
+
+

+
+
+
?
?
?
?
?

+
+
+
+
?
+
+
?

+
+
+
+
?
+
+
+

A

+
+
+
+
?
+
+
+

Risk of Bias
E
B

D

C

+
+
+
+
+
+

+
+
+
?
?
?

+
+
+
+
+
+

+
+
+
+
+
+

A

+
+
+
+
+
+

F

+
+
+
?
?
?
?
?

F

+
+
+
?
?
?

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

131

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.4.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 4: Sensitivity analysis: Eczema by 1 to 3 years (including data from all 4 arms of PreventADALL)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Dissanayake 2019
Lowe 2018a
McClanahan 2019
NCT03376243
Skjerven 2020
Yonezawa 2018

-0.05
0.14
-0.51
-0.61
-0.15
0.45
0.01

0.1
0.19
0.42
0.45
0.55
0.18
0.41

598
232
38
31
22
1003
69

Total (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 10.20, df = 6 (P = 0.12); I² = 41%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable

1993

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

612
223
36
29
27
1169
87

32.1%
20.7%
7.1%
6.3%
4.5%
21.8%
7.4%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.60 [0.26 , 1.37]
0.54 [0.22 , 1.31]
0.86 [0.29 , 2.53]
1.57 [1.10 , 2.23]
1.01 [0.45 , 2.26]

2183

100.0%

1.03 [0.81 , 1.31]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.5.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 5: Sensitivity analysis: Eczema by 1 to 3 years (using PreventADALL 36-month outcome)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

598
232
38
31
22
499
69

612
223
36
29
27
573
87

43.4%
12.0%
2.5%
2.1%
1.4%
35.9%
2.6%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.60 [0.26 , 1.37]
0.54 [0.22 , 1.31]
0.86 [0.29 , 2.53]
1.09 [0.88 , 1.36]
1.01 [0.45 , 2.26]

1489

1587

100.0%

1.00 [0.88 , 1.14]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Chalmers 2020
Dissanayake 2019
Lowe 2018a
McClanahan 2019
NCT03376243
Skjerven 2020
Yonezawa 2018

-0.05
0.14
-0.51
-0.61
-0.15
0.09
0.01

0.1
0.19
0.42
0.45
0.55
0.11
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.85, df = 6 (P = 0.56); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)
Test for subgroup differences: Not applicable

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Risk of Bias
E
B

C

D

+
+
+
+
+
+
+

+
+
+
?
?
?
?

+
+
+
+
+
+
?

+
+
+
+
+
+
+

A

+
+
+
+
+
+
+

F

+
+
+
?
?
?
?

Risk of Bias
E
B

D

C

+
+
+
+
+
+
+

+
+
+
?
?
?
?

+
+
+
+
+
+
?

+
+
+
+
+
+
+

A

+
+
+
+
+
+
+

F

+
+
+
?
?
?
?

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

132

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.6.   Comparison 1: Skin care intervention versus standard skin care or no skin
care intervention, Outcome 6: Sensitivity analysis: Eczema by 1 to 3 years - low risk of bias

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

598
232
38

868

612
223
36

71.4%
23.5%
5.1%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.60 [0.26 , 1.37]

871

100.0%

0.97 [0.81 , 1.17]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Chalmers 2020
Dissanayake 2019
Lowe 2018a

-0.05
0.14
-0.51

0.1
0.19
0.42

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.15, df = 2 (P = 0.34); I² = 7%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Chalmers 2020
Dissanayake 2019
McClanahan 2019
NCT03376243
Skjerven 2020
Yonezawa 2018

-0.05
0.14
-0.61
-0.15
0.45
0.01

0.1
0.19
0.45
0.55
0.18
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 8.45, df = 5 (P = 0.13); I² = 41%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Analysis 1.7.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 7: Sensitivity analysis: Eczema by 1 to 3 years - excluding non-prospectively acquired data

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

598
232
31
22
499
69

612
223
29
27
572
87

35.6%
22.2%
6.5%
4.6%
23.4%
7.6%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.54 [0.22 , 1.31]
0.86 [0.29 , 2.53]
1.57 [1.10 , 2.23]
1.01 [0.45 , 2.26]

1451

1550

100.0%

1.08 [0.84 , 1.37]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Risk of Bias
E
B

C

D

+
+
+

+
+
+

+
+
+

+
+
+

A

+
+
+

F

+
+
+

Risk of Bias
E
B

D

C

+
+
+
+
+
+

+
+
?
?
?
?

+
+
+
+
+
?

+
+
+
+
+
+

A

+
+
+
+
+
+

F

+
+
?
?
?
?

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

133

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.8.   Comparison 1: Skin care intervention versus standard skin care or no
skin care intervention, Outcome 8: Sensitivity analysis: Eczema by 6 months to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Dissanayake 2019
Horimukai 2014
Lowe 2018a
McClanahan 2019
NCT03376243
Simpson 2014
Skjerven 2020
Yonezawa 2018

-0.05
0.14
-0.43
-0.51
-0.61
-0.15
-0.6
0.45
0.01

0.1
0.19
0.22
0.42
0.45
0.55
0.3
0.18
0.41

598
232
50
38
31
22
22
499
69

Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 17.85, df = 8 (P = 0.02); I² = 55%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable

1561

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

612
223
49
36
29
27
27
572
87

20.9%
15.5%
13.9%
6.5%
5.9%
4.3%
10.1%
16.1%
6.7%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.65 [0.42 , 1.00]
0.60 [0.26 , 1.37]
0.54 [0.22 , 1.31]
0.86 [0.29 , 2.53]
0.55 [0.30 , 0.99]
1.57 [1.10 , 2.23]
1.01 [0.45 , 2.26]

1662

100.0%

0.89 [0.70 , 1.14]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.9.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 9: Sensitivity analysis: Eczema after the intervention period (at 1 year or beyond - up to 3 years) 

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

598
37
499
69

612
36
573
87

52.4%
1.2%
43.3%
3.1%

0.95 [0.78 , 1.16]
0.47 [0.13 , 1.72]
1.09 [0.88 , 1.36]
1.01 [0.45 , 2.26]

1203

1308

100.0%

1.00 [0.87 , 1.16]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Chalmers 2020
Lowe 2018a
Skjerven 2020
Yonezawa 2018

-0.05
-0.75
0.09
0.01

0.1
0.66
0.11
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.21, df = 3 (P = 0.53); I² = 0%
Test for overall effect: Z = 0.06 (P = 0.96)
Test for subgroup differences: Not applicable

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Risk of Bias
E
B

D

C

+
+
+
+
+
+
+
+
+

+
+
+
+
?
?
?
?
?

+
+
+
+
+
+
+
+
?

+
+
+
+
+
+
+
+
+

A

+
+
+
+
+
+
+
+
+

F

+
+
+
+
?
?
?
?
?

Risk of Bias
E
B

D

C

+
+
+
+

+
+
?
?

+
+
+
?

+
+
+
+

A

+
+
+
+

F

+
+
?
?

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

134

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.10.   Comparison 1: Skin care intervention versus standard skin care or no skin care
intervention, Outcome 10: Subgroup analysis (study level): Eczema by 1 to 3 years by intervention type

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Risk of Bias
E
B

D

C

+
+
+

+
?
?

+
+
+

+
+
+

A

+
+
+

+
+
+
+

+
+
+
+

+
+
?
?

+
+
+
?

+
+
+
+

F

+
?
?

+
+
?
?

612
29
572
1213

32.1%
6.3%
21.8%
60.3%

0.95 [0.78 , 1.16]
0.54 [0.22 , 1.31]
1.57 [1.10 , 2.23]
1.04 [0.66 , 1.65]

223
36
27
87
373

20.7%
7.1%
4.5%
7.4%
39.7%

1.15 [0.79 , 1.67]
0.60 [0.26 , 1.37]
0.86 [0.29 , 2.53]
1.01 [0.45 , 2.26]
1.01 [0.75 , 1.37]

1586

100.0%

1.03 [0.81 , 1.31]

1.10.1 Basic emolient
Chalmers 2020
McClanahan 2019
Skjerven 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.11; Chi² = 8.08, df = 2 (P = 0.02); I² = 75%
Test for overall effect: Z = 0.18 (P = 0.86)

-0.05
-0.61
0.45

0.1
0.45
0.18

1.10.2 Complex emolient
Dissanayake 2019
Lowe 2018a
NCT03376243
Yonezawa 2018
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.09, df = 3 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.08 (P = 0.93)

0.14
-0.51
-0.15
0.01

0.19
0.42
0.55
0.41

598
31
499
1128

232
38
22
69
361

Total (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 10.20, df = 6 (P = 0.12); I² = 41%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.92), I² = 0%

1489

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.11.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 11: Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention duration 

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

A

Risk of Bias
E
B

D

C

F

1.11.1 Intervention prescribed for <6 months
Yonezawa 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.02 (P = 0.98)

0.41

0.01

69
69

87
87

7.4%
7.4%

1.01 [0.45 , 2.26]
1.01 [0.45 , 2.26]

+

+

?

?

+

?

1.11.2 Intervention prescribed for ≥6 months
Chalmers 2020
Dissanayake 2019
Lowe 2018a
McClanahan 2019
NCT03376243
Skjerven 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 10.19, df = 5 (P = 0.07); I² = 51%
Test for overall effect: Z = 0.16 (P = 0.87)

-0.05
0.14
-0.51
-0.61
-0.15
0.45

0.1
0.19
0.42
0.45
0.55
0.18

598
232
38
31
22
499
1420

Total (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 10.20, df = 6 (P = 0.12); I² = 41%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.98), I² = 0%

1489

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

612
223
36
29
27
572
1499

32.1%
20.7%
7.1%
6.3%
4.5%
21.8%
92.6%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.60 [0.26 , 1.37]
0.54 [0.22 , 1.31]
0.86 [0.29 , 2.53]
1.57 [1.10 , 2.23]
1.02 [0.78 , 1.34]

1586

100.0%

1.03 [0.81 , 1.31]

+
+
+
+
+
+

+
+
+
+
+
+

+
+
+
?
?
?

+
+
+
+
+
+

+
+
+
+
+
+

+
+
+
?
?
?

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

135

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.12.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 12: Subgroup analysis (study level): Eczema by 1 to 3 years by prescribed intervention timing

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

1.12.1 Intervention prescribed to start in first week of life
Chalmers 2020
Dissanayake 2019
Lowe 2018a
McClanahan 2019
NCT03376243
Yonezawa 2018
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.80, df = 5 (P = 0.58); I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)

-0.05
0.14
-0.51
-0.61
-0.15
0.01

0.1
0.19
0.42
0.45
0.55
0.41

1.12.2 Intervention prescribed to start after first week of life
0.45
Skjerven 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.50 (P = 0.01)

0.18

598
232
38
31
22
69
990

499
499

612
223
36
29
27
87
1014

32.1%
20.7%
7.1%
6.3%
4.5%
7.4%
78.2%

0.95 [0.78 , 1.16]
1.15 [0.79 , 1.67]
0.60 [0.26 , 1.37]
0.54 [0.22 , 1.31]
0.86 [0.29 , 2.53]
1.01 [0.45 , 2.26]
0.95 [0.81 , 1.12]

572
572

21.8%
21.8%

1.57 [1.10 , 2.23]
1.57 [1.10 , 2.23]

+

+

?

+

+

?

Risk of Bias
E
B

C

D

+
+
+
+
+
+

+
+
+
?
?
?

+
+
+
+
+
?

+
+
+
+
+
+

A

+
+
+
+
+
+

F

+
+
+
?
?
?

Total (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 10.20, df = 6 (P = 0.12); I² = 41%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi² = 6.40, df = 1 (P = 0.01), I² = 84.4%

1489

1586

100.0%

1.03 [0.81 , 1.31]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Analysis 1.13.   Comparison 1: Skin care intervention versus standard skin care or
no skin care intervention, Outcome 13: Participant-level treatment interaction:
Eczema by 1 to 3 years for treatment initiation < 4 days versus ≥ 4 days of age

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Control
Total

Weight

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Lowe 2018a

0.07
-0.28

0.26
1.1

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.10, df = 1 (P = 0.76); I² = 0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable

598
38

636

612
36

94.7%
5.3%

1.07 [0.64 , 1.79]
0.76 [0.09 , 6.53]

648

100.0%

1.05 [0.64 , 1.73]

0.5
Favours skin care intervention for initiation ≥4 days old

0.1

0.2

1

2

5

10

Favours skin care intervention for initiation <4 days old

Analysis 1.14.   Comparison 1: Skin care intervention versus standard skin care or
no skin care intervention, Outcome 14: Participant-level treatment interaction:
Eczema by 6 months to 3 years for treatment initiation < 4 days versus ≥ 4 days of age

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Control
Total

Weight

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Horimukai 2014
Lowe 2018a

0.07
1.56
-0.28

0.26
0.68
1.1

598
50
38

612
49
36

52.8%
30.4%
16.8%

1.07 [0.64 , 1.79]
4.76 [1.26 , 18.04]
0.76 [0.09 , 6.53]

Total (95% CI)
Heterogeneity: Tau² = 0.47; Chi² = 4.42, df = 2 (P = 0.11); I² = 55%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable

686

697

100.0%

1.59 [0.56 , 4.51]

0.5
Favours skin care intervention for initiation ≥4 days old

0.2

0.1

1

2

5

10

Favours skin care intervention for initiation <4 days old

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

136

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.15.   Comparison 1: Skin care intervention versus standard skin care or
no skin care intervention, Outcome 15: Participant-level treatment interaction:
Eczema by 1 to 3 years by FLG genotype (0 mutations versus 1/2 mutations)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
McClanahan 2019 (1)
Skjerven 2020

0.2
0
-0.19

0.28
0
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.62, df = 1 (P = 0.43); I² = 0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable

402
24
397

823

414
23
456

68.2%

31.8%

1.22 [0.71 , 2.11]
Not estimable
0.83 [0.37 , 1.85]

893

100.0%

1.08 [0.69 , 1.70]

0.5
Favours skin care intervention with 1/2 FLG mutations

0.1

0.2

1

2

5

10

Favours skin care intervention with 0 FLG mutations

Footnotes
(1) Not estimable as all standard care participants with FLG mutations (1 or 2 mutations) had eczema.

Analysis 1.16.   Comparison 1: Skin care intervention versus standard skin care or
no skin care intervention, Outcome 16: Participant-level treatment interaction:
Eczema by 6 months to 3 years by FLG genotype (0 mutations versus 1/2 mutations)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
McClanahan 2019 (1)
Simpson 2014
Skjerven 2020

0.2
0
-1.18
-0.19

0.28
0
1.23
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.62, df = 2 (P = 0.44); I² = 0%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable

402
24
35
397

858

414
23
28
456

65.9%

3.4%
30.7%

1.22 [0.71 , 2.11]
Not estimable
0.31 [0.03 , 3.42]
0.83 [0.37 , 1.85]

921

100.0%

1.03 [0.66 , 1.61]

0.5
Favours skin care intervention with 1/2 FLG mutations

0.1

0.2

1

2

5

10

Favours skin care intervention with 0 FLG mutations

Footnotes
(1) Not estimable as all standard care participants with FLG mutations (1 or 2 mutations) had eczema – i.e. the interaction predicts eczema perfectly. In the standard care group 5/22 and 1/1 (mutations) had eczema outcome. In the skin care intervention group 3/21 (no mutations) and 1/3 (mutations) had eczema outcome.

Analysis 1.17.   Comparison 1: Skin care intervention versus standard skin
care or no skin care intervention, Outcome 17: Participant-level treatment
interaction: Eczema by 1 to 3 years by chromosome 11 status (C:C versus C:T or T:T)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Skjerven 2020

0.28
0.25

0.27
0.4

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.95); I² = 0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable

470
393

863

489
455

68.7%
31.3%

1.32 [0.78 , 2.25]
1.28 [0.59 , 2.81]

944

100.0%

1.31 [0.85 , 2.03]

Favours skin care intervention with C:T or T:T genotype 

Favours skin care intervention with C:C genotype 

0.01

0.1

1

10

100

Analysis 1.18.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 18: Participant-level treatment interaction: Eczema by 1 to 3 years by FLG mutation and
chromosome 11 status (no FLG and C:C versus FLG mutation and/or chromosome 11 C:T or T:T)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Skjerven 2020

0.2
0.23

0.36
0.43

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable

392
393

785

404
455

58.8%
41.2%

1.22 [0.60 , 2.47]
1.26 [0.54 , 2.92]

859

100.0%

1.24 [0.72 , 2.12]

Favours skin care intervention with 1/2 FLG mutations &/or C:T or T:T genotype

Favours skin care intervention with 0 FLG mutations & C:C genotype

0.01

0.1

1

10

100

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

137

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.19.   Comparison 1: Skin care intervention versus standard skin care or
no skin care intervention, Outcome 19: Participant-level treatment interaction:
Eczema by 1 to 3 years by ≥ 1 first-degree relative with history of allergic disease 

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Control
Total

Weight

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Dissanayake 2019
Skjerven 2020
Yonezawa 2018

-0.8
-0.14
1.04

1.22
0.64
1.22

232
490
69

223
562
87

17.8%
64.5%
17.8%

0.45 [0.04 , 4.91]
0.87 [0.25 , 3.05]
2.83 [0.26 , 30.91]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.20, df = 2 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable

791

872

100.0%

0.95 [0.35 , 2.61]

Favours skin care intervention with ≥1 first degree relative history

Favours skin care intervention with 0 first degree relative history

0.01

0.1

1

10

100

Analysis 1.20.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 20: Participant-level treatment interaction: Eczema by 1 to 3 years by ≥ 1 first-degree
relative with history of allergic disease and/or FLG genotype (0 mutations versus 1/2 mutations)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Skjerven 2020

-0.48

0.7

Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable

497

497

568

100.0%

0.62 [0.16 , 2.44]

568

100.0%

0.62 [0.16 , 2.44]

Favours skin care intervention with ≥1 first degree relative history &/or 1/2 FLG mutations 

Favours skin care intervention with 0 first degree relative history & 0 FLG mutations 

0.01

0.1

1

10

100

Analysis 1.21.   Comparison 1: Skin care intervention versus standard skin care or no skin care
intervention, Outcome 21: CACE: Eczema by 1 to 3 years for use over intervention period ≥ 3 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Lowe 2018a
Yonezawa 2018

-0.42
-1.14
0.01

0.46
1.39
1.14

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.41, df = 2 (P = 0.81); I² = 0%
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Not applicable

598
38
69

705

612
36
87

78.6%
8.6%
12.8%

0.66 [0.27 , 1.62]
0.32 [0.02 , 4.88]
1.01 [0.11 , 9.43]

735

100.0%

0.65 [0.29 , 1.45]

Favours skin care intervention for compliers

Favours standard care for compliers

0.01

0.1

1

10

100

Analysis 1.22.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 22: CACE sensitivity: Eczema by 1 to 3 years for use over intervention period ≥ 5 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Yonezawa 2018

-0.45
0.03

0.64
0.93

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.18, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable

598
69

667

612
87

67.9%
32.1%

0.64 [0.18 , 2.24]
1.03 [0.17 , 6.38]

699

100.0%

0.74 [0.26 , 2.09]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

138

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.23.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 23: CACE sensitivity: Eczema by 1 to 3 years for use over intervention period 7 days  a week 

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
NCT03376243
Yonezawa 2018

-0.63
-0.32
0.05

1.12
1.4
0.92

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.22, df = 2 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable

598
22
69

689

612
27
87

32.0%
20.5%
47.5%

0.53 [0.06 , 4.78]
0.73 [0.05 , 11.29]
1.05 [0.17 , 6.38]

726

100.0%

0.78 [0.23 , 2.71]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Analysis 1.24.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 24: CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 3 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Yonezawa 2018

0.02
0.01

0.13
1.14

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable

598
69

667

612
87

98.7%
1.3%

1.02 [0.79 , 1.32]
1.01 [0.11 , 9.43]

699

100.0%

1.02 [0.79 , 1.31]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Analysis 1.25.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 25: CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months  ≥ 5 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Yonezawa 2018

-0.2
0.03

0.32
0.93

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable

598
69

667

612
87

89.4%
10.6%

0.82 [0.44 , 1.53]
1.03 [0.17 , 6.38]

699

100.0%

0.84 [0.46 , 1.52]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Analysis 1.26.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 26: CACE sensitivity: Eczema by 1 to 3 years for use over first 3 months 7 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
NCT03376243
Yonezawa 2018

-0.27
-0.13
0.05

0.55
1.59
0.92

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable

598
22
69

689

612
27
87

67.7%
8.1%
24.2%

0.76 [0.26 , 2.24]
0.88 [0.04 , 19.81]
1.05 [0.17 , 6.38]

726

100.0%

0.83 [0.34 , 2.03]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

139

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.27.   Comparison 1: Skin care intervention versus standard skin care
or no skin care intervention, Outcome 27: Sensitivity analysis: Eczema by 1 to 3
years for studies included in CACE for use over intervention period ≥ 3 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Lowe 2018a
Yonezawa 2018

-0.05
-0.51
0.01

0.1
0.42
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.18, df = 2 (P = 0.56); I² = 0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable

598
38
69

705

612
36
87

89.6%
5.1%
5.3%

0.95 [0.78 , 1.16]
0.60 [0.26 , 1.37]
1.01 [0.45 , 2.26]

735

100.0%

0.93 [0.77 , 1.12]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.28.   Comparison 1: Skin care intervention versus standard skin care
or no skin care intervention, Outcome 28: Sensitivity analysis: Eczema by 1 to 3
years for studies included in CACE for use over intervention period ≥ 5 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Yonezawa 2018

-0.05
0.01

0.1
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable

598
69

667

612
87

94.4%
5.6%

0.95 [0.78 , 1.16]
1.01 [0.45 , 2.26]

699

100.0%

0.95 [0.79 , 1.15]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.29.   Comparison 1: Skin care intervention versus standard skin care
or no skin care intervention, Outcome 29: Sensitivity analysis: Eczema by 1 to 3
years for studies included in CACE for use over intervention period 7 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
NCT03376243
Yonezawa 2018

-0.05
-0.15
0.01

0.1
0.55
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 2 (P = 0.97); I² = 0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable

598
22
69

689

612
27
87

91.5%
3.0%
5.4%

0.95 [0.78 , 1.16]
0.86 [0.29 , 2.53]
1.01 [0.45 , 2.26]

726

100.0%

0.95 [0.79 , 1.15]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

140

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.30.   Comparison 1: Skin care intervention versus standard skin care
or no skin care intervention, Outcome 30: Sensitivity analysis: Eczema by 1 to
3 years for studies included in CACE for use over first 3 months ≥ 3 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Yonezawa 2018

-0.05
0.01

0.1
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable

598
69

667

612
87

94.4%
5.6%

0.95 [0.78 , 1.16]
1.01 [0.45 , 2.26]

699

100.0%

0.95 [0.79 , 1.15]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.31.   Comparison 1: Skin care intervention versus standard skin care
or no skin care intervention, Outcome 31: Sensitivity analysis: Eczema by 1 to
3 years for studies included in CACE for use over first 3 months ≥ 5 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Yonezawa 2018

-0.05
0.01

0.1
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable

598
69

667

612
87

94.4%
5.6%

0.95 [0.78 , 1.16]
1.01 [0.45 , 2.26]

699

100.0%

0.95 [0.79 , 1.15]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.32.   Comparison 1: Skin care intervention versus standard skin care
or no skin care intervention, Outcome 32: Sensitivity analysis: Eczema by 1 to
3 years for studies included in CACE for use over first 3 months 7 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
NCT03376243
Yonezawa 2018

-0.05
-0.15
0.01

0.1
0.55
0.41

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 2 (P = 0.97); I² = 0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable

598
22
69

689

612
27
87

91.5%
3.0%
5.4%

0.95 [0.78 , 1.16]
0.86 [0.29 , 2.53]
1.01 [0.45 , 2.26]

726

100.0%

0.95 [0.79 , 1.15]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

141

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.33.   Comparison 1: Skin care intervention versus standard skin
care or no skin care intervention, Outcome 33: Food allergy by 1 to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

A

Risk of Bias
E
B

D

C

Chalmers 2020 (1)

0.93

0.48

482

494

2.53 [0.99 , 6.49]

+

+

−

+

+

Footnotes
(1) *Updated from version 1

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.34.   Comparison 1: Skin care intervention versus standard skin care
or no skin care intervention, Outcome 34: Sensitivity analysis: Food allergy
by 1 to 3 years (diagnosed by oral food challenge or investigator assessment)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

547
424

971

568
491

69.2%
30.8%

1.46 [0.91 , 2.34]
1.43 [0.71 , 2.90]

1059

100.0%

1.45 [0.98 , 2.15]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Risk of Bias
E
B

D

C

+
+

?
?

+
+

+
+

A

+
+

Chalmers 2020
Skjerven 2020

0.38
0.36

0.24
0.36

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 1.87 (P = 0.06)
Test for subgroup differences: Not applicable

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

F

−

F

?
?

Analysis 1.35.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 35: Sensitivity analysis: Food allergy by 1 to 3 years (parent report of doctor diagnosis)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)
Dissanayake 2019 (2)
Yonezawa 2018 (3)

0.11
-0.26
0.15

0.16
0.25
0.33

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.73, df = 2 (P = 0.42); I² = 0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable

493
232
73

798

502
223
91

60.8%
24.9%
14.3%

1.12 [0.82 , 1.53]
0.77 [0.47 , 1.26]
1.16 [0.61 , 2.22]

816

100.0%

1.02 [0.80 , 1.31]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Footnotes
(1) Parent report of doctor diagnosed food allergy by 24 months 
(2) Parent report of doctor diagnosed food allergy to common allergen by 12 months
(3) Parent report of doctor diagnosed food allergy by 24 months

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

142

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.36.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 36: Participant-level treatment interaction: Food allergy by 1 to 3 years (diagnosed by oral
food challenge or investigator assessment) by FLG genotype (0 mutations versus 1/2 mutations)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Skjerven 2020

0.45
-0.19

0.7
1.07

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.25, df = 1 (P = 0.62); I² = 0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable

385
339

724

402
391

70.0%
30.0%

1.57 [0.40 , 6.18]
0.83 [0.10 , 6.73]

793

100.0%

1.29 [0.41 , 4.08]

Favours skin care intervention with 1/2 FLG mutations

 Favours skin care intervention with 0 FLG mutations

0.01

0.1

1

10

100

Analysis 1.37.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 37: Participant-level treatment interaction: Food allergy by 1 to 3 years (diagnosed by
oral food challenge or investigator assessment) by chromosome 11 status (C:C versus C:T or T:T)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Skjerven 2020

0.59
0.23

0.59
0.79

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.13, df = 1 (P = 0.72); I² = 0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable

449
335

784

476
390

64.2%
35.8%

1.80 [0.57 , 5.73]
1.26 [0.27 , 5.92]

866

100.0%

1.59 [0.63 , 4.01]

 Favours skin care intervention with C:T or T:T genotype

 Favours skin care intervention with C:C genotype

0.01

0.1

1

10

100

Analysis 1.38.   Comparison 1: Skin care intervention versus standard skin care or no skin
care intervention, Outcome 38: Participant-level treatment interaction: Food allergy by 1 to
3 years (diagnosed by oral food challenge or investigator assessment) by FLG mutation and
chromosome 11 status (no FLG and C:C versus FLG mutation and/or chromosome 11 C:T or T:T)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Skjerven 2020

0.8
0.2

0.76
0.8

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.30, df = 1 (P = 0.59); I² = 0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable

375
335

710

392
390

52.6%
47.4%

2.23 [0.50 , 9.87]
1.22 [0.25 , 5.86]

782

100.0%

1.67 [0.57 , 4.93]

 Favours skin care intervention with 1/2 FLG mutation &/or C:T or T:T genotype 

Favours skin care intervention with 0 FLG mutations & C:C genotype

0.01

0.1

1

10

100

Analysis 1.39.   Comparison 1: Skin care intervention versus standard skin care or
no skin care intervention, Outcome 39: CACE: Food allergy (oral food challenge or
panel assessment) by 1 to 3 years for use over intervention period ≥ 3 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020

1.4

0.98

547

568

4.06 [0.59 , 27.68]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

143

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.40.   Comparison 1: Skin care intervention versus standard skin care or no
skin care intervention, Outcome 40: CACE sensitivity: Food allergy (oral food challenge
or panel assessment) by 1 to 3 years for use over intervention period ≥ 5 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020

1.55

1.28

547

568

4.71 [0.38 , 57.90]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Analysis 1.41.   Comparison 1: Skin care intervention versus standard skin care or no
skin care intervention, Outcome 41: CACE sensitivity: Food allergy (oral food challenge
or panel assessment) by 1 to 3 years for use over intervention period 7 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020

1.9

1.93

547

568

6.69 [0.15 , 293.75]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Analysis 1.42.   Comparison 1: Skin care intervention versus standard skin care or no
skin care intervention, Outcome 42: CACE sensitivity: Food allergy (oral food challenge
or panel assessment) by 1 to 3 years for use over first 3 months ≥ 3 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020

0.82

0.54

547

568

2.27 [0.79 , 6.54]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Analysis 1.43.   Comparison 1: Skin care intervention versus standard skin care or no
skin care intervention, Outcome 43: CACE sensitivity: Food allergy (oral food challenge
or panel assessment) by 1 to 3 years for use over first 3 months  ≥ 5 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020

0.82

0.58

547

568

2.27 [0.73 , 7.08]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

144

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.44.   Comparison 1: Skin care intervention versus standard skin care or
no skin care intervention, Outcome 44: CACE sensitivity: Food allergy (oral food
challenge or panel assessment) by 1 to 3 years for use over first 3 months 7 days a week

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020

1.2

0.92

547

568

3.32 [0.55 , 20.15]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Analysis 1.45.   Comparison 1: Skin care intervention versus standard skin
care or no skin care intervention, Outcome 45: Adverse event: skin infection

Study or Subgroup

Skin care intervention
Events

Total

Standard care
Total

Events

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Cooke 2015
Lowe 2018a
McClanahan 2019
Simpson 2014
Skjerven 2020

89
1
7
2
1
3

585
76
39
54
65
544

67
0
4
2
2
2

589
39
35
46
60
596

87.5%
0.8%
5.9%
2.1%
1.4%
2.4%

1.34 [1.00 , 1.80]
1.56 [0.06 , 37.39]
1.57 [0.50 , 4.91]
0.85 [0.12 , 5.81]
0.46 [0.04 , 4.96]
1.64 [0.28 , 9.80]

A

+
+
+
+
+
+

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 1.12, df = 5 (P = 0.95); I² = 0%
Test for overall effect: Z = 2.00 (P = 0.05)
Test for subgroup differences: Not applicable

1363

103

77

1365

100.0%

1.33 [1.01 , 1.75]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Risk of Bias
E
B

D

C

+
+
+
+
+
+

+
+
+
+
+
+

?
+
?
?
?
?

+
+
+
+
+
+

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Analysis 1.46.   Comparison 1: Skin care intervention versus standard skin care or no skin
care intervention, Outcome 46: Adverse event: stinging or allergic reaction to moisturisers

Study or Subgroup

Skin care intervention
Events

Total

Standard care
Total

Events

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Cooke 2015
Lowe 2018a
McClanahan 2019
NCT03376243

1
1
5
1

76
39
54
26

0
0
2
0

39
35
46
28

14.3%
14.4%
56.9%
14.5%

1.56 [0.06 , 37.39]
2.70 [0.11 , 64.20]
2.13 [0.43 , 10.46]
3.22 [0.14 , 75.75]

A

+
+
+
+

Risk of Bias
E
B

C

D

+
+
+
+

+
+
+
+

+
?
?
?

+
+
+
+

F

?
+
?
?
?
?

F

+
?
?
?

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 3 (P = 0.99); I² = 0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable

195

2

8

148

100.0%

2.24 [0.67 , 7.43]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

145

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.47.   Comparison 1: Skin care intervention versus standard skin care
or no skin care intervention, Outcome 47: Adverse event: slippage accidents

Study or Subgroup

Skin care intervention
Events

Total

Standard care
Total

Events

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020
Lowe 2018a
Simpson 2014
Skjerven 2020 (1)

15
1
0
0

584
39
64
575

94.4%
5.6%

11
0
0
0

584
35
60
597

1.36 [0.63 , 2.94]
2.70 [0.11 , 64.20]
Not estimable
Not estimable

A

+
+
+
+

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.17, df = 1 (P = 0.68); I² = 0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable

1262

16

11

1276

100.0%

1.42 [0.67 , 2.99]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Risk of Bias
E
B

C

D

+
+
+
+

+
+
+
+

?
?
?
?

+
+
+
+

F

?
?
?
?

Footnotes
(1) PreventADALL reported 0 slippages in each treatment group included in the IPD meta-analysis. There was one accident connected with bathing for a participant in the food and skin care group of this 2x2 factorial trial (food and skin group not included in analysis as a significant interaction between skin care and early introduction of food allergens was identified).

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Analysis 1.48.   Comparison 1: Skin care intervention versus standard skin
care or no skin care intervention, Outcome 48: Serious adverse events

Study or Subgroup

Skin care intervention
Events

Total

Standard care
Total

Events

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Cooke 2015
Lowe 2018a
Skjerven 2020

5
5
38

76
41
575

0
1
47

39
39
597

16.8%
25.3%
57.8%

5.71 [0.32 , 100.76]
4.76 [0.58 , 38.91]
0.84 [0.56 , 1.27]

A

+
+
+

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.82; Chi² = 4.09, df = 2 (P = 0.13); I² = 51%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable

692

48

48

675

100.0%

1.80 [0.45 , 7.18]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Risk of Bias
E
B

D

C

+
+
+

+
+
+

+
+
+

+
+
+

F

+
+
+

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

146

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.49.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 49: Clinician-assessed eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)
Lowe 2018a (2)
NCT03376243 (3)

-0.08
0
0

0.46
0
0

553
35
23

567
32
18

0.92 [0.37 , 2.27]
Not estimable
Not estimable

Footnotes
(1) EASI at 24 months
(2) Objective SCORAD at 12 months. The adjusted treatment effect is not estimatable due to low event rates. In the standard care group 0/32 had the outcome and in the skin care intervention group 1/35 had the outcome.
(3) EASI at 12 months. The adjusted treatment effect is not estimatable due to low event rates. In the standard care group 0/23 had the outcome and in the skin care intervention group 0/18 had the outcome.

Favours standard care

0.1
0.5
Favours skin care intervention

0.2

1

2

5

10

Analysis 1.50.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 50: Clinician-assessed eczema severity at 1 to 3 years (standardised mean difference)

Study or Subgroup

SMD

SE

Skin care intervention
Total

Standard care
Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Chalmers 2020 (1)
Lowe 2018a (2)
NCT03376243 (3)

0.02
-0.2
-0.36

0.06
0.24
0.31

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.15, df = 2 (P = 0.34); I² = 7%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable

Footnotes
(1) EASI at 24 months
(2) objective SCORAD at 12 months
(3) EASI at 12 months

553
35
18

606

567
32
23

85.4%
9.1%
5.5%

0.02 [-0.10 , 0.14]
-0.20 [-0.67 , 0.27]
-0.36 [-0.97 , 0.25]

622

100.0%

-0.02 [-0.17 , 0.12]

Favours skin care intervention

-4

-2

0

2

4
Favours standard care

Analysis 1.51.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 51: Parent-reported eczema severity at 1 to 3 years (clear/mild versus moderate/severe/very severe)

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)

0.16

0.18

576

595

1.17 [0.82 , 1.67]

Footnotes
(1) POEM at 24 months as very severe/severe/moderate versus clear/mild

0.1
0.5
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.52.   Comparison 1: Skin care intervention versus standard skin care or no skin care
intervention, Outcome 52: Parent-reported eczema severity at 1 to 3 years (mean difference)

Study or Subgroup

MD

SE

Skin care intervention
Total

Standard care
Total

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

Chalmers 2020 (1)

0.07

0.23

576

595

0.07 [-0.38 , 0.52]

Footnotes
(1) POEM at 24 months

Favours skin care intervention

-4

-2

0

2

4
Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

147

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of Bias
E
B

C

D

+
+
+
+
+
+
+
+
+

+
+
+
+
?
?
?
?
?

?
+
+
+
+
+
+
+
?

+
+
+
+
+
+
+
+
+

A

+
+
+
+
+
+
+
+
+

F

?
+
+
+
?
?
?
?
?

Risk of Bias
E
B

C

D

+
+
+
+
+
+
+

+
+
+
?
?
?
?

?
+
+
+
+
+
?

+
+
+
+
+
+
+

A

+
+
+
+
+
+
+

F

?
+
+
?
?
?
?

Analysis 1.53.   Comparison 1: Skin care intervention versus standard skin
care or no skin care intervention, Outcome 53: Time to onset of eczema

Study or Subgroup

log[Hazard Ratio]

SE

Skin care intervention
Total

Standard care
Total

Hazard Ratio
IV, Random, 95% CI

Weight

Hazard Ratio
IV, Random, 95% CI

618
217
58
41
54
26
55
499
68

618
214
58
38
46
28
53
572
86

24.0%
14.2%
12.3%
6.5%
5.7%
4.1%
9.6%
18.1%
5.6%

0.93 [0.78 , 1.11]
1.07 [0.64 , 1.79]
0.59 [0.33 , 1.07]
0.54 [0.21 , 1.41]
0.50 [0.18 , 1.40]
0.68 [0.19 , 2.42]
0.49 [0.24 , 1.01]
1.62 [1.11 , 2.35]
1.01 [0.35 , 2.91]

1636

1713

100.0%

0.86 [0.65 , 1.14]

0.1
0.5
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Chalmers 2020
Dissanayake 2019
Horimukai 2014
Lowe 2018a
McClanahan 2019
NCT03376243
Simpson 2014
Skjerven 2020
Yonezawa 2018

-0.07
0.07
-0.52
-0.62
-0.7
-0.39
-0.72
0.48
0.01

0.09
0.26
0.3
0.49
0.53
0.65
0.37
0.19
0.54

Total (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 16.91, df = 8 (P = 0.03); I² = 53%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Analysis 1.54.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 54: Subgroup analysis: Time to onset of eczema (< 1-year follow-up versus ≥ 1-year follow-up)

Study or Subgroup

log[Hazard Ratio]

SE

Skin care intervention
Total

Standard care
Total

Hazard Ratio
IV, Random, 95% CI

Weight

Hazard Ratio
IV, Random, 95% CI

1.54.1 Follow-up ≥ 1 year
Chalmers 2020
Dissanayake 2019
Lowe 2018a
McClanahan 2019
NCT03376243
Skjerven 2020
Yonezawa 2018
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 10.77, df = 6 (P = 0.10); I² = 44%
Test for overall effect: Z = 0.03 (P = 0.98)

-0.07
0.07
-0.62
-0.7
-0.39
0.48
0.01

0.09
0.26
0.49
0.53
0.65
0.19
0.54

1.54.2 Follow-up < 1 year
Horimukai 2014
Simpson 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.18, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 2.57 (P = 0.01)

-0.52
-0.72

0.3
0.37

618
217
41
54
26
499
68
1523

58
55
113

618
214
38
46
28
572
86
1602

24.0%
14.2%
6.5%
5.7%
4.1%
18.1%
5.6%
78.1%

0.93 [0.78 , 1.11]
1.07 [0.64 , 1.79]
0.54 [0.21 , 1.41]
0.50 [0.18 , 1.40]
0.68 [0.19 , 2.42]
1.62 [1.11 , 2.35]
1.01 [0.35 , 2.91]
1.00 [0.75 , 1.33]

58
53
111

12.3%
9.6%
21.9%

0.59 [0.33 , 1.07]
0.49 [0.24 , 1.01]
0.55 [0.35 , 0.87]

+
+

+
+

+
?

+
+

+
+

+
?

1636

1713

100.0%

0.86 [0.65 , 1.14]

0.1
0.5
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Total (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 16.91, df = 8 (P = 0.03); I² = 53%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi² = 4.68, df = 1 (P = 0.03), I² = 78.6%

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

148

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.55.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 55: Parent report of immediate (< 2 hours) reaction to a known common food allergen

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)
NCT03376243 (2)

0.24
0

0.12
0

574
18

597
23

1.27 [1.00 , 1.61]
Not estimable

A

+
+

Risk of Bias
E
B

D

C

+
+

+
?

?
?

+
+

F

?
?

Footnotes
(1) milk, egg, peanut, other nut or other common food allergen at 2 years
(2) The adjusted treatment effect is not estimatable due to low event rates. In the standard care group 0/23 had the outcome and in the skin care intervention group 0/18 had the outcome.

Favours standard care

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Analysis 1.56.   Comparison 1: Skin care intervention versus standard skin care or no skin
care intervention, Outcome 56: Parent report of immediate (< 2 hours) reaction to milk

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020

0.32

0.19

575

598

1.38 [0.95 , 2.00]

0.1
0.5
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.57.   Comparison 1: Skin care intervention versus standard skin care or no skin
care intervention, Outcome 57: Parent report of immediate (< 2 hours) reaction to egg

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020

0.11

0.21

575

598

1.12 [0.74 , 1.68]

0.5
0.1
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Analysis 1.58.   Comparison 1: Skin care intervention versus standard skin care or no skin
care intervention, Outcome 58: Parent report of immediate (< 2 hours) reaction to peanut

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Chalmers 2020

-0.18

0.47

574

598

0.84 [0.33 , 2.10]

0.1
0.5
Favours skin care intervention

0.2

1

2

5

10

Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

149

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.59.   Comparison 1: Skin care intervention versus standard skin care or no skin care
intervention, Outcome 59: Allergic sensitisation to common foods or inhalants at 1 to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)
Lowe 2018a (2)

0.19
-0.36

0.14
0.46

Total (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 1.31, df = 1 (P = 0.25); I² = 24%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable

490
34

524

498
36

81.7%
18.3%

1.21 [0.92 , 1.59]
0.70 [0.28 , 1.72]

534

100.0%

1.09 [0.72 , 1.66]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Risk of Bias
E
B

D

C

+
+

+
?

+
+

+
+

A

+
+

Footnotes
(1) Milk, egg, peanut, cat, dust mite or grass pollen at 24 months via SPT
(2) Milk, egg, peanut, cat, dust mite or rye at 12 months via SPT

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Analysis 1.60.   Comparison 1: Skin care intervention versus standard skin care or no skin
care intervention, Outcome 60: Allergic sensitisation to common foods at 1 to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

487
34
341

862

498
36
398

52.2%
13.0%
34.8%

1.35 [0.93 , 1.96]
0.41 [0.12 , 1.40]
1.02 [0.56 , 1.87]

932

100.0%

1.05 [0.64 , 1.71]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Risk of Bias
E
B

D

C

+
+
+

+
?
?

+
+
+

+
+
+

A

+
+
+

Chalmers 2020 (1)
Lowe 2018a (2)
Skjerven 2020 (3)

0.3
-0.9
0.02

0.19
0.63
0.31

Total (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 3.58, df = 2 (P = 0.17); I² = 44%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable

Footnotes
(1) milk, egg or peanut at 24 months via SPT
(2) milk, egg or peanut at 12 months via SPT
(3) milk, egg, peanut, or wheat at 36 months via SPT

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

F

+
?

F

+
?
?

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

150

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.61.   Comparison 1: Skin care intervention versus standard skin care or
no skin care intervention, Outcome 61: Allergic sensitisation to milk at 1 to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)
Lowe 2018a (2)
Skjerven 2020 (3)

0.26
-0.86
0

0.4
1.18
0

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.81, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable

488
34
341

863

89.7%
10.3%

498
36
397

1.30 [0.59 , 2.84]
0.42 [0.04 , 4.27]
Not estimable

931

100.0%

1.16 [0.55 , 2.43]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Footnotes
(1) at 24 months via SPT
(2) at 12 months via SPT
(3) at 36 months via SPT. The adjusted treatment effect is not estimatable due to low event rates. In the standard care group 3/339 had the outcome and in the skin care intervention group 0/343 had the outcome.

Analysis 1.62.   Comparison 1: Skin care intervention versus standard skin care or
no skin care intervention, Outcome 62: Allergic sensitisation to egg at 1 to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)
Lowe 2018a (2)
Skjerven 2020 (3)

0.28
-1.2
-0.04

0.22
0.76
0.66

Total (95% CI)
Heterogeneity: Tau² = 0.22; Chi² = 3.59, df = 2 (P = 0.17); I² = 44%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable

Footnotes
(1) at 24 months via SPT
(2) at 12 months via SPT
(3) at 36 months via SPT

490
34
341

865

499
36
397

57.0%
19.4%
23.6%

1.32 [0.86 , 2.04]
0.30 [0.07 , 1.34]
0.96 [0.26 , 3.50]

932

100.0%

0.92 [0.42 , 2.00]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Analysis 1.63.   Comparison 1: Skin care intervention versus standard skin care or no
skin care intervention, Outcome 63: Allergic sensitisation to peanut at 1 to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)
Lowe 2018a (2)
Skjerven 2020 (3)

0.14
-1.05
0.11

0.34
1.13
0.34

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.04, df = 2 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable

Footnotes
(1) at 24 months via SPT
(2) at 12 months via SPT
(3) at 36 months via SPT

490
34
343

867

502
36
399

47.8%
4.3%
47.8%

1.15 [0.59 , 2.24]
0.35 [0.04 , 3.21]
1.12 [0.57 , 2.17]

937

100.0%

1.08 [0.68 , 1.71]

0.01
Favours  skin care intervention

0.1

1

10

100

Favours standard care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

151

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.64.   Comparison 1: Skin care intervention versus standard skin care or no
skin care intervention, Outcome 64: Allergic sensitisation to inhalants at 1 to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)
Lowe 2018a (2)

0.06
1.04

0.19
1.13

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.73, df = 1 (P = 0.39); I² = 0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable

Footnotes
(1) Cat, dust mite or grass pollen at 24 months via SPT
(2) Cat, dust mite or rye at 12 months via SPT

492
34

526

499
36

97.3%
2.7%

1.06 [0.73 , 1.54]
2.83 [0.31 , 25.91]

535

100.0%

1.09 [0.76 , 1.57]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Analysis 1.65.   Comparison 1: Skin care intervention versus standard skin care or no skin care intervention,
Outcome 65: Sensitivity analysis: Allergic sensitisation to common foods at 6 months to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

487
235
48
34
341

498
223
44
36
398

16.5%
56.9%
18.1%
1.7%
6.8%

1.35 [0.93 , 1.96]
1.11 [0.94 , 1.29]
0.92 [0.65 , 1.31]
0.41 [0.12 , 1.40]
1.02 [0.56 , 1.87]

1145

1199

100.0%

1.08 [0.92 , 1.27]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Risk of Bias
E
B

D

C

+
+
+
+
+

+
+
+
?
?

+
+
+
+
+

+
+
+
+
+

A

+
+
+
+
+

F

+
+
+
?
?

Chalmers 2020 (1)
Dissanayake 2019 (2)
Horimukai 2014 (3)
Lowe 2018a (4)
Skjerven 2020 (5)

0.3
0.1
-0.08
-0.9
0.02

0.19
0.08
0.18
0.63
0.31

Total (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 4.64, df = 4 (P = 0.33); I² = 14%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable

Footnotes
(1) milk, egg or peanut at 24 months
(2) milk, egg at 9 months via IgE testing
(3) milk, egg or peanut at 8 months (32 weeks) via IgE testing
(4) milk, egg or peanut at 12 months via SPT
(5) milk, egg, peanut or wheat at 36 months via SPT

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

152

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.66.   Comparison 1: Skin care intervention versus standard skin care or no skin care
intervention, Outcome 66: Sensitivity analysis: Allergic sensitisation to milk at 6 months to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

488
233
48
34
341

20.8%
57.9%
18.9%
2.4%

498
223
44
36
397

1.30 [0.59 , 2.84]
0.88 [0.55 , 1.41]
0.51 [0.22 , 1.15]
0.42 [0.04 , 4.27]
Not estimable

1144

1198

100.0%

0.84 [0.59 , 1.21]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Chalmers 2020 (1)
Dissanayake 2019 (2)
Horimukai 2014 (3)
Lowe 2018a (4)
Skjerven 2020 (5)

0.26
-0.13
-0.68
-0.86
0

0.4
0.24
0.42
1.18
0

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.00, df = 3 (P = 0.39); I² = 0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable

Footnotes
(1) at 24 months via SPT
(2) at 9 months via IgE testing
(3) at 8 months (32 weeks) via IgE testing
(4) at 12 months via SPT
(5) at 36 months via SPT

Analysis 1.67.   Comparison 1: Skin care intervention versus standard skin care or no skin care
intervention, Outcome 67: Sensitivity analysis: Allergic sensitisation to egg at 6 months to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

490
233
48
34
341

499
223
44
36
397

13.5%
68.9%
14.8%
1.2%
1.6%

1.32 [0.86 , 2.04]
1.13 [0.95 , 1.35]
0.96 [0.64 , 1.45]
0.30 [0.07 , 1.34]
0.96 [0.26 , 3.50]

1146

1199

100.0%

1.11 [0.94 , 1.30]

0.01
Favours skin care intervention

0.1

1

10

100

Favours standard care

Chalmers 2020 (1)
Dissanayake 2019 (2)
Horimukai 2014 (3)
Lowe 2018a (4)
Skjerven 2020 (5)

0.28
0.12
-0.04
-1.2
-0.04

0.22
0.09
0.21
0.76
0.66

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.13, df = 4 (P = 0.39); I² = 3%
Test for overall effect: Z = 1.21 (P = 0.22)
Test for subgroup differences: Not applicable

Footnotes
(1) at 24 months via SPT
(2) at 9 months via IgE testing
(3) at 8 months (32 weeks) via IgE testing
(4) at 12 months via SPT
(5) at 36 months via SPT

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

153

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.68.   Comparison 1: Skin care intervention versus standard skin care or no skin care
intervention, Outcome 68: Sensitivity analysis: Allergic sensitisation to peanut at 6 months to 3 years

Study or Subgroup

log[RR]

SE

Skin care intervention
Total

Standard care
Total

Risk Ratio
IV, Random, 95% CI

Weight

Risk Ratio
IV, Random, 95% CI

Chalmers 2020 (1)
Horimukai 2014 (2)
Lowe 2018a (1)
Skjerven 2020 (3)

0.14
0
-1.05
0.11

0.34
0
1.13
0.34

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.04, df = 2 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable

Footnotes
(1) at 12 months via SPT
(2) at 8 months (32 weeks) via IgE testing
(3) at 36 months via SPT

490
48
34
340

912

502
44
36
398

47.8%

4.3%
47.8%

1.15 [0.59 , 2.24]
Not estimable
0.35 [0.04 , 3.21]
1.12 [0.57 , 2.17]

980

100.0%

1.08 [0.68 , 1.71]

0.01
Favours  skin care intervention

0.1

1

10

100

Favours standard care

A D D I T I O N A L   T A B L E S

Table 1.   Glossary of terms 

Term

Adolescence

Definition

A period in development, roughly between ages 10 and 19 years, between onset of puberty and ac-
ceptance of adult identity and behaviour

Allergic (atopic) march

Typical pattern of onset of allergic disease from eczema, to food allergy, to asthma and allergic
rhinitis

Allergic rhinitis

Rhinitis is a group of symptoms affecting the nose, typically by sneezing, itching, or congestion. Al-
lergic rhinitis occurs when these symptoms are due to environmental allergies.

Allergic sensitisation

Demonstrated by a positive skin prick test of specific IgE to a known allergen

Anaphylaxis

Acute, potentially life-threatening immediate reaction to an allergen

Angio-oedema

Pronounced swelling of the deep dermis, subcutaneous or submucosal tissue

Atopic dermatitis

(atopic eczema)

Atopy

Ceramides

Eczema

Eczema with IgE sensitisation, either by IgE antibody or by skin prick test, is classified as atopic
eczema.

Genetic predisposition to develop allergic diseases such as eczema, food allergy, asthma, and aller-
gic rhinitis, which is often associated with the production of IgE antibodies

Lipid (fatty) molecules found in the lipid bilayer of the intercellular matrix

Complex chronic skin condition characterised by itch, a form of dermatitis

Filaggrin (FLG)

Gene encoding for filaggrin, a filament-binding protein in the skin

Flare

Food allergy

A period of worsening of eczema signs and symptoms

Adverse health effect arising from a specific immune response that occurs reproducibly on expo-
sure to a given food. Can be IgE-mediated or non-IgE-mediated

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

154

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Table 1.   Glossary of terms  (Continued)

Cochrane Database of Systematic Reviews

Food sensitisation

Production of IgE to a food, in the form of a positive skin prick test or immunoglobulin E; may not
equate to food allergy

Humectant

Substance or product that draws water towards it

Immunoglobulin E (IgE)

Class of antibody that plays a key role in allergic disease. Signs and symptoms of IgE-mediated dis-
ease include urticaria, angio-oedema, wheeze, and anaphylaxis.

Infant

A baby in the first year of life

Inhalant allergen

Allergen that typically enters the immune system via the respiratory tract and is airborne, such as
house dust mite or pollen

Intergenic locus

A stretch of DNA sequences located between genes

Mast cell

Neonate

Phenotype

Prevalence

Quality of life

Granular basophil cell present in connective tissue that releases histamine and other mediators in
allergic reactions

A baby in the first 28 days of life

Observable characteristics from an interaction between genes and the environment

In statistics, refers to the number of cases of a disease, present in a particular population at a given
time

Defined by the World Health Organization as individuals' perceptions of their position in life in the
context of the culture and value systems in which they live and in relation to their goals, expecta-
tions, standards, and concerns

Transepidermal water loss
(TEWL)

Non-invasive measurement of water loss across the epidermis used as a measure of skin barrier
function

Urticaria

Rash that is a transient erythematous itchy swelling of skin

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

155

 
 
 
Table 2.   Baseline characteristics of participants included in meta-analysis 

Characteristic

Chalmers
2020

Cooke
2015

Dis-
sanayake
2019

Horimukai
2014

Lowe
2018a

Migache-
va 2018

McClana-
han 2019

Simpson
2014

Skjer-
ven 2020

Gestational age: mean (SD)

40 (1.3)

40 (1.3)

39 (1.1)

39.1 (1)

39.3 (1.6)

-

-

40.3 (1.3)

39.3 (1.6)

Female: n (%)

661 (47)

49 (43)

275 (50)

50 (42)

41 (51)

29 (48)

49 (49)

41 (53)

1134 (47)

Birth weight: mean grams (SD)

3405 (452)

3048 (322)

3054 (363)

3356 (442)

Vaginal delivery: n (%)

954 (68)

95 (83)

420 (77)

89 (75)

31 (41)

Age intervention began: mean days (SD)

13 (10)

All < 3

-

2 (2)

12 (7)

Family history atopy: n (%)

1394 (100)

37 (79)

457 (83)

118 (100)

80 (100)

Filaggrin (FLG) (1/2 mutations): n (%)

125 (15)

-

Sample size

1394

115

-

549

-

118

-

80

SD: standard deviation

-

-

-

-

-

60

-

3577 (480)

80 (80)

32 (26)

1999 (83)

13 (14)

14 (6)

-

100 (100)

124 (100)

1814 (78)

5 (9)

100

17 (27)

-

124

2396

C
o

l
l
a
b
o
r
a
t
i
o
n

.

C
o
p
y
r
i
g
h
t

©
2
0
2
2
T
h
e
A
u
t
h
o
r
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s
p
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

o
n
b
e
h
a
l
f
o
f
T
h
e
C
o
c
h
r
a
n
e

S
k
i
n
c
a
r
e
i

n
t
e
r
v
e
n
t
i
o
n
s
i

n

i

n
f
a
n
t
s
f
o
r
p
r
e
v
e
n
t
i
n
g
e
c
z
e
m
a
a
n
d
f
o
o
d
a
l
l
e
r
g
y
(
R
e
v
i
e
w

)

1
5
6

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 3.   Baseline characteristics of participants included in meta-analysis (continued) 

Characteristic

Gestational age: mean (SD)

Female: n (%)

 NCT03376243

Yonezawa 2018

-

30 (56)

39.4 (1.3)

98 (43)

Birth weight: mean grams (SD)

3547 (497)

3017 (362)

Vaginal delivery: n (%)

Age intervention began: mean days (SD)

34 (63)

-

194 (85)

6 (2)

Family history atopy: n (%)

54 (100)

62 (27)

Filaggrin (FLG) (1/2 mutations): n (%)

Sample size

SD: standard deviation

Table 4.   Sensitivity analysis for eczema  

Analysis

Primary:

eczema by 1 to 3 years

Sensitivity:

eczema by 1 to 3 years including aggregate
data

Eczema by 1 to 3 years using UK Working
Party Criteria only

Eczema by 1 to 3 years including all 4 arms
from the PreventADALL trial

Eczema by 1 to 3 years (using Preven-
tADALL 36-month outcome)

Eczema by 1 to 3 years, low risk of bias da-
ta only

Eczema by 1 to 3 years, excluding non-
prospectively acquired data

Eczema by 6 months to 3 years

-

54

N

standard care

-

227

Pooled risk
ratio

95% confi-
dence interval

N trials

N skin care
intervention

7a

8b

6c

7a

7a

3d

6e

9f

1489

1586

1.03

0.81 to 1.31

1518

1617

0.97

0.75 to 1.25

1420

1499

1993

2183

1489

1587

868

871

1451

1550

1549

1688

1.02

1.03

1.00

0.97

1.08

0.89

0.78 to 1.34

0.81 to 1.31

0.88 to 1.14

0.81 to 1.17

0.84 to 1.37

0.70 to 1.14

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

157

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Table 4.   Sensitivity analysis for eczema   (Continued)

Eczema after the intervention period (at  1
year or beyond (up to 3 years))

4g

Cochrane Database of Systematic Reviews

1203

1308

1.00

0.87 to 1.16

aChalmers 2020; Dissanayake 2019; Lowe 2018a; McClanahan 2019; Skjerven 2020; NCT03376243; Yonezawa 2018.
bChalmers 2020; Dissanayake 2019; Lowe 2018a; McClanahan 2019; Migacheva 2018; Skjerven 2020; NCT03376243; Yonezawa 2018.
cChalmers 2020; Dissanayake 2019; Lowe 2018a; McClanahan 2019; Skjerven 2020; NCT03376243.
dChalmers 2020; Dissanayake 2019; Lowe 2018a.
eChalmers 2020; Dissanayake 2019; McClanahan 2019; Skjerven 2020; NCT03376243; Yonezawa 2018.
fChalmers  2020;  Dissanayake  2019;  Horimukai  2014;  Lowe  2018a;  McClanahan  2019;  Simpson  2014;  Skjerven  2020;  NCT03376243;
Yonezawa 2018.
gChalmers 2020; Lowe 2018a; Skjerven 2020; Yonezawa 2018.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

158

 
 
 
Table 5.   Complier average causal effect (CACE) analyses for eczema 

Complier 

N trials

N skin care
intervention

N standard
care 

CACE

Intention-to-treat

Pooled risk
ratio

95% confi-
dence interval

Pooled risk
ratio

95% confi-
dence interval

705

735

0.65

0.29 to 1.45

0.93

0.77 to 1.12

667

689

667

667

689

699

699

669

669

726

0.74

0.26 to 2.09

0.95

0.79 to 1.15

0.78

1.02

0.84

0.23 to 2.71

0.79 to 1.31

0.95

0.95

0.79 to 1.15

0.79 to 1.15

0.46 to 1.52

0.95

0.79 to 1.15

0.83

0.34 to 2.03

0.95

0.79 to 1.15

Primary CACE:

≥ 3 days of use over intervention period

Sensitivity CACE:

≥ 5 days of use over intervention period

7 days of use over intervention period

≥ 3 days of use over first 3 months of interven-
tion period

≥ 5 days of use over first 3 months of interven-
tion period

7 days of use over first 3 months of interven-
tion period

3a

2b

3c

2b

2b

3c

aChalmers 2020; Lowe 2018a; Yonezawa 2018.
bChalmers 2020; Yonezawa 2018.
cChalmers 2020; NCT03376243; Yonezawa 2018.

C
o

l
l
a
b
o
r
a
t
i
o
n

.

C
o
p
y
r
i
g
h
t

©
2
0
2
2
T
h
e
A
u
t
h
o
r
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s
p
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

o
n
b
e
h
a
l
f
o
f
T
h
e
C
o
c
h
r
a
n
e

S
k
i
n
c
a
r
e
i

n
t
e
r
v
e
n
t
i
o
n
s
i

n

i

n
f
a
n
t
s
f
o
r
p
r
e
v
e
n
t
i
n
g
e
c
z
e
m
a
a
n
d
f
o
o
d
a
l
l
e
r
g
y
(
R
e
v
i
e
w

)

1
5
9

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 6.   Sensitivity analysis for food allergy 

Analysis

Primary:

food allergy (oral food challenge) by 1 to
3 years

Sensitivity:

food allergy (oral food challenge + panel
assessment) by 1 to 3 years

N trials

N skin care
intervention

N

standard care

Pooled risk
ratio

95% confi-
dence interval

1a

2b

482

494

2.53

0.99 to 6.49

1067

1014

1.43

0.97 to 2.13

Food allergy (parent report of doctor diag-
nosis) by 1 to 3 years

3c

798

816

1.02

0.80 to 1.31

aChalmers 2020.
bChalmers 2020; Skjerven 2020.
cChalmers 2020; Dissanayake 2019; Yonezawa 2018.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

160

 
 
 
 
 
Table 7.   Complier average causal effect (CACE) analyses for food allergy (oral food challenge or panel assessment) 

Complier 

N trials

N skin care
intervention

N standard
care 

CACE

Intention-to-treat

Primary CACE:

≥ 3 days of use over intervention period

Sensitivity:

≥ 5 days of use over intervention period

7 days of use over intervention period

≥ 3 days of use over first 3 months of interven-
tion period

≥ 5 days of use over first 3 months of interven-
tion period

7 days of use over first 3 months of interven-
tion period

1a

1a

1a

1a

1a

1a

Pooled risk
ratio

95% confi-
dence interval

Pooled risk
ratio

95% confi-
dence interval

547

568

4.06

0.59 to 27.68

1.43

0.97 to 2.13

547

547

547

547

547

568

568

568

568

568

4.71

0.38 to 57.90

 1.43

0.97 to 2.13

6.69

2.27

2.27

3.32

0.15 to 293.75

 1.43

0.97 to 2.13

0.79 to 6.54

 1.43

0.97 to 2.13

0.73 to 7.08

 1.43

0.97 to 2.13

0.55 to 20.15

 1.43

0.97 to 2.13

aOne study is included across all presented analyses: Chalmers 2020.

C
o

l
l
a
b
o
r
a
t
i
o
n

.

C
o
p
y
r
i
g
h
t

©
2
0
2
2
T
h
e
A
u
t
h
o
r
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s
p
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

o
n
b
e
h
a
l
f
o
f
T
h
e
C
o
c
h
r
a
n
e

S
k
i
n
c
a
r
e
i

n
t
e
r
v
e
n
t
i
o
n
s
i

n

i

n
f
a
n
t
s
f
o
r
p
r
e
v
e
n
t
i
n
g
e
c
z
e
m
a
a
n
d
f
o
o
d
a
l
l
e
r
g
y
(
R
e
v
i
e
w

)

1
6
1

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Table 8.   Serious adverse events 

Cochrane Database of Systematic Reviews

Trial

Serious adverse event

Skin care

Control 

Total

(N events)

(N events)

(N events)

 Cooke 2015

Jaundice

Viral lung infection

Seizure (benign myoclonic jerks)

 Total events

 Lowe 2018a

Bronchiolitis

Fever infection

Respiratory distress

Total events

 Skjerven 2020

Allergic reaction

Seizure (non-febrile)

Other

Bronchiolitis (respiratory syncytial virus or other)

Croup

Foreign body aspiration

Influenza

Surgery (operation)

Pneumonia

Flu/diarrhoea

Injury or accident

Urinary infection

Unspecified reaction

Total events

3

1

1

5

3

1

1

5

1

1

 0

 0

 0

 0

1

0

0

1

2

1

13

18

9

0

0

0

1

2

3

3

2

6

41

6

1

1

1

5

1

1

4

3

10

54

3

1

1

5

4

1

1

6

3

2

31

15

1

1

1

6

3

4

7

5

16

95

A P P E N D I C E S

Appendix 1. Search strategy for Cochrane Skin Specialised Register

1. (Emollient* or moisturis* or moisturiz* or cream*):ti,ab AND INREGISTER

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

162

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2. (Petrolatum or emulsion* or lubrica* or ointment* or lotion* or oil or oils or gel or gels or paste or pastes or salve* or unguent*):ti,ab

AND INREGISTER

3. (Bath or baths or bathing or bathe* or soap* or water soften* or hard water or water hardness or skin care):ti,ab AND INREGISTER
4. #1 OR #2 OR #3
5. MESH DESCRIPTOR infant EXPLODE ALL AND INREGISTER
6. MESH DESCRIPTOR infant newborn EXPLODE ALL AND INREGISTER
7. (new next born*):ti,ab AND INREGISTER
8. (newly next born*):ti,ab AND INREGISTER
9. (neo next nat*):ti,ab AND INREGISTER
10.(Infant* or infancy or newborn* or perinat* or neonat* or baby* or babies):ti,ab,kw AND INREGISTER
11.#5 OR #6 OR #7 OR #8 OR #9 OR #10
12.#4 AND #11

Appendix 2. Search strategy for CENTRAL (Cochrane Library)

#1 MeSH descriptor: [Emollients] explode all trees
#2 emollient*:ti,ab,kw
#3 moisturis*:ti,ab,kw
#4 moisturiz*:ti,ab,kw
#5 MeSH descriptor: [Skin Cream] explode all trees
#6 cream*:ti,ab,kw
#7 {OR #1-#6}
#8 MeSH descriptor: [Petrolatum] explode all trees
#9 petrolatum:ti,ab,kw
#10 MeSH descriptor: [Emulsions] explode all trees
#11 emulsion*:ti,ab,kw
#12 MeSH descriptor: [Lubricants] explode all trees
#13 lubrica*:ti,ab,kw
#14 MeSH descriptor: [Ointments] explode all trees
#15 ointment*:ti,ab,kw
#16 lotion*:ti,ab,kw
#17 MeSH descriptor: [Oils] explode all trees
#18 (oil or oils):ti,ab,kw
#19 (gel or gels):ti,ab,kw
#20 (paste or pastes or salve* or unguent*):ti,ab,kw
#21 {OR #8-#20}
#22 skin:ti,ab,kw
#23 MeSH descriptor: [Skin] explode all trees
#24 #22 or #23
#25 #21 and #24
#26 (bath? or bathe? or bathing):ti,ab,kw
#27 MeSH descriptor: [Baths] explode all trees
#28 MeSH descriptor: [Soaps] explode all trees
#29 soap*:ti,ab,kw
#30 MeSH descriptor: [Water Softening] explode all trees
#31 water soften*:ti,ab,kw
#32 (hard water or water hardness):ti,ab,kw
#33 MeSH descriptor: [Skin Care] explode all trees
#34 {OR #26-#33}
#35 #7 or #25 or #34
#36 MeSH descriptor: [Infant] explode all trees
#37 MeSH descriptor: [Infant, Newborn] explode all trees
#38 (Infant? or infancy or newborn* or perinat* or neonat* or baby* or babies or new next born* or newly next born* or neo next nat*):ti,ab
#39 #36 or #37 or #38
#40 #35 and #39

Appendix 3. Search strategy for MEDLINE (Ovid)

1. exp Emollients/
2. emollient$.ti,ab.
3. moisturis$.ti,ab.

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

163

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

4. moisturiz$.ti,ab.
5. exp Skin Cream/
6. cream$.ti,ab.
7. or/1-6
8. exp Petrolatum/
9. petrolatum.ti,ab.
10. Emulsions/
11. emulsion$.ti,ab.
12. exp Lubricants/
13. lubrica$.ti,ab.
14. exp Ointments/
15. ointment$.ti,ab.
16. lotion$.ti,ab.
17. exp Oils/
18. oil$1.ti,ab.
19. (gel or gels).ti,ab.
20. (paste$1 or salve$ or unguent$).ti,ab.
21. or/8-20
22. skin.mp.
23. exp Skin/
24. or/22-23
25. 21 and 24
26. bath$3.ti,ab.
27. exp Baths/
28. exp Soaps/
29. soap$.ti,ab.
30. exp Water Softening/
31. water soften$.ti,ab.
32. (hard water or water hardness).ti,ab.
33. exp Skin Care/
34. or/26-33
35. 7 or 25 or 34
36. randomized controlled trial.pt.
37. controlled clinical trial.pt.
38. randomized.ab.
39. placebo.ab.
40. clinical trials as topic.sh.
41. randomly.ab.
42. trial.ti.
43. 36 or 37 or 38 or 39 or 40 or 41 or 42
44. exp animals/ not humans.sh.
45. 43 not 44
46. exp infant/ or exp infant, newborn/
47. (Infan$ or newborn$ or new next born$ or newly next born$ or perinat$ or neonat$ or neo next nat$ or baby$ or babies).mp.
48. 46 or 47
49. 35 and 45 and 48

[ Lines 36-45: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing
version (2008 revision); Ovid format, from section 3.6.1 in Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, Noel-
Storr A, Rader T, Shokraneh F, Thomas J, Wieland LS. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins
JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA (eds). Cochrane Handbook for Systematic Reviews of Interventions
Version 6. Cochrane, 2019. Available from: www.training.cochrane.org/handbook ]

Appendix 4. Search strategy for Embase (Ovid)

1. exp emollient agent/
2. emollient$.ti,ab.
3. moisturis$.mp.
4. moisturiz$.mp.
5. skin cream/
6. cream$.ti,ab.
7. or/1-6

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

164

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

8. exp petrolatum/
9. petrolatum.ti,ab.
10. exp emulsion/
11. emulsion$.ti,ab.
12. exp lubricating agent/
13. lubrica$.ti,ab.
14. exp ointment/
15. ointment$.ti,ab.
16. exp lotion/
17. lotion$.mp.
18. oil$1.ti,ab.
19. (gel or gels).mp.
20. (paste$1 or salve$ or unguent$).ti,ab.
21. exp paste/
22. exp salve/
23. or/8-22
24. exp skin/
25. skin.mp.
26. 24 or 25
27. 23 and 26
28. exp bath/
29. bath$3.ti,ab.
30. exp soap/
31. soap$.ti,ab.
32. water soften$.ti,ab.
33. exp skin care/
34. exp water hardness/
35. (hard water or water hardness).ti,ab.
36. or/28-35
37. 7 or 27 or 36
38. crossover procedure.sh.
39. double-blind procedure.sh.
40. single-blind procedure.sh.
41. (crossover$ or cross over$).tw.
42. placebo$.tw.
43. (doubl$ adj blind$).tw.
44. allocat$.tw.
45. trial.ti.
46. randomized controlled trial.sh.
47. random$.tw.
48. or/38-47
49. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
50. human/ or normal human/
51. 49 and 50
52. 49 not 51
53. 48 not 52
54. infant/ or baby/ or exp newborn/
55. (Infan$ or newborn$ or new next born$ or newly next born$ or perinat$ or neonat$ or neo next nat$ or baby$ or babies).mp.
56. 54 or 55
57. 37 and 53 and 56

[Lines 38-53: Based on terms suggested for identifying RCTs in Embase (section 3.6.2) in Lefebvre C, Glanville J, Briscoe S, Littlewood A,
Marshall C, Metzendorf M-I, Noel-Storr A, Rader T, Shokraneh F, Thomas J, Wieland LS. Technical Supplement to Chapter 4: Searching for and
selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA (eds). Cochrane Handbook for Systematic
Reviews of Interventions Version 6. Cochrane, 2019. Available from: www.training.cochrane.org/handbook]

Appendix 5. Search strategy for ClinicalTrials.gov

emollient OR emollients OR moisturiser OR moisturisers OR moisturizer OR moisturizers OR barrier OR skin OR skincare OR bath OR bathing
OR water softener OR water softeners OR water treatment

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

165

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Appendix 6. Search strategy for WHO ICTRP search portal

emollient OR emollients OR moisturiser OR moisturisers OR moisturizer OR moisturizers OR barrier OR skin OR skincare OR bath OR bathing
OR water softener OR water softeners OR water treatment

Appendix 7. Variables requested from trials for the individual participant data meta-analysis (IPDMA)

Patient identifiers for analysis inclusion

1. Unique patient ID (anonymous - or please give a new SCiPAD ID and keep log of the corresponding trial ID)

2. Randomised treatment allocation

3. Date of randomisation

4. Received randomised treatment (yes/no)

5. Included in the trials' primary analysis (yes/no)

Primary outcomes

6. Eczema (at all time points collected and using all recorded measures of eczema or eczema symptoms, e.g. UK Working Party defin-
ition and investigator-assessed – please send all eczema measures used and additional variables on skin condition (itch etc.) pre-for-
mal eczema diagnosis and time point)

7. Food allergy (at all time points collected and using all recorded measures, e.g. using oral food challenge and investigator-assessed
– please send all food allergy measures used)

Secondary outcomes

8. Slippage accidents around the time of bathing or application of emollienta

9. Skin infections during the intervention perioda

10. Stinging or allergic reactions to moisturisersa

11. Serious adverse eventsa

12. Time of eczema onset (first report of a diagnosis of eczema as a specific date or first visit date eczema recorded)

13. Eczema severity - clinician-assessed: EASI or similar validated measure (at all time points collected)
14. Eczema severity - parent-assessed: POEM or similar validated measure (at all time points collected)
15. Parent-reported of immediate (< 2 hours) reaction to a known food allergen: milk, soya, wheat, fish, seafood, peanut, tree nut,
egg, or local common food allergen (at all time points collected and for each food allergen recorded)
16. Allergic sensitisation to foods and inhalants via skin prick test (at all time points collected and for each food and inhalant record-
ed)

Infant baseline characteristics

17. Gestational age at birth

18. Sexb

19. Birth weight

20. Pre-existing health state in the infant, such as very preterm birth (less than 32 weeks' gestation) or congenital skin condition

21. Infant already diagnosed with eczema at the time of randomisation

22. Infant already diagnosed with food allergy at the time of randomisation

23. Age intervention began (e.g. number of days between birth and randomisation)

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

166

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

  (Continued)

24. FLG genotype (method of analysis and what FLG mutations were genotyped)

25. Ethnicity

26. Mode of delivery (e.g. caesarean, vaginal)

27. Method of feeding (e.g. breastfeeding at all time points recorded)

28. Any additional trial randomisation stratification factors

Family baseline characteristics

29. Age of mother at randomisation or enrolment

30. Age of father at randomisation or enrolment

31. Ethnicity of mother

32. Ethnicity of father

33. Educational status of mother

34. Educational status of father

35. Socioeconomic group

36. Singleton or multiple pregnancy

37. Number of other children living at home (without new child – or indicate if this includes the new child)

38. Whether any cats living in the household/living environment?

39. Whether any dogs living in the household/living environment?

40. Mother took any antibiotics during pregnancy?

41. Mother took any regular probiotic supplements during pregnancy?

42. Smoking status of mother

43. Smoking status of father

Family history of atopic disease

44. Number of first-degree relatives with atopic disease (0, 1, 2, or more)b [Please indicate how atopic disease is defined]

45. Number of first-degree relatives with eczema (0, 1, 2, or more)

46. Number of first-degree relatives with food allergy (0, 1, 2, or more)

47. Number of first-degree relatives with asthma (0, 1, 2, or more)

48. Number of first-degree relatives with rhinitis/hay fever (0, 1, 2, or more)

Compliance data

49. Data on compliance with intervention, including measures such as grams per day and total number of grams of product dis-
pensed over the study

50. Duration of treatment

51. Dates of treatment withdrawal and reason(s) for treatment withdrawal

Non-assigned skin care

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

167

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

52. Frequency of bathing

53. Product used for bathing (if not part of intervention)

54. Prescribed topical treatment use

55. Any other skin treatments

For cluster-randomised trials

56. Cluster-randomisation factors

Food introduction

57. Any data on the time/age when allergenic foods were introduced

58. Any data on the time/age when solid foods were introduced

Abbreviations: EASI: Eczema Area and Severity Index; FLG: filaggrin gene; POEM: Patient-Orientated Eczema Measure; SCiPAD: Skin
Care intervention for Prevention of Atopic Disease

aAdverse events of interest. All adverse events may be sent if trials do not have these separated out.
bCritical baseline variables required for covariate adjustment within primary and secondary analyses.

W H A T ' S   N E W

Date

Event

Description

17 January 2022

New citation required and conclusions
have changed

Based on low- to moderate-certainty evidence, skin care inter-
ventions such as emollients during the first year of life in healthy
infants are probably not effective for preventing eczema; may in-
crease risk of food allergy; and probably increase risk of skin in-
fection.

5 October 2021

New search has been performed

Updated to incorporate food allergy outcomes from Skjer-
ven 2020

H I S T O R Y

Protocol first published: Issue 2, 2020
Review first published: Issue 2, 2021

C O N T R I B U T I O N S   O F   A U T H O R S

RJB and HW conceived of the review scope and design; MK, RP, SJB, SC, VC, KLC, HS, ER, AL, ED, NS, KY, YO, KYH, KM, EA, MC, AC, EVV, JS,
SW, DM, ES, LD, LA, HW, RJB made substantial contributions to data acquisition, analysis, and interpretation for the current update.

RP was the primary statistician for this updated review. SC and VC wrote the statistical analysis plan, to which RJB, MK, and AL contributed;
all 27 authors reviewed and approved the final version of the statistical analysis plan for the current update. EA developed the Methods
section  with  SC  and  VC,  and  reviewed  the  protocol  and  review  and  summary  of  findings  tables  to  ensure  alignment  with  Cochrane
requirements. LA and LD provided advice and expertise on conducting a prospective individual participant data (IPD) meta-analysis. KLC,
HS, ER, AL, ED, NS, KY, YO, KYH, KM, JS, ES, DM, MC, AC, JC, SW, and HW provided IPD from their individual trials.

SC, MK, RJB, and RP screened papers against the eligibility criteria; EVV and MK screened the grey literature. SC and MK obtained data on
ongoing and unpublished studies. SC, MK, VC, RP, and RJB appraised risk of bias in the included studies. SC, MK, VC, RP,  and RJP extracted
data for the review update and sought additional information about papers. SC and RP entered data into Review Manager Web. RP analysed

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

168

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

and interpreted data for the update; RJB and MK reviewed and commented on data analyses; MK, SC, VC, and RJB conducted the GRADE
assessment and drafted the summary of findings table.

EVV co-ordinated the review update development process to ensure that it corresponded to MECIR standards, and together with RJB,
SC, MK, and RP, managed feedback and suggestions from other co-authors and developed the draft of this update. SJB, VC, KLC, HS, ER,
AL,  ED,  NS,  KY,  YO,  KYH,  KM,  EA,  MC,  AC,  JS,  SW,  DM,  ES,  LD,  LA,  and  HW  revised  the  draft  version  extensively  for  intellectual  content.
SC and VC contributed to the rebuttal to specific methods/statistical reviewers' comments. MC provided expert advice on formulation
of topical emollients. SJB provided expert advice on genetic analysis and interpretation. All 27 authors approved the final version of the
current update to be published, and all authors agree to be accountable for all aspects of this update in ensuring that questions related
to accuracy and integrity are adequately addressed.

Disclaimers

This publication presents independent research funded by the National Institute for Health and Care Research (NIHR). The views expressed
are those of the author(s) and not necessarily those of the NHS, NIHR, or the Department of Health and Social Care.

The NIHR also supported this project via Cochrane Infrastructure funding to Cochrane Skin. The views and opinions expressed therein are
those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health.

D E C L A R A T I O N S   O F   I N T E R E S T

interests;  has  written  a  review  on  the  topic 

Maeve  Kelleher:  no  relevant 
food  allergy  –  skin  barrier
interventions' (doi.org/10.1016/j.alit.2019.10.005); Consultant in Paediatric Allergy at Children's Health Ireland; Honorary Clinical Senior
Lecturer at Imperial College London; assisted in the food allergy diagnostic work for the BEEP study, which is included in this review -
funded by a personal research fellowship from National Institute of Health and Care Research (NIHR), UK; the BEEP study was sponsored
by the University of Nottingham, co-ordinated by the Nottingham Clinical Trials Unit (CTU), and funded by the NIHR Health Technology
Assessment Programme. Supplementary funding was obtained for the inclusion of food allergy outcomes and skin prick tests subsequent
to study initiation, which was provided by Goldman Sachs Gives and Sheffield Children's Hospital Charity.

'Prevention  of 

Rachel Phillips: none known.

Sara  Brown:  AbbVie  -  consultant  (payment  to  University  employer,  no  personal  financial  benefit);  British  Skin  Foundation  -  grant  (for
research studentship); British Society for Paediatric Dermatology - honorarium for invited lecture; European Lead Factory - grant (funding
and in-kind support for a phenotypic screen in skin cells); Innovative Medicines Initiative (IMI) - grant (member of the BioMAP network
(Biomarkers  in  Atopic  Dermatitis  and  Psoriasis)  and  receive  funding  for  research);  Sosei  Heptares  -  consultant  (payment  to  University
employer, no personal financial gain); Wellcome Trust - employment (chair of expert review group); Wellcome Trust - grant (Wellcome Trust
Senior Research Fellowship 2015 to 2020 and renewal 2020 onwards); works in an NHS dermatology department and regularly discusses
the use of emollients with patients; involved in BEEP study, published in the The Lancet 2020 (www.thelancet.com/journals/lancet/article/
PIIS0140-6736(19)32984-8/fulltext) (funded by the US National Institutes of Health).

Suzie Cro: none known.

Victoria Cornelius: none known.

Karin C Lodrup Carlsen: no relevant interests; involved in the PreventADALL study - received funding from many sources, all of which
are appropriately declared in all papers relaying the results. The funders had no role in design, analyses, or dissemination of the study
results. A number of sponsors: the Regional Health Board South East, The Norwegian Research Council, Oslo University Hospital, The
University of Oslo, Health and Rehabilitation Norway, The Foundation for Healthcare and Allergy Research in Sweden – Vårdalstiftelsen,
The Swedish Asthma- and Allergy Association’s Research Foundation, The Swedish Research Council – the Initiative for Clinical Therapy
Research, The Swedish Heart-Lung Foundation, SFO-V Karolinska Institutet, Østfold Hospital Trust, The European Union (MeDALL project),
by unrestricted grants from the Norwegian Association of Asthma and Allergy, The Kloster Foundation, Thermo-Fisher, Uppsala, Sweden
(through supplying allergen reagents) and Fürst Medical Laboratory, Oslo, Norway (through performing immunoglobulin E (IgE) analyses),
Norwegian  Society  of  Dermatology  and  Venerology,  Arne  Ingel’s  legat,  Region  Stockholm  (ALF-project  and  individual  grants),  Forte,
Swedish Order of Freemasons Foundation Barnhuset, The Sven Jerring Foundation, The Hesselman Foundation, The Magnus Bergwall
Foundation, The Konsul Th C Bergh’s Foundation, The Swedish Society of Medicine, The King Gustaf V 80th Birthday Foundation, KI grants,
The Cancer and Allergy Foundation, The Pediatric Research Foundation at Astrid Lindgren Children’s Hospital, The Samaritan Foundation
for Pediatric Research.

Håvard  Ove  Skjerven:  no  relevant  interests;  works  as  a  health  professional  at  Oslo  University  Hospital;  involved  in  The  PreventADALL
study, which has received funding from the following sources: The Regional Health Board South East, The Norwegian Research Council,
Oslo University Hospital, The University of Oslo, Health and Rehabilitation Norway, The Foundation for Healthcare and Allergy Research
in Sweden – Vårdalstiftelsen, The Swedish Asthma and Allergy Association Research Foundation, The Swedish Research Council – the
Initiative  for  Clinical  Therapy  Research,  The  Swedish  Heart-Lung  Foundation,  SFO-V  Karolinska  Institutet,  Østfold  Hospital  Trust,  The
European Union (MeDALL project), by unrestricted grants from the Norwegian Association of Asthma and Allergy, The Kloster Foundation,

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

169

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Thermo-Fisher, Uppsala, Sweden (through supplying allergen reagents) and Fürst Medical Laboratory, Oslo, Norway (through performing
IgE analyses), Norwegian Society of Dermatology and Venerology, Arne Ingel’s legat, Region Stockholm (ALF-project and individual grants),
Forte,  Swedish  Order  of  Freemasons  Foundation  Barnhuset,  The  Sven  Jerring  Foundation,  The  Hesselman  Foundation,  The  Magnus
Bergwall Foundation, The Konsul Th C Bergh’s Foundation, The Swedish Society of Medicine, The King Gustaf V 80th Birthday Foundation,
KI grants, The Cancer and Allergy Foundation, The Pediatric Research Foundation at Astrid Lindgren Children’s Hospital, The Samaritan
Foundation for Pediatric Research.

Eva  Maria  Rehbinder:  Leo  Pharma  -  speaking  engagement;  Novartis  -  speaking  engagement;  Perrigo  -  speaking  engagement;  Sanofi
Genzyme - speaking engagement; co-author on paper from the PreventADALL study included in the review on primary prevention of atopic
dermatitis; works as Resident in Dermatology, Oslo University Hospital; involved in The PreventADALL study (Oslo University Hospital,
Norway,  Østfold  Hospital  Trust,  Norway  and  Karolinska  Institutet,  Sweden)  -  the  PreventADALL  study  has  received  funding  from  the
following sources: The Regional Health Board South East, The Norwegian Research Council, Oslo University Hospital, The University of Oslo,
Health and Rehabilitation Norway, The Foundation for Healthcare and Allergy Research in Sweden – Vårdalstiftelsen, The Swedish Asthma
and Allergy Association Research Foundation, The Swedish Research Council – the Initiative for Clinical Therapy Research, The Swedish
Heart-Lung Foundation, SFO-V Karolinska Institutet, Østfold Hospital Trust, The European Union (MeDALL project), by unrestricted grants
from the Norwegian Association of Asthma and Allergy, The Kloster Foundation, Thermo-Fisher, Uppsala, Sweden (through supplying
allergen reagents) and Fürst Medical Laboratory, Oslo, Norway (through performing IgE analyses), Norwegian Society of Dermatology and
Venerology,  Arne  Ingel’s  legat,  Region  Stockholm  (ALF-project),  Forte,  Swedish  Order  of  Freemasons  Foundation  Barnhuset,  The  Sven
Jerring Foundation, The Hesselman Foundation, The Magnus Bergwall Foundation, The Konsul Th C Bergh’s Foundation, The Swedish
Society of Medicine, The King Gustaf V 80th Birthday Foundation, KI grants, The Cancer and Allergy Foundation, The Pediatric Research
Foundation at Astrid Lindgren Children’s Hospital, The Samaritan Foundation for Pediatric Research.

Adrian Lowe: other intellectual property - lead investigator on intervention trials using skin barrier repair creams; publications relating to
the feasibility of this form of intervention; involved in Phase II PEBBLES trial, listed as Lowe et al. (2018). Funded by the Financial Markets
Foundation for Children (FMFC), Asthma Foundation of Victoria, National Health and Medical Research Council (NHMRC) (Project funding:
FMFC, Asthma Foundation of Victoria. Project equipment: NHMRC).

Eishika Dissanayake: no relevant interests; responsible for analysing data and the publication of a randomised controlled trial that aimed
to identify the efficacy of emollients and synbiotics in preventing atopic dermatitis and food allergy in children during the first year of life,
institution: Chiba University, Japan (funding source: Environmental Restoration and Conservation Agency of Japan in fiscal years 2014 to
2016 and grants from the Japan Agency for Medical Research and Development (AMED-CREST)(15652274)).

Naoki Shimojo: no relevant interests; published in Allergology International, the official journal of the Japanese Society of Allergology.

no 

Yonezawa: 

Kaori 
and
aacijournal.biomedcentral.com/articles/10.1186/s13223-019-0385-7, Mitsubishi Foundation (Grants for Social Welfare Activities on 2013)
and the Mishima Kaiun Memorial Foundation - Division of Health Sciences and Nursing, Department of Midwifery and Women’s Health,
Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.

onlinelibrary.wiley.com/doi/10.1111/1346-8138.14080 

interests; 

involved 

relevant 

in 

Yukihiro Ohya: AbbVie - consultant (medical advisory for atopic dermatitis); Janssen Global Services, LLC - consultant (advisory board
meeting); Leo Pharma KK -  consultant (treatment of atopic dermatitis); Maruho - consultant (medical advisory for atopic dermatitis);
Mylan - lecturer; Otsuka Pharmaceutical Co Ltd - consultant (treatment of atopic dermatitis); Regeneron Pharmaceuticals Inc - consultant
(advisory board meeting); Sanofi - lecturer; Torii - lecturer; practice in the National Center for Child Health and Development; committee
member  of  Japanese  guidelines  for  atopic  dermatitis,  Japanese  Society  of  Allergology;  involved  in  purchase  of  tested  emollients,
recruitment for participants in the National Center for Child Health and Development - Application of moisturizer to neonates prevents
development of atopic dermatitis (supported by funding from the Ministry of Health, Labour and Welfare of Japan).

Kiwako Yamamoto-Hanada: AbbVie - consultant (consultation); Bee Case - consultant (advisory); Kao Corporation - consultant (lecture,
consultation); Maruho - speaker engagement; Natural Science -grant/contract (joint research agreement); Otsuka Pharmaceutical Co Ltd -
speaker fee; Pfizer Japan - speaker fee; Takano Medical - grant/contract (commissioned study); Tori Pharmaceutical - speaker engagement;
work as a health professional at National Center for Child Health and Development; involved in data sharing, interpretation of the results,
advice to the manuscript, National Center for Child Health and Development.

Kumiko  Morita:  no  relevant  interests;  involved  in  providing  data  from  our  study  (Journal  of  Allergy  and  Clinical  Immunology
2014;134:824-30)  in  National  Center  for  Child  Health  and  Development  research:  Journal  of  Allergy  and  Clinical  Immunology
2014;134:824-30,  source:  Health  and  Labour  Sciences  Research  Grants  for  Research  on  Allergic  Diseases  and  Immunology  from  the
Ministry of Health, Labour and Welfare of Japan (H22-Men’eki-Ippan-002 to HS and H25-Nanchito-Ippan-001 to MA and HS as principal
investigators).

Emma Axon: no relevant interests; methodologist at Cochrane Skin, University of Nottingham.

Michael Cork: Boots UK Ltd. - consultant; Eli Lilly and Company - consultant; Hyphens Pharma - Singapore - consultant; Johnson & Johnson
Health Care Systems Inc - consultant; Kymab, a Sanofi company - grant/consultant; L'Oreal USA - consultant; LEO Pharma AS - consultant;
Perrigo  (ACO  Nordic)  -  consultant;  Pfizer  Canada  Inc  -  consultant;  Procter  &  Gamble  -  consultant;  Regeneron  Pharmaceuticals  Inc  -

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

170

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

consultant; Sanofi UK - consultant; published for National Eczema Society, UK; affiliated to National Eczema Society, UK; works as a health
professional at Sheffield Teaching Hospitals NHS Trust and Sheffield Children's NHS Trust; involved with “BEEP” - A randomised controlled
trial  to  determine  whether  a  skin  barrier  enhancement  package  can  prevent  eczema  in  high-risk  children  (NIHR  Health  Technology
Assessment Programme, via the University of Nottingham - as Principal Investigator for Sheffield - jointly & severally contracted by The
University of Sheffield & Sheffield Children’s Hospital NHS Foundation Trust & Sheffield Teaching Hospitals NHS Foundation Trust.

Alison Cooke: no relevant interests; Chief investigator of the OBSeRvE (Oil in Baby SkincaRE) study included in this review (funded by
National Institute for Health Research Doctoral Research Fellowship), University of Manchester, pilot randomised controlled trial; has had
several publications and given several conference presentations in the area of neonatal skin care; Assistant Director of Nursing Research
and Innovation at University Hospitals of North Midlands NHS Trust.

Eleanor Van Vogt: none known.

Jochen Schmitt: La Roche-Posay - grant (institutional grant for IIT); Novartis, Sanofi, ALK, and Pfizer - grant (grants for investigator-initiated
research); Sanofi, Lilly, and ALK - consultant (participated in advisory board meetings as a paid consultant); involved in a study funded by
La Roche-Posay (grant for IIT to Universities Kiel and Dresden, Germany).

Stephan  Weidinger:  AbbVie  -  consultant  (consultancies,  lectures);  Almirall  LLC  -  consultant  (consultancies,  lectures);  Eli  Lilly  and
Company - consultant (consultancies, lectures); Genzyme Corporation - consultant (institutional research grant, consultancies, lectures);
GlaxoSmithKline - consultant (consultancies); Janssen Biotech Inc - consultant (consultancies); LEO Pharma AS - consultant (institutional
research grant, consultancies, lectures); Pfizer Pharmaceuticals LLC - consultant (consultancies, lectures); Regeneron Pharmaceuticals Inc
- consultant (consultancies, lectures).

Danielle McClanahan: no relevant interests; Dermatology Resident at Oregon Health & Science University (OHSU); Study Co-ordinator,
OHSU - McClanahan D, Wong A, Kezic S, Samrao A, Hajar T, Hill E, Simpson EL. A randomized controlled trial of an emollient with ceramide
and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. Journal of the European Academy
of Dermatology and Venereology 2019 Nov;33(11):2087-94. doi: 10.1111/jdv.15786. Epub 2019 Jul 30. PMID: 31287580 (investigator initiated,
Galderma provided the product).

Eric  Simpson:  AbbVie  -  consultant  and  speaker;  AbbVie  -  consultant  (consult  on  atopic  dermatitis  (AD)  and  guest  lecture);  Amgen  -
consultant (consulting on AD); Arcutis - grant/contract; Corevitas -grant/contract; Dermira Inc - consultant (consult on AD); Dermira Inc
- grant/contract; Eli Lilly and Company - consultant (consult on AD, lecture and serve on advisory board); Eli Lilly and Company - grant/
contract; ForteBio - consultant (consult on AD); Galderma Research & Development, LLC - consultant (consult on AD); GlaxoSmithKline -
consultant (consultant on AD and on advisory board); Incyte Corporation - consultant (consult on AD and serve on advisory board); Incyte
Corporation - grant/contract; Janssen Biotech - consultant (consultant on AD and on advisory board); Kyowa Hakko Kirin - consultant
(consult on AD and on advisory board); Kyowa Hakko Kirin - grant/contract; LEO Pharma Inc - consultant (consult on AD, lecture and serve
on advisory board); LEO Pharma Inc - grant/contract; Merck - grant/contract; Novartis - grant/contract; Pfizer - consultant (consult on AD,
guest lecture and serve on advisory board); Pfizer - grant/contract; Regeneron Pharmaceuticals - consultant (consult on AD, lecture and
serve on advisory board); Regeneron Pharmaceuticals - grant/contract; Sanofi US Services Inc - consultant (consulting on AD, speaker and
advisory board); TARGET-Derm - grant/contract; works as a professor and patient care MD at Oregon Health & Science University.

Lelia Duley: none known.

Lisa M Askie: none known.

Hywel C Williams: no relevant interests; was an investigator on the following trial published in The BMJ 19 years ago: Thomas KS, Armstrong
S, Avery A, Po AL, O'Neill C, Young S, Williams HC. Randomised controlled trial of short bursts of a potent topical corticosteroid versus
prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ. 2002 Mar 30;324(7340):768. doi: 10.1136/
bmj.324.7340.768. PMID: 11923161; PMCID: PMC100318 - funding source: NHS R&D Trent (a public funder).

Robert J Boyle: no relevant interests; works as a paediatric allergist seeing children and adolescents with atopic eczema, but does not
use  the  treatments  evaluated  in  this  project  for  the  prevention  of  eczema  or  food  allergy.  RB  works  for  the  following  organisations:
Imperial Healthcare NHS Trust and as a self-employed paediatric allergist at HCA Healthcare and Sterling Health; Joint Co-ordinating Editor,
Cochrane Skin (2018-current); Senior Editor for Cochrane Children and Families (2018 to 2021); Senior Editor for Cochrane Mental Health
and Neuroscience (2020 to 2021); co-investigator on BEEP trial (Chalmers 2020), a clinical trial included in this review (funding source: NIHR
Health Technology Assessment Programme).

S O U R C E S   O F   S U P P O R T

Internal sources

• No sources of support provided

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

171

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

External sources

• The National Institute for Health Research (NIHR), UK

The NIHR, UK, is the largest single funder of Cochrane Skin.

• The National Institute for Health Research (NIHR), UK

Cochrane Database of Systematic Reviews

MK  was  supported  by  a  Transitional  Research  Fellowship.  This  funding  provides  for  her  salary,  University  support  (University  of
Nottingham and Imperial College London), and statistical support from authors EA and VC.

• The National Institute for Health Research (NIHR), UK

This paper presents independent research funded by the NIHR under its Research for Patient Benefit (RfPB) Programme (Grant Reference
Number PB-PG-0317-20028). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department
of Health and Social Care. The grant was awarded to author RJB (Nottingham University Hospitals NHS Trust) and provided support
for SC and LT.

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

Objectives: We clarified our Objectives, which included removing some redundant text.

Types of outcome measures: We clarified that the time point for all food allergy and eczema outcome analyses (not just the primary
outcomes) was by age one to three years, using the closest available time point to two years from each included trial.

Sensitivity and subgroup analysis

We prespecified sensitivity analysis by outcome measures for the co-primary outcomes of eczema and food allergy by one to three years.
This included sensitivity analysis for secure diagnosis of food allergy by oral food challenge or investigator decision using an algorithm
developed for the Barrier Enhancement for Eczema Prevention (BEEP) study.

In subgroup analysis, for co-primary outcomes, we planned that we would compare the effects of intervention on participants advised to
commence the skin care intervention within the first four weeks of life compared to those who commenced intervention after four weeks.
As all of the included trials advised skin care commencement during the first four weeks of life, we compared the effects of intervention on
participants advised to commence skin care intervention within the first week of life compared to those who commenced intervention
after the first week of life. We were able to utilise the obtained individual participant data (IPD) and to explore the interaction between
treatment effects of skin care intervention and actual age at treatment initiation as < 4 days versus ≥ 4 days.  We conducted unplanned
sensitivity analysis including outcomes measured at earlier time points for the primary outcome of eczema (six months to three years) and
the secondary outcome of allergic sensitisation (eight months to three years) to fully utilise the obtained IPD and to fully explore the
implications of excluding from the main analysis data on early-onset eczema or allergic sensitisation.

Complier average causal effect analysis

For  the  complier  average  causal  effect  analysis,    we  were  unable  to  provide  thresholds  for  defining  compliance  in  the  protocol,  as
it  was  unknown  exactly  what  interventions  and  data  fields  would  be  available  across  trials.  As  prespecified  in  the  statistical  analysis
plan (Cro 2020a), before commencement of any meta-analysis, we held a Skin Care intervention for Prevention of Atopic Disease (SCiPAD)
Investigators meeting  to establish alternative thresholds for defining compliance based on available data fields. The primary definition of
a complier was use of skin care intervention ≥ 3 days a week over the intervention period, which corresponded to the definition used in the
largest trial reporting compliance data (Chalmers 2020). Secondary definitions of a complier included use ≥ 5 days a week, 7 days a week
over the intervention period, and ≥ 3 days a week, ≥ 5 days a week, and 7 days a week over the first three months of the intervention period.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Allergens  [therapeutic use];  Cattle;  *Eczema  [drug therapy]  [prevention & control];  Emollients  [therapeutic use];  *Food
Hypersensitivity  [prevention & control];  *Milk Hypersensitivity

MeSH check words

Animals; Female

Skin care interventions in infants for preventing eczema and food allergy (Review)
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.

172
